Rank	NCT Number	Title	Acronym	Status	Study Results	Conditions	Interventions	Outcome Measures	Sponsor/Collaborators	Gender	Age	Phases	Enrollment	Funded Bys	Study Type	Study Designs	Other IDs	Start Date	Primary Completion Date	Completion Date	First Posted	Results First Posted	Last Update Posted	Locations	Study Documents	URL
1	NCT03195491	A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia	CheckMate870	Active, not recruiting	No Results Available	Lung Cancer|Non-Small Cell Lung Cancer	Biological: Nivolumab	Incidence of high grade treatment-related select adverse events in non-hepatitis B virus (HBV) infected participants|Severity of high grade treatment-related select adverse events in non-HBV infected participants|Incidence of high grade treatment-related select adverse events in HBV infected participants|Severity of high grade treatment-related select adverse events in HBV infected participants|Laboratory test abnormalities|Incidence of adverse events in all treated patients|Severity of adverse events in all treated patients	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	400	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-870	December 19, 2017	January 15, 2019	July 29, 2022	June 22, 2017	null	September 26, 2018	Local Institution, Dallas, Texas, United States|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Beijing, Hebei, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Wuhan, Hubei, China|Local Institution, Changsha, Hunan, China|Local Institution, Zhengzhou, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Jinan City, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Wulumuqi, Xinjiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Guangzhou, China|Local Institution, Shanghai, China|Local Institution, Shanghai, China|Local Institution, Shenyang, China|Local Institution, Bangkok, Thailand|Local Institution, Khon Kaen, Thailand		https://ClinicalTrials.gov/show/NCT03195491
2	NCT02869789	An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers		Recruiting	No Results Available	Lung Cancer	Drug: Nivolumab in combination with Ipilimumab	Number of participants who experience high grade AEs (Adverse Events)|Percentage of participants who experience high grade AEs|Progression-free survival (PFS)|ORR|Duration of Response (DOR)|Functional Assessment of Cancer Therapy-Lung (FACT-L)|Overall Survival (OS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 4	1100	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-817|2016-002621-10	September 14, 2016	June 16, 2020	November 17, 2021	August 17, 2016	null	November 29, 2018	Alabama Oncology, Birmingham, Alabama, United States|Local Institution, Chandler, Arizona, United States|Arizona Oncology Assoc, Pc-Hal, Phoenix, Arizona, United States|Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope, Tucson, Arizona, United States|Local Institution, Hot Springs, Arkansas, United States|University Of Arkansas For Medical Sciences, Little Rock, Arkansas, United States|CBCC Global Research, Inc., Bakersfield, California, United States|Local Institution, Berkeley, California, United States|Marin Cancer Care, Inc, Greenbrae, California, United States|Local Institution, La Jolla, California, United States|Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States|Ucla, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Local Institution, San Diego, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|St. Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|Florida Cancer Affiliates - Ocala, Ocala, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Northside Hospital, Inc, Atlanta, Georgia, United States|Local Institution, Macon, Georgia, United States|Local Institution, Boise, Idaho, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Local Institution, Skokie, Illinois, United States|Local Institution, Indianapolis, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Kentucky One Health St. Joseph East Cancer Center, Lexington, Kentucky, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, United States|Minnesota Oncology Hematology, Pa, Edina, Minnesota, United States|Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States|St. Francis Cancer Treatment Center, Grand Island, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Cancer Care Specialists, Reno, Nevada, United States|Essex Oncology Of North Jersey P.A., Belleville, New Jersey, United States|Saint Barnabas Medical Cancer Center, Livingston, New Jersey, United States|Local Institution, Morristown, New Jersey, United States|Local Institution, Bronx, New York, United States|Dumc, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|Local Institution, Corvallis, Oregon, United States|Local Institution, Portland, Oregon, United States|Willamette Valley Cancer Center, Springfield, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Local Institution, Langhorne, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Guthrie Medical Group, Pc, Sayre, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|Tennessee Oncology, Pc, Nashville, Tennessee, United States|Texas Oncology, PA - South Austin Cancer Center, Austin, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology-Fort Worth 12th Ave, Fort Worth, Texas, United States|Texas Oncology-Longview, Longview, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Texas Oncology Cancer Care And Research Center, Waco, Texas, United States|Virginia Cancer Specialists, Pc, Fairfax, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Local Institution, Renton, Washington, United States|Local Institution, Spokane, Washington, United States|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Hospital Italiano De Buenos Aires, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Centro Medico San Roque, Tucuman, Argentina|Local Institution, Gent, Belgium|Local Institution, Liege, Belgium|Local Institution, Sint-Niklaas, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Newmarket, Ontario, Canada|Local Institution, Greenfield Park, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Hopital Du Sacre-Coeur De Montreal, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-Centre-du-Quebec, Trois-Rivieres, Quebec, Canada|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Fundacion Arturo Lopez Perez, Santiago, Chile|Komplexni onkologicke centrum, Novy Jicin, Czechia|Onkologicka klinika VFN a 1. LF UK, Praha 2, Czechia|Local Institution, Bordeaux, France|Local Institution, Dijon Cedex, France|Local Institution, Marseille Cedex 20, France|Local Institution, Nice, France|Local Institution, Paris, France|Local Institution, Pessac cedex, France|Local Institution, Rennes Cedex 9, France|Local Institution, Saint Herblain, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulon Cedex, France|Krankenhaus Nordwest Gmbh, Frankfurt, Frankfurt, Germany|SRH WALD KLINIKUM GERA gGmbH, Gera, Germany|Klinikum Kassel, Kassel, Germany|Klinik Loewenstein, Loewenstein, Germany|Hsk Dr.-Horst-Schmidt-Kliniken Wiesbaden, Wiesbaden, Germany|Sotiria General Hospital, Athens, Greece|Metropolitan Hospital, Neo Faliro, Greece|Papageorgiou General Hospital, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Matrahaza, Hungary|Local Institution, Genova, Italy|Istituto Romagnolo Per Lo Studio E La Cura Dei Tumori, Meldola, Italy|Local Institution, Milan, Italy|Local Institution, Napoli, Italy|Ospedale Degli Infermi, Rimini, Italy|Local Institution, Siena, Italy|Azienda Ospedaliera S. Maria, Terni, Italy|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Cuernavaca, Morelos, Mexico|Local Institution, Mazatlan, Sinaloa, Mexico|Local Institution, Monterrey, NL, Mexico|Local Institution, Queretaro, Mexico|Local Institution, Groningen, Netherlands|Local Institution, Rotterdam, Netherlands|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Oddzial Wewnetrzny, Sucha Beskidzka, Poland|Klinika Nowotworow Pluca i Klatki Piersiowej, Warszawa, Poland|Focus Lab Plus SRL, Bucuresti, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Dep, Romania, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, A Coru?a, Spain|Local Institution, Barcelona, Spain|Local Institution, Jaen, Spain|Local Institution, Madrid, Spain|Local Institution, Majadahonda - Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Zaragoza, Spain|University Hospital Basel, Basel, Switzerland|University Hospital Zurich, Zuerich, Switzerland|Local Institution, Adana, Turkey|Local Institution, Antalya, Turkey|Local Institution, Istanbul, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, Leicester, Leicestershire, United Kingdom|Local Institution, Edinburgh, Midlothian, United Kingdom|Local Institution, Newcastle Upon Tyne, United Kingdom|Local Institution, Wirral, United Kingdom		https://ClinicalTrials.gov/show/NCT02869789
3	NCT03098550	A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread		Active, not recruiting	No Results Available	Advanced Cancer	Biological: Nivolumab|Biological: Daratumumab	Incidence of adverse events (AE)|Incidence of serious adverse events (SAE)|Grade of laboratory abnormalities.|Objective Response rate (ORR)|Progression Free Survival (PFS)|Anti-Drug Antibodies (ADA) positivity|Area under the concentration-time curve (AUC)|Minimum observed concentration (Cmin)	Bristol-Myers Squibb|Janssen Biotech, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	120	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-9GW|2017-000367-33	June 7, 2017	August 30, 2020	August 30, 2020	March 31, 2017	null	November 6, 2018	Pacific Shores Medical Group, Huntington Beach, California, United States|University Of Colorado, Aurora, Colorado, United States|Moffitt Cancer Center, Tampa, Florida, United States|University Of Michigan, Ann Arbor, Michigan, United States|Providence Portland Medical Center, Portland, Oregon, United States|Local Institution, St Leonards, New South Wales, Australia|Local Institution, Edmonton, Canada|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 9, France|Local Institution, Strasbourg Cedex, France|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Medizinische Universitaetsklinik Freiburg, Freiburg, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Fundacion De Investigacion, San Juan, Puerto Rico|Hospital Gral. Univ. Gregorio Maranon, Madrid, Spain|Local Institution, Majadahonda - Madrid, Spain|Klinik Fur Onkologie, Basel, Switzerland|University Hospital of Lausanne, Lausanne, Switzerland		https://ClinicalTrials.gov/show/NCT03098550
4	NCT02985957	A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer	CheckMate 650	Active, not recruiting	No Results Available	Prostate Cancer	Biological: Nivolumab|Biological: Ipilimumab	Objective Response Rate (ORR)|Radiographic Progression-Free Survival (rPFS)|Radiographic/Clinical Progression-Free Survival (rcPFS)|Overall Survival (OS)|Number of patients with adverse events|Number of patients with serious adverse events|Number of patients with adverse events leading to discontinuation|Number of patients with immune-mediated adverse events|Number of patients with deaths|Number of patients with laboratory abnormalities|Number of patients with changes in pain as measured by Brief Pain Inventory-Short Form (BPI-SF)|European Quality of Life- Five Dimensions (EQ-5D-3L) scores	Bristol-Myers Squibb	Male	18 Years and older   (Adult, Older Adult)	Phase 2	90	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-650|2016-001928-54	March 17, 2017	December 16, 2018	March 24, 2022	December 7, 2016	null	June 19, 2018	University of Chicago, Chicago, Illinois, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Icahn School Of Medicine At Mount Sinai, New York, New York, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Local Institution, Clermont-ferrand, France|Local Institution, Lyon, France|Local Institution, Marseille Cedex 9, France|Local Institution, Villejuif, France		https://ClinicalTrials.gov/show/NCT02985957
5	NCT02713867	A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks	CheckMate 384	Active, not recruiting	No Results Available	Lung Cancer	Biological: Nivolumab	Progression Free Survival (PFS) rate at 6 months after randomization|Progression Free Survival (PFS) rate at 12 months after randomization|Progression Free Survival (PFS) rate by tumor histology and by response criteria|Progression Free Survival (PFS) rate|Overall Survival Rate (OSR)|Safety and Tolerability assessed by the incidence and severity of adverse events (AEs)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	350	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-384	April 21, 2016	June 30, 2022	June 30, 2022	March 21, 2016	null	September 17, 2018	Alabama Oncology, Birmingham, Alabama, United States|Arizona Oncology Assoc, Pc-Hal, Phoenix, Arizona, United States|Arizona Oncology Associates PC - NAHOA, Phoenix, Arizona, United States|CBCC Global Research, Inc., Bakersfield, California, United States|Southern California Permanente Medical Group, Bellflower, California, United States|St Jude Hospital Yorba Linda, Fullerton, California, United States|UCLA Hematology/Oncology Clinic, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Sansum Clinic, Santa Barbara, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|Poudre Valley Health Care, Fort Collins, Colorado, United States|Rocky Mountain Cancer Centers Llp, Lone Tree, Colorado, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States|Ocala Oncology Center, Pl, Ocala, Florida, United States|Sacred Heart Medical Oncology Group, Pensacola, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Northwest Georgia Oncology Ctr, Marietta, Georgia, United States|Ingalls Health System, Harvey, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Illinois Cancercare, Pc, Peoria, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Innova Schar Cancer Institute, Indianapolis, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Oncology Associated Of Western Kentucky, Paducah, Kentucky, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Cancer Care Of Maine, Brewer, Maine, United States|Center For Cancer And Blood Disorders, Bethesda, Maryland, United States|Providence Cancer Center, Southfield, Michigan, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|North Mississippi Med Center, Tupelo, Mississippi, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Oncology Hematology West PC, Omaha, Nebraska, United States|New York Oncology Hematology, P.C., Clifton Park, New York, United States|Broome Oncology, Johnson City, New York, United States|First Health Of The Carolinas, Pinehurst, North Carolina, United States|Hematology And Oncology Associates, Canton, Ohio, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|MetroHealth Cancer Care Center, Cleveland, Ohio, United States|Tri-County Hematology & Oncology Associates, Inc, Massillon, Ohio, United States|Hematology Oncology Consultants, Pc, Medford, Oregon, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Jones Clinic PC, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology, P.A., Abilene, Texas, United States|Texas Oncology - Amarillo, Amarillo, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology, P.A., Denton, Texas, United States|Texas Oncology, P.A., El Paso, Texas, United States|Texas Oncology, P.A., Flower Mound, Texas, United States|Texas Oncology, P.A., Houston, Texas, United States|Texas Oncology, P.A., Longview, Texas, United States|Texas Oncology-Midland Allison Cancer Center, Midland, Texas, United States|Texas Oncology, P.A., Plano, Texas, United States|Texas Oncology, P.A., San Antonio, Texas, United States|Texas Oncology, P.A., Sherman, Texas, United States|Texas Oncology, P.A., Sugar Land, Texas, United States|Texas Oncology, Wichita Falls, Texas, United States|Innova Schar Cancer Institute, Falls Church, Virginia, United States|Shenandoah Oncology, Winchester, Virginia, United States|Cancer Care Northwest, Spokane Valley, Washington, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|Local Institution, St. Leonards, New South Wales, Australia|Local Institution, Waratah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Bedford Park, South Australia, Australia|Local Institution, Hobart, Tasmania, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Murdoch, Western Australia, Australia|Local Institution, Elizabeth Vale, Australia|Local Institution, Wien, Austria|Local Institution, Newmarket, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, St. Jerome, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Angers, France|Local Institution, Bayonne, France|Local Institution, Clermont-Ferrand, France|Local Institution, Le Mans, France|Local Institution, Mulhouse, France|Local Institution, Nimes, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Pontoise, France|Local Institution, Suresnes, France|Local Institution, Tours, France|Local Institution, Vandoeuvre-les-Nancy, France|Local Institution, Villefranche-sur-Saone, France|Local Institution, Bad Berka, Germany|Local Institution, Berlin, Germany|Local Institution, Dresden, Germany|Local Institution, Freiburg, Germany|Local Institution, Gauting, Germany|Local Institution, Greifenstein, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Local Institution, Kassel, Germany|Local Institution, Kiel, Germany|Local Institution, Leipzig, Germany|Local Institution, Lostau, Germany|Local Institution, Moers, Germany|Local Institution, Nurnberg, Germany|Local Institution, Lucca, Italy|Local Institution, Monza, Italy|Local Institution, Napoli, Italy|Local Institution, Roma, Italy|Local Institution, El Palmar, Spain|Local Institution, Las Palmas de Gran Canaria, Spain|Local Institution, Sabadell-Barcelona, Spain|Local Institution, Seville, Spain		https://ClinicalTrials.gov/show/NCT02713867
6	NCT03090737	Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer	CheckMate 907	Recruiting	No Results Available	Non-Small Cell Lung Cancer	Biological: Nivolumab	Incidence of high grade (Grades 3-4 and Grade 5) treatment-related adverse events|Progression-free Survival (PFS) as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)|Objective Response Rate (ORR) as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)|Overall Survival (OS)|Duration of Response (DOR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 2	120	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-907|2016-003731-37	May 26, 2017	August 11, 2020	December 7, 2020	March 27, 2017	null	June 19, 2018	Alabama Oncology, Birmingham, Alabama, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|Local Institution, West Covina, California, United States|Cancer Specialists, Llc, Jacksonville, Florida, United States|St Vincent Frontier Cancer Center, Billings, Montana, United States|Broome Oncology, Johnson City, New York, United States|Guthrie Medical Group, Pc, Sayre, Pennsylvania, United States|Cancer Centre Of Southeastern Ontario At Kgh, Kingston, Ontario, Canada|Lakeridge Health, Oshawa, Ontario, Canada|University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Debrecen, Hungary|Local Institution, Farkasgyepu, Hungary|Local Institution, Torokbalint, Hungary|Local Institution, Nagoya, Aichi, Japan|Local Institution, Chuo-ku, Osaka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto, Tokyo, Japan|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Port Elizabeth, Eastern CAPE, South Africa|Local Institution, Parktown, Johannesburg, Gauteng, South Africa|Local Institution, George, Western CAPE, South Africa		https://ClinicalTrials.gov/show/NCT03090737
7	NCT02066636	A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen	CheckMate153	Active, not recruiting	No Results Available	Non Small Cell Lung Cancer (NSCLC)	Drug: Nivolumab	Incidence for high grade (Grade 3-4 and Grade 5) treatment related select adverse events (AEs)|Incidence for high grade (Grade 3-4 and Grade 5) select AEs|Median time to onset and median time to resolution (Grade 3-4)|Percentage of subjects who received immune modulating medication or hormonal replacement therapy, percentage of subjects who received ≥40 mg Prednisone equivalents, total duration of all immune modulating medications given for select event	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	1380	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-153	February 28, 2014	January 31, 2022	January 31, 2022	February 19, 2014	null	August 14, 2018	Southern Cancer Center Pc, Mobile, Alabama, United States|Cancer Center Treatment Center of America, Goodyear, Arizona, United States|Arizona Oncology Associates, Phoenix, Arizona, United States|Arizona Oncology Associates, Sedona, Arizona, United States|Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope, Tucson, Arizona, United States|Comprehensive Blood And Cancer Center, Bakersfield, California, United States|Diablo Valley Oncology, Concord, California, United States|Saint Jude Heritage Medical Group Virginia K Crosson Cancer Center, Fullerton, California, United States|Ucla Hema/Onc-Santa Monica, Los Angeles, California, United States|Torrance Memorial Medical Center, Redondo Beach, California, United States|Sutter Cancer Center, Sacramento, California, United States|Pacific Cancer Care, Salinas, California, United States|Local Institution, San Francisco, California, United States|Central Coast Med Oncology, San Luis Obispo, California, United States|Sansum Santa Barbara Medical Foundation Clinic, Santa Barbara, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|St. Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|Eastern Ct Hem Onc Assoc, Norwich, Connecticut, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Watson Clinic Center For Research,Inc, Lakeland, Florida, United States|Baptist Health Medical Group Oncology, Miami, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Cancer Institute Of Florida, Orlando, Florida, United States|Sacred Heart Medical Oncology Group, Pensacola, Florida, United States|Hematology/Oncology Associates Of The Treasure Coast, Port Saint Lucie, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Space Coast Cancer Center, Titusville, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Piedmont Hospital, Atlanta, Georgia, United States|Central Georgia Cancer Care, Pc, Macon, Georgia, United States|Cancer Treatment Centers Of America, Newnan, Georgia, United States|Summit Cancer Care, Savannah, Georgia, United States|Lewis Hall Singletary Oncology Center, Thomasville, Georgia, United States|Pearlman Cancer Center, Valdosta, Georgia, United States|University Of Illinois Cancer Center, Chicago, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Oncology Specialists, Park Ridge, Illinois, United States|Quincy Medical Group, Quincy, Illinois, United States|Orchard Healthcare Research Inc., Skokie, Illinois, United States|Southern Illinois University School Of Medicine, Springfield, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis, Indiana, United States|University Of Kansas Cancer Center, Kansas City, Kansas, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Norton Cancer Center, Louisville, Kentucky, United States|University Medical Center, Inc, Louisville, Kentucky, United States|West KY Hematology Oncology Group PSC, Paducah, Kentucky, United States|Christus Schumpert Health, Shreveport, Louisiana, United States|Local Institution, Brewer, Maine, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Walter Reed National Mltry Medical Center, Bethesda, Maryland, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, United States|Bay Hematology Oncology, Easton, Maryland, United States|Michigan Cancer Research Consortinum, Ann Arbor, Michigan, United States|Cancer & Hematology Centers Of Western Michigan, Grand Rapids, Michigan, United States|Providence Cancer Center, Southfield, Michigan, United States|Forrest General Cancer Center, Hattiesburg, Mississippi, United States|Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States|North Mississippi Hematology And Oncology Associates, Ltd, Tupelo, Mississippi, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Southeast Nebraska Hematology & Oncology Consultants, P.C., Lincoln, Nebraska, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Comprehensive Cancer Center Of Nevada, Las Vegas, Nevada, United States|VA Sierra Nevada Health Care System, Reno, Nevada, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|Atlantic Health System, Summit, New Jersey, United States|Presbyterian Medical Group, Albuquerque, New Mexico, United States|St. Peters Hospital, Albany, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|Queens Medical Associates, Fresh Meadows, New York, United States|Broome Oncology, Johnson City, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Mount Kisco Medical Group, Mount Kisco, New York, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Hematology-Oncology Associates Of Rockland, Nyack, New York, United States|Randolph Cancer Center, Asheboro, North Carolina, United States|Cancer Care Of Wnc, Asheville, North Carolina, United States|Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States|Moses Cone Regional Cancer Center, Greensboro, North Carolina, United States|East Carolina University Leo W. Jenkins Cancer Center, Greenville, North Carolina, United States|W.G. Bill Hefner VA Medical Center, Salisbury, North Carolina, United States|Mid Dakota Clinic, Pc, Bismarck, North Dakota, United States|Oncology Hematology Care, Incorporated, Cincinnati, Ohio, United States|Local Institution, Cleveland, Ohio, United States|Zangmeister Cancer Center, Columbus, Ohio, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|St. Luke's University Hospital Bethlehem, Bethlehem, Pennsylvania, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Greenville Health System, Greenville, South Carolina, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|The Jones Clinic, Pc, Germantown, Tennessee, United States|The West Clinic, P.C., Germantown, Tennessee, United States|Tennessee Oncology, Pllc, Nashville, Tennessee, United States|Henry-Joyce Cancer Center, Nashville, Tennessee, United States|Texas Oncology-Abilene, Abilene, Texas, United States|Texas Oncology - Amarillo, Amarillo, Texas, United States|Texas Oncology, Arlington, Texas, United States|Texas Oncology-Beaumont, Beaumont, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology, Dallas, Texas, United States|Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology, Denton, Texas, United States|The Center For Cancer And Blood Disorders, Fort Worth, Texas, United States|Texas Oncology, Grapevine, Texas, United States|Northwest Cancer Center, Houston, Texas, United States|Texas Oncology, McAllen, Texas, United States|Texas Oncology, Mesquite, Texas, United States|Texas Oncology - Odessa, Midland, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Cancer Care Centers Of South Texas, San Antonio, Texas, United States|Texas Cancer Center - Sherman, Sherman, Texas, United States|Texas Oncology Cancer Care And Research Center, Waco, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University Of Virginia Health System., Charlottesville, Virginia, United States|Shenandoah Oncology, Winchester, Virginia, United States|Local Institution, Calgary, Alberta, Canada|Local Institution, Halifax, Nova Scotia, Canada|Kingston General Hospital, Kingston, Ontario, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Levis, Quebec, Canada|Local Institution, Montreal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT02066636
8	NCT01721759	Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens		Active, not recruiting	Has Results	Squamous Cell Non-small Cell Lung Cancer	Drug: Nivolumab	Objective Response Rate (ORR) as Assessed by Independent Radiology Review Committee (IRC)|Objective Response Rate (ORR) as Assessed by Investigator	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	140	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-063|2012-003965-16	November 14, 2012	January 22, 2014	December 30, 2018	November 6, 2012	October 22, 2015	September 8, 2017	University Of California, Davis Medical Center, Sacramento, California, United States|Va San Diego Healthcare System, San Diego, California, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Local Institution, Metairie, Louisiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|Providence Cancer Institute, Southfield, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Beth Israel Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States|University Hospitals Of Cleveland, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Providence Oncology And Hematology, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Network Office Of Research And Innovation, Allentown, Pennsylvania, United States|University Of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Oncology Consultants, Pa, Houston, Texas, United States|Local Institution, Caen, France|Local Institution, Creteil, France|Local Institution, Pierre Benite, France|Local Institution, Rennes, France|Local Institution, Strasbourg, France|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Local Institution, Berlin, Germany|Local Institution, Koeln, Germany|Local Institution, Muenchen, Germany|Local Institution, Livorno, Italy|Local Institution, Lucca, Italy|Local Institution, Terni, Italy		https://ClinicalTrials.gov/show/NCT01721759
9	NCT02538666	An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy	CheckMate 451	Active, not recruiting	No Results Available	Lung Cancer	Biological: Nivolumab|Biological: Ipilimumab|Other: Placebo	Overall Survival (OS)|Progression Free Survival (PFS)|An OS descriptive analysis will be performed to evaluate nivolumab monotherapy versus nivolumab with Ipilimumab treatment regimen|A PFS descriptive analysis will be performed to evaluate nivolumab monotherapy versus nivolumab with Ipilimumab treatment regimen|Tumor mutation burden (TMB)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	1327	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA209-451|2015-002441-61	September 30, 2015	October 1, 2018	November 20, 2019	September 2, 2015	null	November 6, 2018	Sutter Cancer Center, Sacramento, California, United States|Yale University, New Haven, Connecticut, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University, Durham, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|Sanford Health, Fargo, North Dakota, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Donald Guthrie Foundation, Sayre, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Sanford Health, Sioux Falls, South Dakota, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Local Institution, Berazategui, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Tucuman, Argentina|Local Institution, Kogarah, New South Wales, Australia|Local Institution, Wollongong, New South Wales, Australia|Local Institution, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, East Melbourne, Victoria, Australia|Local Institution, Innsbruck, Austria|Local Institution, Salzburg, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Charleroi, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Itajai, Santa Catarina, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Salvador, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Oshawa, Ontario, Canada|Health Sciences North, Sudbury, Ontario, Canada|Local Institution, Windsor, Ontario, Canada|Local Institution, Hefei, Anhui, China|Local Institution, Hefei, Anhui, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Wuhang, Hubei, China|Local Institution, Changsha, Hunan, China|Local Institution, Nantong, Jiangsu, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Kunming, Yunnan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Wenzhou, Zhejiang, China|Local Institution, Guangzhou, China|Local Institution, Monteria, Cordoba, Colombia|Local Institution, Bogota, Colombia|Local Institution, Medellin, Colombia|Local Institution, Oulu, Finland|Local Institution, Tampere, Finland|Local Institution, Turku, Finland|Local Institution, Vaasa, Finland|Local Institution, Avignon Cedes 9, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 20, France|Local Institution, Paris Cedex 20, France|Local Institution, Pierre Benite, France|Local Institution, Rennes Cedex 9, France|Local Institution, Saint Herblain, France|Local Institution, Strasbourg, France|Local Institution, Toulouse, France|Local Institution, Augsburg, Germany|Local Institution, Bad Berka, Germany|Local Institution, Berlin, Germany|Local Institution, Bochum, Germany|Local Institution, Gauting, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Immenhausen, Germany|Local Institution, Tuebingen, Germany|Agioi Anargyroi Cancer Center, Nea Kifissia, Greece|Interbalkan European Medical Center, Thessaloniki, Greece|Local Institution, Hong Kong, Hong Kong|Local Institution, Wilton, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Limerick, Ireland|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Zerifin, Israel|Local Institution, Avellino, Italy|Local Institution, Bologna, Italy|Local Institution, Messina, Italy|Local Institution, Milan, Italy|Local Institution, Perugia, Italy|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Gifu-shi, Gifu, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Takatsuki-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Wakayama-shi, Wakayama, Japan|Local Institution, Seongnam-si, Gyeonggi-do, Korea, Republic of|Local Institution, Suwon-si, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Leon de los Aldama, Guanajuato, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Santiago de Queretaro, Queretaro, Mexico|Local Institution, 's-Hertogenbosch, Netherlands|Local Institution, Eindhoven, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Miraflores, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Gdansk, Poland|Local Institution, Gdynia, Poland|Local Institution, Olsztyn, Poland|Local Institution, Warszawa, Poland|Local Institution, Bucharest, Romania|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Lasi, Romania|Local Institution, Romania, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, George, Western CAPE, South Africa|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Sevilla, Spain|Local Institution, Lund, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Aarau, Switzerland|Local Institution, Geneve, Switzerland|Local Institution, St. Gallen, Switzerland|Local Institution, Tainan, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Truro, Cornwall, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Sheffield, United Kingdom|Local Institution, Wirral, United Kingdom		https://ClinicalTrials.gov/show/NCT02538666
10	NCT02409368	An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC	Checkmate 171	Active, not recruiting	No Results Available	Non-Small Cell Lung Cancer	Drug: Nivolumab	Incidence of high-grade (CTCAE v4.0 Grades 3-4), treatment-related, select adverse events in subjects with advanced or metastatic SqNSCLC|Incidence and to characterize the outcome of all high-grade (CTCAE v4.0 Grades 3-4), select adverse events|Overall survival (OS) in all treated subject|Investigator-assessed objective response rate (ORR)|Median time to onset (Grades 3-4) of select adverse events|Median time to resolution (Grades 3-4) of select adverse events	Bristol-Myers Squibb|PPD	All	18 Years and older   (Adult, Older Adult)	Phase 2	800	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	CA209-171|2014-001285-10	April 23, 2015	September 15, 2019	December 24, 2019	April 6, 2015	null	October 3, 2018	Southampton University Hospitals NHS Trust, Raleigh, North Carolina, United States|Local Institution, Salzburg, Austria|Local Institution, Wels, Austria|Local Institution, Wien, Austria|Local Institution, Aalborg, Denmark|Local Institution, Herlev, Denmark|Local Institution, Odense C, Denmark|Local Institution, Oulu, Finland|Local Institution, Pori, Finland|Local Institution, Athens, Greece|Local Institution, Athens, Greece|Local Institution, Heraklion, Greece|Local Institution, Rio, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Pecs, Hungary|Local Institution, Dublin 8, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Gdansk, Poland|Local Institution, Gliwice, Poland|Instytut Medyczny Santa Familia Sp. z o.o., Lodz, Poland|Local Institution, Poznan, Poland|Local Institution, Warszawa, Poland|Local Institution, Zabrze, Poland|Local Institution, Coimbra, Portugal|Local Institution, Lisboa, Portugal|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Local Institution, Porto, Portugal|Local Institution, Porto, Portugal|Local Institution, Bucharest, Romania|Local Institution, Bucharest, Romania|Local Institution, Cluj Napoca, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Oradea, Romania|Local Institution, Timisoara, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Saint Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, A Coruna, Spain|Local Institution, Alicante, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Burgos, Spain|Local Institution, Granada, Spain|Local Institution, La Laguna, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Palma de Mallorca, Spain|Local Institution, Santander, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Valencia, Spain|Local Institution, Zaragoza, Spain|Local Institution, Solna, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Bristol, United Kingdom|Local Institution, Cardiff, United Kingdom|Local Institution, Cottingham, United Kingdom|Local Institution, Glasgow, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|North Middlesex Hospital, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Maidstone Hospital, Maidstone, United Kingdom|Local Institution, Northwood, United Kingdom|Local Institution, Plymouth, United Kingdom|Royal Preston Hospital, Preston, United Kingdom|Local Institution, Sheffield, United Kingdom|Local Institution, Wirral, United Kingdom		https://ClinicalTrials.gov/show/NCT02409368
11	NCT03417037	An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer		Withdrawn	No Results Available	Lung Cancer|Non-Small Cell Lung Cancer	Drug: BMS-986205|Biological: Nivolumab|Drug: Chemotherapy	Objective response rate (ORR) measured by number of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) divided by the number of randomized participants for each treatment group|Progression free survival (PFS) measured by the time between the date of randomization and the first date of documented progression, as determined by the Blinded Independent Central Review, or death, due to any cause, whichever occurs first|Overall survival (OS) measured by the time between the date of randomization and the date of death due to any cause|Number of treatment-related adverse events (AE)|Number of treatment-related serious adverse events	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	0	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA017-062|2017-003058-18	May 24, 2018	April 25, 2021	August 20, 2025	January 31, 2018	null	April 30, 2018	Local Institution, San Diego, California, United States|Local Institution, Fort Myers, Florida, United States|Local Institution, Jacksonville, Florida, United States|Local Institution, Saint Petersburg, Florida, United States|Local Institution, Tallahassee, Florida, United States|Local Institution, West Palm Beach, Florida, United States|Local Institution, Decatur, Georgia, United States|Local Institution, Marietta, Georgia, United States|Local Institution, Wichita, Kansas, United States|Local Institution, Louisville, Kentucky, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Bridgeton, Missouri, United States|Local Institution, Lincoln, Nebraska, United States|Local Institution, Cleveland, Ohio, United States|Local Institution, Gettysburg, Pennsylvania, United States|Local Institution, Greenville, South Carolina, United States|Local Institution, Lebanon, Tennessee, United States|Local Institution, Fort Worth, Texas, United States|Local Institution, Lubbock, Texas, United States|Local Institution, Darlinghurst, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Murdoch, Western Australia, Australia|Local Institution, North Tamworth, Australia|Local Institution, Vienna, Austria|Local Institution, Wels, Austria|Local Institution, Ipatinga, Minas Gerais, Brazil|Local Institution, Jd. Petropolis-Londrina, Parana, Brazil|Local Institution, Centro-porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Morumbi, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Quebec, Canada|Local Institution, Praha 2, Czechia|Local Institution, Besancon, France|Local Institution, La Tronche, France|Local Institution, Paris Cedex 5, France|Local Institution, Pessac cedex, France|Local Institution, Pringy Cedex, France|Local Institution, Rennes Cedex 9, France|Local Institution, Saint Herblain, France|Local Institution, Toulon, France|Local Institution, Berlin, Germany|Local Institution, Gauting, Germany|Local Institution, Gera, Germany|Local Institution, Gottingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Oldenburg, Germany|Local Institution, Paderborn, Germany|Local Institution, Wiesbaden, Germany|Local Institution, Athens, Greece|Local Institution, Athens, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Modena, Italy|Local Institution, Monza (MB), Italy|Local Institution, Napoli, Italy|Local Institution, Perugia, Italy|Local Institution, Ravenna, Italy|Local Institution, Reggio Emilia, Italy|Local Institution, Fukushima-shi, Fukushima, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Merida, Yucatan, Mexico|Local Institution, A Coruna, Galicia, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Majadahonda - Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Valencia, Spain|Local Institution, Basel, Switzerland|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, ?stanbul, Turkey|Local Institution, Adana, Turkey|Local Institution, Antalya, Turkey|Local Institution, Istanbul, Turkey		https://ClinicalTrials.gov/show/NCT03417037
12	NCT03001882	An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)	CheckMate 592	Recruiting	No Results Available	Non-Small Cell Lung Cancer	Biological: Nivolumab|Biological: Ipilimumab	Objective Response Rate (ORR)|Objective Response Rate (ORR) of patient subgroups defined by baseline biomarkers|Disease Control Rate (DCR) of patient subgroups defined by baseline biomarkers|Duration of Response (DOR) of patient subgroups defined by baseline biomarkers|Time to Response (TTR) of patient subgroups defined by baseline biomarkers|Progression Free Survival (PFS) of patient subgroups defined by baseline biomarkers|Overall Survival (OS) of patient subgroups defined by baseline biomarkers|Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	250	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-592|2018-000462-11	March 14, 2017	September 28, 2021	December 14, 2021	December 23, 2016	null	November 20, 2018	Highland Oncology Group, Fayetteville, Arkansas, United States|Yale University, New Haven, Connecticut, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Local Institution, Bronx, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Bon Secours-St Francis Hosp, Greenville, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Local Institution, Gent, Belgium|Local Institution, Gent, Belgium|Local Institution, Haine Saint Paul, Belgium|Local Institution, Liege, Belgium|Local Institution, Sint-Niklaas, Belgium|Local Institution, Pierre Benite, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulon, France|Klinik Essen-Mitte, Essen, Germany|Klinikverbund Kempten-Oberallgau, Immenstadt, Germany|Local Institution, Lowenstein, Germany|Klinikum Stuttgart, Stuttgart, Germany|ASST Papa Giovanni XXIII, Bergamo, Italy|Aou Policlinico V. Emanuele Di Catania, Catania, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Azienda Ospedaliera Di Perugia, Perugia, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Instituto Catalan De Oncologia, Barcelona, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hosp Univ Virgen Macarena, Sevilla, Spain		https://ClinicalTrials.gov/show/NCT03001882
13	NCT03048136	A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer	CheckMate 955	Withdrawn	No Results Available	Non-Small Cell Lung Cancer	Drug: Nivolumab|Drug: Ipilimumab	Incidence of high grade (Grade 3-4 and Grade 5) treatment-related select adverse events|Incidence of high grade (Grade 3-4 and Grade 5) immune-mediated adverse events|Progression-free survival (PFS) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST v1.1)|Objective Response Rate (ORR) as assessed by the Investigator using tumor progression per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)|Overall survival (OS) as defined as the time from first dosing to the date of death|Duration of Response (DOR) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST v1.1)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	0	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-955	March 9, 2018	September 29, 2019	September 29, 2019	February 9, 2017	null	April 17, 2018	Local Institution, San Francisco, California, United States|Local Institution, Lincoln, Nebraska, United States|Local Institution, Hackensack, New Jersey, United States|Local Institution, Columbus, Ohio, United States|Local Institution, Lancaster, Pennsylvania, United States|Local Institution, Langhorne, Pennsylvania, United States|Local Institution, Sayre, Pennsylvania, United States|Local Institution, Charleston, South Carolina, United States|Local Institution, Saint George, Utah, United States|Local Institution, Viedma, RIO Negro, Argentina|Local Institution, Montreal, Quebec, Canada|Local Institution, Dresden, Germany|Local Institution, Gauting, Germany|Local Institution, Gerlingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Lima, Peru|Local Institution, Lima, Peru		https://ClinicalTrials.gov/show/NCT03048136
14	NCT01642004	Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)		Active, not recruiting	Has Results	Squamous Cell Non-small Cell Lung Cancer	Biological: Nivolumab|Drug: Docetaxel	Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint|Overall Survival (OS) Rate in All Randomized Participants|Number of Deaths From Any Cause in All Randomized Participants at Primary Endpoint|Objective Response Rate (ORR) in All Randomized Participants at Primary Endpoint|Time To Response (TTR) in Months for All Confirmed Responders at Primary Endpoint|Duration of Objective Response (DOR) in Months for All Confirmed Responders at Primary Endpoint|Progression-Free Survival (PFS) at Primary Endpoint|Progression-Free Survival (PFS) Time in Months for All Randomized Participants at Primary Endpoint|Percentage of Participants Experiencing Disease-related Symptom Improvement by Week 12|Overall Survival (OS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint|Objective Response Rate (ORR) by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint|Progression Free Survival (PFS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	352	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-017|2011-004792-36	September 26, 2012	November 17, 2014	December 29, 2018	July 17, 2012	March 17, 2016	April 10, 2018	Mayo Clinic Arizona, Scottsdale, Arizona, United States|City Of Hope, Duarte, California, United States|Yale University, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Northwest Georgia Oncology Ctr, Marietta, Georgia, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Winthrop University Hospital, Mineola, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|St Mary Medical Center, Langhorne, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Guthrie Medical Group, P.C., Sayre, Pennsylvania, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|West Virginia University-Mbrcc, Morgantown, West Virginia, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Local Institution, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Wollongong, New South Wales, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, East Bentleigh, Victoria, Australia|Local Institution, Linz, Austria|Local Institution, Salzburg, Austria|Local Institution, Vienna, Austria|Local Institution, Wels, Austria|Cancercare Manitoba, Winnipeg, Manitoba, Canada|Jewish General Hospital, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Recoleta, Santiago DE Chile, Chile|Local Institution, Vi?a Del Mar, Valparaiso, Chile|Local Institution, Antofagasta, Chile|Local Institution, Santiago, Chile|Local Institution, Praha 8, Czechia|Local Institution, Avignon Cedes 9, France|Local Institution, Caen, France|Local Institution, Dijon, France|Local Institution, La Roche Sur Yon Cedex 9, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 20, France|Local Institution, Pierre Benite, France|Local Institution, Rennes Cedex 9, France|Local Institution, Strasbourg, France|Local Institution, Toulouse, France|Local Institution, Bad Berka, Germany|Local Institution, Essen, Germany|Local Institution, Gerlingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Heidelberg, Germany|Local Institution, Koeln, Germany|Local Institution, Krefeld, Germany|Local Institution, Budapest, Hungary|Local Institution, Dublin 8, Dublin, Ireland|Local Institution, Dublin 9, Dublin, Ireland|Local Institution, Bologna, Italy|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Perugia, Italy|Local Institution, Ravenna, Italy|Local Institution, Siena, Italy|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Leon, Guanajato, Guanajuato, Mexico|Local Institution, Hermosillo, Sonora, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Arequipa, Peru|Local Institution, Lima, Peru|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Olsztyn, Poland|Local Institution, Szczecin, Poland|Local Institution, Warszawa, Poland|Local Institution, Bucuresti, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Constanta, Romania|Local Institution, Craiova, Romania|Local Institution, Iasi, Romania|Local Institution, Timisoara, Romania|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Barakaldo, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Cottingham, EAST Yorkshire, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Withington, Manchester, United Kingdom|Local Institution, Sheffield, Yorkshire, United Kingdom		https://ClinicalTrials.gov/show/NCT01642004
15	NCT02659059	Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer	CheckMate 568	Active, not recruiting	No Results Available	Non-Small-Cell Lung Cancer	Biological: Nivolumab|Biological: Ipilimumab|Drug: Platinum Doublet Chemotherapy	Objective response rate (ORR)|ORR|Number of Patients with dose Limiting Toxicities (DLTs)|Number of Adverse Events (AEs)|Number of Serious Adverse Events (SAEs)|Number of Deaths|Number of Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE)|Progression free survival (PFS)|Overall Response Rate (ORR)|Overall Survival (OS)|PFS|OS	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	507	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-568	February 10, 2016	November 6, 2018	April 20, 2022	January 20, 2016	null	September 19, 2018	Sharp Memorial Hospital, San Diego, California, United States|Cancer Center Of Central Connecticut, Plainville, Connecticut, United States|Cleveland Clinic Florida, Weston, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Summit Cancer Care, Savannah, Georgia, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|University Of Louisville Medical Center, Inc., Dba, Louisville, Kentucky, United States|Johns Hopkins Cancer Center, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center., Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Nebraska Hematology Oncology Pc, Lincoln, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|New Mexico Hematology Oncology Consultants, Albuquerque, New Mexico, United States|Lovelace Cancer Care, Albuquerque, New Mexico, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States|Presbyterian Rust Medical Center, Albuquerque, New Mexico, United States|The Cancer Center at Presbyterian, Albuquerque, New Mexico, United States|Winthrop University Hospital, Mineola, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University, Durham, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Kingston Regional Cancer Centre, Kingston, Ontario, Canada|Sault Area Hospital, Sault Ste Marie, Ontario, Canada|Csss De St-Jerome, St.Jerome, Quebec, Canada		https://ClinicalTrials.gov/show/NCT02659059
16	NCT02613507	Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer	CheckMate 078	Active, not recruiting	No Results Available	Non-Small Cell Lung Cancer	Drug: Nivolumab|Drug: Docetaxel	Overall survival|Objective Response Rate (ORR)|Progression Free Survival (PFS),|Rate of Disease-related Symptom Improvement:	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	644	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-078|2015-001893-16	December 10, 2015	September 15, 2017	January 15, 2019	November 24, 2015	null	May 1, 2018	Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Changsha, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Chang Chun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Shanghai, China|Local Institution, Hong Kong, Hong Kong|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St.petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore		https://ClinicalTrials.gov/show/NCT02613507
17	NCT02872116	Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer	CheckMate649	Recruiting	No Results Available	Gastric Cancer|Gastroesophageal Junction Cancer	Drug: Nivolumab|Drug: Ipilimumab|Drug: Oxaliplatin|Drug: Capecitabine|Drug: Leucovorin|Drug: Fluorouracil	Overall survival (OS) of nivolumab in combination with oxaliplatin + fluoropyrimidine versus oxaliplatin + fluoropyrimidine in programmed cell death ligand 1 (PD-L1) positive participants|Progression-free survival (PFS), as assessed by Blinded Independent Central Review (BICR), of nivolumab in combination with oxaliplatin plus fluoropyrimidine versus oxaliplatin plus fluoropyrimidine in PD-L1 positive participants|OS in all randomized participants|PFS, as assessed by BICR, in all randomized participants|Objective Response Rate (ORR), as assessed by BICR, in all randomized participants|Time to symptom deterioration (TTSD) of nivolumab + ipilimumab vs oxaliplatin + fluoropyrimidine in all randomized participants	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	1649	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-649|2016-001018-76	October 4, 2016	March 28, 2021	October 6, 2022	August 19, 2016	null	November 6, 2018	Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|University Of Colorado, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Georgetown University Med Ctr, Washington, District of Columbia, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Baptist Health Medical Group Oncology LLC, Miami, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Willamette Valley Cancer Center, Eugene, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, Pc, Nashville, Tennessee, United States|Texas Oncology, Bedford, Texas, United States|Texas Oncology, Texas Cancer Center At Medical City, Dallas, Texas, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Virginia Oncology Associates, Newport News, Virginia, United States|Hospital Municipal De Gastroenterologia Dr.Udaondo, Capital Federal, Buenos Aires, Argentina|Hospital Britanico, Capital Federal, Buenos Aires, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Instituto Alexander Fleming, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, La Rioja, Argentina|Blacktown Hospital, Blacktown, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|Tasman Oncology Research Pty Ltd, Southport, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Ballarat Base Hospital, Ballarat, Victoria, Australia|Goulburn Valley Health, Shepparton, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|St John of God Murdoch Hospital, Perth, Western Australia, Australia|Local Institution, Subiaco, Western Australia, Australia|Local Institution, Salvador, Bahia, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, London, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Centre integre universitaire de sante et de service sociaux de l'estrie - CHUS, Sherbrooke, Quebec, Canada|Local Institution, Trois-Rivieres, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Pontificia Universidad Catolica de Chile, Santiago, Metropolitana, Chile|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Hospital Clinico de la Universidad De Chile, Independencia, Santiago, Chile|Instituto Oncologico Clinica Renaca, Vina Del Mar, Valparaiso, Chile|ICOS - Inmunomedica, Temuco, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Ha Erbin, Heilongjiang, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Changzhou, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Qingdao, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Hangzhou, China|Local Institution, Tianjin, China|Local Institution, Bogota, Cundinamarca, Colombia|Administradora Del Country S.A. - Clinica Del Country, Bogota, Colombia|Local Institution, Pasto, Colombia|Interni hematologicka a onkologicka klinika, Brno, Czechia|Klinika komplexni onkologicke pece, Brno, Czechia|Local Institution, Caen, France|Local Institution, Dijon, France|Local Institution, Lille, France|Local Institution, Montpellier, France|Local Institution, Nantes, France|Local Institution, Nice Cedex 2, France|Local Institution, Paris, France|Local Institution, Plerin, France|Charite Campus Virchow Klinikum, Berlin, Germany|University Hospital Of Cologne, Cologne, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Universitatsklinikum Dusseldorf, Dusseldorf, Germany|Universitaetsklinikum Essen, Essen, Germany|Medizinische Universitaetsklinik Freiburg, Freiburg, Germany|Universitaets-Krankenhaus Eppendorf, Hamburg, Germany|Johannes -Gutenberg Universitat, Mainz, Germany|Klinikum Rechts Der Isar, Muenchen, Germany|Laiko General Hospital Of Athens, Athens, Greece|Ioannina University Hospital, Ioannina, Greece|Agioi Anargyroi Cancer Center, Nea Kifissia, Greece|University General Hospital of Patras, Patras, Greece|Local Institution, Hong Kong, Hong Kong|Local Institution, Hong Kong, Hong Kong|Semmelweis Egyetem Onkologiai Kozpont, Budapest, Hungary|Orszagos Onkologiai Intezet, Budapest, Hungary|DE KK Onkologiai Intezet, Debrecen, Hungary|Local Institution, Gyula, Hungary|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Tel Aviv, Israel|ASST Papa Giovanni XXIII, Bergamo, Italy|Local Institution, Firenze, Italy|Azienda Ospedaliera Universitaria Di Modena, Modena, Italy|Aorn Dei Colli, Napoli, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Osp. Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa, Chiba, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Minato-ku, Tokyo, Japan|Local Institution, Kita-gun, Japan|Local Institution, Tokyo, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Toluca, Estado DE Mexico, Mexico|Local Institution, Queretaro, Mexico|Clinica Anglo Americana, Lima, Peru|Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru|Hospital Nacional Cayetano Heredia, Lima, Peru|Clinica Internacional sede San Borja, Lima, Peru|II Klinika Chirurgii Ogolnej, Gastroenterologicznej i Nowotworow Ukladu Pokarmowego, Lublin, Poland|Local Institution, Nowy Sacz, Poland|Centrum Onkologiczne: Oddzial Onkologii Klinicznej oraz Poradnia Onkologiczna, Tarnobrzeg, Poland|Klinika Gastroenterologii Onkologicznej, Warszawa, Poland|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Local Institution, Baia Mare, JUD Maramures, Romania|Local Institution, Bucharest, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Suceava, Romania|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Kazan, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Badajoz, Spain|Local Institution, Badalona-barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Pozuelo De Alarcon, Madrid, Spain|Local Institution, Valencia, Spain|Local Institution, Zaragoza, Spain|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Diyarbak?r, Turkey|Local Institution, Edrine, Turkey|Local Institution, Istanbul, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Nottingham, Nottinghamshire, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Southampton, United Kingdom		https://ClinicalTrials.gov/show/NCT02872116
18	NCT03338790	An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer	CheckMate 9KD	Recruiting	No Results Available	Prostate Cancer	Biological: Nivolumab|Drug: Docetaxel|Drug: Enzalutamide|Drug: Rucaparib|Drug: Prednisone	Objective Response Rate (ORR)|Prostate-specific antigen response rate (RR-PSA)|Radiographic progression-free survival (rPFS)|Time to response (TTR)|Duration of response (DOR)|Time to prostate-specific antigen progression (TTP-PSA)|Overall Survival (OS)|Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)	Bristol-Myers Squibb|Clovis Oncology|Astellas Pharma Inc	Male	18 Years and older   (Adult, Older Adult)	Phase 2	330	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-9KD	December 15, 2017	February 18, 2020	November 18, 2020	November 9, 2017	null	November 12, 2018	Southern Cancer Center Pc, Daphne, Alabama, United States|Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States|Local Institution, San Francisco, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Baptist Health Medical Group Oncology, Miami, Florida, United States|Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Tulane University, New Orleans, Louisiana, United States|Maryland Oncology Hematology, P.A., Rockville, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Detroit, Michigan, United States|Local Institution, Minneapolis, Minnesota, United States|Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|New York Oncology Hematology, P.C., Amsterdam, New York, United States|Local Institution, New York, New York, United States|Duke University, Durham, North Carolina, United States|Providence Portland Medical Center, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Virginia Cancer Care Specialist, PC, Fairfax, Virginia, United States|Local Institution, Caba, Buenos Aires, Argentina|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Britanico De Buenos Aires, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Camperdown, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Local Institution, South Brisbane, Queensland, Australia|Monash Medical Centre Clayton, Clayton, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Local Institution, Elizabeth Vale, Australia|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Campinas, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Santa Catarina, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|BC Cancer - Kelowna, Kelowna, British Columbia, Canada|Local Institution, Vancouver, British Columbia, Canada|The Moncton Hospital, Moncton, New Brunswick, Canada|Local Institution, Saint John, New Brunswick, Canada|Juravinski Cancer Center, Hamilton, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Bradford Hill Centro de Investigaciones Clinicas, Santiago de Chile, Metropolitana, Chile|Instituto Oncologico, Vina Del Mar, Valparaiso, Chile|Local Institution, Monteria, Cordoba, Colombia|Local Institution, Bogota, Colombia|Local Institution, Medellin, Colombia|Local Institution, Besancon, France|Local Institution, Clermont-ferrand, France|Local Institution, Lyon, France|Local Institution, Marseille, France|Local Institution, Villejuif, France|Universitaetsklinikum Essen, Essen, Germany|Universitaetsmedizin Goettingen, Goettingen, Germany|Uniklinik Heidelberg, Heidelberg, Germany|Universitaetsklinikum Jena, Jena, Germany|Praxisklinik Fuer Haematologie Und Onkologie, Koblenz, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany|Local Institution, Leon, Guanajuato, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Culiacan, Sinaloa, Mexico|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Sevilla, Spain		https://ClinicalTrials.gov/show/NCT03338790
19	NCT03519256	A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder	CheckMate 9UT	Recruiting	No Results Available	Bladder Cancer|Bladder Tumors|Neoplasms, Bladder	Biological: Nivolumab|Biological: BCG|Drug: BMS-986205	Proportion of carcinoma in situ (CIS) participants with complete response (CR), per Pathology Review Committee (PRC)|Duration of complete response (DOCR), per PRC, in CIS participants with CR|Event Free Survival (EFS), per PRC, for all non-CIS participants|Progression-free Survival (PFS)|Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)|Incidence of AEs leading to discontinuation|Incidence of deaths|Incidence of laboratory abnormalities	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	436	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-9UT|2017-003581-27	May 25, 2018	January 4, 2022	April 16, 2023	May 8, 2018	null	November 20, 2018	Local Institution, Phoenix, Arizona, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Local Institution, Riverside, California, United States|Local Institution, San Francisco, California, United States|Emory University, Atlanta, Georgia, United States|The University Of Chicago, Chicago, Illinois, United States|Local Institution, Westwood, Kansas, United States|Local Institution, Wichita, Kansas, United States|Local Institution, Shreveport, Louisiana, United States|Local Institution, Baltimore, Maryland, United States|Local Institution, Ann Arbor, Michigan, United States|Local Institution, Minneapolis, Minnesota, United States|Adult & Pediatric Urology, Omaha, Nebraska, United States|Local Institution, Voorhees, New Jersey, United States|Local Institution, New York, New York, United States|Local Institution, New York, New York, United States|Local Institution, New York, New York, United States|Local Institution, Columbus, Ohio, United States|Local Institution, Springfield, Oregon, United States|Local Institution, Bala-Cynwyd, Pennsylvania, United States|Local Institution, Hershey, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Erlanger Health System, Chattanooga, Tennessee, United States|Local Institution, Nashville, Tennessee, United States|Local Institution, Dallas, Texas, United States|Local Institution, Houston, Texas, United States|Local Institution, Lubbock, Texas, United States|Local Institution, San Antonio, Texas, United States|Local Institution, Virginia Beach, Virginia, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Local Institution, Viedma, RIO Negro, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Campinas, SAN Paulo, Brazil|Local Institution, Itacorubi, Florianopolis, Santa Catarina, Brazil|Local Institution, Jau, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, St. John's, Newfoundland and Labrador, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Sherbrooke, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Angers, France|Local Institution, Bordeaux, France|Local Institution, LILLE Cedex, France|Local Institution, Strasbourg Cedex, France|Local Institution, Suresnes, France|Local Institution, Hong Kong, Hong Kong|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Local Institution, Modena, Italy|Local Institution, Napoli, Italy|Local Institution, Pisa, Italy|Local Institution, Tuxtla Gutierrez, Chiapas, Mexico|Local Institution, Ciudad de Mexico, Distrito Federal, Mexico|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Utrecht, Netherlands|Local Institution, Omsk, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, Barcelona, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hospital Universitario Virgen De La Victoria, Malaga, Spain|Local Institution, Istanbul, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Chelmsford, Essex, United Kingdom|Local Institution, Lancaster, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Southampton, United Kingdom		https://ClinicalTrials.gov/show/NCT03519256
20	NCT03400332	An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination With Nivolumab in Patients With Advanced Cancers		Recruiting	No Results Available	Cancer	Drug: BMS-986253|Biological: Nivolumab	Incidence of adverse events (AE)|Incidence of serious adverse events (SAE)|Incidence of AEs meeting protocol-defined dose limiting toxicities (DLT) criteria|Incidence of AEs leading to discontinuation|Incidence of deaths|Incidence of labornatory abnormalities|Overall response rate (ORR)|Median duration of response (mDOR)|Incidence of anti-drug antibody (ADA) to BMS-986253|Serum biomarker concentration|Maximum observed serum concentration (Cmax)|Time of maximum observed serum concentration (Tmax)|Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]|Area under the serum concentration-time curve in 1 dosing interval [AUC(TAU)]|Observed serum concentration at the end of a dosing interval (Ctau)|Trough observed serum concentration at the end of the dosing interval (Ctrough)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	260	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA027-002	January 31, 2018	February 28, 2023	March 1, 2023	January 17, 2018	null	October 4, 2018	Rocky Mountain Cancer Centers, Denver, Colorado, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Lutherville, Maryland, United States|Maryland Oncology Hematology P.A., Rockville, Maryland, United States|Local Institution, Ann Arbor, Michigan, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Local Institution, New Brunswick, New Jersey, United States|Local Institution, New York, New York, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Local Institution, Oklahoma City, Oklahoma, United States|Willamette Valley Cancer Institute And Research Center, Eugene, Oregon, United States|Local Institution, Philadelphia, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Greenville Health System, Greenville, South Carolina, United States|Texas Oncology, Austin, Texas, United States|Texas Oncology - Baylor Charles A. Simmons Cancer Center, Dallas, Texas, United States|Texas Oncology-Fort Worth 12th Ave, Fort Worth, Texas, United States|Local Institution, Houston, Texas, United States|Texas Oncology-San Antonio Medical Center, San Antonio, Texas, United States|Texas Oncology, P.A., Tyler, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Local Institution, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Birmingham, WEST Midlands, United Kingdom		https://ClinicalTrials.gov/show/NCT03400332
21	NCT02832167	An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread	CheckMate 627	Recruiting	No Results Available	Cancer	Biological: Nivolumab	Objective Response Rate (ORR) as determined by investigator|Overall Survival (OS) is defined as the time from the first dosing date to the date of death|Duration of clinical response|Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Clinical Benefit Rate (CBR) defined as the number of participants with a best overall response of confirmed complete response (CR) or partial response (PR), or stable disease divided by the number of all treated participants|Time to Response (TTR) defined as the time from first dosing date to the date of the first confirmed response, as assessed by investigator|Programmed death-ligand 1 (PD-L1) expression as determined by biomarker analysis|MisMatch Repair (MMR) alterations as determined by biomarker analysis	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	250	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-627|2016-000461-23	September 13, 2016	June 16, 2019	December 20, 2019	July 14, 2016	null	May 22, 2018	Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States|St. Jude Hospital Yorba Linda, Fullerton, California, United States|LACN, Los Angeles, California, United States|UCLA Main Campus - University California Los Angeles, Los Angeles, California, United States|Torrence Health Association, DBA Torrance Memorial;Physician Network/Cancer Care Associates, Redondo Beach, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Cancer Center of Santa Barbara with Sansum Clinic, Santa Barbara, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|St. Mary's Hospital And Regional Medical Center, Grand Junction, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Memorial Healthcare System, Hollywood, Florida, United States|Florida Cancer Affiliates, Ocala, Florida, United States|UF Health Cancer Center - Orlando Health, Orlando, Florida, United States|Florida Cancer Specialists & Research Institute, Saint Petersburg, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States|Local Institution, Wichita, Kansas, United States|Maryland Oncology Hematology P.A., Columbia, Maryland, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|Research Medical Center, Kansas City, Missouri, United States|Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|Comprehensive Cancer Centers Of Nevada, Las Vegas, Nevada, United States|Saint Barnabas Medical Cancer Center, Livingston, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Hematology Oncology Associates, PC, Medford, Oregon, United States|Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States|Northwest Cancer Specialists, P.C., Tualatin, Oregon, United States|Greenville Health System, Greenville, South Carolina, United States|West Cancer Center, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology - Baylor Charles A. Simmons Cancer Center, Dallas, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Texas Oncology, P.A., San Antonio, Texas, United States|Texas Oncology The Woodlands, The Woodlands, Texas, United States|Texas Oncology - Waco, Waco, Texas, United States|Virginia Cancer Care Specialist, PC, Fairfax, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Wytheville, Virginia, United States|Local Institution, Berlin, Germany|Local Institution, Bonn, Germany|Local Institution, Dresden, Germany|Local Institution, Essen, Germany|Local Institution, Freiburg, Germany|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Munchen, Germany		https://ClinicalTrials.gov/show/NCT02832167
22	NCT02481830	Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer	CheckMate331	Active, not recruiting	No Results Available	Lung Cancer	Drug: Nivolumab|Drug: Topotecan|Drug: Amrubicin	Overall survival (OS) in subjects with relapsed SCLC|Progression free survival (PFS)|Objective response rate (ORR)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	803	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-331|2015-001097-18	August 28, 2015	August 17, 2018	November 30, 2019	June 25, 2015	null	November 20, 2018	Univ Of Ark For Med Sci, Little Rock, Arkansas, United States|Smilow Cancer Hospital. At Yale New Haven, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Nebraska Hematology Oncology Pc, Lincoln, Nebraska, United States|Broome Oncology, Johnson City, New York, United States|Duke University, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|St. Luke's University Health Network, Bethlehem, Pennsylvania, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Tennessee Oncology, Pllc, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Local Institution, Waratah, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Elizabeth Vale, Australia|Local Institution, Murdoch, Australia|Local Institution, Graz, Austria|Local Institution, Wels, Austria|Akh Wien, Wien, Austria|Local Institution, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Leuven, Belgium|Local Institution, Yvoir, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Recoleta, Santiago DE Chile, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Guanzhou, Guangdong, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Xian, Shaanxi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Guangzhou, China|Local Institution, Hangzhou, China|Local Institution, Shanghai, China|Local Institution, Brno, Czechia|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika plicnich nemoci a tuberkulozy, Olomouc, Czechia|Pneumologicka klinika 1. LF a TN, Praha 4, Czechia|Local Institution, Copenhagen, Denmark|Local Institution, Herlev, Denmark|Local Institution, Odense, Denmark|Local Institution, Brest, France|Local Institution, Lille Cedex, France|Local Institution, Paris Cedex 14, France|Local Institution, Pringy Cedex, France|Local Institution, Reims, France|Local Institution, Toulon Cedex, France|Local Institution, Bamberg, Germany|Local Institution, Berlin, Germany|Local Institution, Essen, Germany|Local Institution, Frankfurt am Main, Germany|Local Institution, Gera, Germany|Local Institution, Gerlingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Halle (saale), Germany|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Immenstadt, Germany|Local Institution, Koeln, Germany|Local Institution, Muenchen, Germany|Local Institution, Oberhausen, Germany|Local Institution, Regensburg, Germany|University Hospital Of Heraklion, Heraklion, Creta, Greece|Sotiria General Hospital, Athens, Greece|Papageorgiou General Hospital, Thessaloniki, Greece|Orsz.Koranyi Tbc es Pulm.Int., Budapest, Hungary|Pulmonologiai Klinika, Budapest, Hungary|Local Institution, Beer Sheva, Israel|Local Institution, Kfar Saba, Israel|Local Institution, Ramat -Gan, Israel|Ospedale Bellaria-Maggiore, Bologna, Italy|Ospedale Civile Di Livorno, Livorno, Italy|Ospedale San Luca, Lucca, Italy|Istituto Romagnolo Per Lo Studio E La Cura Dei Tumori, Meldola, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Azienda Ospedaliera - Nuovo Ospedale San Gerardo, Monza, Italy|Ospedale Degli Infermi, Rimini, Italy|Azienda Ospedaliera S. Andrea, Roma, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kashiwa, Chiba, Japan|Local Institution, Matsuyama, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Akashi-shi, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Habikino-shi, Osaka, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sakai, Osaka, Japan|Local Institution, Kitaadachigun, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Wakayama, Japan|Local Institution, Cheongju-si, Chungcheonbuk-do, Korea, Republic of|Local Institution, Suwon, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Bergen, Norway|Local Institution, Oslo, Norway|Wojewodzki Szpital Zespolony W Elblagu, Elblag, Poland|Klinika Onkologii I Radioterapii Am, Gdansk, Poland|Oddzial Onkologiczny, Krakow, Poland|Regionalny Osrodek Onkologiczny, Lodz, Poland|Oddzial Onkologii Klinicznej, Poznan, Poland|Klinika Nowotworow Pluca i Klatki Piersiowej, Warszawa, Poland|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Romania, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Ryazan, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Basel, Switzerland|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|Local Institution, Winterthur, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Taichung, Taiwan|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Maidstone, Kent, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT02481830
23	NCT02387996	A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer		Active, not recruiting	Has Results	Various Advanced Cancer	Drug: Nivolumab	Objective Response Rate Per BIRC Assessment|ORR Per BIRC Assessment by PD-L1 Expression Level|Progression-Free Survival (PFS) Per BIRC Assessment|PFS Per BIRC Assessment by PD-L1 Expression Level|Overall Survival|OS by PD-L1 Expression Level|Objective Response Rate (ORR) Per Investigator|ORR Per Investigator by PD-L1 Expression Level	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 2	386	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-275	March 4, 2015	April 15, 2016	October 2, 2019	March 13, 2015	May 24, 2017	February 15, 2018	Mayo Clinic, Scottsdale, Arizona, United States|City Of Hope, Duarte, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|University Of Colorado, Aurora, Colorado, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Indiana University Health - University Hospital, Indianapolis, Indiana, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Crescent City Research Consortium, LLC, Marrero, Louisiana, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|GU Research Network, LLC, Omaha, Nebraska, United States|Mount Sinai Medical Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Providence Portland Medical Center, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Local Institution, Waratah, New South Wales, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Brussels, Belgium|Local Institution, Edegem, Belgium|Local Institution, Hasselt, Belgium|Local Institution, Brno, Czechia|Local Institution, Olomouc, Czechia|Local Institution, Praha 5, Czechia|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Erfurt, Germany|Local Institution, Erlangen, Germany|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Jena, Germany|Local Institution, Muenchen, Germany|Local Institution, Rostock, Germany|Local Institution, Tuebingen, Germany|Local Institution, Arezzo, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Pavia, Italy|U.O. Oncologia Medica Azienda, Roma, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Osaka-Sayama-Shi, Osaka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Szczecin, Poland|Local Institution, Wroclaw, Poland|Local Institution, Badalona-barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Hospitalet de Llobregat - Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Lund, Sweden		https://ClinicalTrials.gov/show/NCT02387996
24	NCT03158272	A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread		Recruiting	No Results Available	Advanced Malignancies	Biological: Cabiralizumab|Biological: Nivolumab	Incidenence of Adverse Events (AEs)|Incidence of serious adverse events (SAEs)|Incidence of laboratory abnormalities|Incidence of death|Incidence of AEs|Trough observed concentration (Ctrough) Accumulation Index; ratio of Ctrough at steady-state (AI_Ctrough)|Area under the serum concentration-time curve from time zero to [AUC(0-T)|Maximum observed serum concentration (Cmax)|Trough observed serum concentration (Ctrough)|Effective elimination half-life that explains the degree of Ctrough (T-HALFeff_Ctrough)|Time of maximum observed serum concentration (Tmax)|Volume of distribution at steady state (Vss)|Incidence of Antidrug Antibodies (ADA)|Best overall response (BOR)|Duration of response	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	20 Years and older   (Adult, Older Adult)	Phase 1	36	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA025-001	May 25, 2017	November 29, 2020	November 30, 2020	May 18, 2017	null	October 3, 2018	Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Chuo-ku, Tokyo, Japan		https://ClinicalTrials.gov/show/NCT03158272
25	NCT02617589	An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)	CheckMate 498	Recruiting	No Results Available	Brain Cancer	Drug: Nivolumab|Drug: Temozolomide|Radiation: Radiotherapy	Overall survival (OS)|Progression free survival (PFS)|Overall survival	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	550	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-498|2015-003739-37	February 29, 2016	March 10, 2019	October 1, 2019	December 1, 2015	null	November 20, 2018	University of Alabama at Birmingham, Birmingham, Alabama, United States|St. Joseph Hospital And Medical Center, Phoenix, Arizona, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|UCLA Neuro-Oncology Program, Los Angeles, California, United States|Sutter Institute For Medical Research, Sacramento, California, United States|Sharp Memorial Hospital, San Diego, California, United States|The Regents of the University of California, San Francisco, San Francisco, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University - Winship Cancer Institute, Atlanta, Georgia, United States|The University Of Chicago, Chicago, Illinois, United States|University Of Kansas Medical Center, Westwood, Kansas, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|JFK Medical Center, Edison, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Local Institution, Liverpool, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Prahran, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Kepler Universitaetsklinikum, Linz, Austria|Medical University Of Vienna, Vienna, Austria|Universitair Ziekenhuis Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Uz Leuven, Leuven, Belgium|BC Cancer - Vancouver, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|Local Institution, Copenhagen, Denmark|Local Institution, Odense, Denmark|Local Institution, Bron Cedex, France|Local Institution, Lille Cedex, France|Local Institution, Marseille, France|Local Institution, Paris cedex 13, France|Local Institution, Paris, France|Local Institution, Rennes Cedex, France|Local Institution, Toulouse, France|Local Institution, Vandoeuvre Les Nancy, France|Universitaetsklinikum Bonn, Bonn, Germany|Uniklinik Erlangen, Erlangen, Germany|Klinikum Der J. W. Goethe-Universitaet Frankfurt/Main, Frankfurt am Main, Germany|Medizinische Universitaetsklinik Freiburg, Freiburg, Germany|Universitaetsklinikum Hamburg, Hamburg, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Universitaetsklinik Koeln, Koeln, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany|Bezirksklinikum Regensburg, Regensburg, Germany|Universitasklinikum Tubingen, Tuebingen, Germany|Local Institution, Petach Tikva, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Rozzano (milano), Italy|Local Institution, Siena, Italy|Azienda Ospedaliera Citta della Salute e della Scienza, Torino, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Onsen-gun, Ehime, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe, Hyogo, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Sagamihara-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Tokyo, Japan|NKI AVL, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Erasmus Mc, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Local Institution, Oslo, Norway|Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radiote, Gdansk, Poland|Local Institution, Warszawa, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Badalona-Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Santiago De Compostela, Spain|Local Institution, Valencia, Spain|Local Institution, Lund, Sweden|Local Institution, Solna, Sweden|University Hospital Geneva, Geneve, Switzerland|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|Universitaetsspital Zuerich, Zuerich, Switzerland|University College Hospital, London, Greater London, United Kingdom|Christie Hospital Nhs Found. Trust, Manchester, Greater Manchester, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Beaston West of Scotland Cancer Centre, Glasgow, United Kingdom		https://ClinicalTrials.gov/show/NCT02617589
26	NCT03351231	An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer		Terminated	No Results Available	Cancer	Drug: BMS-986242|Biological: Nivolumab	Incidence of adverse events (AE)|Incidence of serious adverse events (SAE)|Incidence of dose limiting toxicities (DLT)|Incidence of AE's leading to discontinuation|Incidence of death|Incidence of laboratory abnormalities|Maximum observed plasma concentration (Cmax)|Time of maximum observed plasma concentration (Tmax)|Area under the concentration-time curve in 1 dosing interval [AUC(TAU)]|Area under the concentration-time curve from time zero to infinity [AUC(INF)]|Trough observed plasma concentration at the end of the dosing interval (Ctrough)|Apparent elimination half-life (T-HALF)|Apparent total body clearance (CLT/F)|Apparent volume of distribution at steady state (Vss/F)|Accumulation index (AI)|Percent urinary recovery over 24 hours (%UR24)|Percent urinary recovery over 72 hours (%UR72)|Incidence of anti-drug antibody (ADA) to nivolumab in combination with BMS-986242|Overall response rate (ORR)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	7	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA024-001|2017-003603-21	November 27, 2017	August 28, 2018	August 28, 2018	November 22, 2017	null	September 28, 2018	University Of Alabama At Birmingham, Birmingham, Alabama, United States|Hoag Memorial Hospital Presbyterian, Los Angeles, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Local Institution, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT03351231
27	NCT03363776	An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers		Recruiting	No Results Available	Cancer	Biological: BMS-986277|Biological: Nivolumab	Number of adverse events (AE)|Number of serious adverse events (SAE)|Number of AEs meeting dose limiting toxities criteria|Number of AEs leading to discontinuation|Number of AEs resulting in death|Incidence of clinical laboratory test abnormalities|Incidence of vital sign abnormalities|Objective response rate (ORR)|Disease control rate (DCR)|Median duration of response (mDOR)|Median progression-free survival (mPFS)|Progression-free survival (PFS)|Maximum observed blood concentration (Cmax)|Time of maximum observed blood concentration (Tmax)|Area under the blood concentration-time curve from time zero to time of last quanitifiable concentration [AUC(0-T)]|Area under the blood concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]|Apparent terminal half-life (T-HALF)|Total body clearance (CLT)|Volume of distribution at steady-state (Vss)|Volume of distribution of the elimination phase (Vz)|Average plasma concentration over a dosing interval (AUC[0-48]/48) (Css-avg)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	200	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA034-001|2017-002199-24	November 24, 2017	September 28, 2022	December 29, 2022	December 6, 2017	null	October 4, 2018	Local Institution, New York, New York, United States|Local Institution, Hamilton, Ontario, Canada|Local Institution, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain		https://ClinicalTrials.gov/show/NCT03363776
28	NCT01968109	An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors		Recruiting	No Results Available	Neoplasms by Site	Biological: Relatlimab|Biological: Nivolumab|Biological: BMS-986213	Proportion of subjects with Adverse Events (AEs)|Proportion of subjects with Serious Adverse Events (SAEs)|Proportion of Deaths|Proportion of subjects with laboratory abnormalities|Objective response rate (ORR)|Disease control rate (DCR)|Duration of response (DOR)|Proportion of participants with AEs meeting acute safety criteria|Maximum observed serum concentration (Cmax) of BMS-986016 administered both alone and in combination with nivolumab|Time of maximum observed serum concentration (Tmax) of BMS-986016 administered both alone and in combination with nivolumab|Trough observed serum concentration (Ctrough) of BMS-986016 administered both alone and in combination with nivolumab|Concentration at the end of a dosing interval (Ctau) [Eg: concentration at 336 hours] of BMS-986016 administered both alone and in combination with nivolumab|Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-986016 administered both alone and in combination with nivolumab|Total body clearance (CLT) of BMS-986016 administered both alone and in combination with nivolumab|Volume of distribution at steady state (Vss) of BMS-986016 administered both alone and in combination with nivolumab|Effective elimination half-life that explains the degree of area under the concentration-time curve (AUC) accumulation observed (T-HALFeff AUC) of BMS-986016 administered both alone and in combination with nivolumab|Effective elimination half-life that explains the degree of Cmax accumulation observed (T-HALFeff Cmax) of BMS-986016 administered both alone and in combination with nivolumab|Accumulation index; ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI_AUC) of BMS-986016 administered both alone and in combination with nivolumab|Cmax accumulation index; ratio of Cmax at steady state to Cmax after the first dose (AI_Cmax) of BMS-986016 administered both alone and in combination with nivolumab|Ctau accumulation index; ratio of Ctau at steady state to Ctau after the first dose (AI_Ctau) of BMS-986016 administered both alone and in combination with nivolumab|Degree of fluctuation (DF) or fluctuation index ([Cmax - Ctau]/Css,avg]) of BMS-986016 administered both alone and in combination with nivolumab|Immunogenicity measured by anti-drug antibody (ADA) for BMS-986016 (all subjects) and nivolumab|QTc interval from centrally read electrocardiograms (ECGs)|Best overall response (BOR)|ORR|DCR|Progression-free survival (PFS)|Overall survival (OS)	Bristol-Myers Squibb	All	12 Years and older   (Child, Adult, Older Adult)	Phase 1|Phase 2	1000	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA224-020|2014-002605-38	October 14, 2013	August 28, 2020	December 18, 2020	October 23, 2013	null	November 6, 2018	UCSD Moores Cancer Center, La Jolla, California, United States|University Of Colorado, Aurora, Colorado, United States|H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Advocate Health and Hospitals Corporation, Niles, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic - PPDS, Rochester, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Lehigh Valley Hospital and Health Network, Allentown, Pennsylvania, United States|UPMC Eye and Ear Institute, Pittsburgh, Pennsylvania, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|Md Anderson Can Cnt, Houston, Texas, United States|University Of Washington Cancer Care Alliance, Seattle, Washington, United States|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Wien, Austria|Local Institution, Wien, Austria|Local Institution, Toronto, Ontario, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Local Institution, Copenhagen, Denmark|Local Institution, Herlev, Denmark|Local Institution, Helsinki, Finland|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes Cedex 01, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Vlllejuif, France|Local Institution, Essen, Germany|Local Institution, Heilbronn, Germany|Local Institution, Wuerzburg, Germany|Istituto Europeo Di Oncologia, Milano, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Istituto Oncologico Veneto - I.R.C.C.S., Padova, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|Local Institution, Oslo, Norway|H. Univ. Vall dHebron, Barcelona, Spain|Hospital Universitario Virgen De La Victoria, Malaga, Spain|Clinica Universitaria De Navarra, Pamplona, Spain|Local Institution, Lausanne, Switzerland|Local Institution, Zurich, Switzerland|University College Hospital, London, Greater London, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|Christie Hospital, Manchester, United Kingdom		https://ClinicalTrials.gov/show/NCT01968109
29	NCT02477826	An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)	CheckMate 227	Recruiting	No Results Available	Non-Small Cell Lung Cancer	Drug: Nivolumab|Drug: Ipilimumab|Drug: Carboplatin|Drug: Cisplatin|Drug: Gemcitabine|Drug: Pemetrexed|Drug: Paclitaxel	Overall survival (OS)|Progression-free Survival (PFS) as determined by blinded independent central review (BICR)|Objective response rate (ORR)|Disease related symptom improvement as measured by the Lung Cancer Symptom Score (LCSS) in all subjects	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	2220	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-227|2014-003630-23	August 5, 2015	January 31, 2019	December 31, 2020	June 23, 2015	null	November 29, 2018	Southern Cancer Center, Inc., Mobile, Alabama, United States|Local Institution, La Jolla, California, United States|California Pacific Medical Center, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|Emory University Hospital, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Southfield, Michigan, United States|Local Institution, Rochester, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Guthrie Medical Group, Pc, Sayre, Pennsylvania, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Greenville Health System, Greenville, South Carolina, United States|St Francis Hospital, Greenville, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|The University Of Texas, Dallas, Texas, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States|Huntsman Cancer Institute At The Univ. Of Utah, Salt Lake City, Utah, United States|Kadlec Clinical Hematology and Oncology, Kennewick, Washington, United States|COIBA, Berazategui, Buenos Aires, Argentina|Instituto Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Fundacion Investigar, Ciudad de Buenos Aires, Buenos Aires, Argentina|Hospital Privado De Comunidad, Mar Del Plata, Buenos Aires, Argentina|Hospital Privado Centro Medico De Cordoba, Córdoba, Cordoba, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Tucuman, Argentina|Local Institution, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Clinica Privada Universitaria Reina Fabiola, Cordoba, Argentina|Local Institution, Garran, Australian Capital Territory, Australia|Blacktown Hospital, Blacktown, New South Wales, Australia|Local Institution, Gosford, New South Wales, Australia|Tamworth Hospital, Tamworth, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Clayton, Victoria, Australia|St Vincent's Hospital, Fitzroy, Victoria, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Murdoch, Australia|Medizinische Universitatsklinik, Graz, Austria|Akh Wien, Vienna, Austria|Klinikum Wels-Grieskirchen Gmbh, Wels, Austria|Local Institution, Charleroi, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Hasselt, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Sint Niklaas, Belgium|Local Institution, Salvador, Bahia, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Dr. H.Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada|London Regional Cancer Program, London, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Centre integre universitaire de sante et de service sociaux de l'estrie - CHUS, Sherbrooke, Quebec, Canada|Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-Centre-du-Quebec, Trois-Rivieres, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Quebec - Universite Laval, Quebec, Canada|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Instituto Oncologico, Vina Del Mar, Valparaiso, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guanzhou, Guangdong, China|Local Institution, Haikou, Hainan, China|Local Institution, Haerbin, Heilongjiang, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Changchun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Xi'an, Shaanxi, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Qingdao, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Hanghzou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Changsha, China|Local Institution, Chongqing, China|Local Institution, Chongqing, China|Local Institution, Hangzhou, China|Local Institution, Hangzhou, China|Local Institution, Kunming, China|Local Institution, Shanghai, China|Oncologos Del Occidente Sa, Pereira, Risaralda, Colombia|Administradora Del Country S.A. - Clinica Del Country, Bogota, Colombia|Hospital Universitario San Ignacio, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Plicni klinika, Hradec Kralove, Czechia|Klinika plicnich nemoci a tuberkulozy, Olomouc, Czechia|Pneumologicka klinika 1. LF a TN, Praha 4, Czechia|Oddeleni Onkologie, Pribram, Czechia|Local Institution, Oulu, Finland|Local Institution, Turku, Finland|Local Institution, ANGERS Cedex 2, France|Local Institution, Besançon Cedex, France|Local Institution, Bron Cedex, France|Local Institution, Caen, France|Local Institution, Creteil, France|Local Institution, Limoges cedex, France|Local Institution, Marseille Cedex 20, France|Local Institution, Paris, France|Local Institution, Pessac, France|Local Institution, Rennes Cedex 9, France|Local Institution, Rouen, France|Local Institution, Saint Herblain, France|Local Institution, Saint Priest En Jarez, France|Local Institution, Strasbourg, France|Local Institution, Toulon, France|Zentralklinik Bad Berka Gmbh, Bad Berka, Thuringen, Germany|Local Institution, Berlin, Germany|Universitaetsklinikum Essen, Essen, Germany|Universitatsklinikum Frankfurt, Frankfurt, Germany|SRH WALD KLINIKUM GERA gGmbH, Gera, Germany|Klinik Schillerhoehe, Gerlingen, Germany|Krankenhaus Grosshansdorf, Grosshansdorf, Germany|Stadtisches Krankenhaus Martha Maria Halle-Dolau, Halle, Germany|Thoraxklinik-Heidelberg Ggmbh, Heidelberg, Germany|Lungenklinik Hemer, Hemer, Germany|Klinikverbund Kempten-Oberallgau, Immenstadt, Germany|Universitaetsklinikum Magdeburg A. o. R., Magdeburg, Germany|Klinikum Bogenhausen, Muenchen, Germany|Hsk Dr.-Horst-Schmidt-Kliniken Wiesbaden, Wiesbaden, Germany|Local Institution, Athens, Greece|Local Institution, Heraklio, Greece|Local Institution, Neo Faliro, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Matrahaza, Hungary|Local Institution, Dublin 8, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Limerick, Ireland|Local Institution, Jerusalem, Israel|Local Institution, Kfar-saba, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Tel-hashomer, Israel|Local Institution, Zerifin, Israel|Local Institution, Avellino, Italy|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Livorno, Italy|Local Institution, Messina, Italy|Local Institution, Milano, Italy|Local Institution, Milan, Italy|Local Institution, Napoli, Italy|Local Institution, Ravenna, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, S.Andrea Fratte PG, Italy|Local Institution, Terni, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Ota-shi, Gunma, Japan|Local Institution, Hiroshima-shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Akashi-shi, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Yokohama-Shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osakasayama-shi, Osaka, Japan|Local Institution, Takatsuki-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Wakayama-shi, Wakayama, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Local Institution, Cheongju-si, Chungcheonbuk-do, Korea, Republic of|Local Institution, Seongnam-si, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Beirut, Lebanon|Local Institution, Beirut, Lebanon|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Phylasis Clinicas Research S de R. L. de C. V., Cuautitlan, Estado DE Mexico, Mexico|Local Institution, Toluca, Estado DE Mexico, Mexico|Instituto Jalisciense De Cancerologia, Guadalajara, Jalisco, Mexico|Local Institution, Morelia, Michoacan, Mexico|Axis Heilsa S de Rl de Cv, Monterrey, Nuevo LEON, Mexico|Medical Care & Research, Merida, Yucatan, Mexico|Local Institution, Chihuahua, Mexico|Local Institution, San Luis Potosi, Mexico|Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi S.C., San Luis Potosi, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Amsterdam, Netherlands|Local Institution, Breda, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Veldhoven, Netherlands|Clinica Ricardo Palma, Lima, Peru|Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru|Clinica San Felipe- Unidad de Oncologia Medica, Lima, Peru|Instituto Oncologico Miraflores, Lima, Peru|Oncocenter Peru SAC - Oncosalud, Lima, Peru|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Wojewodzkie Centrum Onkologii, Gdansk, Poland|Oddzial Onkologii I Radioterapii Szpital Morski Im. Pck, Gdynia, Poland|Centrum Onkologii-Inst.Im.M.Sklodowskiej-Curie O.W Gliwicach, Gliwice, Poland|Regionalny Osrodek Onkologiczny, Lodz, Poland|Klinika Nowotworow Pluca i Klatki Piersiowej, Warszawa, Poland|ORTHOS Szpital Wielospecjalistyczny Sp. z o.o., Wroclaw, Poland|Institute Of Oncology "Prof.Dr.Alexandru Trestioreanu" Bucha, Bucharest, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|S.C. Radiotherapy Center Cluj S.R.L., Floresti, Romania|Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Dep, Romania, Romania|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Kazan, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Ufa, Russian Federation|Local Institution, Riyadh 11426, Saudi Arabia|Local Institution, Riyadh-11211, Saudi Arabia|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Saxonwold, Johannesburg, Gauteng, South Africa|Local Institution, Vereeniging, South Africa|Local Institution, Majadahonda, Madrid, Spain|Local Institution, Badalona (Barcelona), Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Klinik Fur Onkologie, Basel, Switzerland|Kantonsspital Graubuenden, Chur, Switzerland|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|Local Institution, Winterthur, Switzerland|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Tao-Yuan County, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Kayseri, Turkey|Local Institution, Al Ain, United Arab Emirates|Local Institution, Middlesborough, Cleveland, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Leicester, Leicestershire, United Kingdom|Local Institution, Birmingham, WEST Midlands, United Kingdom|Local Institution, Cambridgeshire, United Kingdom|Local Institution, Edinburgh, United Kingdom|Local Institution, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT02477826
30	NCT03369223	An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread		Recruiting	No Results Available	Advanced Cancer	Biological: BMS-986249|Biological: Nivolumab	Incidence of Adverse Events (AE)|Incidence of Serious Adverse Events (SAE)|Incidence of AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria|Incidence of AEs leading to discontinuation|Incidence of death|Incidence of Laboratory abnormalities|Cmax (Maximum observed serum concentration)|Tmax (Time of maximum observed concentration)|AUC(0-T) (Area under the serum concentration-time curve from time zero to time of last quantifiable concentration)|AUC(TAU) (Area under the concentration-time curve in 1 dosing interval)|Ctau (Observed concentration at the end of a dosing interval)|Ctrough (Trough observed concentrations)|Best overall response (BOR)|Duration of response (DOR)|Progression-Free survival (PFS)|Time to response (TTR)|Total body clearance (CLT)|Average serum concentration over a dosing interval (AUC[TAU]/tau) at steady state (Css-avg)|Terminal serum half-life if data permit (T-HALF)|Ratio of an exposure measure at steady state to that after the first dose [exposure measure includes AUC[TAU] and Cmax (AI)]	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	300	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA030-001|2018-000416-21	December 5, 2017	July 30, 2020	July 30, 2020	December 11, 2017	null	October 4, 2018	University of Colorado Cancer Center, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Baptist Health Medical Group Oncology LLC, Miami, Florida, United States|Local Institution, Baltimore, Maryland, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Willamette Valley Cancer Institute And Research Center, Eugene, Oregon, United States|Northwest Cancer Specialists, Portland, Oregon, United States|Local Institution, Philadelphia, Pennsylvania, United States|Greenville Health System, Greenville, South Carolina, United States|Texas Oncology-Austin Midtown, Austin, Texas, United States|Texas Oncology - Baylor Charles A. Simmons Cancer Center, Dallas, Texas, United States|Local Institution, Houston, Texas, United States|Texas Oncology-San Antonio Medical Center, San Antonio, Texas, United States|Texas Oncology, P.A., Tyler, Texas, United States|Virginia Cancer Specialists (Leesburg) - USOR, Leesburg, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Frankston, Victoria, Australia		https://ClinicalTrials.gov/show/NCT03369223
31	NCT03444753	An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed		Recruiting	No Results Available	Advanced Cancer	Biological: BMS-986299|Biological: Nivolumab|Biological: Ipilimumab	Incidence of dose-limiting toxicities (DLTs)|Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Incidence of AEs leading to discontinuation and deaths|Incidence of clinical laboratory abnormalities|Maximum observed plasma concentration (Cmax)|Time of maximum observed plasma concentration (Tmax)|Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]|Area under the plasma concentration-time curve from time zero to 24 hours postdose [AUC(0-24)]	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	90	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA039-001	March 20, 2018	November 14, 2021	December 19, 2021	February 23, 2018	null	October 4, 2018	University Of California San Diego Moores Cancer Center, La Jolla, California, United States|Washington University, Saint Louis, Missouri, United States|MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03444753
32	NCT02743494	An Investigational Immuno-therapy Study of Nivolumab or Placebo in Patients With Resected Esophageal or Gastroesophageal Junction Cancer	CheckMate 577	Recruiting	No Results Available	Advanced Cancer	Drug: Nivolumab|Other: Placebo	Disease-Free Survival of adjuvant nivolumab in subjects with resected esophageal cancer or gastroesophageal junction cancer who have received chemoradiotherapy followed by surgery|Overall Survival of adjuvant nivolumab in subjects with resected esophageal cancer or gastroesophageal junction cancer who have received chemoradiotherapy followed by surgery|Overall survival rate	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	760	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CA209-577|2015-005556-10	May 23, 2016	September 14, 2020	October 11, 2024	April 19, 2016	null	November 20, 2018	Univ. Of Southern Calif. /Norris Comprehensive Cancer Center, Los Angeles, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|Ucsf Cancer Center, San Francisco, California, United States|University Of Colorado, Aurora, Colorado, United States|Georgetown University Med Ctr, Washington, District of Columbia, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Sacred Heart Medical Group, Pensacola, Florida, United States|SCRI Florida Cancer Specialists North, Saint Petersburg, Florida, United States|University Of Chicago, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Mass General/North Shore Cancer Center for Outpatient Care, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Albert Einstein Cancer Center At The Montefiore Medical Park, Bronx, New York, United States|NYU Langone Medical Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke Cancer Center, Durham, North Carolina, United States|Local Institution, Fargo, North Dakota, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|Oregon Health & Sci Univ, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Local Institution, Sioux Falls, South Dakota, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt University Med Ctr, Nashville, Tennessee, United States|Dallas VA Medical Center, Dallas, Texas, United States|Local Institution, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Scott & White Memorial Hospital And Clinic, Temple, Texas, United States|Local Institution, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States|University Of Wisconsin, Madison, Wisconsin, United States|Hospital Municipal De Gastroenterologia Dr.Udaondo, Capital Federal, Buenos Aires, Argentina|Hospital Aleman, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Hospital Provincial Del Centenario, Rosario, Santa FE, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Fundacion Favaloro, Buenos Aires, Argentina|Hospital Britanico, Buenos Aires, Argentina|Instituto Medico Especialazado Alexander Fleming, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Blacktown, New South Wales, Australia|Local Institution, Gosford, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Local Institution, Tamworth, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Local Institution, Hobart, Tasmania, Australia|Moorabbin Hospital, Clayton, Victoria, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Local Institution, Liege, Belgium|Local Institution, Namur, Belgium|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Itacorubi, Florianopolis, Santa Catarina, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose De Rio Preto, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Salvador, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency-Vancouver Ctr, Vancouver, British Columbia, Canada|Nova Scotia Health Authority QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|London Regional Cancer Program, London, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Montreal General Hospital, Montreal, Quebec, Canada|Local Institution, Ottawa, Quebec, Canada|Local Institution, Trois-Rivieres, Quebec, Canada|Hotel Dieu De Quebec, Quebec, Canada|Local Institution, Beijing, Beijing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Linhai, Zhejiang, China|Local Institution, Changsha, China|Local Institution, Shanghai, China|Local Institution, Tianjin, China|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Onkologicka klinika, Olomouc, Czechia|Aarhus University Hospital, Aarhus C, Denmark|Local Institution, Avignon Cedes 9, France|Local Institution, Dijon Cedex, France|Local Institution, LILLE Cedex, France|Local Institution, Paris, France|Local Institution, Pessac, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Rennes Cedex 9, France|Local Institution, Rouen, France|Local Institution, Toulouse, France|Charite Campus Virchow Klinikum, Berlin, Germany|Kliniken Essen-Mitte/Huyssens-Stift, Essen, Germany|Local Institution, Hamburg, Germany|University Hospital Of Cologne, Koeln, Germany|Johannes -Gutenberg Universitat, Mainz, Germany|Universitaets-Klinikum Marburg, Marburg, Germany|Klinikum Rechts Der Isar, Munich, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Budapest, Hungary|Orszagos Onkologiai Intezet, Budapest, Hungary|DE KK Onkologiai Intezet, Debrecen, Hungary|Local Institution, Kaposvar, Hungary|Local Institution, Wilton, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Bergamo, Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Reggio Emilia, Italy|Local Institution, Roma, Italy|Local Institution, Akita-Shi, Akita, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Gifu-shi, Gifu, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Minato-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Shinjuuku-ku, Tokyo, Japan|Local Institution, Fukuoka, Japan|Local Institution, Kita-gun, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Centro de Estudios y Prevencion Del Cancer, AC, Tuxtla Gutierrez, Chiapas, Mexico|Instituto Nacional De Cancerologia, Tlalpan, Distrito Federal C.P., Mexico|Fundacion Rodolfo Padilla Padilla A.C., Leon de los Aldama, Guanajuato, Mexico|Hospital Cardiologica De Aguascalientes, Aguascalientes, Mexico|Supere Centro de Infusion S.A de C.V., Ciudad de Mexico, Mexico|Instituto Nacional De Ciencias Medicas Y Nutricion S.Z., Distrito Federal, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Maastrict, Netherlands|Hospital Nacional Daniel Alcides Carrion, Callao, Peru|Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru|Hospital Nacional Cayetano Heredia, Lima, Peru|Oncosalud Sac, Lima, Peru|Local Institution, Lima, Peru|II Klinika Radioterapii i Chemioterapii, Gliwice, Poland|Oddzial Kliniczny Chirurgii Klatki Piersiowej, Krakow, Poland|II Klinika Chirurgii Ogolnej, Gastroenterologicznej i Nowotworow Ukladu Pokarmowego, Lublin, Poland|Oddzial Onkologii Klinicznej i Doswiadczalnej, Poznan, Poland|Klinika Gastroenterologii Onkologicznej, Warszawa, Poland|Local Institution, San Juan, Puerto Rico|SC Oncopremium Team SRL, Baia Mare, Romania|Fundeni Clinical Institute Gastroenterology; Hepatology Clin, Bucharest, Romania|Focus Lab Plus SRL, Bucuresti, Romania|Bendis Clinic Srl, Cluj-napoca, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|S.C. Radiotherapy Center Cluj S.R.L., Floresti, Romania|Local Institution, Cheboksary, Russian Federation|Local Institution, Moscow, Russian Federation|N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Saint-Petersburg Medical University Named After I.P.Pavlov, Saint-Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Cordoba, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Universitaetsspital Basel, Basel, Switzerland|Kantonsspital St Gallen, St Gallen, Switzerland|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Baskent University Adana Hospital, Adana, Turkey|Local Institution, Ankara, Turkey|Ataturk University, Erzurum, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi Onkoloji, Istanbul, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Withington, Manchester, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Cardiff, United Kingdom		https://ClinicalTrials.gov/show/NCT02743494
33	NCT02667587	An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)	CheckMate548	Recruiting	No Results Available	Brain Neoplasms	Drug: Nivolumab|Drug: Temozolomide|Radiation: Radiotherapy|Other: Nivolumab Placebo	Overall survival (OS) defined as time from the date of randomization to the date of death.|Progression free survival (PFS), defined as the time from randomization to the date of the first documented tumor progression or death to any cause.|Correlation of PFS and OS	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	693	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	CA209-548|2015-004722-34	May 5, 2016	February 11, 2022	August 1, 2023	January 29, 2016	null	October 23, 2018	University of Alabama at Birmingham, Birmingham, Alabama, United States|St. Joseph Hospital And Medical Center, Phoenix, Arizona, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|UCLA Neuro-Oncology Program, Los Angeles, California, United States|Sutter Institute For Medical Research, Sacramento, California, United States|Sharp Memorial Hospital, San Diego, California, United States|The Regents of the University of California, San Francisco, San Francisco, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Local Institution, Chicago, Illinois, United States|University Of Kansas Medical Center, Westwood, Kansas, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|JFK Medical Center, Edison, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|Local Institution, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Local Institution, Liverpool, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Prahran, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Kepler Universitaetsklinikum, Linz, Austria|Medical University Of Vienna, Vienna, Austria|Universitair Ziekenhuis Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Uz Leuven, Leuven, Belgium|BC Cancer - Vancouver, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|Local Institution, Copenhagen, Denmark|Local Institution, Odense, Denmark|Local Institution, Lille Cedex, France|Local Institution, Lyon Cedex 03, France|Local Institution, Marseille, France|Local Institution, Nancy, France|Local Institution, Paris cedex 13, France|Local Institution, Paris, France|Local Institution, Rennes Cedex, France|Local Institution, Toulouse, France|Universitaetsklinikum Bonn, Bonn, Germany|Uniklinik Erlangen, Erlangen, Germany|Klinikum Der J. W. Goethe-Universitaet Frankfurt/Main, Frankfurt Am Main, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|Universitaetsklinikum Hamburg, Hamburg, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Universitaetsklinik Koeln, Koeln, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany|Bezirksklinikum Regensburg, Regensburg, Germany|Universitasklinikum Tubingen, Tuebingen, Germany|Local Institution, Petach Tikva, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Rozzano (milano), Italy|Local Institution, Siena, Italy|Local Institution, Torino, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Sagamihara-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Kyoto, Japan|NKI AVL, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Erasmus Mc, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Local Institution, Oslo, Norway|Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radiote, Gdansk, Poland|Klinika Nowotworow Glowy i Szyi, Warszawa, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Badalona-barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Santiago Compostela, Spain|Local Institution, Valencia, Spain|Local Institution, Lund, Sweden|Local Institution, Solna, Sweden|University Hospital Geneva, Geneve, Switzerland|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|UniversitaetsSpital Zurich, Zuerich, Switzerland|University College Hospital, London, Greater London, United Kingdom|Christie Hospital Nhs Found. Trust, Manchester, Greater Manchester, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Beaston West of Scotland Cancer Centre, Glasgow, United Kingdom		https://ClinicalTrials.gov/show/NCT02667587
34	NCT01714739	A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors		Active, not recruiting	No Results Available	CANCER,NOS	Drug: Lirilumab|Drug: Nivolumab|Drug: Ipilimumab	Safety and tolerability of BMS-986015 given in combination with BMS-936558 or BMS-936558 plus BMS-734016 as measured by incidence of adverse events|Safety and tolerability of BMS-986015 given in combination with BMS-936558 or BMS-936558 plus BMS-734016 as measured by incidence of clinical laboratory test abnormalities including hematology, serum chemistry, and thyroid panel abnormalities|Objective response rate (ORR)|Maximum observed serum concentration (Cmax) of BMS-986015 derived from serum concentration versus time|Time of maximum observed serum concentration (Tmax) of BMS-986015 derived from serum concentration versus time|Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of BMS-986015 derived from serum concentration versus time|Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986015 derived from serum concentration versus time|Trough observed serum concentration (Ctrough) of BMS-986015 derived from serum concentration versus time|Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-986015 derived from serum concentration versus time|Clearance (CL) of BMS-986015 derived from serum concentration versus time|Volume of distribution at steady state (Vss) of BMS-986015 derived from serum concentration versus time|Half-life (t1/2) of BMS-986015 derived from serum concentration versus time|Anti-drug antibody (ADA) response to BMS-986015 in combination with BMS-936558 or BMS-734016|Overall survival (OS)|Progression-Free Survival (PFS)|Duration of response (DOR)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	337	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	CA223-001	October 7, 2012	October 15, 2019	October 16, 2019	October 26, 2012	null	September 5, 2018	Ucsf, San Francisco, California, United States|Florida Cancer Affiliates - Ocala, Ocala, Florida, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Lutherville, Maryland, United States|Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|UPMC Eye and Ear Institute, Pittsburgh, Pennsylvania, United States|West Cancer Center, Germantown, Tennessee, United States|Texas Oncology-Central Austin Cancer Center, Austin, Texas, United States|University Of Texas Medical Branch Of Galveston, Galveston, Texas, United States|University Of Washington, Seattle, Washington, United States|Juravinski Cancer Center, Hamilton, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Bordeaux, France|Local Institution, Lyon Cedex 08, France|Local Institution, Nice Cedex 2, France|Local Institution, Paris, France|Local Institution, Villejuif Cedex, France|Local Institution, Milano, MI, Italy|Local Institution, Siena, Italy|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Kantonsspital Graubuenden, Chur, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland		https://ClinicalTrials.gov/show/NCT01714739
35	NCT01629758	Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors		Completed	No Results Available	Neoplasms by Site	Biological: Denenicokin|Biological: Nivolumab	Safety, as measured by the rate of adverse events and serious adverse events|Efficacy as measured by tumor assessment (RECIST)|Immunogenicity as measured by incidence of specific antidrug antibodies (ADA) to BMS-98470 and BMS-936558	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	33	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA220-008	June 2012	December 2014	December 2014	June 28, 2012	null	March 6, 2015	Oncology Research Associates, Pllc D/B/A, Scottsdale, Arizona, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Moffitt Cancer Center, Tampa, Florida, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT01629758
36	NCT02041533	An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)		Active, not recruiting	Has Results	Stage IV or Recurrent Non-Small Cell Lung Cancer	Biological: Nivolumab|Drug: Gemcitabine|Drug: Cisplatin|Drug: Carboplatin|Drug: Paclitaxel|Drug: Pemetrexed	Progression-Free Survival in Participants With PD-L1 Expression >= 5%|Progression-Free Survival in All Randomized Participants|Overall Survival in Participants With PD-L1 Expression >= 5%|Overall Survival in All Randomized Participants|Objective Response Rate (ORR) in Participants With PD-L1 Expression >= 5%|Duration of Response in Participants With PD-L1 Expression>= 5%|Time to Response in Participants With PD-L1 Expression >= 5%|Disease-related Symptom Improvement Rate by Week 12	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	1325	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-026|2012-004502-93	March 25, 2014	July 1, 2016	October 1, 2018	January 22, 2014	July 26, 2017	February 14, 2018	Southern Cancer Center, Inc., Mobile, Alabama, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope, Tucson, Arizona, United States|Stanford Cancer Institute, Stanford, California, United States|University Of Colorado Hosp, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Baptist Health Medical Group Oncology, Miami, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Emory University - Winship Cancer Institute, Atlanta, Georgia, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Rush University Med Ctr, Chicago, Illinois, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Crescent City Research Consortium, LLC, Marrero, Louisiana, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center., Boston, Massachusetts, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|New York University Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|University Hospitals, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Hollings Cancer Center, Charleston, South Carolina, United States|St Francis Hospital, Greenville, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|Univ Of Tx. Md Anderson, Houston, Texas, United States|Cancer Centers of South Texas, San Antonio, Texas, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|COIBA, Berazategui, Buenos Aires, Argentina|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Clinica Colombo, Cordoba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Fitzroy, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Wels, Austria|Local Institution, Wien, Austria|Universitair Ziekenhuis Brussel, Brussels, Belgium|Antwerp University Hospital, Edegem, Belgium|Uz Gent, Gent, Belgium|Uz Leuven, Leuven, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Local Institution, Olomouc, Czechia|Local Institution, Ostrava - Poruba, Czechia|Local Institution, Praha 8, Czechia|Local Institution, Usti nad Labem, Czechia|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Vaasa, Finland|Local Institution, Caen, France|Local Institution, Lille, France|Local Institution, Marseille Cedex 20, France|Local Institution, Pontoise Cedex, France|Local Institution, Rennes Cedex 9, France|Local Institution, Strasbourg, France|Sozialstiftung Bamberg, Bamberg, Germany|Klinik Schillerhoehe, Gerlingen, Germany|Krankenhaus Grosshansdorf, Grosshansdorf, Germany|Thoraxklinik-Heidelberg Ggmbh, Heidelberg, Germany|Local Institution, Koeln, Germany|Local Institution, Wiesbaden, Germany|Local Institution, Heraklion, Creta, Greece|Local Institution, Athens, Greece|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Matrahaza, Hungary|Azienda Ospedaliera Moscati, Avellino, Italy|Local Institution, Livorno, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Perugia, Italy|Local Institution, Terni, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sakai-shi, Osaka, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Akashi, Hyogo, Japan|Local Institution, Habikino City, Osaka, Japan|Local Institution, Kobe, Hyogo, Japan|Local Institution, Ota, Gunma, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Tokyo, Japan|Local Institution, Wakayama, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Merida, Yucatan, Mexico|Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|Umcg, Universitair Medisch Centrum Groningen, Groningen, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Bydgoszcz, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Warszawa, Poland|Local Institution, Wodzislaw Slaski, Poland|Local Institution, Cluj Napoca, Romania|Local Institution, Cluj-napoca, Romania|Local Institution, Ploiesti, Romania|Local Institution, Barcelona, Spain|Local Institution, Las Palmas De Gran Canaria, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Stockholm, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Chur, Switzerland|Local Institution, Lausanne, Switzerland|Local Institution, Zuerich, Switzerland|Local Institution, Taipei, Taiwan|Local Institution, Kayseri, Turkey|North Middlesex University Hospital, London, Greater London, United Kingdom|Christie Hospital Nhs Trust, Manchester, Greater Manchester, United Kingdom|St James'S University Hospital, Leeds, Yorkshire, United Kingdom		https://ClinicalTrials.gov/show/NCT02041533
37	NCT03184870	A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors		Recruiting	No Results Available	Colorectal Cancer|Pancreatic Cancer	Drug: BMS-813160|Biological: Nivolumab|Drug: Nab-paclitaxel|Drug: Gemcitabine|Drug: 5-fluorouracil (5-FU)|Drug: Leucovorin|Drug: Irinotecan	Adverse events (AEs)|Serious adverse events (SAEs)|AEs meeting protocol-defined dose limiting toxicity criteria|AEs leading to discontinuation|Death|Incidence of laboratory abnormalities|Electrocardiogram (ECG)|Summary measures of vital signs|Overall response rate (ORR)|Median duration of response (DOR)|Progression free survival (PFS) rate|Decrease in regulatory T cells (Treg) & tumor-associated macrophages (TAM) in tumor samples|Maximum observed plasma concentration (Cmax)|Time of maximum observed plasma concentration (Tmax)|Trough observed plasma concentration (Ctrough)|Observed plasma concentration at 24 hours post dose (C24)|Area under the concentration-time curve from time 0 to 8 hours postdose [AUC(0-8)]|Area under the concentration-time curve from time 0 to 24 hours post dose [AUC(0-24)]|Apparent total body clearance (CLT/F)|Accumulation index, calculated based on ratio of AUC(0-24) and Cmax at steady state to after the first dose (AI)|Renal clearance (CLR)|Percent urinary recovery over 24 hours corrected for molecular weight (%UR)|Ratio of metabolite Cmax to parent Cmax, corrected for molecular (MR_Cmax)|Ratio of metabolite AUC(0-24) to parent AUC(0-24), corrected for molecular weight [MR_AUC(0-24)]|Frequency of positive anti-drug antibody (ADA) to nivolumab during combination therapy	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	348	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CV202-103|2017-001725-40	August 4, 2017	December 10, 2020	December 20, 2021	June 14, 2017	null	October 4, 2018	University Of Alabama At Birmingham, Birmingham, Alabama, United States|Local Institution, Scottsdale, Arizona, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States|University Of Colorado, Aurora, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Johns Hopkins University, Baltimore, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Local Institution, Rochester, New York, United States|Local Institution, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Local Institution, Nashville, Tennessee, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Local Institution, Malvern, Victoria, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Besancon Cedex, France|Local Institution, Lyon Cedex 08, France|Local Institution, Montpellier, France|Local Institution, Paris, France|Local Institution, Dresden, Germany|Local Institution, Heidelberg, Germany|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Majadahonda - Madrid, Spain		https://ClinicalTrials.gov/show/NCT03184870
38	NCT01454102	Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)		Active, not recruiting	No Results Available	Non-small Cell Lung Cancer	Biological: Nivolumab|Drug: Gemcitabine|Drug: Cisplatin|Drug: Pemetrexed|Drug: Paclitaxel|Drug: Carboplatin|Drug: Bevacizumab|Drug: Erlotinib|Biological: Ipilimumab	Safety and tolerability of Nivolumab in combination with chemotherapy measured by frequency of drug related adverse events|Safety and tolerability of Nivolumab in combination with chemotherapy measured by frequency of serious adverse events|Safety and tolerability of Nivolumab in combination with chemotherapy measured by frequency of clinical laboratory test by worst toxicity grade|ORR based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of subjects treated in arms A, B, C and D|PFSR based on RECIST 1.1 of subjects treated in arms A, B, C and D|ORR based on RECIST 1.1 of subjects treated in arms E, F, K, L, M, O, P, Q, R, S|PFSR based on RECIST 1.1 of subjects treated in arms E, F, K, L, M, O, P, Q, R, S|ORR based on RECIST 1.1 of subjects treated in arms G, H, I, J and N|PFSR based on RECIST 1.1 of subjects treated in arms G, H, I, J and N	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	472	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-012	December 9, 2011	July 20, 2016	December 29, 2018	October 18, 2011	null	November 7, 2017	Ucla, Santa Monica, California, United States|Yale University, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Ut Southwestern Medical Center At Dallas, Dallas, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Hamilton, Ontario, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT01454102
39	NCT03446040	An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread		Recruiting	No Results Available	Advanced Cancer	Biological: BMS-986258|Biological: Nivolumab|Drug: rHuPH20	Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Incidence of AEs leading to discontinuation and deaths|Incidence of AEs meeting protocol defined dose-limiting toxicities (DLTs) criteria|Objective response rate (ORR)|Median duration of response (mDOR)|Progression free survival rate (PFSR)|Maximum observed serum concentration (Cmax)|Time of maximum observed concentration (Tmax)|Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]|Observed concentration at the end of a dosing interval (Ctau)|Area under the serum concentration-time curve in 1 dosing interval [AUC(TAU)]|Trough observed serum concentration at the end of the dosing interval (Ctrough)|Concentration at the end of infusion (Ceoi)|Incidence of anti-drug antibody (ADA) to BMS-986258	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	308	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA031-002	March 1, 2018	July 4, 2023	July 5, 2023	February 26, 2018	null	October 4, 2018	Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Local Institution, Aurora, Colorado, United States|Local Institution, Pittsburgh, Pennsylvania, United States|The West Clinic, P.C., Germantown, Tennessee, United States|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Chuo-ku, Tokyo, Japan		https://ClinicalTrials.gov/show/NCT03446040
40	NCT03661632	An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors		Recruiting	No Results Available	Advanced Cancer	Drug: BMS-986310|Biological: Nivolumab	Incidence of Adverse Events (AE)|Incidence of Serious Adverse Events (SAE)|Incidence of AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria|Incidence of AEs leading to discontinuation|Incidence of Laboratory abnormalities|Incidence of death|Objective response rate (ORR)|Median duration of response (mDOR)|Progression free survival rate (PFSR)|Maximum observed serum concentration (Cmax)|Observed serum concentration at the end of a dosing interval (Ctau)|Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]|Apparent total body clearance (CLT/F)|Area under the serum concentration-time curve in 1 dosing interval [AUC(TAU)]|AUC accumulation index (AI_AUC)|Cmax accumulation index (AI_Cmax)|Summary changes of prostaglandin E metabolite (PGEM) in urine|Summary changes of tumor necrosis factor (TNFa) in blood	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	280	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA044-001|2018-002108-15	August 30, 2018	March 31, 2023	March 31, 2023	September 7, 2018	null	November 9, 2018	Local Institution, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Local Institution, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Edmonton, Alberta, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Haifa, Israel|Local Institution, Tel Aviv, Israel		https://ClinicalTrials.gov/show/NCT03661632
41	NCT02061761	Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies		Recruiting	No Results Available	Hematologic Neoplasms	Biological: BMS-986016|Biological: BMS-936558	Proportion of subjects with Adverse Events (AEs)|Proportion of subjects with Serious Adverse Events (SAEs)|Proportion of Deaths|Proportion of subjects with clinical laboratory test abnormalities|Objective response rate (ORR)|Duration of Response (DOR)|Maximum observed serum concentration (Cmax) of BMS-986016 administered alone and in combination with Nivolumab|Time of maximum observed serum concentration (Tmax) of BMS-986016 administered both alone and in combination with Nivolumab|Trough observed serum concentration (Ctrough) of BMS-986016 administered both alone and in combination with Nivolumab|Concentration at the end of a dosing interval (Ctau) of BMS-986016 administered both alone and in combination with Nivolumab|Average concentration over a dosing interval [AUC(TAU)/tau] (Css,avg) of BMS-986016 administered both alone and in combination with Nivolumab|Area under the concentration-time curve in one dosing interval (AUC(TAU)) of BMS-986016 administered both alone and in combination with Nivolumab|Total body clearance (CLT) of BMS-986016 administered both alone alone and in combination with Nivolumab|Volume of distribution at steady state (Vss) of BMS-986016 administered both alone and in combination with Nivolumab|Effective elimination half-life that explains the degree of AUC administered alone accumulation observed (T-HALFeff AUC) of BMS-986016 administered both alone and in combination with Nivolumab|Effective elimination half-life that explains the degree of Cmax administered alone accumulation observed (T-HALFeff Cmax) of BMS-986016 administered both alone and in combination with Nivolumab|Accumulation index; ration of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI_AUC) of BMS-986016 administered both alone and in combination with Nivolumab|Cmax accumulation index; ratio of Cmax at steady state to Cmax after the first dose (AI_Cmax) of BMS-986016 administered both alone and in combination with Nivolumab|Ctau accumulation index; ratio of Ctau at steady state to Ctau after the first dose (AI_Ctau) of BMS-986016 administered both alone and in combination with Nivolumab|Degree of fluctuation or fluctuation index ([Cmax - Ctau]/Css,avg) (DF) of BMS-986016 administered both alone and in combination with Nivolumab|Incidence of ADA to nivolumab and BMS-986016|Summary of AEs of special interest by	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	132	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA224-022	February 25, 2014	March 29, 2019	January 15, 2020	February 13, 2014	null	November 15, 2018	The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Weill Cornell Medical College, New York, New York, United States|Oregon Health & Science University, Portland, Oregon, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Washington, Seattle, Washington, United States|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT02061761
42	NCT02966548	Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors		Recruiting	No Results Available	Cancer	Drug: Relatlimab|Drug: Nivolumab	Number of adverse events (AE)|Number of serious adverse events (SAE)|Number of deaths|Number of laboratory abnormalities|Maximum observed serum concentration (Cmax) of BMS-986016|Time of maximum observed serum concentration (Tmax) of BMS-986016|Trough observed serum concentration (Ctrough) of BMS-986016|Concentration at the end of a dosing interval (Ctau) of BMS-986016|Average concentration over a dosing interval [AUC(TAU)/tau] (Css,avg) of BMS-986016|Area under the serum concentration-time curve in 1 dosing interval [AUC(TAU)] of BMS-986016|Total body clearance (CLT) of BMS-986016|Volume of distribution at steady state (Vss) of BMS-986016|Effective elimination half-life (T-HALFeff) that explains the degree of AUC accumulation observed (T-HALFeff AUC) of BMS-986016|Effective elimination half-life that explains the degree of Cmax accumulation observed (T-HALFeff Cmax) of BMS-986016|Accumulation index; ration of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI_AUC) of BMS-986016|Cmax accumulation index; ratio of Cmax at steady state to Cmax after the first dose (AI_Cmax) of BMS-986016|Ctau accumulation index; ratio of Ctau at steady state to Ctau after the first dose (AI_Ctau) of BMS-986016|Degree of fluctuation or fluctuation index ([Cmax - Ctau]/Css,avg) (DF) of BMS-986016|Best overall response (BOR)|Duration of response (DOR)|Frequency of positive anti-drug antibody (ADA) to BMS-986016|Frequency of positive anti-drug antibody (ADA) to Nivolumab	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	20 Years and older   (Adult, Older Adult)	Phase 1	45	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA224-034	November 28, 2016	June 30, 2020	July 1, 2020	November 17, 2016	null	August 14, 2018	Local Institution, Kashiwa-shi, Chiba, Japan		https://ClinicalTrials.gov/show/NCT02966548
43	NCT02935634	A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer	FRACTION-GC	Recruiting	No Results Available	Advanced Gastric Cancer	Biological: Nivolumab|Biological: Ipilimumab|Biological: Relatlimab|Biological: BMS-986205	Objective Response Rate (ORR)|Duration of Response (DOR)|Progression-free Survival Rate (PFSR)|Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)|AEs leading to discontinuation|AEs leading to death	Bristol-Myers Squibb	All	18 Years to 110 Years   (Adult, Older Adult)	Phase 2	300	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA018-003|2016-002807-24	November 23, 2016	November 17, 2021	November 18, 2021	October 17, 2016	null	November 28, 2018	Local Institution, Phoenix, Arizona, United States|City Of Hope National Medical Center, Duarte, California, United States|University Of Colorado, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Georgetown University Med Ctr, Washington, District of Columbia, United States|UF Health Medical Oncology - Davis Cancer Pavilion, Gainesville, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|John Hopkins, Baltimore, Maryland, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|UPMC, Pittsburgh, Pennsylvania, United States|Seattle Cancer Care Assoc. Univ of Washington, Seattle, Washington, United States|Westmead Hospital, Westmead, New South Wales, Australia|Austin Health, Heidelberg, Victoria, Australia|Local Institution, Randwick, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto,, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 9, France|Local Institution, Montpellier Cedex 5, France|Local Institution, Villejuif, France|Nationales Centrum Fur Tumorerkrankungen (Nct), Heidelberg, Germany|Universitaetsklinikum Leipzig, Leipzig, Germany|Local Institution, Ramat Gan, Israel|Local Institution, Tel Aviv, Israel|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Istituto Europeo Di Oncologia, Milan, Italy|Amsterdam UMC ? locatie AMC, Amsterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Local Institution, Singapore, Singapore|Local Institution, Badalona-barcelona, Spain|Local Institution, Madrid, Spain|Kantonsspital Graubunden, Chur, Switzerland|Local Institution, Zuerich, Switzerland		https://ClinicalTrials.gov/show/NCT02935634
44	NCT03745807	An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors		Not yet recruiting	No Results Available	Advanced Cancer	Biological: NKTR-214|Biological: Nivolumab	Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Incidence of AEs leading to discontinuation|Incidence of deaths|Incidence of AEs meeting protocol-defined dose limiting toxicity (DLT) criteria|Incidence of laboratory abnormalities|Maximum observed concentration (Cmax)|Time of maximum observed concentration (Tmax)|Area under the concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]|Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]|Total body clearance (CLT)|Volume of distribution (Vz)|Apparent terminal phase half-life (T-HALF)|Trough observed serum concentration at the end of the dosing interval (Ctrough)|Incidence of anti-drug antibodies (ADA) to NKTR-214|Incidence of anti-drug antibodies (ADA) to nivolumab|Best overall response (BOR)|Duration of response (DOR)	Bristol-Myers Squibb|Nektar Therapeutics|Ono Pharmaceutical Co. Ltd	All	20 Years and older   (Adult, Older Adult)	Phase 1	6	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA045-010|18-214-14	December 25, 2018	June 1, 2021	June 2, 2021	November 19, 2018	null	November 19, 2018	Local Institution, Chuo-ku, Tokyo, Japan		https://ClinicalTrials.gov/show/NCT03745807
45	NCT03192943	A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors		Active, not recruiting	No Results Available	Advanced Cancer	Drug: BMS-986205|Biological: Nivolumab	Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)|Incidence of Death|Incidence of Laboratory Abnormalities|AEs leading to discontinuation|Maximum observed plasma concentration (Cmax)|Time of maximum observed plasma concentration (Tmax)|Area under the plasma concentration-time curve in one dosing interval [AUC(TAU)]|Trough observed plasma concentration at the end of the dosing interval (Ctrough)|Apparent total body clearance (CLT/F)|Apparent volume of distribution at steady-state (Vss/F)|Percent urinary recovery over 24 hours (%UR24)|Biomarker Availability|Incidence of anti-drug antibody (ADA)|Best Overall Response (BOR)|Duration of Response (DOR)	Bristol-Myers Squibb	All	20 Years and older   (Adult, Older Adult)	Phase 1	18	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA017-048	June 23, 2017	July 21, 2019	July 21, 2019	June 20, 2017	null	October 4, 2018	Local Institution, Chuo-ku, Tokyo, Japan		https://ClinicalTrials.gov/show/NCT03192943
46	NCT03377361	An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread	CheckMate9N9	Recruiting	No Results Available	Colorectal Cancer|Colorectal Tumors|Colorectal Carcinoma|Colorectal Neoplasm	Biological: Nivolumab|Drug: Trametinib|Biological: Ipilimumab	Number of Adverse Events (AEs)|Number of Serious Adverse Events (SAEs)|Objective response rate (ORR)|Disease control rate (DCR)|Duration of response (DoR)|Time to response (TTR)|Progression free survival (PFS)|Overall survival (OS)	Bristol-Myers Squibb|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	345	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-9N9|2017-001830-24	January 22, 2018	September 21, 2021	November 24, 2022	December 19, 2017	null	October 9, 2018	University Of Alabama At Birmingham, Birmingham, Alabama, United States|Local Institution, Phoenix, Arizona, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Usc, Los Angeles, California, United States|University of California San Francisco (UCSF), San Francisco, California, United States|Local Institution, Fort Collins, Colorado, United States|Local Institution, New Haven, Connecticut, United States|Local Institution, Indianapolis, Indiana, United States|Local Institution, Baltimore, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Rochester, Minnesota, United States|Local Institution, New York, New York, United States|Local Institution, New York, New York, United States|Local Institution, Charlotte, North Carolina, United States|Local Institution, Durham, North Carolina, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Local Institution, Houston, Texas, United States|University Of Wisconsin, Madison, Wisconsin, United States|Local Institution, Blacktown, New South Wales, Australia|Local Institution, Herston, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Brussels, Belgium|Local Institution, Brussel, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Leuven, Belgium|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Quebec, Canada|Local Institution, Cologne, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Local Institution, Heilbronn, Germany|Local Institution, Mannheim, Germany|Local Institution, Munich, Germany|Local Institution, Ulm, Germany|Local Institution, Wuerzburg, Germany|Local Institution, Milano, Italy|Local Institution, Modena, Italy|Local Institution, Padova, Italy|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Aberdeen, Aberdeenshire, United Kingdom|Local Institution, Bristol, Avon, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Coventry, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT03377361
47	NCT01673867	Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC	CheckMate057	Active, not recruiting	Has Results	Non-Squamous Cell Non-small Cell Lung Cancer	Biological: Nivolumab|Drug: Docetaxel	Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint|One-year Overall Survival (OS) Rate in All Randomized Participants|Number of Deaths From Any Cause in All Randomized Participants at Primary Endpoint|Objective Response Rate (ORR) in All Randomized Participants at Primary Endpoint|Duration of Objective Response (DOR) in Months for All Confirmed Responders at Primary Endpoint|Time To Response (TTR) in Months for All Confirmed Responders at Primary Endpoint|Progression-Free Survival (PFS) Rate at 12 Months|Progression-Free Survival (PFS) Time in Months for All Randomized Participants at Primary Endpoint|Percentage of Participants Experiencing Disease-related Symptom Improvement by Week 12|Overall Survival (OS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint|Objective Response Rate (ORR) by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	792	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-057|2012-002472-14	October 10, 2012	February 5, 2015	December 21, 2018	August 28, 2012	February 26, 2016	April 10, 2018	Mayo Clinic Arizona, Scottsdale, Arizona, United States|City Of Hope National Medical Center, Duarte, California, United States|City Of Hope, Duarte, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|San Francisco Oncology Associates, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|The Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Winthrop University Hospital Oncology/Hematology, Mineola, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Guthrie Clinic, Ltd, Sayre, Pennsylvania, United States|Guthrie Medical Group, P.C., Sayre, Pennsylvania, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Henry-Joyce Cancer Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Univ Of Tx. Md Anderson, Houston, Texas, United States|Columbia Basin Hematology And Oncology, Kennewick, Washington, United States|Kadlec Clinical Hematology and Oncology, Kennewick, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|West Virginia University-Mbrcc, Morgantown, West Virginia, United States|West Virginia University-Mbrcc, Morgantown, West Virginia, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad De Buenos Aires, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, La Rioja, Argentina|Local Institution, Tweed Heads, New South Wales, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, Frankston, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Linz, Austria|Local Institution, Salzburg, Austria|Local Institution, Vienna, Austria|Local Institution, Wels, Austria|Local Institution, Salvador, Bahia, Brazil|Local Institution, Salvador, Bahia, Brazil|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Barretos, Sao Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Rio De Janeiro, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Local Institution, London, Ontario, Canada|Centre De Sante Et De Services Sociaux Rimouski Neigette, Rimouski, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Recoleta, Santiago DE Chile, Chile|Local Institution, Vi?a Del Mar, Valparaiso, Chile|Local Institution, Praha 8, Czechia|Local Institution, Creteil, France|Local Institution, Dijon Cedex, France|Local Institution, La Roche Sur Yon Cedex 9, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 20, France|Local Institution, Poitiers, France|Local Institution, Rennes Cedex 9, France|Local Institution, Toulouse, France|Local Institution, Bad Berka, Germany|Local Institution, Gerlingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Heidelberg, Germany|Local Institution, Koeln, Germany|Local Institution, Mainz, Germany|Local Institution, Recklinghausen, Germany|Local Institution, Ulm, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Budapest, Hungary|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Parma, Italy|Local Institution, Perugia, Italy|Local Institution, Ravenna, Italy|Local Institution, Siena, Italy|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Hermosillo, Sonora, Mexico|Local Institution, Oslo, Norway|Local Institution, Miraflores, Lima, Peru|Local Institution, Arequipa, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Olsztyn, Poland|Local Institution, Szczecin, Poland|Local Institution, Warszawa, Poland|Local Institution, Bucuresti, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Iasi, Romania|Local Institution, Timisoara, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Vizcaya, Spain|Local Institution, Chur, Graubuenden, Switzerland|Local Institution, Basel, Switzerland|Local Institution, Chur, Switzerland		https://ClinicalTrials.gov/show/NCT01673867
48	NCT03656718	A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)		Recruiting	No Results Available	Neoplasms by Site	Biological: Nivolumab|Drug: rHuPH20	Maximum observed serum concentration (Cmax)|Time of maximum observed serum concentration (Tmax)|Area under the serum concentration-time curve in 1 dosing interval [AUC(TAU)]|Observed serum concentration at the end of a dosing interval (Ctau)|Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), AEs leading to discontinuation|Incidence of death|Incidence of clinical laboratory test abnormalities|Incidence of AEs in the MedDRA Anaphylactic Reaction broad scope SMQ|Incidence of events within the hypersensitivity/infusion reaction select AE category|Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies to nivolumab	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-8KX|2018-001585-42	September 24, 2018	September 26, 2021	October 25, 2024	September 3, 2018	null	October 12, 2018	Local Institution, Atlanta, Georgia, United States|Local Institution, Detroit, Michigan, United States|Local Institution, Charlotte, North Carolina, United States|Willamette Valley Cancer Institute And Research Center, Eugene, Oregon, United States|Local Institution, Greenville, South Carolina, United States|Texas Oncology- Austin Midtown, Austin, Texas, United States|Texas Oncology-Beaumont, Beaumont, Texas, United States|Local Institution, Dallas, Texas, United States|Us Oncology, Tyler, Texas, United States|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Dunedin, New Zealand|Local Institution, Tauranga, New Zealand|Local Institution, Wellington, New Zealand|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain		https://ClinicalTrials.gov/show/NCT03656718
49	NCT02737475	An Investigational Immuno-therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Patients With Solid Cancers That Are Advanced or Have Spread		Recruiting	No Results Available	Advanced Cancer	Drug: BMS-986178|Drug: Nivolumab|Drug: Ipilimumab	Incidence of AE's (adverse events) and SAE's (serious adverse events), AE's leading to discontinuation, deaths and clinical laboratory test abnormalities|Cmax (maximum observed serum concentration) for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|Tmax (time of maximum observed concentration) for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|AUC(0-t) (area under the concentration-time curve from time zero to the time) for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|AUC(TAU) (area under the concentration-time curve in 1 dosing interval) for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|Ctau (the observed concentration at the end of a dosing interval) for BMS- 986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|CLT (total body clearance) for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|Css-avg [average concentration over a dosing interval (AUC(TAU)/tau)] for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|AI [ratio of an exposure measure at steady state to that after the first dose (exposure measure includes AUC(TAU), Cmax and Ctau)] for BMS- 986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|T-HALFeff [effective elimination half-life to explain degree of accumulation for a specific exposure measure (exposure measure includes AUC(TAU), Cmax and Ctau)] for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|Ctrough [trough observed plasma concentrations (this includes pre-dose concentrations (C0) and Ctau)] for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|Immunoassay of anti-nivolumab antibody in combination with anti-BMS- 986178 antibody|Immunoassay of anti-ipilimumab antibody in combination with anti-BMS-986178 antibody|Objective Response Rate (ORR)|Progression Free Survival Rate (PFSR)|Immunoassay of anti-BMS-986178 antibody alone|Number of participants showing a change in one of the pharmacodynamic biomarkers of BMS-986178 administered in combination with nivolumab	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	435	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA012-004|2015-004816-39	June 16, 2016	May 12, 2021	October 15, 2021	April 14, 2016	null	October 3, 2018	University Of Colorado, Aurora, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Local Institution, Ramat Gan, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Milano, Italy|Local Institution, Rozzano, Italy|Local Institution, Amsterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|H. Univ. Vall dHebron, Barcelona, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Hosp. Univ. Puerta De Hierro, Majadahonda - Madrid, Spain|Hospital Universitario Virgen De La Victoria, Malaga, Spain|Clinica Universitaria De Navarra, Pamplona, Spain		https://ClinicalTrials.gov/show/NCT02737475
50	NCT03130959	An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies	CheckMate 908	Recruiting	No Results Available	Various Advanced Cancer	Biological: Nivolumab|Biological: Ipilimumab	Incidence of dose limiting toxicity (DLT)|Incidence of serious adverse events (SAEs)|Incidence of adverse events (AEs)|Overall Survival (OS)|Progression Free Survival (PFS)|Incidence of AEs|Incidence of SAEs|Incidence of laboratory abnormalities|Overall Survival|Progression Free Survival	Bristol-Myers Squibb	All	6 Months to 21 Years   (Child, Adult)	Phase 2	170	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-908|2016-004441-82	June 6, 2017	June 14, 2021	June 15, 2021	April 27, 2017	null	September 11, 2018	Children's Hospital Of Los Angeles, Los Angeles, California, United States|Local Institution, San Francisco, California, United States|Children'S Hospital, Aurora, Colorado, United States|Local Institution, New Haven, Connecticut, United States|Mcknight Brain Institute, Gainesville, Florida, United States|Children'S Memorial Hospital, Chicago, Illinois, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Dana-Farber Cancer Inst, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|The Herbert Irving Pavilion, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Local Institution, Rochester, New York, United States|Cincinnati Children'S Hospital Medical Center, Cincinnati, Ohio, United States|Children'S Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|St Jude Children'S Research Hospital, Memphis, Tennessee, United States|Baylor College Of Medicine, Houston, Texas, United States|Local Institution, Randwick, New South Wales, Australia|Local Institution, Sth Brisbane, Queensland, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Parkville, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Curitiba, Parana, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Ribeirao Preto, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Toronto, Ontario, Canada|The Montreal Children's Hospital of the MUHC, Montreal, Quebec, Canada|CHU de Quebec, Quebec, Canada|Local Institution, Angers, France|Local Institution, Bordeaux Cedex, France|Local Institution, Lille, France|Local Institution, Lyon, France|Local Institution, Marseille, France|Local Institution, Paris, France|Local Institution, Vandoeuvre les Nancy, France|Local Institution, VIillejuif, France|Universitaetsklinik Essen, Essen, Germany|Universitaetsklinikum Hamburg, Hamburg, Germany|Hopp Children?s Cancer Center at NCT Heidelberg, Heidelberg, Germany|Univ. Klinikum Wuerzburg, Wuerzburg, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Haifa, Israel|Local Institution, Ramat Gan, Israel|Erasmus Mc , Locatie Sophia, Rotterdam, Netherlands|Prinses Maxima Centrum voor Kinderoncologie, Utrecht, Netherlands|Local Institution, Oslo, Norway|Local Institution, Warszawa, Poland|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Esplugues de Llobregat, Spain|Local Institution, Madrid, Spain|Local Institution, Valencia, Spain|Local Institution, Solna, Sweden|Great Ormond Street Hospital For Children, London, Greater London, United Kingdom|Alder Hey Children'S Hospital, Liverpool, Merseyside, United Kingdom|Royal Victoria Infirmary, Newcastle Upon Tyne, Tyne and Wear, United Kingdom|Local Institution, Birmingham, United Kingdom		https://ClinicalTrials.gov/show/NCT03130959
51	NCT03203876	A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors		Active, not recruiting	No Results Available	Advanced Cancer	Biological: Lirilumab|Biological: Nivolumab|Biological: Ipilimumab	Incidence of dose-limiting toxicity (DLT)|Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Incidence of death|Frequency of laboratory test toxicity grade shifting from baseline|Incidence of AEs leading to discontinuation|Maximum serum observed concentration (Cmax)|Time of maximum observed serum concentration (Tmax)|Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration [AUC(0-T)]|Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]|Trough observed serum concentration (Ctrough)|Area under the serum concentration-time curve in one dosing interval [AUC(TAU)]|Clearance (CL)|Volume of distribution at steady state (Vss)|Ratio of an exposure measure at steady-state to that after the first dose (AI)|Half-life (T-HALF)|Effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (T-HALF eff)|Best overall response (BOR)|Duration of response (DOR)|Incidence of anti-drug antibody (ADA)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	20 Years and older   (Adult, Older Adult)	Phase 1	21	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA223-030	July 5, 2017	December 9, 2018	December 10, 2018	June 29, 2017	null	August 29, 2018	Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Kobe-shi, Hyogo, Japan		https://ClinicalTrials.gov/show/NCT03203876
52	NCT03110107	First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors		Recruiting	No Results Available	Advanced Cancer	Biological: Ipilimumab|Biological: BMS-986218|Biological: Nivolumab	Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)|Objective Response Rate (ORR) of BMS-986218 monotherapy relative to Ipilimumab in immuno-oncology (IO) progressed melanoma cohort|Median Duration of Response (mDOR) of BMS-986218 monotherapy relative to Ipilimumab in IO progressed melanoma cohort|Progression Free Survival (PFS) of BMS-986218 monotherapy relative to Ipilimumab in IO progressed melanoma cohort|ORR of BMS-986218 alone or in combination with Nivolumab|mDOR of BMS-986218 alone or in combination with Nivolumab|PFS of BMS-986218 alone or in combination with Nivolumab|Incidence of anti-drug antibody (ADA) to BMS-986218|Percentage of change from baseline in T-regulatory cells (Tregs)|Maximum observed serum concentration (Cmax)|Time of maximum observed concentration (Tmax)|Area under the concentration-time curve from time zero to the time of the|Area under the concentration-time curve in 1 dosing interval [AUC(TAU)]|Trough observed serum concentration (Ctrough)|Total body clearance (CLT)|Average serum concentration over a dosing interval (AUC[TAU]/tau) at steady state (Css-avg)|Ratio of an exposure measure at steady state to that after the first dose [exposure measure includes AUC[TAU] and Cmax (AI)]|Terminal serum half-life if data permit (T-HALF)|Observed concentration at the end of a dosing interval (Ctau)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	452	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA022-001|2017-000597-11	April 28, 2017	April 6, 2020	March 20, 2021	April 12, 2017	null	October 3, 2018	Local Institution, Aurora, Colorado, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Las Vegas, Nevada, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Lyon Cedex 08, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Villejuif, France|Local Institution, Ramat Gan, Israel|Local Institution, Napoli, Italy|Local Institution, Siena, Italy|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain		https://ClinicalTrials.gov/show/NCT03110107
53	NCT03036098	Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer	CheckMate901	Recruiting	No Results Available	Urothelial Cancer	Biological: nivolumab|Biological: ipilimumab|Drug: gemcitabine|Drug: cisplatin|Drug: carboplatin	Progression free survival (PFS) in cisplatin-ineligible participants using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Overall survival (OS) of cisplatin-ineligible participants|PFS based on BICR assessment of nivolumab combined with standard of care (SOC) chemotherapy to SOC chemotherapy in cisplatin-ineligible participants with previously untreated, unresectable or metastatic Urothelial Cancer (UC)|Progression free survival (PFS) in all participants using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Overall survival (OS) in all participants|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- Core 30 (EORTC QLQ-C30) Global Health Status score|OS in cisplatin-eligible participants with previously untreated, unresectable or metastatic UC.	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	897	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-901|2016-003881-14	March 24, 2017	April 26, 2020	December 23, 2022	January 30, 2017	null	November 6, 2018	Local Institution, Birmingham, Alabama, United States|Local Institution, Birmingham, Alabama, United States|Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage, Alaska, United States|Local Institution, Little Rock, Arkansas, United States|VA of Central California Health Care System, Fresno, California, United States|St Joseph Heritage Healthcare, Santa Rosa, California, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Lewis Hall Singletary Oncology Center, Thomasville, Georgia, United States|University Of Illinois At Chicago, Chicago, Illinois, United States|Local Institution, Iowa City, Iowa, United States|Ochsner Clinic, New Orleans, Louisiana, United States|Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Milford Regional Medical Center, Boston, Massachusetts, United States|South Shore Hospital Cancer Center, Boston, Massachusetts, United States|St. Joseph Mercy Hospital, Ypsilanti, Michigan, United States|Ridges Cancer Clinic, Burnsville, Minnesota, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|St Lukes Hospital, Kansas City, Missouri, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|GU Research Network, LLC, Omaha, Nebraska, United States|Nh Hematology - Oncology, Hooksett, New Hampshire, United States|University Of New Mexico, Albuquerque, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Icahn School Of Medicine At Mount Sinai, New York, New York, United States|Local Institution, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Local Institution, Houston, Texas, United States|Local Institution, Salt Lake City, Utah, United States|Seattle Cancer Care Alliance, Kirkland, Washington, United States|Local Institution, Milwaukee, Wisconsin, United States|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Privado De Comunidad, Mar Del Plata, Buenos Aires, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Centro De Diagnostico Urologico S.R.L., Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Clinica Privada Universitaria Reina Fabiola, Cordoba, Argentina|Local Institution, Darlinghurst, New South Wales, Australia|Local Institution, Waratah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Chermside, Queensland, Australia|Local Institution, Tugun, Queensland, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Doubleview, Western Australia, Australia|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Passo Fundo, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Florianopolis, Santa Catarina, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose do Rio Preto, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Nova Scotia Health Authority QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada|Centre integre universitaire de sante et de service sociaux de l'estrie - CHUS, Sherbrooke, Quebec, Canada|CHU de Quebec - L'Hotel-Dieu de Quebec, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Hospital Clinico Vina Del Mar, Vina Del Mar, Valparaiso, Chile|Local Institution, Vitacura, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Wuhan, Hubei, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, China|Local Institution, Shanghai, China|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Local Institution, Aalborg, Denmark|Local Institution, Herlev, Denmark|Local Institution, Helsinki, Finland|Local Institution, Lille, France|Local Institution, Marseille Cedex 9, France|Local Institution, Nimes Cedex 09, France|Local Institution, Saint Priest En Jarez, France|Local Institution, Suresnes, France|Local Institution, Tours Cedex, France|Local Institution, Villejuif, France|Universitat Dresden, Dresden, Germany|Universitaetsklinikum Essen, Essen, Germany|Medizinische Universitaetsklinik Freiburg, Freiburg, Germany|Asklepios Klinik Altona, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinikum Jena, Jena, Germany|Local Institution, Muenchen, Germany|Klinikum Nuernberg Nord, Urologische Klinik, Nuernberg, Germany|Uniklinik Tuebingen, Tuebingen, Germany|Kliniken Nordoberpfalz AG, Weiden, Germany|Univ. Klinikum Wuerzburg, Wuerzburg, Germany|Alexandra General Hospital, Athens, Greece|Ioannina University Hospital, Ioannina, Greece|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Miskolc, Hungary|Local Institution, Kfar Saba, Israel|Local Institution, Ramat Gan, Israel|Ospedale S. Donato - Usl 8, Arezzo, Italy|Ospedale Per Gli Infermi, Faenza, Italy|Istituto Romagnolo Per Lo Studio E La Cura Dei Tumori, Forli, Italy|Ospedale Della Misericordia Grosseto, Grosseto, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli, Napoli, Italy|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Sapporo-city, Hokkaido, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Kita-Gun, Kagawa, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osakasayama, Osaka, Japan|Local Institution, Takatsuki-shi, Osaka, Japan|Local Institution, Hamamatsu-shi, Shizuoka, Japan|Local Institution, Arakawa-ku,tokyo, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Ube City, Yamaguchi, Japan|Local Institution, Goyang-si, Korea, Republic of|Local Institution, Seongnam-si, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Comite Mexicano para la Prevenion de la Osteoporosis A.C., Ciudad de Mexico, Distrito Federal, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Centro Universitario Contra el Cancer UANL, Monterrey, Nuevo LEON, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Enschede, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Leeuwarden, Netherlands|Local Institution, Bergen, Norway|Local Institution, Lorenskog, Norway|Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru|Clinica El Golf, Lima, Peru|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Local Institution, Koszalin, Poland|Klinika Nowotworow Ukladu Moczowego Centrum Onkologii - Inst, Warszawa, Poland|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Novosibirsk, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Comp. Hosp. Univ. A Coruna, A Coruna, Spain|Hospital Santa Creu I Sant Pau, Barcelona, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|H. U. Marques de Valdecilla, Santander, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Instituto Valenciano De Oncologia, Valencia, Spain|Local Institution, Jonkoping, Sweden|Local Institution, Linkoping, Sweden|Local Institution, Lund, Sweden|Kantonsspital Baden, Baden, Switzerland|Kantonsspital Graubuenden, Chur, Switzerland|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Izmir, Turkey		https://ClinicalTrials.gov/show/NCT03036098
54	NCT02060188	An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread	CheckMate142	Recruiting	No Results Available	Microsatellite Unstable Colorectal Cancer|Microsatellite Stable Colorectal Cancer|Mismatch Repair Proficient Colorectal Cancer|Mismatch Repair Deficient Colorectal Cancer	Drug: Ipilimumab|Drug: Nivolumab|Drug: Cobimetinib|Drug: Daratumumab|Drug: anti-LAG-3 antibody	Objective response rate (ORR) in all MSI-High and non-MSI-High subjects as determined by Investigators|ORR in all MSI-H and non-MSI-H subjects based on IRRC determination	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	340	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-142|2013-003939-30	March 7, 2014	December 3, 2019	December 30, 2020	February 11, 2014	null	November 20, 2018	Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|Emory University, Atlanta, Georgia, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Allina Health System, Minneapolis, Minnesota, United States|Duke University Office of Research Administration, Durham, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|Providence Cancer Center Oncology and Hematology Care- Eastside, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|University Of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Vanderbilt University Med Ctr, Nashville, Tennessee, United States|Md Anderson Can Cnt, Houston, Texas, United States|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Tasman Oncology Research Pty Ltd, Southport, Queensland, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Local Institution, Brussels, Belgium|Local Institution, Brussels, Belgium|Local Institution, Leuven, Belgium|Local Institution, Edmonton, Alberta, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Paris, France|Local Institution, Dublin 4, Ireland|Local Institution, Dublin 9, Ireland|Local Institution, Galway, Ireland|Local Institution, Candiolo, TO, Italy|Local Institution, Modena, Italy|Local Institution, Padova, Italy|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain		https://ClinicalTrials.gov/show/NCT02060188
55	NCT03662659	An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers		Recruiting	No Results Available	Gastric Cancer|Cancer of the Stomach|Esophagogastric Junction	Biological: BMS-986213|Biological: Nivolumab|Drug: XELOX|Drug: FOLFOX|Drug: SOX	Objective Response Rate (ORR)|Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)|Incidence of AEs leading to discontinuation|Incidence of death|Incidence of laboratory abnormalities|Duration of Response (DOR)|Overall survival (OS)|Progression Free Survival (PFS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	250	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA224-060|2018-001069-18	October 4, 2018	December 27, 2020	July 1, 2023	September 7, 2018	null	November 6, 2018	Local Institution, Duarte, California, United States|Local Institution, Fresno, California, United States|Local Institution, La Jolla, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Newport Beach, California, United States|Local Institution, Orange, California, United States|Local Institution, Aurora, Colorado, United States|Local Institution, New Haven, Connecticut, United States|Local Institution, Hackensack, New Jersey, United States|Local Institution, New York, New York, United States|Local Institution, Bismarck, North Dakota, United States|Local Institution, Fargo, North Dakota, United States|Local Institution, Sioux Falls, South Dakota, United States|Local Institution, Dallas, Texas, United States|Local Institution, Seattle, Washington, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Local Institution, Caba, Argentina|Local Institution, Tucuman, Argentina|Local Institution, Westmead, New South Wales, Australia|Local Institution, Herston, Queensland, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Malvern, Victoria, Australia|St John of God Murdoch Hospital, Murdoch, Western Australia, Australia|Local Institution, Bedford Park, Australia|Local Institution, Bruxelles, Belgium|Local Institution, Leuven, Belgium|Local Institution, Edmonton, Alberta, Canada|Local Institution, Kelowna, British Columbia, Canada|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Sherbrooke, Quebec, Canada|Local Institution, Trois-Rivieres, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Rancagua, L.g.bernardoohiggins, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Vina Del Mar, Valparaiso, Chile|Local Institution, Brno, Czechia|Local Institution, Olomouc, Czechia|Local Institution, Avignon cedex 9, France|Local Institution, Dijon, France|Local Institution, Paris, France|Local Institution, Rouen Cedex, France|Local Institution, Essen, Germany|Local Institution, Frankfurt, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Mannheim, Germany|Local Institution, Marburg, Germany|Local Institution, San Juan, Puerto Rico|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Nottingham, Nottinghamshire, United Kingdom|Local Institution, Coventry, WEST Midlands, United Kingdom|Local Institution, Lancaster, United Kingdom|Local Institution, Northwood, United Kingdom|Local Institution, Southampton, United Kingdom|Local Institution, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT03662659
56	NCT02534506	Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors		Recruiting	No Results Available	Malignant Tumors	Drug: Urelumab|Drug: Nivolumab	Safety of urelumab monotherapy as measured by the dose limiting toxicity (DLT) in subjects with advanced and/or metastatic malignant tumors|Safety of urelumab monotherapy as measured by adverse events (AEs) and serious adverse events (SAEs) in subjects with advanced and/or metastatic malignant tumors|Tolerability of urelumab monotherapy as measured by the DLT in subjects with advanced and/or metastatic malignant tumors|Tolerability of urelumab monotherapy as measured by AEs and SAEs in subjects with advanced and/or metastatic malignant tumors|Safety of urelumab-nivolumab combination therapy as measured by AEs and SAEs in subjects with advanced and/or metastatic malignant tumors|Tolerability of urelumab-nivolumab combination therapy as measured by AEs and SAEs in subjects with advanced and/or metastatic malignant tumors|Cmax (Maximum observed serum concentration) of urelumab when administered alone|Ctrough (Trough observed serum concentration) of urelumab when administered alone|Tmax (Time of maximum observed serum concentration) of urelumab when administered alone|AUC(0-T) [Area under the concentration-time curve from time zero to the last quantifiable concentration] of urelumab when administered alone|AUC(TAU) [Area under the concentration-time curve in one dosing interval] of urelumab when administered alone|AUC(INF) [Area under the concentration-time curve from time zero to infinity and the extrapolated area] of urelumab when administered alone|T-HALF (Elimination half life) of urelumab when administered alone|CLT (Total body clearance) of urelumab when administered alone|Vss (Volume of distribution at steady state) of urelumab when administered alone|AI (Accumulation Index: ratio of AUC(TAU) and Cmax in cycle at steady state to those after the first cycle) of urelumab when administered alone|Cmax of urelumab when co-administered|Coeff of urelumab when co-administered|Ctrough of urelumab and nivolumab when co-administered|Tmax of urelumab and nivolumab when co-administered|AUC(0-T) of urelumab and nivolumab when co-administered|AUC(TAU) of urelumab and nivolumab when co-administered|AUC(INF) of urelumab and nivolumab when co-administered|T-HALF of urelumab when co-administered|CLT of urelumab when co-administered|Vss of urelumab when co-administered|Anti-drug Antibody (ADA) status of the subject in response to Urelumab when administered alone|ADA status of the subject in response to Urelumab and Nivolumab when co-administered|Best overall response (BOR) of urelumab monotherapy|BOR of urelumab and nivolumab combination therapy	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	20 Years and older   (Adult, Older Adult)	Phase 1	18	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA186-110	November 6, 2015	June 17, 2019	June 18, 2019	August 27, 2015	null	October 3, 2018	Local Institution, Kobe-shi, Hyogo, Japan		https://ClinicalTrials.gov/show/NCT02534506
57	NCT02658890	An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread		Recruiting	No Results Available	Advanced Cancer|Melanoma|Non-Small Cell Lung Cancer	Drug: BMS-986205|Drug: Nivolumab|Drug: Ipilimumab	Safety and tolerability of BMS-986205 as measured by a composite of the incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, deaths, and clinical laboratory test abnormalities.|Safety of BMS-986205 plus nivolumab as measured by a composite of the incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, deaths, and clinical laboratory test abnormalities.|Safety of BMS-986205 plus both nivolumab and ipilimumab as measured by incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, deaths, and clinical laboratory test abnormalities.|Anti-tumor activity of BMS 986205 administered in combination with nivolumab as measured by the best overall response (BOR)|Anti-tumor activity of BMS 986205 administered in combination with nivolumab as measured by the duration of response (DOR)|Anti-tumor activity of BMS 986205 administered in combination with nivolumab as measured by progression-free survival rates (PFSRs)|Anti-tumor activity of BMS 986205 administered in combination with both nivolumab and ipilimumab as measured by the best overall response (BOR)|Anti-tumor activity of BMS 986205 administered in combination with both nivolumab and ipilimumab as measured by the duration of response (DOR)|Anti-tumor activity of BMS 986205 administered in combination with both nivolumab and ipilimumab as measured by progression-free survival rates (PFSRs)|Maximum observed plasma concentration (Cmax) of BMS-986205|Time of maximum observed plasma concentration (Tmax) of BMS-986205|Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986205|Area under the concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)] of BMS-986205|Area under the concentration-time curve in 1 dosing interval [AUC(TAU)] of BMS-986205|Trough observed plasma concentration at the end of the dosing interval (Ctrough) of BMS-986205|Observed plasma concentration at 24 hours (C24) of BMS-986205|Apparent terminal phase half-life (T-HALF) of BMS-986205|Apparent total body clearance (CLT/F) of BMS-986205|Apparent renal clearance (CLR/F) of BMS-986205|Volume of distribution of terminal phase (Vz/F) of BMS-986205|Apparent volume of distribution at steady state (Vss/F) of BMS-986205|Accumulation index (AI) of BMS-986205|Percent urinary recovery (%UR) of BMS-986205|Percent urinary recovery over 24 hours(%UR24) of BMS-986205|Ratio of metabolite Cmax to parent Cmax, corrected for molecular weight (MR_Cmax) of BMS-986205|Ratio of metabolite AUC(0-T) to parent AUC(0-T), corrected for molecular weight (single dose in clinical pharmacology substudy only) [MR_AUC(0-T)] of BMS-986205|Ratio of metabolite AUC(TAU) to parent AUC(TAU), corrected for molecular weight [MR_AUC(TAU)] of BMS-986205|Ratio of metabolite AUC(INF) to parent AUC(INF), corrected for molecular weight (single dose in clinical pharmacology substudy only) [MR_AUC(INF)] of BMS-986205|Anti-drug antibody (ADA) response to Nivolumab in combination with BMS-986205|Anti-drug antibody (ADA) response to Ipilimumab in combination with BMS-986205	Bristol-Myers Squibb	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 1|Phase 2	907	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA017-003|2015-004914-79	February 18, 2016	April 29, 2019	February 28, 2020	January 20, 2016	null	October 4, 2018	Local Institution, Phoenix, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|UCSD Moores Cancer Center, La Jolla, California, United States|Local Institution, Jacksonville, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Emory Winship Cancer Institute, Atlanta, Georgia, United States|Northside Hospital, Inc, Atlanta, Georgia, United States|University Of Chicago, Chicago, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Lutherville, Maryland, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Local Institution, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|New York University, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia|Melanoma Institute Australia, North Sydney, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Local Institution, Clayton, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Linear Clinical Research Ltd, Nedlands, Western Australia, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Greenfield Park, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Local Institution, Helsinki, Finland|Local Institution, Helsinki, Finland|Local Institution, Lille CEDEX, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes Cedex 01, France|Local Institution, Paris, France|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Local Institution, Essen, Germany|Local Institution, Heilbronn, Germany|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Rozzano MI, Italy|Local Institution, Oslo, Norway|Oddzial Badan Wczesnych Faz, Warszawa, Mazowieckie, Poland|Local Institution, Gdansk, Poland|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Solna, Sweden		https://ClinicalTrials.gov/show/NCT02658890
58	NCT02913313	An Investigational Immuno-therapy Study to Evaluate the Safety and Effectiveness of Experimental Medication BMS-986207 by Itself and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread		Recruiting	No Results Available	Broad Solid Tumor	Drug: BMS-986207|Biological: Nivolumab	Incidence of adverse events of BMS-986207|Incidence of adverse events of nivolumab (BMS-936558) and BMS-986207 when given in combination|Incidence of clinically significant abnormalities in general laboratory tests of BMS-986207|Incidence of clinically significant abnormalities in general laboratory tests of nivolumab(BMS-936558) and BMS-986207 when given in combination|Best Overall Response (BOR)|Objective Response Rate (ORR)|median Duration of Response (mDOR)|Progression Free Survival Rate (PFSR)|Maximum observed plasma concentration (Cmax) of BMS-986207|Time of maximum observed plasma concentration (Tmax) of BMS-986207|Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-t)] of BMS-986207|Trough observed plasma concentration (Ctrough) of BMS-986207|Area under the concentration-time curve in one dosing interval [AUC(tau)] of BMS-986207|Total body clearance (CLT) of BMS-986207|Observed concentration at the end of a dosing interval (Ctau) of BMS-986207|Effective elimination half-life (T-HALFeff) of BMS-986207|Accumulation Index (AI) of BMS-986207|Average concentration of BMS-986207 over a dosing interval|Immunogenicity measured by the occurrence of anti-drug antibody after the administration of BMS-986207|Immunogenicity measured by the occurrence of anti-drug antibody after the administration of BMS-986207 in combination with nivolumab (BMS-936558)|Tumor infiltrating lymphocyte (TIL) evaluations for BMS-986207|Serum cytokines profiling for BMS-986207|Serum proteome analysis for BMS-986207|Flow-cytometry evaluation of circulating immune cell subsets for BMS-986207|Tumor-specific immune cells for BMS-986207|Tumor infiltrating lymphocyte (TIL) evaluations for BMS-986207 in combination with nivolumab (BMS-936558)|Serum cytokines profiling for BMS-986207 in combination with nivolumab (BMS-936558)|Serum proteome analysis for BMS-986207 in combination with nivolumab(BMS-936558)|Flow-cytometry evaluation of circulating immune cell subsets for BMS-986207 in combination with nivolumab (BMS-936558)|Tumor-specific immune cells for BMS-986207 in combination with nivolumab(BMS-936558)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	170	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA020-002|2016-002263-34	November 29, 2016	December 15, 2022	December 16, 2022	September 23, 2016	null	October 3, 2018	John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University Medical Center (Cumc), New York, New York, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Ottawa, Ontario, Canada|University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Chuo-ku, Tokyo, Japan		https://ClinicalTrials.gov/show/NCT02913313
59	NCT03444766	Study of Nivolumab for Advanced Cancers in India		Recruiting	No Results Available	Non-Small Cell Lung Cancer (NSCLC)|Non-Small-Cell Lung Carcinoma|Nonsmall Cell Lung Cancer|Kidney Cancer|Kidney Neoplasms|Renal Cancer|Renal Neoplasms	Drug: Nivolumab	Number of Adverse Events (AE)|Number of treatment-related Serious Adverse Events (SAE)|Number of AE that lead to discontinuation from treatment with nivolumab	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 4	100	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-887	March 6, 2018	December 30, 2018	April 29, 2020	February 23, 2018	null	October 10, 2018	Local Institution, Bangalore, India|Local Institution, Bangalore, India|Local Institution, Bangalore, India|Local Institution, Bengaluru, India|Local Institution, Hyderabad, India|Local Institution, Jaipur, India|Local Institution, Kolkata, India|Local Institution, Kolkata, India|Local Institution, Mumbai, India|Local Institution, New Delhi, India|Local Institution, Vellore, India		https://ClinicalTrials.gov/show/NCT03444766
60	NCT02574078	A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)	CheckMate370	Active, not recruiting	No Results Available	Non-Small Cell Lung Cancer	Drug: Nivolumab|Drug: Bevacizumab|Drug: Pemetrexed|Other: Best Supportive Care|Drug: nab-Paclitaxel|Drug: Paclitaxel|Drug: Docetaxel|Drug: Gemcitabine|Drug: Erlotinib|Drug: Crizotinib|Drug: Carboplatin	Group A: Progression-free survival (PFS)|Group A: Overall survival (OS)|Group B: Progression-free survival (PFS)|Group B: Overall survival (OS)|Group C: Progression-free survival (PFS)|Group C: Overall survival (OS)|Group D: Progression-free survival (PFS)|Group E: Number of Incidence of treatment-related Adverse events (AEs) leading to both study drugs discontinuation|Group A: Duration of response (DOR)|Group A: Objective Response rate (ORR)|Group B: Duration of response (DOR)|Group B: Objective Response rate (ORR)|Group C: Duration of response (DOR)|Group C: Objective Response rate (ORR)|Group D: Overall survival(OS)|Group D: Duration of response (DOR)|Group D: Objective Response rate (ORR)|Group E: PFS|Group E: ORR	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	342	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-370	November 13, 2015	April 15, 2019	April 15, 2019	October 12, 2015	null	May 2, 2018	Alabama Oncology, Birmingham, Alabama, United States|Southern Cancer Center Pc, Mobile, Alabama, United States|Arizona Oncology Assoc, Pc-Hal, Phoenix, Arizona, United States|Northern Arizona Hematology & Oncology Associates, Sedona, Arizona, United States|Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope, Tucson, Arizona, United States|Arizona Clinical Research Center, Inc., Tucson, Arizona, United States|Comprehensive Blood And Cancer Center, Bakersfield, California, United States|St. Joseph Heritage Medical Group, Fullerton, California, United States|Scripps Cancer Center, La Jolla, California, United States|UCLA Hematology/Oncology Clinic, Los Angeles, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Sansum Santa Barbara Medical Foundation Clinic, Solvang, California, United States|St. Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Eastern Ct Hem Onc Assoc, Norwich, Connecticut, United States|Stamford Hospital, Stamford, Connecticut, United States|Va Ct Healthcare System, West Haven, Connecticut, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|University of Florida at Shands, Gainesville, Florida, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Baptist Health Medical Group Oncology, Miami, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Hematology Oncology Associates Of The Treasure Coast, Port Saint Lucie, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Tallahassee Memorial Cancer Center, Tallahassee, Florida, United States|Florida Cancer Affiliates, Trinity, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Cancer Treatment Centers Of America, Newnan, Georgia, United States|Summit Cancer Care, Savannah, Georgia, United States|Lewis Hall Singletary Oncology Center, Thomasville, Georgia, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Community Clinical Research Center, Anderson, Indiana, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Cotton-O-Neil Clinical Research Center, Topeka, Kansas, United States|West KY Hematology Oncology Group PSC, Paducah, Kentucky, United States|Christus St. Francis Cabrini Cancer Center, Alexandria, Louisiana, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|New England Cancer Specialists, Scarborough, Maine, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|University Of Maryland, Baltimore, Maryland, United States|Sinai Hospital Of Baltimore, Baltimore, Maryland, United States|Center For Cancer And Blood Disorders, Bethesda, Maryland, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, United States|Bay Hematology Oncology, Easton, Maryland, United States|Cancer & Hematology Centers Of Western Michigan, Grand Rapids, Michigan, United States|Minnesota Oncology Hematology, P.A., Edina, Minnesota, United States|Forrest General Cancer Center, Hattiesburg, Mississippi, United States|Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States|St. Louis Cancer Care, Llp, Bridgeton, Missouri, United States|Saint Vincent Frontier Cancer Center, Billings, Montana, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|Summit Medical Group, Morristown, New Jersey, United States|Atlantic Health System, Summit, New Jersey, United States|Morristown Medical Center, Summit, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|New York Oncology Hematology, Pc, Albany, New York, United States|Glens Falls Hospital, Glens Falls, New York, United States|Broome Oncology, Johnson City, New York, United States|Northern Westchester Hospital, Mount Kisco, New York, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Hematology-Oncology Associates Of Rockland, Nyack, New York, United States|White Plains Hospital, White Plains, New York, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|Moses Cone Health System, Greensboro, North Carolina, United States|Randolph Cancer Center, Greensboro, North Carolina, United States|First Health Of The Carolinas, Pinehurst, North Carolina, United States|W.G. Bill Hefner VA Medical Center, Salisbury, North Carolina, United States|Cancer Care Center, Bismarck, North Dakota, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Mid Ohio Oncology Hematology, Columbus, Ohio, United States|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States|Oncology Associates Of Oregon, Pc, Eugene, Oregon, United States|Hematology Oncology Associates, Medford, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|St. Luke's University Hospital Bethlehem, Bethlehem, Pennsylvania, United States|Erie Regional Cancer Center, Erie, Pennsylvania, United States|Abington Hematology Oncology Associates, Inc, Willow Grove, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Greenville Health System, Greenville, South Carolina, United States|Sanford Research, Sioux Falls, South Dakota, United States|Sanford Health, Sioux Falls, South Dakota, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|The Jones Clinic, Pc, Germantown, Tennessee, United States|West Cancer Center, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology-Abilene, Abilene, Texas, United States|Texas Oncology - Amarillo, Amarillo, Texas, United States|Texas Oncology-Arlington North, Arlington, Texas, United States|Texas Oncology-Beaumont, Beaumont, Texas, United States|Texas Oncology, Bedford, Texas, United States|Texas Oncology/Methodist Charlton Cancer Ctr, Dallas, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology, Denton, Texas, United States|Texas Oncology, El Paso, Texas, United States|Texas Oncology, Flower Mound, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Texas Oncology, Fort Worth, Texas, United States|The Center For Cancer And Blood Disorders, Fort Worth, Texas, United States|Texas Oncology, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Investigational Products Ctr, Irving, Texas, United States|Texas Cancer Center Of Mesquite, Mesquite, Texas, United States|Texas Oncology, Pa, Midland, Texas, United States|Texas Oncology, New Braunfels, Texas, United States|Texas Oncology, Paris, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Texas Oncology Plano West Cancer Center, Plano, Texas, United States|Cancer Centers of South Texas, San Antonio, Texas, United States|Texas Cancer Center - Sherman, Sherman, Texas, United States|Texas Oncology Cancer Center - Sugar Land, Sugar Land, Texas, United States|Texas Oncology-Tyler, Tyler, Texas, United States|Texas Oncology Cancer Care And Research Center, Waco, Texas, United States|Texas Oncology, P.A., Webster, Texas, United States|Texas Oncology, Weslaco, Texas, United States|Texas Oncology-Wichita Falls, Wichita Falls, Texas, United States|Oncology & Hematology Associates Of Southwest Virginia, Inc., Blacksburg, Virginia, United States|Virginia Cancer Specialists, Pc, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Shenandoah Oncology, Winchester, Virginia, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Cancer Care Northwest, Spokane Valley, Washington, United States|Northwest Cancer Specialists, Pc, Vancouver, Washington, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|Edwards Comprehensive Cancer Center, Huntington, West Virginia, United States		https://ClinicalTrials.gov/show/NCT02574078
61	NCT03195478	Study of Nivolumab in Combination With Ipilimumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors		Recruiting	No Results Available	Solid Tumor	Drug: Nivolumab|Drug: Ipilimumab	Composite of Number and percent of all treated subjects that experience Adverse Events (AEs)|Composite of Number and percent of all treated subjects that experience serious adverse events (SAEs)|Composite of Number and percent of all treated subjects that experience AEs leading to discontinuation|Composite of Number and percent of all treated subjects that experience AEs leading to death|Composite of Number and percent of subjects with clinical laboratory abnormalities|Maximum observed serum concentration (Cmax)|Time of maximum observed serum concentration (Tmax)|Area under the plasma concentration-time curve from time zero to the last time of the last quantifiable concentration (AUC[0-T])|Area under the concentration-time curve in one dosing interval (AUC[TAU])|Serum concentration achieved at the end of study drug infusion (Ceoinf)|Trough observed serum concentration at the end of dosing interval (Ctrough)|Concentration at the end of dosing interval (Ctau)|Anti-drug Antibody (ADA)|Best overall response (BOR) by investigator using Response Evaluation Criteria in Solid Tumor (RECIST v1.1)|Objective response rate (ORR)|Progression Free Survival Rate (PFSR) at 6 months	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	27	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-672	July 27, 2017	November 26, 2019	June 25, 2020	June 22, 2017	null	July 25, 2018	Local Institution, Beijing, China		https://ClinicalTrials.gov/show/NCT03195478
62	NCT02998528	A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)	CheckMate 816	Recruiting	No Results Available	Non Small Cell Lung Cancer	Biological: Nivolumab|Biological: ipilimumab|Drug: cisplatin|Drug: vinorelbine|Drug: gemcitabine|Drug: docetaxel|Drug: pemetrexed|Drug: carboplatin	Event-Free Survival|Pathological Complete Response|Overall survival (OS)|Major pathological response (MPR)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	642	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-816|2016-003536-21	January 13, 2017	May 8, 2023	November 8, 2028	December 20, 2016	null	October 3, 2018	Arizona Oncology Assoc, Pc-Hal, Phoenix, Arizona, United States|HOPE Cancer Center of East Texas, Phoenix, Arizona, United States|Local Institution, Phoenix, Arizona, United States|Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Sacramento, California, United States|Local Institution, Santa Barbara, California, United States|Local Institution, Santa Rosa, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Cancer Center Of Central Connecticut, Plainville, Connecticut, United States|University of Miami, Deerfield Beach, Florida, United States|Local Institution, Hollywood, Florida, United States|Local Institution, Jacksonville, Florida, United States|Cancer Institute Of Florida, Orlando, Florida, United States|Local Institution, Orlando, Florida, United States|Indian River Medical Center, Vero Beach, Florida, United States|Local Institution, Athens, Georgia, United States|Local Institution, Fort Gordon, Georgia, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Northwestern Medicine, Chicago, Illinois, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Local Institution, Tinley Park, Illinois, United States|Local Institution, Fort Wayne, Indiana, United States|Local Institution, Wichita, Kansas, United States|Local Institution, Elizabethtown, Kentucky, United States|Local Institution, Lexington, Kentucky, United States|Local Institution, Louisville, Kentucky, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Medstar Franklin Sqaure Medical Center, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Local Institution, Fairhaven, Massachusetts, United States|Local Institution, Worcester, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Local Institution, Columbia, Missouri, United States|St Vincent Frontier Cancer Center, Billings, Montana, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States|Valley Hospital Luckow Pavili, Westwood, New Jersey, United States|New York Oncology Hematology, Pc, Albany, New York, United States|Laura & Isaac Perlmutter Cancer Center, New York, New York, United States|Local Institution, New York, New York, United States|Local Institution, High Point, North Carolina, United States|Christ Hospital, Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Genesis Health Care System, Zanesville, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Local Institution, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Bon Secours-St Francis Hosp, Greenville, South Carolina, United States|Tennessee Oncology, Pc, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology, PA - South Austin Cancer Center, Austin, Texas, United States|Texas Oncology, Bedford, Texas, United States|WBAMC Oncology Department, El Paso, Texas, United States|Local Institution, Fort Worth, Texas, United States|Local Institution, Houston, Texas, United States|Millenium Oncology, Houston, Texas, United States|Local Institution, Lubbock, Texas, United States|Texas Cancer Center - Sherman, Sherman, Texas, United States|Texas Oncology, Waco, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|Local Institution, Saint George, Utah, United States|Southwest Regional Cancer Clinic, Saint George, Utah, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Vermont Cancer Center, Burlington, Vermont, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Local Institution, Fredericksburg, Virginia, United States|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Belo Horizonte, MG, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Ijui, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|CISSS de l'Outaouais, Gatineau, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Mcgill University Health Center, Montreal, Quebec, Canada|Local Institution, St. Jerome, Quebec, Canada|Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-Centre-du-Quebec, Trois-Rivieres, Quebec, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Local Institution, Beijing, Beijing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Shanghai, China|Local Institution, Marseille Cedex 20, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Pierre Benite, France|Local Institution, Rennes Cedex 9, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulouse, France|Local Institution, Tours Cedex, France|Sotiria General Hospital, Athens, Greece|Interbalkan European Medical Center, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Szekesfehervar, Hungary|Local Institution, Bari, Italy|Local Institution, Genova, Italy|Local Institution, Perugia, Italy|Local Institution, Ravenna, Italy|Local Institution, Roma, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Kitakyushu-shi, Fukuoka, Japan|Local Institution, Fukushima-shi, Fukushima, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sakai-shi, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Hwasun-gun, Jeonnam, Korea, Republic of|Local Institution, Busan, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Institute Of Oncology "Prof.Dr.Alexandru Trestioreanu" Bucha, Bucharest, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Dep, Romania, Romania|Local Institution, Parktown, Johannesburg, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|H. Univ. Vall dHebron, Barcelona, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hosp. Univ. Puerta De Hierro, Majadahonda - Madrid, Spain|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, ?stanbul, Turkey|Local Institution, Adana, Turkey|Local Institution, Ankara, Turkey|Local Institution, Ankara, Turkey|Local Institution, Istanbul, Turkey		https://ClinicalTrials.gov/show/NCT02998528
63	NCT02593786	A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors	CheckMate 077	Recruiting	No Results Available	Solid Tumors	Drug: Nivolumab	Safety measured by number of subjects who experience AEs, SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations|Tolerability measured by number of subjects who experience AEs, SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations|Objective response rate (ORR)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	56	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-077	December 25, 2015	October 8, 2019	October 8, 2019	November 2, 2015	null	October 4, 2018	Local Institution, Guangzhou, Guangdong, China		https://ClinicalTrials.gov/show/NCT02593786
64	NCT03668119	A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)	CheckMate 848	Recruiting	No Results Available	Pan Tumor	Biological: Nivolumab|Biological: Ipilimumab	Objective Response Rate (ORR)|Duration of response (DOR)|ORR|TTR|Clinical benefit rate (CBR)|Overall survival (OS)|PFS|Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)|Incidence of laboratory abnormalities|Incidence of anti-drug antibody (ADA)	Bristol-Myers Squibb	All	12 Years and older   (Child, Adult, Older Adult)	Phase 2	159	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-848|2016-002898-35	October 29, 2018	March 14, 2021	September 8, 2023	September 12, 2018	null	November 20, 2018	Local Institution, Birmingham, Alabama, United States|Local Institution, Bakersfield, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Orange, California, United States|Local Institution, Santa Monica, California, United States|Local Institution, Truckee, California, United States|Local Institution, Lakewood, Colorado, United States|Local Institution, Hollywood, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, Chicago, Illinois, United States|Local Institution, Niles, Illinois, United States|Local Institution, Fort Wayne, Indiana, United States|Local Institution, Minneapolis, Minnesota, United States|Local Institution, Rochester, Minnesota, United States|Local Institution, Saint Louis, Missouri, United States|Local Institution, Livingston, New Jersey, United States|Local Institution, Johnson City, New York, United States|Local Institution, Durham, North Carolina, United States|Local Institution, Columbus, Ohio, United States|Local Institution, Portland, Oregon, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Germantown, Tennessee, United States|Local Institution, Austin, Texas, United States|Local Institution, Dallas, Texas, United States|Local Institution, Houston, Texas, United States|Local Institution, Houston, Texas, United States|Local Institution, Tyler, Texas, United States|Local Institution, Charlottesville, Virginia, United States|Local Institution, Madison, Wisconsin, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma Beunos Aires, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Local Institution, Viedma, RIO Negro, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Caba, Argentina|Local Institution, Caba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Darlinghurst, New South Wales, Australia|Local Institution, St Leonards, New South Wales, Australia|Local Institution, Sydney, New South Wales, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Leuven, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Passo Fundo, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose Do Rio Preto, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Hamilton, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Santiago de Chile, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Vina Del Mar, Valparaiso, Chile|Local Institution, Copenhagen, Denmark|Local Institution, Herlev, Denmark|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris Cedex 5, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Villejuif, France|Local Institution, Berlin, Germany|Local Institution, Bonn, Germany|Local Institution, Dresden, Germany|Local Institution, Essen, Germany|Local Institution, Heidelberg, Germany|Local Institution, Wuerzburg, Germany|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Surquillo, Lima, Peru|Local Institution, Arequipa, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Warszawa, Mazowieckie, Poland|Local Institution, Gdansk, Poland|Local Institution, San Juan, Puerto Rico|Local Institution, Bucuresti, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Floresti, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Preston, United Kingdom|Local Institution, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT03668119
65	NCT02598960	An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.		Active, not recruiting	No Results Available	Solid Tumors	Drug: BMS-986156|Drug: Nivolumab	Safety of BMS-986156 based on number of incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation and deaths in addition to clinical laboratory test abnormalities|Objective response rate (ORR)|Progression free survival rate (PFSR)|Duration of response|Maximum observed concentration (Cmax) of BMS-986156|Time of maximum observed concentration (Tmax) of BMS-986156|Area under the concentration-time curve in one dosing interval (AUC [TAU]) of BMS-986156|Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T) of BMS-986156|Anti-drug antibody (ADA) response to BMS-986156|Anti-drug antibody response to BMS-986156 and Nivolumab	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	310	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA009-002|2015-002505-11	October 9, 2015	January 30, 2020	May 28, 2020	November 6, 2015	null	November 12, 2018	University Of Alabama At Birmingham, Birmingham, Alabama, United States|UCSD Moores Cancer Center, La Jolla, California, United States|Emory University, Atlanta, Georgia, United States|The Ohio State University, Columbus, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|The West Clinic, P.C., Germantown, Tennessee, United States|Local Institution, Liverpool, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Nedlands, Western Australia, Australia|Universitair Ziekenhuis Gent, Gent, Belgium|Local Institution, Edmonton, Alberta, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Paris Cedex 5, France|Centre Claudius Regaud, Toulouse Cedex 9, France|Institut Gustave Roussy, Vlllejuif, France|Local Institution, Bonn, Germany|Local Institution, Freiburg, Germany|Local Institution, Wuerzburg, Germany|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Istituto Europeo Di Oncologia, Milan, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Cantonal Hospital St. Gallen, St. Gallen, Switzerland|Local Institution, Zurich, Switzerland		https://ClinicalTrials.gov/show/NCT02598960
66	NCT00441337	A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies	MDX1106-01	Completed	Has Results	Carcinoma, Non-Small-Cell Lung|Colorectal Cancer|Malignant Melanoma|Renal Cancer|Prostate Cancer	Biological: MDX-1106	Number of Participants With Severe Adverse Events (AEs), Serious Adverse Events (SAEs), Drug-Related AEs, Deaths, Discontinuation of Study Drug Due to AE, Dose-Limiting Toxicity (DLT) AE and Immune-related AEs (irAEs) in Safety Population|Geometric Mean Maximum Serum Concentration (Cmax) Observed Post-Single Dose|Median Time at Which the Maximum Serum Concentration Occurred (Tmax) Post-Single Dose|Geometric Mean Area Under the Curve (AUC) From Time of Dosing to Time of Last Observation (0-T) and Extrapolated to Infinity (INF) Observed Post-Single Dose|Mean Elimination Half-life (T-HALF) Post-Single Dose|Geometric Mean Total Body Clearance of Drug From Serum (CLT) Post-Single Dose|Mean Volume of Distribution (Vz) Post-Single Dose|Percent of Participants With Best Overall Response Rate in Safety Population and in Tumor Evaluable Population|Percent of Participants With Prostate-Specific Antigen (PSA) Response After the First Dose by Day 85 In Participants With Hormone-Refractory Prostate Adenocarcinoma (HRPC)|Number of Participants With Best Overall Response (BOR) by Category in Safety Population|Percentage of Participants With Disease Control and Major Durable Disease Control|Median Time to Tumor Response and Duration of Tumor Response|Time to Tumor Progression and Tumor Progression Free Survival|Median Time to PSA Progression in Days and Median PSA Progression Free Survival in Days in PSA Evaluable Population|Mean Change From Baseline in PSA Relative Velocity at Days 29, 57, and 85 With Cycle 1 in PSA Evaluable Population|Mean Change From Baseline in Electrocardiogram Parameters PR, QRS and QT in Safety Population|Mean Diastolic Blood Pressure at Baseline and Post-Infusion Day 1 (Cycle 1) in 0.3 mg Cohort - Safety Population|Mean Systolic Blood Pressure at Baseline and Post-Infusion Day 1 (Cycle 1) in 0.3 mg Cohort - Safety Population|Mean Diastolic Blood Pressure at Baseline and Post-Infusion Day 1 (Cycle 1) in 1mg, 3mg, and 10 mg Cohorts - Safety Population|Mean Systolic Blood Pressure at Baseline and Post-Infusion Day 1 (Cycle 1) in in 1mg, 3mg, and 10 mg Cohorts - Safety Population	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	39	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-001 ST|MDX1106-01	August 2006	November 2009	November 2009	February 28, 2007	February 20, 2015	February 20, 2015	Johns Hopkins Unv., School of Medicine, Baltimore, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School of Medicine - Barnes Jewish Hospital, St. Louis, Missouri, United States|Carolina BioOncology Institute, PLLC, Huntersville, North Carolina, United States		https://ClinicalTrials.gov/show/NCT00441337
67	NCT03459222	An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread		Recruiting	No Results Available	Advanced Cancer	Biological: Relatlimab|Biological: Nivolumab|Drug: BMS-986205|Biological: Ipilimumab	Number of clinical laboratory test abnormalities|Number of Adverse Events (AEs)|Number of Serious Adverse Events (SAEs)|Number of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria|Number of AEs leading to discontinuation and deaths|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Median Duration of Response (mDOR)|Progression Free Survival (PFS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	230	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA224-048|2018-000058-22	May 25, 2018	April 4, 2022	May 16, 2022	March 8, 2018	null	November 20, 2018	City of Hope National Medical Center, Duarte, California, United States|University Of Colorado, Aurora, Colorado, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|The West Clinic, P.C., Germantown, Tennessee, United States|Local Institution, Seattle, Washington, United States|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Marseille Cedex 5, France|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Local Institution, Lausanne, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Newcastle Upon Tyne, United Kingdom|Local Institution, Oxford, United Kingdom		https://ClinicalTrials.gov/show/NCT03459222
68	NCT02341625	A Study of BMS-986148 in Patients With Select Advanced Solid Tumors		Active, not recruiting	No Results Available	Advanced Cancer	Drug: BMS-986148|Biological: Nivolumab	Safety is measured by incidence of adverse events (AEs) at its worst grade, serious adverse events (SAEs) at its worst grade, adverse events leading to discontinuations, deaths, frequency of laboratory test toxicity grade shifting from baseline|Maximum observed serum or plasma concentration (Cmax) of BMS-986148|Time of maximum observed serum or plasma concentration (Tmax) of BMS-986148|Concentration at the end of a dosing interval (Ctau) of BMS-986148|Trough observed serum or plasma concentration (this includes pre-dose concentrations and Ctau concentrations) (Ctrough) of BMS-986148|Area under the concentration-time curve from time 0 to time t (AUC(0-t)) of BMS-986148 (t= t last)|Area under the concentration-time curve in one dosing interval (AUC(TAU)) of BMS-986148|Terminal serum or plasma half-life (T-Half) of BMS-986148|Total body clearance calculated as Dose divided by AUC(TAU) (CLT) of BMS-986148|Volume of distribution at steady-state (Vss) of BMS-986148|Volume of distribution of terminal phase (Vz) of BMS-986148|Accumulation index; ratio of Cmax at steady-state to Cmax after the first dose (AI_Cmax) of BMS-986148|Accumulation index; ratio of Ctau at steady-state to Ctau after the first dose (AI_Ctau) of BMS-986148|Average concentration over a dosing interval calculated by dividing AUC(TAU) by tau (Cavg) of BMS-986148|Best overall response (BOR) of BMS-986148|Objective Response rate (ORR)|Duration of response|Progression free survival|Progression free survival rate|Overall survival|Overall survival rate|Changes in QTcF of BMS-986148|Immunogenicity of BMS-986148	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	407	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA008-002|2014-002485-70	June 17, 2015	June 14, 2021	August 29, 2022	January 19, 2015	null	October 3, 2018	UC San Diego Moores Cancer Ctr, La Jolla, California, United States|Duke University Medical Center, Durham, North Carolina, United States|Local Institution, Liverpool, New South Wales, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Gent, EAST Flanders, Belgium|Local Institution, Bruxelles, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Milano, Italy|Istituto Europeo Di Oncologia, Milan, Italy|Istituto Clinico Humanitas, Rozzano (milano), Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Southampton, Hampshire, United Kingdom|The Beatson West Of Scotland Cancer Centre, Glasgow, Lanarkshire, United Kingdom		https://ClinicalTrials.gov/show/NCT02341625
69	NCT02632409	An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer	CheckMate 274	Recruiting	No Results Available	Various Advanced Cancer	Biological: Nivolumab|Other: Placebo	Disease free survival (DFS)|Non-Urothelial track recurrence free survival (NUTRFS)|Disease specific survival (DSS)|Overall survival (OS)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	640	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	CA209-274|2014-003626-40	February 11, 2016	April 30, 2020	May 1, 2020	December 16, 2015	null	November 6, 2018	Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage, Alaska, United States|Arizona Oncology Associates, Tucson, Arizona, United States|University Of California San Francisco-Fresno, Fresno, California, United States|University Of California - Davis, Sacramento, California, United States|California Pacific Medical Center, San Francisco, California, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|University Of Florida, Gainesville, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Loyola University Medical Center, Maywood, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Tulane University, New Orleans, Louisiana, United States|Cancer & Hematology Centers Of Western Michigan, Grand Rapids, Michigan, United States|Fairview Health Services, Burnsville, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|GU Research Network, LLC, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Of North Carolina, Chapel Hill, North Carolina, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Northwest Cancer Specialists, Pc, Tualatin, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute Cancer Services, Pittsburgh, Pennsylvania, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Local Institution, Virginia Beach, Virginia, United States|COIBA, Berazategui, Buenos Aires, Argentina|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Hospital Britanico De Buenos Aires, Ciudad Autonoma de BuenosAires, Buenos Aires, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Liverpool Hospital, Liverpool, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Local Institution, Frankston, Victoria, Australia|St John of God Murdoch Hospital, Perth, Western Australia, Australia|Lyell McEwin Hospital, Elizabeth Vale, Australia|Krankenhaus Der Barmherzigen Schwestern, Linz, Austria|Salzburger Landeskliniken Lkh, Salzburg, Austria|Akh Wien, Vienna, Austria|AKH Allgemeines Krankenhaus Wien, Wien, Austria|Local Institution, Hasselt, Belgium|Chu De Liege, Liege, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, S?o Paulo, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Mcgill University Health Center - Royal Victoria Hospital, Montreal, Quebec, Canada|Local Institution, Sherbrooke, Quebec, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Canada|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Instituto Oncologico Clinica Renaca, Vina Del Mar, Valparaiso, Chile|Clinica Alemana de Temuco S.A., Temuco, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Nanning, Guangxi, China|Local Institution, Wuhan, Hubei, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Yantai, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Wenzhou, Zhejiang, China|Local Institution, Shanghai, China|Administradora Del Country S.A. - Clinica Del Country, Bogota, Colombia|Fundacion Oftalmologica De Santander - Foscal, Floridablanca, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Local Institution, Aalborg, Denmark|Local Institution, Aarhus C, Denmark|Local Institution, Copenhagen, Denmark|Local Institution, La Roche sur Yon, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris, France|Local Institution, Strasbourg, France|Local Institution, Suresnes, France|Local Institution, Villejuif, France|Zeisigwaldkliniken Bethanien, Chemnitz, Germany|Klinik Essen-Mitte, Essen, Germany|Univ Klinikum Der Ernst-Moritz-Arndt-Univ Greifswald, Greifswald, Germany|Uni Hamburg-Eppendorf, Hamburg, Germany|Local Institution, Heidelberg, Germany|Universitaetsklinikum Jena, Jena, Germany|Universitatsklinikum Giessen Und Marburg, Marburg, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany|Local Institution, Nuernberg, Germany|Klinikum Der Universitaet Regensburg, Regensburg, Germany|Klinikum Stuttgart, Stuttgart, Germany|Alexandra General Hospital, Athens, Greece|Theagenio Hospital, Thessaloniki, Greece|Local Institution, Wilton, Cork, Ireland|Adelaide And Meath Hospital, Dublin, Ireland|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Ramat Gan, Israel|Local Institution, Zerifin, Israel|Ospedale S. Donato - Usl 8, Arezzo, Italy|ASST Papa Giovanni XXIII, Bergamo, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Local Institution, Pavia, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Arcispedale S. Maria Nuova - A.O. Reggio Emilia, Reggio Emilia, Italy|Istituto Regina Elena, Roma, Italy|Azienda Ospedaliera S. Camillo Forlanini, Roma, Italy|AOUS - Policlinico S.Maria Alle Scotte, Siena, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Sapporo-shi, Hokai-do, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Nagasaki-shi, Nagasaki, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Higashinari-ku, Osaka, Japan|Local Institution, Osaka-Sayama-Shi, Osaka, Japan|Local Institution, Hamamatsu-shi, Shizuoka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Seongnam-si, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Df, Distrito Federal, Mexico|Instituto Nacional De Cancerologia, Mexico City, Distrito Federal, Mexico|Arke Estudios Clinicos Sa De Cv, Mexico, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Maastrict, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Arequipa, Peru|Clinica Internacional sede San Borja, Lima, Peru|Klinika Onkologii i Radioterapii, Gdansk, Poland|Regionalny Osrodek Onkologiczny, Lodz, Poland|Mazovia Szpital, Warsaw, Poland|Local Institution, Wroclaw, Poland|Oddzial Onkologii Klinicznej, Wroclaw, Poland|Local Institution, Bucuresti, Romania|Local Institution, Craiova, Romania|Local Institution, Floresti, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Hospital Universitari Germans Trias I Pujol, Badalona-barcelona, Spain|Hospital General Universitari Vall D'Hebron, Barcelona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Ramon Y Cajal, Madrid, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|H. U. Marques de Valdecilla, Santander, Spain|Hospital General Universitario Virgen Del Rocio, Sevilla, Spain|Local Institution, Lund, Sweden|Kantonsspital Basel, Basel, Switzerland|OnkoZentrum Zurich, Zuerich, Switzerland|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Cardiff, Cardiganshire, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Edinburgh, Midlothian, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Cancer Research Centre, Sheffield, Yorkshire, United Kingdom|Local Institution, London, United Kingdom		https://ClinicalTrials.gov/show/NCT02632409
70	NCT02419417	Study of BMS-986158 in Subjects With Select Advanced Cancers	BET	Recruiting	No Results Available	Advanced Tumors	Drug: BMS-986158|Biological: Nivolumab	Number of Adverse Events (AEs)|Number of Serious Adverse Events (SAEs)|Number of AEs leading to discontinuation|Number of laboratory test toxicity grade shifting from baseline|Best Overall Response|Objective Response Rate (ORR)|Duration of Response|Maximum observed plasma concentration (Cmax)|Time of maximum observed plasma concentration (Tmax)|Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))|Area under the concentration-time curve in one dosing interval (AUC(TAU))|Apparent terminal phase half-life (T-HALF)|Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))|Apparent total body clearance, reported only for parent, not for metabolite (CLT/F)|Apparent volume of distribution of terminal phase, reported only for parent, not for metabolite (Vz/F)|Minimum observed concentration within a dosing interval (Cmin)|Concentration at the end of a dosing interval (Ctau)|Trough observed plasma concentration (this includes predose concentrations (C0) and concentrations at the end of dosing interval (Ctau)) (Ctrough)|Degree of Fluctuation or Fluctuation Index ([Cmax-Cmin)/Css-avg])|[Cmax - Cmin] / Cmin; to be calculated at steady-state (Swing)|Accumulation Index (AI)|Effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (T-HALFeff)|Ratio of metabolite Cmax to parent Cmax, corrected for molecular weight (MR_Cmax)|Ratio of metabolite AUC(0-T) to parent AUC(0-T), corrected for molecular weight (MR_AUC(0-T))|Ratio of metabolite AUC(INF) to parent AUC(INF), corrected for molecular weight (following single dose only) (MR_AUC(INF))|Ratio of metabolite AUC(TAU) to parent AUC(TAU), corrected for molecular weight (MR_AUC(TAU))|Electrocardiogram (ECG) QT (time of ventricular activity including both depolarization and repolarization) Interval	Bristol-Myers Squibb	All	12 Years and older   (Child, Adult, Older Adult)	Phase 1|Phase 2	150	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA011-001|2015-000324-29	June 5, 2015	December 2, 2021	December 3, 2021	April 17, 2015	null	August 29, 2018	City Of Hope National Medical Center, Duarte, California, United States|University Of Colorado, Aurora, Colorado, United States|Local Institution, Portland, Oregon, United States|Institute for Translational Oncology Research-ITOR, Greenville, South Carolina, United States|Local Institution, Melbourne, Victoria, Australia|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Lyon Cedex 08, France|Local Institution, Villejuif, France|Local Institution, Maastrict, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Newcastle Upon Tyne, United Kingdom|Local Institution, Whitchurch, United Kingdom		https://ClinicalTrials.gov/show/NCT02419417
71	NCT02472977	Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors	CXCessoR4	Terminated	Has Results	Solid Tumor	Drug: Ulocuplumab|Drug: Nivolumab	Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Immune-mediated AEs|Objective Response Rate (ORR) Per RECIST 1.1 Criteria|Overall Survival (OS)|Number of Participants With Laboratory Abnormalities|Number of Participants With Electrocardiogram Abnormalities|Progression-Free Survival (PFS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	61	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	CA212-115|2015-000136-15	July 13, 2015	January 27, 2017	January 27, 2017	June 16, 2015	March 29, 2018	November 1, 2018	University Of Colorado Hosp, Aurora, Colorado, United States|Indiana University Health, Indianapolis, Indiana, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Local Institution, Helsinki, Finland	"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02472977/SAP_000.pdf|"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02472977/Prot_001.pdf	https://ClinicalTrials.gov/show/NCT02472977
72	NCT02488759	An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors	CheckMate358	Recruiting	No Results Available	Various Advanced Cancer	Drug: Nivolumab|Drug: Ipilimumab|Drug: Relatlimab|Drug: Daratumumab	The safety and tolerability will be measured by the incidence of drug-related adverse events (AEs) and serious adverse events (SAEs)|Objective response rate|Rate of surgery delay|Progression-free survival|Overall survival|Duration of response	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	600	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-358|2015-000230-29	October 8, 2015	May 13, 2019	December 31, 2019	July 2, 2015	null	October 19, 2018	H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Local Institution, New Orleans, Louisiana, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Lutherville, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Desc. Med Ctr, Boston, Massachusetts, United States|University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Memorial Sloan-Kettering Cancer Center-Breast Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|UPMC Eye and Ear Institute, Pittsburgh, Pennsylvania, United States|Sanford Clinic Clinical Research, Sioux Falls, South Dakota, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Brussels, Belgium|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Marseille Cedex 9, France|Local Institution, Paris, France|Centre Claudius Regaud, Toulouse Cedex 9, France|Institut Gustave Roussy, Vlllejuif, France|Local Institution, Essen, Germany|Local Institution, Heidelberg, Germany|Local Institution, Heilbronn, Germany|Local Institution, Wuerzburg, Germany|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Ciudad de Mexico, Distrito Federal, Mexico|Local Institution, Oaxaca de Juarez, Oaxaca, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Utrecht, Netherlands|Local Institution, Craiova, Romania|H. Univ. Vall dHebron, Barcelona, Spain|Hospital Madrid Norte Sanchinarro, Madrid, Spain|Clinica Universitaria De Navarra, Navarra, Spain|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Birmingham, WEST Midlands, United Kingdom|Local Institution, Glasgow, United Kingdom|Local Institution, London, United Kingdom		https://ClinicalTrials.gov/show/NCT02488759
73	NCT02253992	An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma		Active, not recruiting	No Results Available	Advanced Solid Tumors|Advanced B-cell NHL	Biological: Urelumab|Biological: Nivolumab	Safety as measured by the rate of adverse events (AEs) and Serious Adverse Events (SAEs)|Best Overall Response (BOR)|Objective response rate (ORR)|Duration of Response (DOR)|Progression-free survival rate (PFSR)|Maximum observed serum concentration (Cmax) of Urelumab,(µg/mL)|Time of maximum observed serum concentration (Tmax) of Urelumab, (hr)|Area under the concentration-time curve in one dosing interval (AUCTAU) of Urelumab (µg.hr/mL)|Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUCinf) of Urelumab (µg.hr/mL)|Total body clearance (CLT) of Urelumab (L/day)|Volume of distribution at steady state (Vss) of Urelumab|Half life (t1/2) of Urelumab|Trough concentration (Cmin) of Urelumab (µg/mL)|Occurrence of specific anti-drug antibodies (ADA) to Urelumab and Nivolumab|Anti-drug Antibody (ADA) status of the subject in response to Urelumab and Nivolumab|Nivolumab end of Infusion concentration (EOI)|Trough concentration (Cmin) of Nivolumab (µg/mL)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	232	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA186-107|2014-002241-22	September 29, 2014	June 27, 2019	September 27, 2019	October 1, 2014	null	October 25, 2018	Stanford University School Of Medicine, Palo Alto, California, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|University Of Chicago, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Lutherville, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|NYU Langone Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Md Anderson, Houston, Texas, United States|Local Institution, Besancon, France|Local Institution, Marseille, France|Local Institution, Rennes Cedex 9, France|Local Institution, Villejuif, France|Universitaetsklinikum Essen, Essen, Germany|Clinica Universitaria De Navarra, Pamplona, Spain		https://ClinicalTrials.gov/show/NCT02253992
74	NCT03704077	An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma		Not yet recruiting	No Results Available	Gastric Cancer|Cancer of the Stomach|Stomach Cancer|Gastroesophageal Junction	Biological: Relatlimab + Nivolumab|Biological: Nivolumab|Drug: Paclitaxel|Drug: Ramucirumab	Overall response rate (ORR)|Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Incidence of AEs leading to discontinuation|Incidence of deaths|Incidence of laboratory abnormalities|ORR|Duration of response (DOR)|Progression free survival (PFS)|Overall survival (OS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	610	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA224-061|2018-001070-20	May 15, 2019	January 3, 2021	July 11, 2023	October 12, 2018	null	November 14, 2018	Local Institution, Daphne, Alabama, United States|Local Institution, Bakersfield, California, United States|Local Institution, Fullerton, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Redondo Beach, California, United States|Local Institution, Santa Barbara, California, United States|Local Institution, Aurora, Colorado, United States|Local Institution, Lakewood, Colorado, United States|Local Institution, Miami, Florida, United States|Local Institution, Tampa, Florida, United States|Local Institution, Marietta, Georgia, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Saint Louis, Missouri, United States|Local Institution, New Brunswick, New Jersey, United States|Local Institution, Chapel Hill, North Carolina, United States|Local Institution, Charlotte, North Carolina, United States|Local Institution, Fargo, North Dakota, United States|Local Institution, Allentown, Pennsylvania, United States|Local Institution, Sioux Falls, South Dakota, United States|Local Institution, Vancouver, Washington, United States|Local Institution, Viedma, RIO Negro, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Caba, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Northmead, New South Wales, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Malvern, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Murdoch, Western Australia, Australia|Local Institution, Bedford Park, Australia|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Jau, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Hamilton, Ontario, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Sherbrooke, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Medellin, Colombia|Local Institution, Berlin, Germany|Local Institution, Cologne, Germany|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Frankfurt am Main, Germany|Local Institution, Freiburg, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Local Institution, Jena, Germany|Local Institution, Mainz, Germany|Local Institution, Mannheim, Germany|Local Institution, Marburg, Germany|Local Institution, Paderborn, Germany|Local Institution, Reutlingen, Germany|Local Institution, Wiesbaden, Germany|Local Institution, Bergamo, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Napoli, Italy|Local Institution, Reggio Emilia, Italy|Local Institution, Tuxtla Gutierrez, Chiapas, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, ZONA Centro. LEON, Guanajuato, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Local Institution, Rio Piedras, Puerto Rico|Local Institution, Bucuresti, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Floresti, Romania|Local Institution, Badajoz, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Valencia, Spain		https://ClinicalTrials.gov/show/NCT03704077
75	NCT03143153	A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin	CheckMate 648	Recruiting	No Results Available	Various Advanced Cancer	Biological: Nivolumab|Biological: Ipilimumab|Drug: Cisplatin|Drug: Fluorouracil	Overall survival (OS)|Progression-free Survival (PFS)|Objective Response Rate (ORR)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	939	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-648|2016-001514-20	June 19, 2017	May 25, 2020	December 30, 2021	May 8, 2017	null	November 20, 2018	Southern Cancer Center, Inc., Mobile, Alabama, United States|Local Institution, Tucson, Arizona, United States|Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Baptist Health Medical Group Oncology LLC, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Local Institution, Chicago, Illinois, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Local Institution, Durham, North Carolina, United States|Oncology Associates Of Oregon, Pc, Eugene, Oregon, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, United States|Local Institution, Austin, Texas, United States|Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Oncology & Hematology Associates Of Southwest Virginia, Inc., Roanoke, Virginia, United States|West Virginia University-Mbrcc, Morgantown, West Virginia, United States|Hospital Municipal De Gastroenterologia Dr.Udaondo, Capital Federal, Buenos Aires, Argentina|Hospital Provincial Del Centenario, Rosario, Santa FE, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Centro Oncologico Riojano Integral, La Rioja, Argentina|Local Institution, Randwick, New South Wales, Australia|Local Institution, Tamworth, New South Wales, Australia|Local Institution, Douglas, Queensland, Australia|Local Institution, Murdoch, Western Australia, Australia|Local Institution, Salzburg, Austria|Local Institution, Salvador, Bahia, Brazil|Local Institution, Ipatinga, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Jau, SAO Paulo, Brazil|Local Institution, Sao Jose Do Rio Preto, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Trois-Rivieres, Quebec, Canada|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Local Institution, Independencia, Santiago, Chile|Local Institution, Santiago, Chile|Local Institution, Hefei, Anhui, China|Local Institution, Hefei, Anhui, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Shantou, Guangdong, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Xian, Shaanxi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Shanghai, China|Oncologos Del Occidente Sa, Pereira, Risaralda, Colombia|Instituto Nac. de Cancerologia, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Interni hematologicka a onkologicka klinika, Brno, Czechia|Klinika komplexni onkologicke pece, Brno, Czechia|Komplexni onkologicke centrum, Novy Jicin, Czechia|Local Institution, Odense, Denmark|Local Institution, Caen, France|Local Institution, Lille, France|Local Institution, Montpellier, France|Local Institution, Rennes Cedex, France|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Local Institution, Hong Kong, Hong Kong|Local Institution, Kowloon, Hong Kong|ASST Papa Giovanni XXIII, Bergamo, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|I.O.V. Istituto Oncologico Veneto Ircss, Padova, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Fukushima-shi, Fukushima, Japan|Local Institution, Gifu City, Gifu, Japan|Local Institution, Ota, Gunma, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Kobe, Hyogo, Japan|Local Institution, Kanazawa, Ishikawa, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Isehara, Kanagawa, Japan|Local Institution, Kawasaki-shi, Kanagawa, Japan|Local Institution, Sagamihara-shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Sendai, Miyagi, Japan|Local Institution, Niigata-City, Niigata, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Chuo-ku, Osaka, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Osaka Sayama-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Takatsuki City, Osaka, Japan|Local Institution, Hidaka, Saitama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Shimotsuga-gun, Tochigi, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Minato-ku, Tokyo, Japan|Local Institution, Shinagawa-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Toyama-shi, Toyama, Japan|Local Institution, Wakayama-shi, Wakayama, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Local Institution, Akashi, Japan|Local Institution, Chiba, Japan|Local Institution, Kyoto, Japan|Local Institution, Shizuoka, Japan|Local Institution, Yokohama, Japan|Local Institution, Busan, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Daejeon, Korea, Republic of|Local Institution, Jeonju-si, Korea, Republic of|Local Institution, Seongnam-si, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Ulsan, Korea, Republic of|Local Institution, Tuxtla Gutierrez, Chiapas, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Merida, Yucatan, Mexico|Hospital Nacional Daniel Alcides Carrion, Callao, Peru|Local Institution, Lima, Peru|Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|II Klinika Chirurgii Ogolnej, Gastroenterologicznej i Nowotworow Ukladu Pokarmowego, Lublin, Poland|Klinika Gastroenterologii Onkologicznej, Warszawa, Poland|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Focus Lab Plus SRL, Bucuresti, Romania|CF Clinical Hospital Cluj-Napoca, Cluj-Napoca, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|County Emergency Hospital Suceava, Suceava, Romania|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Changhua, Taiwan|Local Institution, Kaohsiung City, Taiwan|Local Institution, Kaohsiung, Taiwan|Local Institution, Kaohsiung, Taiwan|Local Institution, Keelung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan City, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei City, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Diyarbak?r, Turkey|Local Institution, Edrine, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT03143153
76	NCT03414983	An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread	CheckMate 9X8	Recruiting	No Results Available	Colorectal Cancer	Biological: Nivolumab|Drug: Oxaliplatin|Drug: Leucovorin|Drug: Fluorouracil|Drug: Bevacizumab	Progression Free Survival (PFS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Duration of Response (DoR)|Time to Response (TTR)|Overall Survival (OS)|Number of Adverse Events ( AEs)|Number of Serious Adverse Events ( SAEs)|Number of deaths|Number of clinical abnormalities	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	180	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-9X8|2017-003662-27	February 14, 2018	August 16, 2021	August 18, 2022	January 30, 2018	null	November 20, 2018	Uab Comprehensive Cancer Center, Birmingham, Alabama, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Local Institution, San Diego, California, United States|Local Institution, Santa Barbara, California, United States|University of Colorado, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Local Institution, Jacksonville, Florida, United States|Baptist Health Medical Group, Miami, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, United States|Local Institution, Indianapolis, Indiana, United States|Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States|Regional Cancer Care Associates, LLC, Bethesda, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Papillion, Nebraska, United States|Comprehensive Cancer Centers Of Nevada, Henderson, Nevada, United States|Broome Oncology, Johnson City, New York, United States|Laura & Isaac Perlmutter Cancer Ctr at NYU Langone, New York, New York, United States|Local Institution, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Northwest Cancer Specialists, P.C., Tualatin, Oregon, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Sanford Research, Sioux Falls, South Dakota, United States|Local Institution, Chattanooga, Tennessee, United States|Local Institution, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology, P.A., Bedford, Texas, United States|Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology-Fort Worth 12th Ave, Fort Worth, Texas, United States|Texas Oncology-Tyler, Longview, Texas, United States|Cancer Centers of South Texas, San Antonio, Texas, United States|Virginia Cancer Center, Richmond, Virginia, United States|Oncology & Hematology Associates Of Southwest Virginia, Inc., Roanoke, Virginia, United States|University Of Wisconsin, Madison, Wisconsin, United States|Local Institution, Edmonton, Alberta, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Quebec, Canada|Centre integre universitaire de sante et de service sociaux de l'estrie - CHUS, Sherbrooke, Quebec, Canada|Local Institution, Trois-Rivieres, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Fundacion De Investigacion De Diego, San Juan, Puerto Rico|H. Univ. Vall dHebron, Barcelona, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Hosp. Univ. Puerta De Hierro, Majadahonda - Madrid, Spain		https://ClinicalTrials.gov/show/NCT03414983
77	NCT02823574	Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	CheckMate 714	Active, not recruiting	No Results Available	Head and Neck Cancer	Biological: Nivolumab|Biological: Ipilimumab|Other: Placebo	Overall response rate (ORR) in platinum refractory subgroup|Duration of Response (DOR) in platinum refractory subgroup|ORR in platinum eligible subgroup|Progression Free Survival (PFS) in platinum eligible and refractory subgroups|Overall Survival (OS) in platinum eligible and refractory subgroups|DOR in platinum eligible subgroup|Tumor mutation burden (TMB) in platinum eligible and refractory subgroups	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	400	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CA209-714|2016-001645-64	September 22, 2016	January 30, 2019	January 30, 2024	July 6, 2016	null	November 6, 2018	University of Arizona Cancer Center, Tucson, Arizona, United States|City Of Hope, Duarte, California, United States|Los Angeles Cancer Network, Los Angeles, California, United States|Ucla Department Of Medicine, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Sutter Cancer Center, Sacramento, California, United States|Ucsf, San Francisco, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Dekalb Medical Center, Decatur, Georgia, United States|University Of Chicago, Chicago, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|University Of Louisville, Louisville, Kentucky, United States|Oncology Associated Of Western Kentucky, Paducah, Kentucky, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mass General Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Mission Hospital, Inc, Asheville, North Carolina, United States|University Of Cincinnati Medical School, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|UPMC, Pittsburgh, Pennsylvania, United States|Donald Guthrie Foundation, Sayre, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University Of Washington, Seattle, Washington, United States|Centro de Investigacion Pergamino SA- Clinica Pergamino, Pergamino, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Buenos Aires, Argentina|Universitair Ziekenhuis Gent, Gent, Belgium|Az Nikolaas, Sint-Niklaas, Belgium|Ucl Mont-Godinne, Yvoir, Belgium|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ipatinga, Minas Gerais, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Caxias do Sul, RIO Grande DO SUL, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Santo Andre, SAO Paulo, Brazil|Local Institution, Sao Jose do Rio Preto, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Cross Cancer Institute., Edmonton, Alberta, Canada|The Ottawa General Hospital, Ottawa, Ontario, Canada|University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Quebec, Canada|CHU de Quebec - Universite Laval - Hopital de l'Enfant Jesus, Quebec, Canada|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Onkologicka klinika, Olomouc, Czechia|Helsinki University Hospital, Helsinki, Finland|Chu Amiens - Groupe Hospitalier Sud, Amiens Cedex 1, France|Local Institution, Bordeaux, France|Centre Jean Perrin, Clermont Ferrand cedex 01, France|Local Institution, Clichy, France|Centre Leon Berard, Lyon Cedex 08, France|Hopital De La Timone, Marseille Cedex 5, France|Local Institution, Nice, France|Local Institution, Rennes Cedex, France|Local Institution, Villejuif, France|St. James'S Hospital, Dublin 8, Dublin, Ireland|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Local Institution, Merida, Yucatan, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Oaxaca, Mexico|NKI AVL, Amsterdam, Netherlands|Vu Medical Centre, Amsterdam, Netherlands|Umcg, Universitair Medisch Centrum Groningen, Groningen, Netherlands|Haukeland University Hospital, Bergen, Norway|The Norwegian Radium Hospital, Oslo, Norway|Centrul Medical Sanador, Bucharest, Romania|CF Clinical Hospital Cluj-Napoca, Cluj-Napoca, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|Institutul Regional de Oncologie Iasi, Iasi, Romania|County Emergency Hospital Suceava, Suceava, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Ryazan, Russian Federation|Local Institution, Port Elizabeth, Eastern CAPE, South Africa|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, A Coruna, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Marbella, Spain|Local Institution, San Sabastian Gipuzkoa, Spain|Sahlgrenska University Hospital, Goteborg, Sweden|Local Institution, Lund, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Adana, Turkey|Local Institution, Antalya, Turkey|Local Institution, Izmir, Turkey|Aberdeen Royal Infirmary, Aberdeen, Aberdeenshire, United Kingdom|Royal Marsden Nhs Foundation Trust, London, Greater London, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, Merseyside, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, Tyne and Wear, United Kingdom|Local Institution, Cardiff, United Kingdom|Beatson Oncology Centre, Glasgow, United Kingdom		https://ClinicalTrials.gov/show/NCT02823574
78	NCT02750514	An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer	FRACTION-Lung	Recruiting	No Results Available	Advanced Cancer	Biological: Nivolumab|Drug: Dasatinib|Biological: Relatlimab|Biological: Ipilimumab|Drug: BMS-986205	Objective Response Rate (ORR)|Duration of Response (DOR)|Progression-free Survival Rate (PFSR)|Safety and tolerability of Nivolumab based on incidence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths|Safety and tolerability of Nivolumab & Dasatinib combination based on incidence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths|Safety and tolerability of Nivolumab & BMS-986016 combination based on incidence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths|Safety and tolerability of Nivolumab & Ipilimumab combination based on incidence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths|Safety and tolerability of Nivolumab & BMS-966205 combination based on incidence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	504	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA018-001	May 6, 2016	April 28, 2021	April 29, 2021	April 25, 2016	null	October 4, 2018	City of Hope National Medical Center, Duarte, California, United States|University of California San Diego (UCSD), La Jolla, California, United States|University of Southern California (USC), Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of Californa, Los Angeles (UCLA), Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Local Institution, Washington, District of Columbia, United States|Local Institution, Atlanta, Georgia, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|University of Maryland - Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute (DFCI), Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University, The Center for Advanced Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Univ of NC Shool of Medicine, Chapel Hill, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Northwest Cancer Specialists, Portland, Oregon, United States|Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|The West Clinic, P.C. d/b/a West Cancer Center, Germantown, Tennessee, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Sammons Cancer Center (Uso), Dallas, Texas, United States|Texas Oncology, P.A., Fort Sam Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Us Oncology, Tyler, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Virginia Cancer Care Specialist, PC, Fairfax, Virginia, United States|University of Washington-Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Clayton, Australia|Local Institution, Salzburg, Austria|Juravinski Cancer Centre, Hamilton Health Sciences-Mcmaster Univeristy's Faculty Of Health Sciences, Hamilton, Ontario, Canada|University Of Ottawa - The Ottawa Hospital Cancer centre, Ottawa, Ontario, Canada|Local Institution, Edmonton, Canada|Local Institution, Copenhagen, Denmark|Local Institution, Paris, France|Local Institution, Toulouse, France|Local Institution, Villejuif Cedex, France|Local Institution, Milano, Italy|Local Institution, Milan, Italy|Local Institution, Rozzano, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Oslo, Norway|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Stockholm, Sweden|Local Institution, Lausanne, Switzerland|Local Institution, London, Greater London, United Kingdom		https://ClinicalTrials.gov/show/NCT02750514
79	NCT01928394	A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors		Active, not recruiting	No Results Available	Advanced or Metastatic Solid Tumors	Biological: Nivolumab|Biological: Ipilimumab|Drug: Cobimetinib	Objective response rate (ORR)|Number of treatment-related adverse events (AEs) leading to drug discontinuations|Progression Free Survival (PFS)|Overall Survival (OS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	1620	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-032|2013-002844-10	October 7, 2013	May 31, 2019	December 22, 2020	August 23, 2013	null	November 19, 2018	Northwest Alabama Cancer Center, Pc, Muscle Shoals, Alabama, United States|University Of Colorado, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|University Of Florida, Gainesville, Florida, United States|H. Lee Moffitt Cancer Center & Research Inst, Inc, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Dana Farber/Partners Cancercare, Inc., Boston, Massachusetts, United States|Dana-Farber/ Partners Cancer Care, Inc., Boston, Massachusetts, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Winthrop University Hospital, Mineola, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke Cancer Institute, Durham, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Copenhagen, Denmark|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Bonn, Germany|Local Institution, Frankfurt, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kassel, Germany|Azienda Ospedaliera S.Orsola-Malpighi, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Istituto Oncologico Veneto IOV, Padova, Italy|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT01928394
80	NCT03215706	A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC	CheckMate 9LA	Recruiting	No Results Available	Non-Small Cell Lung Cancer	Biological: Ipilimumab|Biological: Nivolumab|Drug: Carboplatin|Drug: Paclitaxel|Drug: Pemetrexed|Drug: Cisplatin	Overall Survival (OS)|Progression Free Survival (PFS)|Overall Response Rate (ORR)|ORR|PFS|OS	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	700	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-9LA|2017-001195-35	July 20, 2017	August 25, 2019	May 20, 2020	July 12, 2017	null	November 29, 2018	Memorial Health Systems, Colorado Springs, Colorado, United States|Cancer Center Of Central Connecticut, Plainville, Connecticut, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, LaGrange, Georgia, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Henry Ford Health System, Detroit, Michigan, United States|Broome Oncology, Johnson City, New York, United States|Winthrop University Hospital, Mineola, New York, United States|The Ohio State University, Columbus, Ohio, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Southwest Regional Cancer Clinic, Saint George, Utah, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|Local Institution, Milwaukee, Wisconsin, United States|Instituto Alexander Fleming, Caba, Buenos Aires, Argentina|Instituto Medico Rio Cuarto S.A., Rio Cuarto, Cordoba, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Sanatorio Parque, Rosario, Santa FE, Argentina|Local Institution, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Gosford, New South Wales, Australia|Local Institution, Bedford Park, South Australia, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|St John of God Murdoch Hospital, Murdoch, Western Australia, Australia|Local Institution, Charleroi, Belgium|Local Institution, Leuven, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Natal, RIO Grande DO Norte, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Blumenau, Santa Catarina, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose De Rio Preto, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Mcgill University Health Center - Royal Victoria Hospital, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Bradford Hill Centro de Investigaciones Clinicas, Santiago de Chile, Metropolitana, Chile|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Hospital Clinico Vina Del Mar, Vina Del Mar, Valparaiso, Chile|Local Institution, Changchun, Jilin, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Amiens Cedex 1, France|Local Institution, Caen, France|Local Institution, Lille Cedex, France|Local Institution, Lyon Cedex 08, France|Local Institution, Montpellier Cedex, France|Local Institution, Nantes, France|Local Institution, Paris, France|Local Institution, Pierre Benite, France|Local Institution, Saint-Brieuc, France|Local Institution, Berlin, Germany|Asklepios Fachkliniken Munchen-Gauting Thorakale Onkologie, Gauting, Germany|Klinik Schillerhoehe, Gerlingen, Germany|Krankenhaus Grosshansdorf, Grosshansdorf, Germany|Lungenklinik Hemer, Hemer, Germany|Fachklinik Fuer Lungenkrankheiten, Immenhausen, Germany|Universitaetsklinikum Magdeburg A. o. R., Magdeburg, Germany|Klinikum Bogenhausen, Muenchen, Germany|Local Institution, Dublin, Ireland|Local Institution, Limerick, Ireland|Ospedale San Luca, Lucca, Italy|Ospedale San Raffaele, Milano, Italy|Azienda Ospedaliera Monaldi, Napoli, Italy|Local Institution, Fukushima-shi, Fukushima, Japan|Local Institution, Maebashi-shi, Gunma, Japan|Local Institution, Ota-shi, Gunma, Japan|Local Institution, Hiroshima-shi, Hiroshima, Japan|Local Institution, Hiroshima-shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Akashi-shi, Hyogo, Japan|Local Institution, Himeji-shi, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Yokohama-Shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Habikino-shi, Osaka, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Oncotech, La Paz, BAJA Californa SUR, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Faicic S. de Rl. de Cv, Veracruz, Veracruz, Mexico|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Oddzial Onkologii, Bytom, Poland|Local Institution, Elblag, Poland|Local Institution, Gdansk, Poland|Local Institution, Bucharest, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Moscow, Russian Federation|Local Institution, St.petersburg, Russian Federation|Comp. Hosp. Univ. A Coruna, A Coru?a, Spain|H. Univ. Vall dHebron, Barcelona, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hospital Carlos Haya De Malaga, Malaga, Spain|Hospital Universitario La Fe, Valencia, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Maidstone, Kent, United Kingdom|Local Institution, Guildford, Surrey, United Kingdom|Local Institution, Tauton, United Kingdom		https://ClinicalTrials.gov/show/NCT03215706
81	NCT03251924	A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors		Recruiting	No Results Available	Cancer|Tumors|Neoplasm|Malignancy	Drug: BMS-986226|Biological: Nivolumab|Biological: Ipilimumab	Incidence of adverse events (AE)|Incidence of serious adverse events (SAE)|Incidence of AE due to discontinuation|Incidence of AE resulting in death|Incidence of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria|Incidence of clinical laboratory test abnormalities graded according to common terminology criteria for adverse events (CTCAE)|Objective response rate (ORR) measure by Clopper-Pearson method|Median Duration of Response (mDOR) measured by Kaplan-Meier method|Progression Free Survival (PFS) measured by Kaplan-Meier method|Maximum observed plasma concentration (Cmax)|Time of maximum observed plasma concentration (Tmax)|Area under the concentration-time curve from time 0 to the time of the last [AUC (0-T)]|Area under the concentration-time curve in 1 dosing interval [AUC(TAU)]|Incidence of anti-drug antibodies to BMS-986226 assessed by immunoassay|Change from baseline in immunoassay for BMS-986226	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	277	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA021-002|2017-000238-73	August 31, 2017	April 6, 2020	December 5, 2020	August 16, 2017	null	October 4, 2018	Local Institution, Boston, Massachusetts, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Local Institution, Hamilton, Ontario, Canada|Local Institution, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT03251924
82	NCT03386838	An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck		Terminated	No Results Available	Head and Neck Cancer	Biological: Nivolumab|Drug: BMS-986205|Biological: Cetuximab|Drug: Cisplatin|Drug: Carboplatin|Drug: Fluorouracil	Progression-free survival (PFS) as determined by Blinded Independent Central Review (BICR) using RECIST 1.1|Overall survival (OS)|Objective response rate (ORR) determined by BICR using RECIST 1.1|Number of adverse events (AE)|Number of serious adverse events (SAE)|Time to meaningful symptomatic deterioration (TTSD)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	1	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA017-063|2017-003059-46	March 28, 2018	April 19, 2018	April 19, 2018	December 29, 2017	null	April 30, 2018	Allegheny General Hospital, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03386838
83	NCT03661320	A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC		Recruiting	No Results Available	Bladder Cancer|Muscle-Invasive Bladder Cancer|BMS-986205	Biological: Nivolumab|Drug: BMS-986205|Drug: Gemcitabine|Drug: Cisplatin|Drug: BMS-986205 Placebo	Pathological Complete Response (pCR) rate of neoadjuvant Nivo/BMS-986205 +Chemo|Event-Free Survival (EFS) of neoadjuvant Nivo/BMS-986205 + Chemo followed by continued Nivo/BMS-986205 after RC|Pathological Complete Response (pCR) rate of neoadjuvent Chemo Alone|Pathological Complete Response (pCR) rate of neoadjuvant Nivo + Chemo|Event-Free Survival (EFS) of SOC Chemo after RC|Event-Free Survival (EFS) of neoadjuvant Nivo + Chemo followed by continued Nivo after RC|Overall Survival (OS)|Incidence of Adverse Events (AE)|Incidence of Serious Adverse Events (SAE)|Incidence of Laboratory abnormalities	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	1200	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA017-078|2017-004692-31	October 12, 2018	November 28, 2023	December 30, 2026	September 7, 2018	null	November 29, 2018	Local Institution, Mobile, Alabama, United States|Arizona Oncology Associates, Tucson, Arizona, United States|Local Institution, Irvine, California, United States|Local Institution, La Jolla, California, United States|Local Institution, Sacramento, California, United States|Local Institution, Littleton, Colorado, United States|Local Institution, New Haven, Connecticut, United States|Local Institution, Newark, Delaware, United States|Local Institution, Pensacola, Florida, United States|Local Institution, Tampa, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, Chicago, Illinois, United States|Local Institution, Peoria, Illinois, United States|Local Institution, Boston, Massachusetts, United States|Minnesota Oncology Hematology, Minneapolis, Minnesota, United States|Local Institution, Minneapolis, Minnesota, United States|Local Institution, Omaha, Nebraska, United States|Comprehensive Cancer Centers Of Nevada, Las Vegas, Nevada, United States|New York Oncology Hematology, Pc, Albany, New York, United States|Local Institution, Lake Success, New York, United States|Local Institution, New York, New York, United States|Local Institution, Tualatin, Oregon, United States|Local Institution, Nashville, Tennessee, United States|Local Institution, Austin, Texas, United States|Local Institution, Dallas, Texas, United States|Local Institution, Fort Sam Houston, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Local Institution, Woden, Australian Capital Territory, Australia|Local Institution, Kingswood, New South Wales, Australia|Local Institution, St Leonards, New South Wales, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Murdoch, Western Australia, Australia|Local Institution, Klagenfurt Am Woerthersee, Austria|Local Institution, Krems, Austria|Local Institution, Linz, Austria|Local Institution, Wien, Austria|Local Institution, Antwerpen, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Ipatinga, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Jau, SAO Paulo, Brazil|Local Institution, Sao Jose Do Rio Preto, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, ?lborg, Denmark|Local Institution, Arhus, Denmark|Local Institution, Herlev, Denmark|Local Institution, Besancon, France|Local Institution, Bordeaux, France|Local Institution, Marseille, France|Local Institution, Nice, France|Local Institution, Strasbourg Cedex, France|Local Institution, TOULOUSE Cedex 9, France|Local Institution, Aachen, Germany|Local Institution, Erfurt, Germany|Local Institution, Essen, Germany|Local Institution, Goettingen, Germany|Local Institution, Heidelberg, Germany|Local Institution, Herne, Germany|Local Institution, Jena, Germany|Local Institution, Luebeck, Germany|Local Institution, Magdeburg, Germany|Local Institution, Mainz, Germany|Local Institution, Mainz, Germany|Local Institution, Muenchen, Germany|Local Institution, Nuernberg, Germany|Local Institution, Trier, Germany|Local Institution, Athens, Greece|Local Institution, Larissa, Greece|Local Institution, Beer Sheva, Israel|Local Institution, Haifa, Israel|Local Institution, Ramat Gan, Israel|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Colima, Mexico|Local Institution, Auckland, New Zealand|Local Institution, Christchurch, New Zealand|Local Institution, Lorenskog, Norway|Local Institution, Oslo, Norway|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, Lugo, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Glasgow, United Kingdom|Local Institution, Oxford, United Kingdom		https://ClinicalTrials.gov/show/NCT03661320
84	NCT02247349	BMS-986012 in Relapsed/Refractory SCLC		Active, not recruiting	No Results Available	Small Cell Lung Cancer	Biological: BMS-986012 (anti-fucosyl-GM1)|Biological: Nivolumab	Safety as measured by frequency of worst grade of adverse events (AEs), worst grade of serious adverse events (SAEs), incidence of adverse events leading to discontinuations, and deaths|Maximum observed serum concentration (Cmax) for BMS-986012 (anti-fucosyl-GM1)|Maximum observed serum concentration (Cmax) for BMS-986012 (anti-fucosyl-GM1) in combination with Nivolumab|Time of maximum observed serum concentration (Tmax) for BMS-986012 (anti-fucosyl-GM1)|Time of maximum observed serum concentration (Tmax) for BMS-986012 (anti-fucosyl-GM1) in combination with Nivolumab|Observed serum concentration at the end of a dosing interval (Ctau) for BMS-986012 (anti-fucosyl-GM1)|Observed serum concentration at the end of a dosing interval (Ctau) for BMS-986012 (anti-fucosyl-GM1) in combination with Nivolumab|Area under the serum concentration-time curve from time zero to time t (AUC(0-t)) for BMS-986012 (anti-fucosyl-GM1) in combination with Nivolumab|Area under the serum concentration-time curve from time zero to time t (AUC(0-t)) for BMS-986012 (anti-fucosyl-GM1)|Area under the serum concentration-time curve in one dosing interval (AUC(TAU)) for BMS-986012 (anti-fucosyl-GM1)|Area under the serum concentration-time curve in one dosing interval (AUC(TAU)) for BMS-986012 (anti-fucosyl-GM1) in combination with Nivolumab|Best overall response (BOR) for BMS-986012 (anti-fucosyl-GM1)|Objective Response Rate (ORR) for BMS-986012 (anti-fucosyl-GM1)|Duration of Response for BMS-986012 (anti-fucosyl-GM1)|Progression Free Survival (PFS) for BMS-986012 (anti-fucosyl-GM1)|Progression Free Survival Rate (PFSR) at week "t"; for BMS-986012 (anti-fucosyl-GM1)|Overall Survival (OS) for BMS-986012 (anti-fucosyl-GM1)|Overall Survival Rate (OSR) at month "t" for BMS-986012 (anti-fucosyl-GM1)|Occurrence of specific anti-drug antibodies (ADA) to BMS-986012 every 3 weeks for first 3 cycles then every 4 cycles, at end of treatment and during clinical follow-up|Occurrence of specific anti-drug antibodies (ADA) to BMS-986012 in combination with Nivolumab every 3 weeks for first 3 cycles then every 4 cycles, at end of treatment and during clinical follow-up|Changes in the QTcF following administration of BMS-986012 at multiple timepoints during first cycle, then Day 1 of subsequent cycles and at end of treatment|Changes in the QTcF following administration of BMS-986012 in combination with Nivolumab at multiple timepoints during first cycle, then Day 1 of subsequent cycles and at end of treatment	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	172	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA001-030|2014-002372-89	October 30, 2014	October 16, 2018	October 17, 2018	September 25, 2014	null	October 3, 2018	Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Local Institution, St. Leonards, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Clayton, Victoria, Australia|Uz Gent, Gent, Belgium|Local Institution, Liege, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|Nova Scotia Health Authority QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Seoul, Korea, Republic of|Radboud Universitair Medisch Centrum, Nijmegen, Netherlands|Local Institution, San Juan, Puerto Rico		https://ClinicalTrials.gov/show/NCT02247349
85	NCT03329846	An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma		Active, not recruiting	No Results Available	Melanoma|Skin Cancer	Drug: BMS-986205|Biological: Nivolumab|Drug: Placebo	Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)	Bristol-Myers Squibb	All	12 Years and older   (Child, Adult, Older Adult)	Phase 3	72	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA017-055|2017-002499-14	November 21, 2017	July 31, 2020	July 31, 2020	November 6, 2017	null	October 9, 2018	Angeles Clinic and Research Institute, Los Angeles, California, United States|University Of Colorado, Aurora, Colorado, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|The University of Chicago Medicine, Chicago, Illinois, United States|Oregon Health & Science University, Portland, Oregon, United States|Local Institution, Seattle, Washington, United States|Local Institution, Blacktown, New South Wales, Australia|Melanoma Institute Australia, North Sydney, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Montreal, Quebec, Canada|Local Institution, Quebec, Canada|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Dermatovenerologicka klinika 3. LF UK a FNKV, Praha 10, Czechia|Dermatovenerologicka klinika VFN a 1. LF UK, Praha 2, Czechia|Local Institution, Boulogne-billancourt, France|Local Institution, Saint Etienne Cedex 2, France|Local Institution, Villejuif Cedex, France|Elbe Klinikum Buxtehude, Buxtehude, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Universitaetsklinikum Essen, Essen, Germany|SRH Wald-Kliniken Gera GmbH, Gera, Germany|Georg August Universitaet Goettingen, Goettingen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Nationales Centrum Fuer Tumorerkrakungen (Nct) Heidelberg, Heidelberg, Germany|Ludwig-Maximilians-Universitaet, Muenchen, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Local Institution, Thessaloniki, Greece|Local Institution, Dooradoyle, Limerick, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Meldola, Italy|Local Institution, Milano, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Local Institution, Siena, Italy|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Christchurch, New Zealand|Local Institution, Wellington, New Zealand|Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow, Warszawa, Poland|Hospital Clinic I Provincial, Barcelona, Spain|Complejo Hospitalario de Jaen, Jaen, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Comp. H. U. De Santiago, Santiago Compostela, Spain|Local Institution, Valencia, Spain|Universitaetsspital Zuerich, Zurich, Switzerland|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Belfast, United Kingdom|Local Institution, Cambridge, United Kingdom|Local Institution, Cottingham, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Tauton, United Kingdom		https://ClinicalTrials.gov/show/NCT03329846
86	NCT02741570	Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	CheckMate 651	Recruiting	No Results Available	Head and Neck Cancer	Biological: Nivolumab|Biological: Ipilimumab|Drug: Cetuximab/Erbitux|Drug: Cisplatin/Platinol|Drug: Carboplatin/Paraplatin|Drug: Fluorouracil/Adrucil	Overall Survival (OS) in participants with PD-L1 expressing tumors|Progression Free Survival (PFS) in pariticipants with PD-L1 expressing tumors|OS in all participants|PFS in all pariticipants|Objective Response Rate (ORR) in all participants|Duration of Response (DOR) in all participants	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	930	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-651|2016-000725-39	August 4, 2016	August 14, 2020	August 15, 2025	April 18, 2016	null	July 6, 2018	University of Arizona Cancer Center, Tucson, Arizona, United States|City Of Hope, Duarte, California, United States|Local Institution, San Francisco, California, United States|Board of Trustees of the Leland Stanford Junior University, Stanford, California, United States|21st Century Oncology Of Jacksonville, Llc, Jacksonville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Univ Of Chicago, Chicago, Illinois, United States|Mass General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan, Ann Arbor, Michigan, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|James Cancer Hospital, Columbus, Ohio, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Houston Methodist Medical Center, Houston, Texas, United States|Univ Of Tx. Md Anderson, Houston, Texas, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|Local Institution, Fairfax, Virginia, United States|West Virginia University, Morgantown, West Virginia, United States|Blacktown Hospital, Blacktown, New South Wales, Australia|St Vincent'S Hospital (Nsw), Darlinghurst, New South Wales, Australia|Local Institution, Gosford, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Douglas, Queensland, Australia|Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|Monash Medical Center, Clayton, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Melbourne, Australia|Krankenhaus Der Barmherzigen Schwestern, Linz, Austria|Medical University Of Vienna, Wien, Austria|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RS, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose De Rio Preto, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Amiens, France|Local Institution, Bordeaux, France|Local Institution, La Tronche, France|Local Institution, Lille, France|Local Institution, Lyon, France|Local Institution, Lyon, France|Local Institution, Marseille, France|Local Institution, Nice Cedex 2, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Strasbourg, France|Local Institution, Villejuif Cedex, France|Universitaetsklinikum Bonn, Bonn, Germany|Klinikum Der Albrecht-Ludwigs-Universitat, Freiburg, Germany|Uniklinikum Hamburg-Eppendorf, Hamburg, Germany|Klinikum Der Universitaet, Hannover, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Universitaetsklinikum Leipzig, Leipzig, Germany|Universitaetsmedizin Der Johannes Gutenberg-Universitaet, Mainz, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Muenchen, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Universitat Wurzburg, Wuerzburg, Germany|Local Institution, Athens, Greece|Local Institution, Nea Kifissia, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Dublin 8, Dublin, Ireland|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petah-tikva, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Tel Aviv, Israel|Istituto Romagnolo Per Lo Studio E La Cura Dei Tumori, Meldola, FC, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, MI, Italy|Azienda Ospedaliera Citta della Salute e della Scienza, Torino, TO, Italy|Local Institution, Mestre, VE, Italy|A.O. Santa Croce E Carle, Cuneo, Italy|Azienda Ospedaliera Universitaria Di Modena, Modena, Italy|Aorn Dei Colli, Napoli, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Local Institution, Perugia, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Kashiwa, Chiba, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Akashi-shi, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Isehara, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Natori, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Osakasayaha, Osaka, Japan|Local Institution, Takatsuki-shi, Osaka, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Shimotsuke-shi, Tochigi, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Kita-gun, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Leon de los Aldama, Guanajuato, Mexico|Local Institution, Morelia, Michoacan, Mexico|Joaquin Gabriel Reinoso Toledo, Monterrey, Nuevo LEON, Mexico|Local Institution, Oaxaca, Mexico|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Klinika Onkologii i Radioterapii, Gdansk, Poland|Centrum Onkologii-Inst.Im.M.Sklodowskiej-Curie O.W Gliwicach, Gliwice, Poland|Osrodek Badan Klinicznych, Krakow, Poland|Klinika Nowotworow Glowy i Szyi, Warszawa, Poland|Local Institution, Barcelona, Spain|Local Institution, L?Hospitalet De Llobregat, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Klinik Fur Onkologie, Basel, Switzerland|Universitatsspital Zurich, Zuerich, Switzerland|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Newcastle Upon Tyne, Durham, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Birmingham, WEST Midlands, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Sheffield, United Kingdom		https://ClinicalTrials.gov/show/NCT02741570
87	NCT02996110	A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma	FRACTION-RCC	Recruiting	No Results Available	Advanced Cancer	Biological: Nivolumab|Biological: Ipilimumab|Biological: Relatlimab|Drug: BMS-986205	Objective Response Rate (ORR)|Duration of Response (DOR)|Progression-free Survival Rate (PFSR)|Safety as measured by incidence of AEs (Adverse Events)|Safety as measured by incidence of SAEs (Serious Adverse Events)|Tolerability as measured by incidence of AEs|Tolerability as measured by SAEs	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA018-005|2016-003082-26	January 17, 2017	January 17, 2022	January 18, 2022	December 19, 2016	null	November 28, 2018	Local Institution, San Francisco, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Augusta University, Augusta, Georgia, United States|Rush University Med Ctr, Chicago, Illinois, United States|Sidney Kimmel Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Tennessee Oncology, Pc, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Westmead Hospital, Westmead, New South Wales, Australia|Monash Medical Centre Clayton, Bentleigh, Victoria, Australia|Krankenhaus Der Barmherzigen Schwestern, Linz, Austria|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Hamilton, Ontario, Canada|Local Institution, Oshawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Haifa, Israel|Local Institution, Ramat Gan, Israel|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy		https://ClinicalTrials.gov/show/NCT02996110
88	NCT00730639	A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies	MDX1106-03	Active, not recruiting	Has Results	Metastatic Castration-resistant Prostrate Cancer|Renal Cell Carcinoma|Metastatic Melanoma|Non-small Cell Lung Cancer	Biological: BMS-936558 (MDX-1106)	Number of Participants With Severe Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs|Number of Participants With Abnormal Serum Chemistry Laboratory Values|Number of Participants With Abnormal Hematology Laboratory Values|Immunogenicity Assessment|Objective Response Rate|Duration of Tumor Response|Geometric Mean Maximum Serum Concentration (Cmax)|Median Time of Maximum Serum Concentration (Tmax)|Geometric Mean Area Under the Curve (AUC[TAU]) in One Dosing Interval Observed Post-Single Dose|Geometric Mean Total Body Clearance of Drug From Serum (CLT)|Mean Effective Half-life (T-HALFeff)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 1	395	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-003|MDX1106-03	January 22, 2009	February 4, 2013	May 14, 2019	August 8, 2008	April 15, 2016	August 2, 2018	Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University Of Michigan Cancer Center, Ann Arbor, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Carolina Biooncology Institute, Huntersville, North Carolina, United States|Christ Hospital, Cincinnati, Ohio, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT00730639
89	NCT03348904	Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer		Terminated	No Results Available	Lung Cancer	Drug: Nivolumab|Drug: Epacadostat|Drug: Placebo|Drug: Carboplatin|Drug: Cisplatin|Drug: Gemcitabine|Drug: Paclitaxel|Drug: Pemetrexed	Overall survival (OS) of nivolumab plus epacadostat in combination with chemotherapy (Arm A) compared to chemotherapy (Arm B)|Progression-free survival (PFS) of nivolumab plus epacadostat in combination with chemotherapy (Arm A) compared to chemotherapy (Arm B)|Objective response rate (ORR) of nivolumab plus epacadostat in combination with chemotherapy (Arm A) compared to chemotherapy (Arm B)|Duration of response (DOR) of nivolumab plus epacadostat in combination with chemotherapy (Arm A) compared to chemotherapy (Arm B)|Estimate of OS of nivolumab and placebo in combination with chemotherapy (Arm C)|Estimate of PFS of nivolumab and placebo in combination with chemotherapy (Arm C)|Estimate of ORR of nivolumab and placebo in combination with chemotherapy (Arm C)|Estimate of DOR of nivolumab and placebo in combination with chemotherapy (Arm C)	Incyte Corporation|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	2	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA2099NC/ECHO-309	December 27, 2017	May 22, 2018	May 22, 2018	November 21, 2017	null	July 20, 2018	Pacific Cancer Medical Center, Inc, Anaheim, California, United States|Cancer Center of Kansas, Wichita, Kansas, United States		https://ClinicalTrials.gov/show/NCT03348904
90	NCT02754141	An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab		Recruiting	No Results Available	Malignant Solid Tumor	Biological: BMS-986179|Biological: Nivolumab|Drug: rHuPH20	Number of adverse events (AE), serious adverse events (SAE), AEs leading to discontinuation, and deaths|BMS-986179 enzyme assays in pre- and on-treatment biopsies|BMS-986179 immunohistochemistry (IHC) in pre- and on-treatment biopsies|Objective response rate (ORR)|Duration of response (DOR)|Progression free survival rate (PFSR)|Maximum observed serum concentration (Cmax)|Time of maximum observed serum concentration (Tmax)|Area under the serum concentration-time curve from time zero to time of the last quantifiable concentration [AUC(0-T)]|Area under the serum concentration-time curve in 1 dosing interval [AUC(TAU)]|Apparent terminal half-life (T-HALF)|Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]|Effective elimination half-life (T-HALFeff)|Concentration at the end of the dosing interval (Ctau)|Trough observed serum concentration at the end of the dosing interval (Ctrough)|Total body clearance (CLT)|Volume of distribution at steady state (Vss)|Accumulation index (AI)|Apparent volume of distribution of terminal phase (Vz)|Degree of fluctuation or fluctuation index (DF)|Frequency of positive anti-drug antibody (ADA) to BMS-986179|Frequency of positive anti-drug antibody (ADA) to nivolumab	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	221	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA013-004|2016-000603-91	June 20, 2016	March 11, 2019	May 21, 2020	April 28, 2016	null	July 30, 2018	Johns Hopkins University, Baltimore, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia|Scientia Clinical Research Limited, Randwick, New South Wales, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Marseille Cedex 5, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Villejuif Cedex, France|Local Institution, Freiburg, Germany|Klinikum rechts der Isar der Technischen Universitat Muenchen Klinik und Poliklinik fur Innere Mediz, Munich, Germany|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Amsterdam, Netherlands		https://ClinicalTrials.gov/show/NCT02754141
91	NCT03383458	A Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation	CheckMate 9DX	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cancer	Biological: Nivolumab|Other: Placebo	Recurrence-free Survival (RFS)|Overall Survival (OS)|Time to recurrence (TTR)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	530	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA209-9DX	December 18, 2017	April 17, 2022	June 7, 2025	December 26, 2017	null	November 20, 2018	Pinnacle Research Group, Llc, Anniston, Alabama, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|UCLA School Of Medicine, Los Angeles, California, United States|Stanford Cancer Center, Palo Alto, California, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|Sylvester Comprehensive Cancer Center/ UMHC, Miami, Florida, United States|H. Lee Moffit Cancer center and research institute, Tampa, Florida, United States|Winship Cancer Institute-Emory University, Atlanta, Georgia, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Laura and Issac Perlmutter Cancer Center at NYU Langone - Belleview Hospital, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|McGuire VA Medical Center, Richmond, Virginia, United States|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Concord, New South Wales, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Impact Migration, Belgium|Local Institution, Leuven, Belgium|Local Institution, Calgary, Alberta, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Bondy, France|Local Institution, Brest, France|Local Institution, Clermont-Ferrand, France|Local Institution, Clichy, France|Local Institution, Creteil Cedex, France|Local Institution, GRENOBLE Cedex 09, France|Local Institution, Lyon Cedex 4, France|Local Institution, Montpellier Cedex 5, France|Local Institution, Nice cedex 3, France|Local Institution, Paris, France|Local Institution, Poitiers, France|Local Institution, Reims Cedex, France|Local Institution, Rennes Cedex 9, France|Local Institution, Saint Etienne, France|Local Institution, Vandoeuvre-les-Nancy, France|Local Institution, Messina, ME, Italy|Local Institution, Cagliari, Italy|Local Institution, Firenze, Italy|Local Institution, Meldola, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Rome, Italy|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Nishinomiya-shi, Hyogo, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Kawasaki-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Tokushima-shi, Tokushima, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Musashino-shi, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Suwon-si, Gyeonggi-do, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Gyeongsangnam-do, Korea, Republic of|Local Institution, Jeonnam, Korea, Republic of|Local Institution, Seongnam-si, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Brasov, Romania|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Timisoara, Romania|Local Institution, Arkhangelsk, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Barcelona, Spain|Local Institution, Cordoba, Spain|Local Institution, Donostia-San Sebastian, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Sabadell, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Zaragoza, Spain|Local Institution, Chiayi, Taiwan|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Yunlin, Taiwan|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Wirral, United Kingdom		https://ClinicalTrials.gov/show/NCT03383458
92	NCT02864251	A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy	CheckMate722	Recruiting	No Results Available	Non-Small-Cell Lung Carcinoma	Biological: Nivolumab|Biological: Ipilimumab|Drug: Pemetrexed|Drug: Cisplatin|Drug: Carboplatin	Progression free survival (PFS) in subjects with epidermal growth factor receptor (EGFR) mutation, T790M negative non-small cell lung carcinoma (NSCLC)|Overall survival (OS)|Objective response rate (ORR)|Duration of response (DOR)|Progression free survival (PFS) rate	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	465	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-722	October 20, 2016	September 30, 2019	December 31, 2023	August 11, 2016	null	September 25, 2018	Pacific Shores Medical Group, Long Beach, California, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|UCLA Cancer Hematology Oncology, Los Angeles, California, United States|St Joseph Hospital, Orange, California, United States|Torrance Memorial Physican Network, Redondo Beach, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Chicago, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|NYU Langone Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Texas Health Physicians Group, Fort Worth, Texas, United States|Baylor Scott and White Research Institute, Temple, Texas, United States|Tyler Hematology/Oncology PA, Tyler, Texas, United States|Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Changchun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Xi`an, Shan1xi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Hanghzou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Shanghai, China|Local Institution, Marseille, France|Local Institution, Paris, France|Local Institution, Rennes, France|Local Institution, Toulouse, France|Local Institution, Hong Kong, Hong Kong|Local Institution, Hong Kong, Hong Kong|Local Institution, Hong Kong, Hong Kong|Local Institution, Hong Kong, Hong Kong|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Iizuka-shi, Fukuoka, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Fukushima-shi, Fukushima, Japan|Local Institution, Fukuyama, Hiroshima, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Himeji, Hyogo, Japan|Local Institution, Itami, Hyogo, Japan|Local Institution, Kobe City, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Yokohama-Shi, Kanagawa, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Kiriyama-shi, Niigata, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Kishiwada shi, Osaka, Japan|Local Institution, Osakasayama-shi, Osaka, Japan|Local Institution, Sakai-shi, Osaka, Japan|Local Institution, Hidaka, Saitama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo, Tokyo, Japan|Local Institution, Koto, Tokyo, Japan|Local Institution, Ube, Yamaguchi, Japan|Local Institution, Chiba, Japan|Local Institution, Fukuoka, Japan|Local Institution, Niigata, Japan|Local Institution, Tokyo, Japan|Local Institution, Toyama, Japan|Local Institution, Wakayama, Japan|Local Institution, Cheogju-si, Korea, Republic of|Local Institution, Goyang, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Inchoen, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, L'Hospitalet de Llobregat, Spain|Local Institution, Madrid, Spain|Local Institution, Majadahonda, Spain|Local Institution, Malaga, Spain|Local Institution, Zaragoza, Spain|Local Institution, Chiayi, Taiwan|Local Institution, Kaohsiung City, Taiwan|Local Institution, Kaohsiung city, Taiwan|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei City, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT02864251
93	NCT03349710	Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer		Active, not recruiting	No Results Available	Squamous Cell Carcinoma of the Head and Neck	Biological: Nivolumab|Drug: Cetuximab|Drug: Cetuximab Placebo|Drug: Nivolumab Placebo|Drug: Cisplatin|Radiation: Radiotherapy	Event Free Survival (EFS)|Duration of loco-regional control (DLRC)|Overall Survival (OS)|European Organisation for the Research and Treatment of Cancer (EORTC)|Quality of Life Questionnaire-Core 30 (QLQ-C30)|European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Head and Neck (QLQQH&N35)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	1046	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CA209-9TM|2017-002676-87	December 15, 2017	November 9, 2022	November 10, 2022	November 21, 2017	null	October 23, 2018	Pinnacle Research Group, Llc, Anniston, Alabama, United States|Cancer Treatment Centers of Phoneix, Goodyear, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States|University of California San Diego (UCSD), La Jolla, California, United States|UCLA Health, Los Angeles, California, United States|Cancer Care - Torrance Memorial Physician Network, Redondo Beach, California, United States|Pacific Central Coast Health Centers - San Luis Obispo Oncology and Hematology Health Center, San Luis Obispo, California, United States|Cancer Center of Central Connecticut, Plainville, Connecticut, United States|Helen F. Graham Cancer Center, Newark, Delaware, United States|Orlando Health, Inc., Orlando, Florida, United States|Winship Cancer Insitute, Emory Crawford Long Hospital, Atlanta, Georgia, United States|CTCA Southeastern Region, Newnan, Georgia, United States|Lewis Hall Singletary Oncology Center at John D. Archbold Memorial Hospital, Thomasville, Georgia, United States|Northshore University HealthSystem, Evanston, Illinois, United States|Midwestern Regional medical Center, Zion, Illinois, United States|Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States|Medical Oncology And Hematology Associates Of Iowa, Des Moines, Iowa, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Dana Farber Cancer Institute (DFCI), Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Forrest General Cancer Center, Hattiesburg, Mississippi, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Nebraska Cancer Specialists (Ncs) At Methodist Estabrook Cancer Center, Omaha, Nebraska, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Louis Stokes Cleveland VA Medical Center - Wade Park Campus Location, Cleveland, Ohio, United States|Eastern Regional Medical Center, Philadelphia, Pennsylvania, United States|Upmc- Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|St. Joseph Regional Cancer Center, Bryan, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|UT Health Science Center San Antonio, San Antonio, Texas, United States|Inova Health System, Falls Church, Virginia, United States|HHP Hematology & Oncology Bremerton, Bremerton, Washington, United States|Local Institution, Darlinghurst, New South Wales, Australia|Local Institution, Kogarah, New South Wales, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Grenoble, France|Local Institution, Marseille, France|Local Institution, Montpellier, France|Local Institution, Nice, France|Local Institution, Rouen Cedex 1, France|Local Institution, Firenze, Italy|Local Institution, Lucca, Italy|Local Institution, Meldola, Italy|Local Institution, Milan, Italy|Local Institution, Naples, Italy|Local Institution, Ravenna, Italy|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Akashi-shi, Hyogo, Japan|Local Institution, Kobe City, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Isehara, Kanagawa, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Japan|Local Institution, Osaka, Japan|Local Institution, Cheongju-si, Korea, Republic of|Local Institution, Jeollanam-do, Korea, Republic of|Local Institution, Seongnam-si, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Bielsko-Biala, Poland|Local Institution, Gdynia, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Yekaterinburg, Russian Federation|Local Institution, A Coruna, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Majadahonda, Spain|Local Institution, Valencia, Spain|Local Institution, Valencia, Spain|Local Institution, Valencia, Spain|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Izmir, Turkey|Local Institution, Kocaeli, Turkey		https://ClinicalTrials.gov/show/NCT03349710
94	NCT03336216	A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer		Recruiting	No Results Available	Advanced Pancreatic Cancer	Biological: Cabiralizumab|Drug: Nab-paclitaxel|Drug: Onivyde|Biological: Nivolumab|Drug: Fluorouracil|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Leucovorin|Drug: Irinotecan Hydrochloride	Median progression free survival (mPFS)|Trough observed serum concentration (Ctrough)|Objective response rate (ORR)|Median duration of response (MDOR)|Overall survival rate (OSR)|Incidence of Adverse Events (AE)|Incidence of Serious Adverse Events (SAE)|Incidence of death|Incidence of laboratory abnormalities|Incidence of Adverse Events (AE) leading to discontinuation	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	160	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA025-006	December 15, 2017	December 14, 2020	December 15, 2020	November 8, 2017	null	October 3, 2018	Local Institution, Phoenix, Arizona, United States|HonorHealth Research Institute, Scottsdale, Arizona, United States|HonorHealth, Scottsdale, Arizona, United States|Ucla Medical Center, Los Angeles, California, United States|University Of Colorado, Aurora, Colorado, United States|Johns Hopkins University, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|Laura & Isaac Perlmutter Cancer Ctr at NYU Langone, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|UPMC, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Md Anderson, Houston, Texas, United States|Local Institution, Seattle, Washington, United States|Local Institution, Edmonton, Alberta, Canada|Local Institution, Kingston, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Heidelberg, Germany|Local Institution, Mannheim, Germany|Local Institution, Ulm, Germany|Local Institution, Wuerzburg, Germany|Local Institution, Padova, Italy|Local Institution, Rome, Italy|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Chur, Switzerland|Local Institution, Lausanne, Switzerland|Local Institution, Taipei, Taiwan|Local Institution, Glasgow, Strathclyde, United Kingdom		https://ClinicalTrials.gov/show/NCT03336216
95	NCT03040791	Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)	ImmunoProst	Recruiting	No Results Available	Prostate Cancer	Drug: Nivolumab	PSA response rate|Time to PSA progression|PSA Response Rate at 6 and 12 months|Radiological progression-free survival (rPFS)|Time to Radiographic Progression|Progression free survival (PFS)|Overall survival	Hospital Moinhos de Vento|Bristol-Myers Squibb	Male	18 Years and older   (Adult, Older Adult)	Phase 2	29	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	64121317.4.1001.5330	June 1, 2018	July 1, 2019	July 1, 2019	February 2, 2017	null	July 31, 2018	Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Instituto do Câncer do Estado de São Paulo, Sao Paulo, São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT03040791
96	NCT03637543	Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer		Not yet recruiting	No Results Available	Prostate Cancer	Drug: Nivolumab	Disease Control|Maximal change in prostate specific antigen (PSA) during nivolumab treatment|Best PSA response during nivolumab treatment as an absolute change relative to baseline|Change in PSA doubling time (PSADT) at end-of-study relative to baseline|Time from enrollment to development of radiographic metastatic disease|Time from enrollment to initiation of androgen deprivation therapy (ADT)|Treatment-related adverse events as assessed by CTCAE v5.0	Beth Israel Deaconess Medical Center|Bristol-Myers Squibb|Dana-Farber Cancer Institute	Male	18 Years and older   (Adult, Older Adult)	Phase 2	34	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18-249	September 30, 2018	March 31, 2022	March 31, 2025	August 20, 2018	null	August 22, 2018	Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03637543
97	NCT03414684	Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer		Recruiting	No Results Available	Breast Cancer	Drug: Carboplatin|Drug: Nivolumab	Progression-free survival (PFS)|Overall Response Rate|Overall Survival|Clinical Benefit Rate|Duration of Response|Time to Objective Response|BRCA carriers|Incidence Rate of each Toxicity (safety and tolerability)	Dana-Farber Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	132	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-512|CA209-9JX	January 30, 2018	June 30, 2021	June 30, 2025	January 30, 2018	null	October 2, 2018	The Stamford Hospital, Stamford, Connecticut, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|St. Elizabeth's Medical Center, Boston, Massachusetts, United States|Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center, Milford, Massachusetts, United States|Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital, South Weymouth, Massachusetts, United States|Dana-Farber/New Hampshire Oncology-Hematology, Londonderry, New Hampshire, United States|Ohio State University, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT03414684
98	NCT03246958	Nivolumab Plus Ipilimumab in Thyroid Cancer		Recruiting	No Results Available	Thyroid Cancer	Drug: Nivolumab|Drug: Ipilimumab	Radiographic Response Rate|Progression Free Survival|Overall Survival|Tolerability	Dana-Farber Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	54	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-255	September 20, 2017	March 31, 2021	March 31, 2025	August 11, 2017	null	August 24, 2018	Dana Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03246958
99	NCT02829918	Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers		Active, not recruiting	No Results Available	Biliary Tract Cancer|Biliary Tract Neoplasms	Drug: Nivolumab	Overall Response Rate (ORR) After 4 Cycles of Treatment|Overall Survival (OS)|Progression Free Survival (PFS)	H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	52	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-18684	September 19, 2016	October 31, 2019	October 31, 2020	July 12, 2016	null	November 29, 2018	City of Hope Cancer Center, Duarte, California, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States		https://ClinicalTrials.gov/show/NCT02829918
100	NCT03532451	Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer	PrE0807	Recruiting	No Results Available	Bladder Cancer	Drug: Nivolumab|Drug: Nivolumab/Lirilumab	Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE V5.0|Change in CD8+ Tumor-Infiltrating Lymphocytes (TIL) Density|Percent Change in CD8+ TIL Density|Number of Patients unable to undergo RC|Complete Response Rate|Recurrence-Free Survival (RFS)|Immunohistochemistry (IHC) Change|Peripheral Blood Mononuclear Cell (PBMC) T-Cell Subset Change	PrECOG, LLC.|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	43	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PrE0807|CA209-9DF	November 2018	December 2020	September 2022	May 22, 2018	null	November 6, 2018	University of TX Southwestern, Dallas, Texas, United States		https://ClinicalTrials.gov/show/NCT03532451
101	NCT03106610	Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy		Terminated	No Results Available	Bladder Cancer	Drug: Nivolumab|Behavioral: Questionnaires	Safety of Nivolumab in Subjects Previously Treated with Intravesical Bacillus Calmette-Guerin (BCG) Immunotherapy assessed per NCI CTCAE version 4|Tolerability of Nivolumab in Subjects Previously Treated with Intravesical Bacillus Calmette-Guerin (BCG) Immunotherapy assessed using AUASS|Systemic Symptom Burden of Nivolumab in Subjects Previously Treated with Intravesical Bacillus Calmette-Guerin (BCG) Immunotherapy assessed using MDASI	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	1	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2016-0432|NCI-2017-00647	July 7, 2017	May 16, 2018	May 16, 2018	April 10, 2017	null	May 24, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03106610
102	NCT03712943	Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer		Recruiting	No Results Available	Colorectal Cancer|Metastatic Colorectal Cancer|Colon Cancer	Drug: Regorafenib|Drug: Nivolumab	Maximum Tolerated Dose|Response Rate|Overall Survival (OS)|Frequency and Severity of Adverse Events	H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	28	Other|Industry	Interventional	Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-19581	October 12, 2018	October 2020	October 2022	October 19, 2018	null	October 19, 2018	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT03712943
103	NCT03104439	Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer		Recruiting	No Results Available	Microsatellite Stable Colorectal Cancer|Pancreatic Cancer|MSI High Colorectal Cancer	Drug: Nivolumab|Drug: Ipilimumab|Radiation: Radiation Therapy	Disease Control Rate|Median Progression free Survival|Median Overall Survival	Massachusetts General Hospital|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	80	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-021	May 10, 2017	October 31, 2020	October 31, 2024	April 7, 2017	null	October 12, 2018	Massachusetts general Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03104439
104	NCT03061539	Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature		Recruiting	No Results Available	Prostate Cancer	Drug: Nivolumab & Ipilimumab	Composite response rate|Overall survival|Radiological progression free survival|PSA progression free survival|Change in patient reported outcome measures (NCI's PRO-CTCAE)|Frequency and severity of adverse events	University College, London|Bristol-Myers Squibb	Male	18 Years and older   (Adult, Older Adult)	Phase 2	175	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-935	February 6, 2018	April 2019	July 2024	February 23, 2017	null	July 12, 2018	University College London Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT03061539
105	NCT03171025	Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer	NEXT	Recruiting	No Results Available	Bladder Cancer	Drug: Nivolumab	Two-year rate of failure-free survival (FFS)|Rate of failure-free survival at two years in subjects with intact bladder (FFSIB).|Rate of acute and late grade 2 or higher treatment related Genitourinary, Gastrointestinal, hematologic and immune related adverse events.|Effect of treatment on Quality of Life|Cystoscopic Local Control|Rate of salvage cystectomy|Rate of distant failure free survival|Overall Survival	University of Utah|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	28	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCI100769	July 10, 2017	June 2024	June 2024	May 31, 2017	null	May 16, 2018	Huntsman Cancer Institute, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT03171025
106	NCT02982954	A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer	CHECKMATE 920	Active, not recruiting	No Results Available	Renal Cell Carcinoma	Drug: Nivolumab|Drug: Ipilimumab	Incidence of high grade immune-mediated adverse events (IMAEs)|Time to onset of all high grade IMAEs|Time to resolution of all high grade IMAEs|Percentage of patients who received immune modulating medication due to high grade IMAEs|Progression-free survival at time of initial progression (PFS 1) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator|Objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator|Time to response (TTR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator|Duration of response (DOR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 4	200	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-920	December 7, 2016	March 30, 2020	February 28, 2023	December 6, 2016	null	July 18, 2018	Northwest Alabama Cancer Center, Pc, Muscle Shoals, Alabama, United States|Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage, Alaska, United States|Ironwood Cancer And Research Centers, Pc, Chandler, Arizona, United States|Highlands Oncology Group, P.A., Fayetteville, Arkansas, United States|eCare, Encinitas, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Los Angeles Cancer Network, Los Angeles, California, United States|UCLA Hematology Oncology, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Kaiser Permanente Medical Group - Southern California, Riverside, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|University Of Miami/Sylvester Cancer Center, Miami, Florida, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Emory University - Winship Cancer Institute, Atlanta, Georgia, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Minnesota Oncology Hematology, Minneapolis, Minnesota, United States|Southdale Cancer Clinic, Minneapolis, Minnesota, United States|Park Nicollet Clinic Cancer Center, Saint Louis Park, Minnesota, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States|HCA Midwest Division, Kansas City, Missouri, United States|St. Francis Cancer Treatment Center, Grand Island, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|University Of New Mexico, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|Broome Oncology, Johnson City, New York, United States|Laura & Isaac Perlmutter Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States|Va Medical Center Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology, Austin, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology-Fort Worth 12th Ave, Fort Worth, Texas, United States|Texas Oncology-Midland Allison Cancer Center, Midland, Texas, United States|Texas Oncology, San Antonio, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Inova Research Center, Fairfax, Virginia, United States|Bon Secours St Francis Hospital, Midlothian, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Medical Oncology Associates, Spokane, Washington, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT02982954
107	NCT03298893	Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months	NiCOL	Recruiting	No Results Available	Cervical Cancer|Locally Advanced Cervical Cancer	Drug: Nivolumab Injection|Drug: Cisplatin|Radiation: radiotherapy	rate of occurrence of dose-limiting toxicity (DLT)|Objective Response Rate (ORR)|Progression Free Survival (PFS)|Disease Free Survival (DFS)|Incidence of Serious Adverse Events (SAEs) to assess the overall safety profile of the association of nivolumab and pelvic radio-chemotherapy|Incidence of Adverse Events (AEs) to assess the overall safety profile of the association of nivolumab and pelvic radio-chemotherapy|validation of molecular alterations detected by molecular analyses|ctDNA heterogeneity|tumor microenvironment description|tumor PD-L1 immunohistochemistry	Institut Curie|Bristol-Myers Squibb	Female	18 Years to 99 Years   (Adult, Older Adult)	Phase 1|Phase 2	21	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IC 2016-08	November 27, 2017	April 2020	April 2020	October 2, 2017	null	April 9, 2018	Institut Curie, Paris, France|Hopital Européen Georges Pompidou, Paris, France|Institut Curie Hopital René Huguenin, Saint Cloud, France		https://ClinicalTrials.gov/show/NCT03298893
108	NCT03172624	Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer		Recruiting	No Results Available	Salivary Gland Cancer	Drug: Nivolumab|Drug: Ipilimumab	best overall response rate	Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	64	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-219	May 26, 2017	May 2019	May 2019	June 1, 2017	null	August 20, 2018	Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States		https://ClinicalTrials.gov/show/NCT03172624
109	NCT03026166	A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer		Active, not recruiting	No Results Available	Small Cell Lung Cancer	Drug: ipilimumab|Drug: nivolumab|Drug: rovalpituzumab tesirine	Number of participants with dose-limiting toxicities (DLT)|Clinical benefit rate (CBR)|Duration of response (DOR)|PFS status after 6 months from the initiation of study treatment|Objective Response Rate (ORR)|Progression-free survival (PFS)|Overall survival (OS)	AbbVie|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	42	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	M16-300|2016-003686-26	March 31, 2017	July 3, 2019	July 3, 2019	January 20, 2017	null	October 26, 2018	Ucsd /Id# 161030, La Jolla, California, United States|Florida Hospital /ID# 161017, Orlando, Florida, United States|University Cancer & Blood Cent /ID# 161028, Athens, Georgia, United States|University of Chicago /ID# 161006, Chicago, Illinois, United States|The University of Kansas Clini /ID# 162915, Fairway, Kansas, United States|Washington University-School of Medicine /ID# 161011, Saint Louis, Missouri, United States|Rutgers Cancer Institute of NJ /ID# 161032, New Brunswick, New Jersey, United States|Memorial Sloan Kettering Cancer Center /ID# 161010, New York, New York, United States|Duke Univ Med Ctr /ID# 161009, Durham, North Carolina, United States|Oregon Health and Science University /ID# 161029, Portland, Oregon, United States|Medical University of South Carolina /ID# 161007, Charleston, South Carolina, United States|Tennessee Oncology, PLLC /ID# 161012, Nashville, Tennessee, United States|Vanderbilt University Med Ctr /ID# 162916, Nashville, Tennessee, United States|Virginia Cancer Institute /ID# 161025, Richmond, Virginia, United States|University of Wisconsin Clinic /ID# 161013, Madison, Wisconsin, United States|CHU de Besancon - Jean Minjoz /ID# 165173, Besancon, Doubs, France|Centre Oscar Lambret /ID# 165169, Lille, Hauts-de-France, France|Institut Gustave Roussy /ID# 165168, Villejuif, Val-de-Marne, France|Institut Sainte Catherine /ID# 165172, Avignon, France|CHRU de Brest - Hospital Morva /ID# 165170, Brest Cedex, France|Hopital La Timone /ID# 165171, Marseille, France|Universitaetsklinik Heidelberg /ID# 165184, Heidelberg, Baden-Wuerttemberg, Germany|KH Martha-Maria Halle Dolau /ID# 165180, Halle (Saale), Sachsen-Anhalt, Germany|Asklepios Fachkliniken M. Gaut /ID# 165183, Gauting, Germany|Lungen Clinic Grosshansdorf /ID# 165182, Grosshansdorf, Germany|Lungenfachklinik Immenhausen /ID# 165181, Immenhausen, Germany|Istituto Clinico Humanitas /ID# 165176, Rozzano, Milano, Italy|Centro di Riferimento Oncologi /ID# 165174, Aviano, Italy|Universitaria di Bologna Polic /ID# 165179, Bologna, Italy|A.O. Uni Policlinico Vittorio /ID# 165178, Catania, Italy|Istituto Europeo di Oncologia /ID# 165175, Milan, Italy|AO Univ di Modena /ID# 165177, Modena, Italy|Clinica Universitar de Navarra - Pamplona /ID# 165165, Pamplona, Navarra, Comunidad, Spain|Hosp Univ Quiron Dexues /ID# 165166, Barcelona, Spain|ICO l´Hosp- Hosp Duran Reynals /ID# 165167, Barcelona, Spain|Hospital Genl Gregorio Maranon /ID# 165162, Madrid, Spain|Hospital Universitario Fundaci /ID# 165164, Madrid, Spain|Hospital Universitario Madrid /ID# 165163, Madrid, Spain		https://ClinicalTrials.gov/show/NCT03026166
110	NCT03670056	A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy		Not yet recruiting	No Results Available	Small Cell Lung Cancer	Drug: Combination immunotherapy with Ipilimumab and Nivolumab	Change in the ratio of Teff/Treg cells|Response rate|Duration of response|Progression-free survival	Yale University|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2000023361|CA209-9YT	September 15, 2018	September 30, 2020	September 30, 2022	September 13, 2018	null	September 13, 2018	Yale University, Yale Cancer Center, New Haven, Connecticut, United States		https://ClinicalTrials.gov/show/NCT03670056
111	NCT03544736	Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)		Recruiting	No Results Available	Esophageal Cancer	Drug: Nivolumab|Radiation: Radiotherapy|Drug: Chemotherapy|Procedure: Surgery	Incidence of Treatment-Emergent Adverse Events|Response to treatment|Overall Survival|Progression Free Survival|Health Related Quality of Life (EQ-5D)|Health Related Quality of Life (EORTC QLQ-C30)|Health Related Quality of Life (EORTC QLQ-OG25)	Oslo University Hospital|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	54	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-9M9-01	April 26, 2018	December 31, 2025	December 31, 2040	June 4, 2018	null	June 4, 2018	Oslo University Hospital, Oslo, Norway		https://ClinicalTrials.gov/show/NCT03544736
112	NCT02866383	Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients	CheckPAC	Recruiting	No Results Available	Metastatic Pancreatic Cancer|Metastatic Biliary Tract Cancer	Drug: Nivolumab|Drug: Ipilimumab|Radiation: Radiotherapy	Clinical benefit rate (CBR)|Incidence of Treatment-Emergent Adverse Events [Safety]|CBR|Overall response rate (ORR) according to RECIST 1.1|Overall response rate (ORR) according to modified irRC|Progression free survival (PFS) per RECIST 1.1|Progression free survival (PFS) per modified irRC|Overall survival (OS) probability at 6 months|OS|Quality of Life	Herlev Hospital|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	160	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GI 1616	November 2016	November 2018	November 2019	August 15, 2016	null	September 13, 2018	Herlev & Gentofte Hospital, Herlev, Denmark		https://ClinicalTrials.gov/show/NCT02866383
113	NCT03294304	BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy		Recruiting	No Results Available	Muscle Invasive Bladder Cancer	Drug: Nivolumab|Drug: Cisplatin|Drug: Gemcitabine	Pathologic Response Rate (PaR) at time of radical cystectomy. PaR is defined as absence of residual MIBC at cystectomy in the surgical specimen (pathologic down-staging to ≤pT1pN0, which includes pT0, pT1,pTa and pTis)|Safety of Nivolumab with Gemcitabine/Cisplatin (cycle 1)|Safety of Nivolumab with Gemcitabine/Cisplatin (cycle 2)|Safety of Nivolumab with Gemcitabine/Cisplatin (cycle 3)|Safety of Nivolumab with Gemcitabine/Cisplatin (cycle 4)|Safety of Nivolumab with Gemcitabine/Cisplatin|Progression Free Survival (PFS)	Masonic Cancer Center, University of Minnesota|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	41	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017LS039	January 29, 2018	November 1, 2019	November 1, 2021	September 27, 2017	null	September 28, 2018	Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Masonic Cancer Center - University of Minnesota, Minneapolis, Minnesota, United States|Huntsman Cancer Institute - University of Utah Health, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT03294304
114	NCT03043599	Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer		Active, not recruiting	No Results Available	Small Cell Lung Cancer|Extensive-stage Small Cell Lung Cancer	Radiation: Thoracic Radiation Therapy|Drug: Ipilimumab|Drug: Nivolumab	Phase I: Confirmation of Recommended Phase II Dose|Phase II: Progression Free Survival (PFS)|Overall Survival (OS)	H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	21	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-18914|CA209-840	February 13, 2017	April 2021	April 2022	February 6, 2017	null	October 3, 2018	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT03043599
115	NCT01658878	An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer	CheckMate040	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Biological: Nivolumab|Drug: Sorafenib|Drug: Ipilimumab|Drug: Cabozantinib	Safety of nivolumab as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Tolerability of nivolumab as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Objective response rate (ORR) for Expansion phase of nivolumab|ORR for Nivolumab vs Sorafenib Cohort|Safety of nivolumab plus ipilimumab as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Tolerability of nivolumab plus ipilimumab as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|ORR for Nivolumab plus Ipilimumab Combination Cohort|ORR for Child-Pugh B Cohort|Safety of nivolumab plus ipilimumab plus cabozantinib as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Tolerability of nivolumab plus ipilimumab plus cabozantinib as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|ORR for Nivolumab plus Ipilimumab plus Cabozantinib Combination Cohort|Complete response (CR) Rate|Disease control rate (DCR)|Duration of response (DOR)|Time to response (TTR)|Time to progression (TTP)|TTP Rate|Progression free survival (PFS)|Overall survival (OS)|Overall survival rate (OSR)|PD-L1 expression|Maximum observed serum concentration (Cmax) of nivolumab|Time of maximum observed serum concentration (Tmax) of nivolumab|Area under the serum concentration time curve in the dosing interval AUC(TAU) of nivolumab|Serum concentration achieved at the end of dosing interval (trough concentration) (Ctrough) of nivolumab|Serum concentration achieved at the end of the infusion (Ceoinf) of nivolumab|Cmax at Cycle 3/ Cmax at Cycle 1 (AI_Cmax) of nivolumab|AUC(TAU) at Cycle 3/ AUC(TAU) at Cycle 1 (AI_AUC) of nivolumab|Effective T-Half of nivolumab	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	620	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-040|2012-001514-42	September 26, 2012	March 31, 2019	December 26, 2019	August 7, 2012	null	November 6, 2018	USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Georgetown University Medical Center Lombardi Cancer Center, Washington, District of Columbia, United States|Sacred Heart Medical Group, Pensacola, Florida, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Univ Of Michigan, Ann Arbor, Michigan, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Saint Joseph's Regional Medical Center, Paterson, New Jersey, United States|Providence Portland Medical Center, Portland, Oregon, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHUM, Montreal, Quebec, Canada|Local Institution, Angers, France|Local Institution, Creteil Cedex, France|Local Institution, Marseille Cedex 5, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris Cedex 13, France|Local Institution, Reims Cedex, France|Local Institution, Vandoeuvre les Nancy, France|Universitaetsklinikum Essen, Essen, Germany|Johann Wolfgang Goethe Universitaet, Frankfurt, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Local Institution, Hong Kong, Hong Kong|Azienda Ospedaliera Di Bologna S. Orsola-Malpighi, Bologna, Italy|A.O.U. Careggi, Firenze, Italy|Istituto Romagnolo Per Lo Studio E La Cura Dei Tumori, Meldola (FC), Italy|Istituto Europeo Di Oncologia, Milano, Italy|Istituto Nazionale Tumori, Napoli, Italy|I.O.V. Istituto Oncologico Veneto Ircss, Padova, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Saga, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, San Juan, Puerto Rico|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Clinica Universitaria De Navarra, Pamplona, Spain|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, Wirral, Merseyside, United Kingdom|Local Institution, Birmingham, WEST Midlands, United Kingdom|Local Institution, London, United Kingdom		https://ClinicalTrials.gov/show/NCT01658878
116	NCT03355560	Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy		Recruiting	No Results Available	Head and Neck Cancer	Drug: Nivolumab	Percentage of patients with Grade 3 and 4 adverse events of nivolumab|Percentage of patients any grade adverse events of nivolumab|Disease free survival	Trisha Wise-Draper|Bristol-Myers Squibb|University of Cincinnati	All	18 Years and older   (Adult, Older Adult)	Phase 2	24	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UCCI-HN-17-01|CA209-997	December 6, 2017	May 2020	November 2020	November 28, 2017	null	October 2, 2018	UC Health, Cincinnati, Ohio, United States		https://ClinicalTrials.gov/show/NCT03355560
117	NCT02923934	A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers		Recruiting	No Results Available	Gastrointestinal Cancer|Neuroendocrine Tumours|Malignant Female Reproductive System Neoplasm	Drug: Ipilimumab|Drug: Nivolumab	To determine the clinical efficacy of the combination treatment of ipilimumab with nivolumab in rare cancers.|To identify whether a common predictive biomarker or immune signature can be identified in responding patients that can occur irrespective of tumour type.	Olivia Newton-John Cancer Research Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	120	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ONJ2016-001	August 22, 2017	August 2023	December 2023	October 5, 2016	null	November 14, 2018	Border Medical Oncology Unit, Albury, New South Wales, Australia|Blacktown Hospital, Sydney, New South Wales, Australia|Monash Health, Clayton, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia		https://ClinicalTrials.gov/show/NCT02923934
118	NCT02991196	Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer		Terminated	No Results Available	Colorectal Neoplasm	Drug: DS-8273a + nivolumab	Dose Escalation Part: Number of Participants with Dose-Limiting Toxicities (DLT)|Dose Escalation and Dose Expansion Parts: Number of Participants with Clinically Significant Safety Parameters|Dose Escalation Part: Maximum Tolerated Dose (MTD)|Dose Expansion Part: Overall Objective Response Rate (per Response Evaluation Criteria in Solid Tumors [RECIST] Version 1.1)|Dose Expansion Part: Number of Participants in each Category of Best Overall Response (per Response Evaluation Criteria in Solid Tumors [RECIST] Version 1.1)|Dose Expansion Part: Disease Control Rate (DCR) for 6 Months|Dose Expansion Part: Number of Participants with Progression-Free Survival (PFS)|Dose Expansion Part: Time to Progression (TTP)|Dose Expansion Part: Duration of Response|Dose Escalation Part: Number of Participants with Immune-related Response (per Criteria Modified from RECIST Version 1.1 [irRECIST])|Plasma Concentrations of DS-8273a|Number of Participants with Primary Pharmacodynamic (PDy) Effects of the Combination Regimen on Myeloid-Derived Suppressor Cells (MDSCs) and their Subsets in Peripheral Blood	Daiichi Sankyo, Inc.|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	4	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	DS8273-A-U103|Protocol ID CA209-860	December 1, 2016	September 22, 2017	September 22, 2017	December 13, 2016	null	October 2, 2017	Georgetown University Medical Center, Washington, D.C., District of Columbia, United States|South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States|MD Anderson Cancer Center, Houston, Texas, United States|South Texas Accelerated Research Therapeutics, LLC (START), San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT02991196
119	NCT03350126	Interest of iRECIST Evaluation for DCR for Evaluation of Patients With Deficient MMR and /or MSI Metastatic Colorectal Cancer Treated With Nivolumab and Ipilimumab	NIPICOL	Recruiting	No Results Available	Metastatic Cancer Colorectal	Drug: Ipilimumab 200 MG in 40 ML Injection|Drug: Nivolumab 10 MG/ML	Disease Control Rate (DCR)|Progression Free Survival (PFS)|Overall Response Rate (ORR)|Overall Survival (OS)|Toxicity according to NCI-CTCAE version 4.0 (National Cancer Institute Common Terminology Criteria for Adverse Events),	GERCOR - Multidisciplinary Oncology Cooperative Group|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	57	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NIPICOL C17-01	December 4, 2017	December 2018	December 2019	November 22, 2017	null	January 23, 2018	Institut Sainte Catherine, Avignon, France|CHRU Besançon, Besançon, France|Henri Mondor Hospital, Créteil, France|IHFB, Levallois-Perret, France|Centre Leon Berard, Lyon, France|CHU Nantes - Hôtel Dieu, Nantes, France|Hospital Saint Antoine, Paris, France|CHU Poitiers, Poitiers, France		https://ClinicalTrials.gov/show/NCT03350126
120	NCT03316586	A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer		Recruiting	No Results Available	Breast Cancer	Drug: Nivolumab|Drug: Cabozantinib	Overall Response Rate|Number of participants with adverse events|Clinical Benefit Rate|Progression Free Survival Rate|Overall Response Rate per Immune Criteria	Dana-Farber Cancer Institute|Bristol-Myers Squibb|Exelixis	Female	18 Years and older   (Adult, Older Adult)	Phase 2	35	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-324	November 30, 2017	May 31, 2021	May 31, 2025	October 20, 2017	null	August 28, 2018	Dana-Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03316586
121	NCT02569242	Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer		Active, not recruiting	No Results Available	Esophageal Cancer	Drug: Nivolumab|Drug: Docetaxel/Paclitaxel	Overall survival|Progression-free survival|Objective response rate|Duration of response|Safety will be analyzed through the incidence of adverse events, serious adverse events|Safety will be analyzed through the incidence of laboratory abnormalities	Ono Pharmaceutical Co. Ltd|Bristol-Myers Squibb	All	20 Years and older   (Adult, Older Adult)	Phase 3	390	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ONO-4538-24/CA209-473	December 2015	September 2019	null	October 6, 2015	null	September 25, 2017	Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Georgetown University Med Ctr, Washington, D.C., District of Columbia, United States|Orlando Health, Inc, Orlando, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Duke Cancer Institute, Durham, North Carolina, United States|Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Odense University Hospital, Odense C, Denmark|RWTH Aachen University, Aachen, Germany|Charite Campus Virchow Klinikum, Berlin, Germany|University Hospital Heidelberg, Heidelberg, Germany|Universitatsklinikum Jena, Innere Medizin II, Jena, Germany|MVZ Mitte, Leipzig, Germany|University Of Mainz Medical Center, Mainz, Germany|Klinikum reechts der Isar, Technical University Munchen, Munich, Germany|HPG23, Bergamo, Italy|Fondazione Irccs Istituto Nazionale Tumori, Milan, Italy|Irccs Istituto Oncologico Veneto Iov, Padova, Italy|Aichi Clinical Site, Nagoya, Aichi, Japan|Aichi Clinical Site, Nagoya, Aichi, Japan|Aomori Clinical Site, Hirosaki, Aomori, Japan|Chiba Clinical Site, Kashiwa, Chiba, Japan|Ehime Clinical Site, Matsuyama, Ehime, Japan|Hokkaido Clinical Site, Sapporo, Hokkaido, Japan|Hokkaido Clinical Site, Sapporo, Hokkaido, Japan|Hyogo Clinical Site, Akashi, Hyogo, Japan|Hyogo Clinical Site, Kobe, Hyogo, Japan|Kanagawa Clinical Site, Isehara, Kanagawa, Japan|Kanagawa Clinical Site, Kawasaki, Kanagawa, Japan|Kanagawa Clinical Site, Yokohama, Kanagawa, Japan|Kanagawa Clinical Site, Yokohama, Kanagawa, Japan|Mie Clinical Site, Tsu, Mie, Japan|Miyagi Clinical Site, Sendai, Miyagi, Japan|Nagano Clinical Site, Saku, Nagano, Japan|Niigata Clinical Site, Nigatake, Niigata, Japan|Osaka Clinical Site, Osakasayama, Osaka, Japan|Osaka Clinical Site, Suita, Osaka, Japan|Osaka Clinical Site, Takatsuki, Osaka, Japan|Saitama Clinical Site, Hidaka, Saitama, Japan|Saitama Clinical Site, Kita-Adachi county, Saitama, Japan|Shizuoka Clinical Site, Suntou county, Shizuoka, Japan|Tochigi Clinical Site, Shimotsuke, Tochigi, Japan|Tokyo Clinical Site, Bunkyo-ku, Tokyo, Japan|Tokyo Clinical Site, Chuo-ku, Tokyo, Japan|Tokyo Clinical Site, Chuo-ku, Tokyo, Japan|Tokyo Clinical Site, Koto-ku, Tokyo, Japan|Tokyo Clinical Site, Meguro-ku, Tokyo, Japan|Tokyo Clinical Site, Minato-ku, Tokyo, Japan|Tokyo Clinical Site, Shinagawa-ku, Tokyo, Japan|Tokyo Clinical Site, Shinjuku-ku, Tokyo, Japan|Tokyo Clinical Site, Shinjuku-ku, Tokyo, Japan|Akita Clinical Site, Akita, Japan|Chiba Clinical Site, Chiba, Japan|Chiba Clinical Site, Chiba, Japan|Fukuoka Clinical Site, Fukuoka, Japan|Fukushima Clinical Site, Fukushima, Japan|Hiroshima Clinical Site, Hiroshima, Japan|Kagoshima Clinical Site, Kagoshima, Japan|Kumamoto Clinical Site, Kumamoto, Japan|Kyoto Clinical Site, Kyoto, Japan|Kyoto Clinical Site, Kyoto, Japan|Niigata Clinical Site, Niigata, Japan|Osaka Clinical Site, Osaka, Japan|Shizuoka Clinical Site, Shizuoka, Japan|Busan Clinical Site, Busan, Korea, Republic of|Daegu Clinical Site, Daegu, Korea, Republic of|Daegu Clinical Site, Daegu, Korea, Republic of|Daejeon Clinical Site, Daejeon, Korea, Republic of|Gyeonggi-do Clinical Site, Gyeonggi-do, Korea, Republic of|Hwasun-Gun Clinical Site, Hwasun-Gun, Korea, Republic of|Seoul Clinical Site, Seoul, Korea, Republic of|Seoul Clinical Site, Seoul, Korea, Republic of|Seoul Clinical Site, Seoul, Korea, Republic of|Seoul Clinical Site, Seoul, Korea, Republic of|Seoul Clinical Site, Seoul, Korea, Republic of|Ulsan Clinical Site, Ulsan, Korea, Republic of|Changhua Clinical Site, Changhua, Taiwan|Chiayi Clinical Site, Chiayi, Taiwan|Kaohsiung Clinical Site, Kaohsiung, Taiwan|Kaohsiung Clinical Site, Kaohsiung, Taiwan|Kaohsiung Clinical Site, Kaohsiung, Taiwan|Keelung Clinical Site, Keelung, Taiwan|Taichung Clinical Site, Taichung, Taiwan|Tainan Clinical Site, Tainan, Taiwan|Taipei Clinical Site, Taipei, Taiwan|Taipei Clinical Site, Taipei, Taiwan|Taoyuan Clinical Site, Taoyuan, Taiwan|Velindre Cancer Centre, Cardiff, Cardiganshire, United Kingdom|The Beatson West Of Scotland Cancer Centre, Glasgow, Lanarkshire, United Kingdom		https://ClinicalTrials.gov/show/NCT02569242
122	NCT03425331	Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC		Recruiting	No Results Available	Non-small Cell Lung Cancer	Drug: Ipilimumab|Drug: Nivolumab	Best overall objective response rate|Progression-free survival (PFS)|Overall survival|Duration of response|Toxicity	Dana-Farber Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	80	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-566	February 28, 2018	August 28, 2021	August 28, 2025	February 7, 2018	null	June 28, 2018	Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03425331
123	NCT02696993	Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-Small Cell Lung Cancer		Recruiting	No Results Available	Metastatic Brain Cancer	Drug: Nivolumab|Drug: Ipilimumab|Radiation: Stereotactic Radiosurgery (SRS)|Radiation: Whole Brain Radiation Therapy (WBRT)|Behavioral: Neurocognitive Exam	Recommended Phase 2 Dose (RP2D) of Nivolumab in Combination with Stereotactic Radiosurgery (SRS)|Recommended Phase 2 Dose (RP2D) of Nivolumab in Combination with Whole Brain Radiation Therapy (WBRT)|Recommended Phase 2 Dose (RP2D) of Nivolumab in Combination with Ipilimumab and Stereotactic Radiosurgery (SRS)|Recommended Phase 2 Dose (RP2D) of Nivolumab in Combination with Ipilimumab and Whole Brain Radiation Therapy (WBRT)|Intracranial Progression Free Survival|Neurocognitive Changes	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	80	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2015-0883|NCI-2016-00661	December 2016	December 2020	December 2020	March 2, 2016	null	May 31, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02696993
124	NCT03383302	SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects	STILE	Not yet recruiting	No Results Available	Non-small Cell Lung Cancer Stage II|Non-small Cell Lung Cancer Stage I	Radiation: Stereotactic body radiotherapy|Drug: Nivolumab	Assessment of lung toxicity (pneumonitis) from treatment with Nivolumab after SBRT for early stage NSCLC|Adverse events (toxicity) assessment using CTCAE v.4|Number of doses of Nivolumab received by patients within 16 weeks of commencing adjuvant nivolumab after SBRT for early stage NSCLC|Disease relapse|Relapse at specified timepoints|Overall survival|Disease free survival|Health-related quality of life (HRQoL) using Patient Generated Subjective Global Assessment in patients treated with Nivolumab after SBRT for early stage NSCLC|Health-related quality of life (HRQoL) using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) in patients treated with Nivolumab after SBRT for early stage NSCLC|HRQoL using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) in patients treated with Nivolumab after SBRT for early stage NSCLC.	Royal Marsden NHS Foundation Trust|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	31	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CCR4644	January 2018	June 2021	January 2022	December 26, 2017	null	December 26, 2017			https://ClinicalTrials.gov/show/NCT03383302
125	NCT02873962	A Phase II Study Of Nivolumab/ Bevacizumab		Active, not recruiting	No Results Available	Peritoneal Cancer|Ovarian Cancer|Fallopian Tube Cancer	Drug: Bevacizumab|Drug: Nivolumab	Objective Response Rate|Progression Free|Best Overall Response Rate|Duration Of Response|The Association Of Baseline PD-L1 Expression With Anti-Tumor Activity	Dana-Farber Cancer Institute|Bristol-Myers Squibb	Female	18 Years and older   (Adult, Older Adult)	Phase 2	38	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-263	November 10, 2016	February 2020	February 2024	August 22, 2016	null	July 18, 2018	Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT02873962
126	NCT03689699	Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)		Not yet recruiting	No Results Available	Prostate Cancer|Adenocarcinoma of the Prostate	Drug: Nivolumab|Drug: Degarelix|Drug: BMS-986253	Rate of PSA recurrence|Number of adverse events|Percentage change in PSA|Relapse-free survival (RFS)	Charles G. Drake|Bristol-Myers Squibb|Columbia University	Male	18 Years to 99 Years   (Adult, Older Adult)	Phase 1|Phase 2	60	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AAAR7949	October 2018	January 2020	August 2022	September 28, 2018	null	September 28, 2018	Weill Cornell Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Sidney Kimmel Cancer Center- Thomas Jefferson University, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03689699
127	NCT03006705	Study of Adjuvant ONO-4538 With Resected Gastric Cancer		Recruiting	No Results Available	Gastric Cancer	Drug: Nivolumab|Drug: Tegafur-gimeracil-oteracil potassium|Drug: Oxaliplatin|Drug: Capecitabine|Drug: Placebo	Relapse-free survival (RFS)|Overall survival (OS)|3-year OS rate|5-year OS rate|3-year RFS rate|5-year RFS rate|Safety will be analyzed through the incidence of adverse events, serious adverse events|Safety will be analyzed through the incidence of laboratory abnormalities	Ono Pharmaceutical Co. Ltd|Bristol-Myers Squibb	All	20 Years to 80 Years   (Adult, Older Adult)	Phase 3	700	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ONO-4538-38	January 2017	June 2021	null	December 30, 2016	null	October 2, 2018	Anhui Province Clinical Site, Anhui Province, China|Beijing Clinical Site1, Beijing, China|Beijing Clinical Site2, Beijing, China|Cuangdong Province Clinical Site, Cuangdong Province, China|Guangdong Province Clinical Site1, Guangdong, China|Guangdong Province Clinical Site2, Guangdong, China|Henan Province Clinical Site1, Henan, China|Henan Province Clinical Site2, Henan, China|Jiangsu Province Clinical Site1, Jiangsu Province, China|Jiangsu Province Clinical Site3, Jiangsu Province, China|Jiangsu Province Clinical Site4, Jiangsu Province, China|Jiangsu Province Clinical Site5, Jiangsu Province, China|Jiangxi Province Clinical Site1, Jiangxi, China|Jiangxi Province Clinical Site2, Jiangxi, China|Jilin Province Clinical Site, Jilin, China|Shanghai Clinical Site1, Shanghai, China|Shanghai Clinical Site2, Shanghai, China|Shanxi Province Clinical Site, Shanxi, China|Tianjin Clinical Site1, Tianjin, China|Tianjin Clinical Site2, Tianjin, China|Zhejiang Province Clinical Site, Zhejiang, China|Zhengjiang Province Clinical Site, Zhengjiang Province, China|Aichi Clinical Site1, Nagoya, Aichi, Japan|Aichi Clinical Site2, Nagoya, Aichi, Japan|Chiba Clinical Site, Kamogawa, Chiba, Japan|Ehime Clinical Site, Matsuyama, Ehime, Japan|Ehime Clinicla Site, Matsuyama, Ehime, Japan|Gifu Clinical Site, Ōgaki, Gifu, Japan|Gunma Clinical Site, Ota, Gunma, Japan|Gunma Clinical Site, Takasaki, Gunma, Japan|Hiroshima Clinical Site, Fukuyama, Hiroshima, Japan|Hokkaido Clinical Site, Hakodate, Hokkaido, Japan|Hokkaido Clinical Site, Sapporo, Hokkaido, Japan|Hyogo Clinical Site, Akashi, Hyogo, Japan|Hyogo Clinical Site, Amagasaki, Hyogo, Japan|Hyogo Clinical Site, Nishinomiya, Hyogo, Japan|Iwate Clinical Site, Morioka, Iwate, Japan|Kanagawa Clinical Site, Sagamihara, Kanagawa, Japan|Kanagawa Clinical Site, Yokohama, Kanagawa, Japan|Miyagi Clinical Site, Osaki, Miyagi, Japan|Nagano Clinical Site, Saku, Nagano, Japan|Okayama Clinical Site, Kurashiki, Okayama, Japan|Osaka Clinical Site, Hirakata, Osaka, Japan|Osaka Clinical Site, Sakai, Osaka, Japan|Osaka Clinical Site, Suita, Osaka, Japan|Osaka Clinical Site, Takatsuki, Osaka, Japan|Osaka Clinical Site, Toyonaka, Osaka, Japan|Osaka Clinical Site, Ōsaka-sayama, Osaka, Japan|Saitama Clinical Site, Hidaka, Saitama, Japan|Saitama Clinical Site, Kitaadachi-gun, Saitama, Japan|Shizuoka Clinical Site, Sunto-gun, Shizuoka, Japan|Tochigi Clinical Site, Shimotsuke, Tochigi, Japan|Tokyo Clinical Site, Bunkyo-ku, Tokyo, Japan|Tokyo Clinical Site, Chuo-ku, Tokyo, Japan|Tokyo Clinical Site, Koto-ku, Tokyo, Japan|Tokyo Clinical Site, Shinjuku-ku, Tokyo, Japan|Chiba Clinical Site, Chiba, Japan|Fukuoka Clinical Site, Fukuoka, Japan|Gifu Clinical Site, Gifu, Japan|Hiroshima Clinical Site1, Hiroshima, Japan|Hiroshima Clinical Site2, Hiroshima, Japan|Hiroshima Clinical Site3, Hiroshima, Japan|Kochi Clinical Site, Kochi, Japan|Kumamoto Clinical Site, Kumamoto, Japan|Kyoto Clinical Site, Kyoto, Japan|Niigata Clinical Site, Niigata, Japan|Osaka Clinical Site1, Osaka, Japan|Osaka Clinical Site2, Osaka, Japan|Osaka Clinical Site3, Osaka, Japan|Osaka Clinical Site4, Osaka, Japan|Shizuoka Clinical Site, Shizuoka, Japan|Toyama Clinical Site, Toyama, Japan|Wakayama Clinical Site, Wakayama, Japan|Yamagata Clinical Site, Yamagata, Japan|Busan Clinical Site1, Busan, Korea, Republic of|Busan Clinical Site2, Busan, Korea, Republic of|Busan Clinical Site3, Busan, Korea, Republic of|Daegu Clinical Site1, Daegu, Korea, Republic of|Daegu Clinical Site2, Daegu, Korea, Republic of|Daegu Clinical Site3, Daegu, Korea, Republic of|Daejeon Clinical Site, Daejeon, Korea, Republic of|Gwangju Clinical Site, Gwangju, Korea, Republic of|Gyeonggi-do Clinical Site1, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site2, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site3, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site4, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site5, Gyeonggi-do, Korea, Republic of|Jeollabuk-do Clinical Site, Jeollabuk-do, Korea, Republic of|Seoul Clinical Site1, Seoul, Korea, Republic of|Seoul Clinical Site2, Seoul, Korea, Republic of|Seoul Clinical Site3, Seoul, Korea, Republic of|Seoul Clinical Site4, Seoul, Korea, Republic of|Seoul Clinical Site5, Seoul, Korea, Republic of|Seoul Clinical Site6, Seoul, Korea, Republic of|Seoul Clinical Site7, Seoul, Korea, Republic of|Kaohsiung Clinical Site2, Kaohsiung, Taiwan|Kaohsiung Clinical Site, Kaohsiung, Taiwan|New Taipei Clinical Site, New Taipei, Taiwan|Taichung Clinical Site, Taichung, Taiwan|Tainan Clinical Site2, Tainan, Taiwan|Tainan Clinical Site, Tainan, Taiwan|Taipei Clinical Site1, Taipei, Taiwan|Taipei Clinical Site2, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT03006705
128	NCT03647839	Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer	MODULATE	Recruiting	No Results Available	Colorectal Cancer Metastatic	Drug: Nivolumab 10 MG/ML|Drug: BNC 105|Drug: BBI608	Objective response per iRECIST|Objective response per RECIST1.1|Progression free survival (PFS).|Adverse event assessed using CTCAE version 5.0|Overall survival	Australasian Gastro-Intestinal Trials Group	All	18 Years and older   (Adult, Older Adult)	Phase 2	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209‐99U	September 6, 2018	August 2022	August 2022	August 27, 2018	null	October 29, 2018	Border Cancer Hospital, Albury, New South Wales, Australia|Newcastle Private Hospital, Newcastle, New South Wales, Australia|Northern Cancer Institute, St Leonards, New South Wales, Australia|Sydney Adventist Hospital, Wahroonga, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane Hospital, Herston, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Ballarat Health Service, Ballarat, Victoria, Australia|Eastern Health, Box Hill, Victoria, Australia|Monash Health, Clayton, Victoria, Australia|Olivia Newton-John Cancer Wellness and Research Centre, Heidelberg, Victoria, Australia|Peninsula Health/Frankston Hospital, Mornington Peninsula, Victoria, Australia|Western Health, Saint Albans, Victoria, Australia		https://ClinicalTrials.gov/show/NCT03647839
129	NCT02329847	A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies		Active, not recruiting	No Results Available	Hematologic Neoplasms	Drug: Ibrutinib|Drug: Nivolumab	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Overall Response Rate (ORR)|Duration of Stable Disease|Duration of response|Progression-Free Survival (PFS)|Overall survival|1-year Progression-Free Survival (PFS) Rate|Plasma and serum concentration of Ibrutinib and nivolumab	Janssen Research & Development, LLC|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	136	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR106681|PCI-32765LYM1002|2014-005191-28	March 11, 2015	July 15, 2019	July 31, 2020	January 1, 2015	null	November 9, 2018	New York, New York, United States|Bedford Park, Australia|Darlinghurst, Australia|Woolloongabba, Australia|Haifa, Israel|Jeursalem, Israel|Ramat Gan, Israel|Tel Aviv, Israel|Chorzow, Poland|Gdansk, Poland|Krakow, Poland|Wroclaw, Poland|Barcelona, Spain|Madrid, Spain|Salamanca, Spain|Ankara, Turkey|Istanbul, Turkey|İzmir, Turkey		https://ClinicalTrials.gov/show/NCT02329847
130	NCT02828124	A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer		Terminated	No Results Available	Hepatocellular Carcinoma	Biological: BMS-986183|Biological: Nivolumab	Incidence and Adverse Events (AEs) at its worst grade|Incidence of Serious Adverse Events (SAEs) at its worst grade|Incidence of AEs leading to discontinuations|Incidence of AEs leading to death|Frequency of laboratory test toxicity grade shifting from baseline|Best overall response (BOR)|Overall response rate (ORR)|Duration of response (DOR)|Progression free survival (PFS)|Changes in Fridericia-corrected QT interval (ΔQTcF)|Frequency of different subject immunogenicity status|Cmax (maximum observed serum and/or plasma concentration)|Tmax (time of maximum observed serum and/or plasma concentration)|AUC(0-t) (area under the concentration-time curve from time 0 to time t)|AUC(TAU) (area under the concentration-time curve in 1 dosing interval)|Ctau (concentration at the end of a dosing interval)|Ctrough (trough observed serum and/or plasma concentration, including predose concentrations and Ctau concentrations)|CLT (total body clearance calculated as dose divided by AUC(TAU)|Vss (apparent volume of distribution at steady-state)|Vz (volume of distribution of terminal phase)|AI_Cmax (accumulation index; ratio of Cmax at steady-state to Cmax after the first dose)|AI_Ctau (accumulation index; ratio of Ctau at steady-state to Ctau after the first dose)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	25	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA015-003	August 23, 2016	January 8, 2018	January 8, 2018	July 11, 2016	null	October 24, 2018	Local Institution, Ottawa, Ontario, Canada|Local Institution, Seoul, Korea, Republic of|Local Institution, Singapore, Singapore|Local Institution, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT02828124
131	NCT03342352	Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)		Withdrawn	No Results Available	Head and Neck Cancer	Drug: Nivolumab|Drug: Epacadostat|Drug: Placebo|Drug: Carboplatin|Drug: Cisplatin|Drug: Cetuximab|Drug: 5-Fluorouracil	Progression-free survival (PFS) with nivolumab plus epacadostat in combination with chemotherapy (Arm A) compared to the EXTREME regimen (Arm B)|Overall survival (OS) with nivolumab plus epacadostat in combination with chemotherapy (Arm A) compared to the EXTREME regimen (Arm B)|Objective response rate (ORR) with nivolumab plus epacadostat in combination with chemotherapy (Arm A) and the EXTREME regimen (Arm B)|Duration of response (DOR) with nivolumab plus epacadostat in combination with chemotherapy (Arm A) and the EXTREME regimen (Arm B)|ORR with nivolumab plus placebo in combination with chemotherapy (Arm C)|PFS with nivolumab plus placebo in combination with chemotherapy (Arm C)|DOR with nivolumab plus placebo in combination with chemotherapy (Arm C)|Time to meaningful symptomatic deterioration (TTSD) with nivolumab plus epacadostat in combination with chemotherapy (Arm A) compared to the EXTREME regimen (Arm B)	Incyte Corporation|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	0	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA2099NA/ECHO-310	December 15, 2017	April 20, 2018	April 20, 2018	November 14, 2017	null	May 23, 2018			https://ClinicalTrials.gov/show/NCT03342352
132	NCT03143270	A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer		Recruiting	No Results Available	Liver Cancer	Drug: Drug Eluting Bead Transarterial Chemoembolization|Drug: Nivolumab	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	14	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-087	April 28, 2017	April 2019	April 2019	May 8, 2017	null	September 11, 2018	Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Abramson Cancer Center at University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03143270
133	NCT03271047	Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation		Active, not recruiting	No Results Available	MSS|RAS-mutant Colorectal Cancer	Drug: binimetinib|Drug: nivolumab|Drug: ipilimumab	(Phase 1b) Incidence of dose-limiting toxicities (DLTs) resulting from binimetinib in combination with nivolumab|(Phase 1b) Incidence of dose-limiting toxicities (DLTs) resulting from binimetinib in combination with nivolumab plus ipilimumab|(Phase 2) Objective Response Rate (ORR)|(Phase 1b) Objective Response Rate (ORR)|(Phase 1b and Phase 2) Duration of Response (DOR)|(Phase 1b and Phase 2) Rate of complete response (CR)|(Phase 1b and Phase 2) Incidence and severity of adverse events (AEs)|(Phase 1b and Phase 2) Sparse plasma concentrations for binimetinib	Array BioPharma|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	90	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ARRAY-162-202	October 4, 2017	June 2019	January 2020	September 1, 2017	null	October 2, 2018	Array BioPharma Investigative Site, Encinitas, California, United States|Array BioPharma Investigative Site, Laguna Hills, California, United States|Array BioPharma Investigative Site, Santa Monica, California, United States|Array BioPharma Investigative Site, Newark, Delaware, United States|Array BioPharma Investigative Sites (2), Port Saint Lucie, Florida, United States|Array BioPharma Investigative Site, Indianapolis, Indiana, United States|Array BioPharma Investigative Site, Saint Louis, Missouri, United States|Array BioPharma Investigative Sites (2), Philadelphia, Pennsylvania, United States|Array BioPharma Investigative Site, Chattanooga, Tennessee, United States|Array BioPharma Investigative Site, Nashville, Tennessee, United States|Array BioPharma Investigative Site, Houston, Texas, United States|Array BioPharma Investigative Site, Leuven, Belgium|Array BioPharma Investigative Site, Amsterdam, Noord-Holland, Netherlands|Array BioPharma Investigative Site, Amsterdam, Noord-Holland, Netherlands|Array BioPharma Investigative Site, Santander, Canabria, Spain|Array BioPharma Investigative Site, Madrid, Madrid, Communidad Delaware, Spain|Array BioPharma Investigative Site, Barcelona, Spain|Array BioPharma Investigative Site, Madrid, Spain|Array BioPharma Investigative Site, Madrid, Spain|Array BioPharma Investigative Sites (2), London, United Kingdom|Array BioPharma Investigative Site, Oxford, United Kingdom		https://ClinicalTrials.gov/show/NCT03271047
134	NCT03110978	Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR		Recruiting	No Results Available	Malignant Neoplasms of Respiratory and Intrathoracic Organs|Non-small Cell Lung Cancer	Radiation: Stereotactic Ablative Radiotherapy|Drug: Nivolumab	Event-Free Survival (EFS)|Overall Survival (OS)|Toxicity Related to SABR and Immunotherapy	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	140	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2016-0737|NCI-2018-01212	June 26, 2017	June 2022	June 2022	April 12, 2017	null	October 8, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03110978
135	NCT03158129	Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection		Recruiting	No Results Available	Non-Small Cell Lung Cancer	Drug: Nivolumab|Drug: Ipilimumab|Procedure: Thoracic Surgery	Major Pathologic Response (mPR)|Toxicity Assessed by the NCI CTCAE Version 4|Quantification of CD8+ TILs|Response Rates to Induction Treatment by RECIST version 1.1	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	66	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2016-0982|NCI-2018-01210	June 9, 2017	June 2021	June 2022	May 17, 2017	null	September 14, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03158129
136	NCT03256136	Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC		Recruiting	No Results Available	Lung Cancer	Drug: Carboplatin|Drug: Nivolumab|Drug: pemetrexed|Drug: Ipilimumab	Objective Response Rate (ORR)|Disease Control Rate (DCR)|Progression Free Survival (PFS)|Overall Survival (OS)|Duration Of Response	Massachusetts General Hospital|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-011	November 22, 2017	October 31, 2020	October 31, 2024	August 21, 2017	null	June 12, 2018	Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts general Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03256136
137	NCT03523572	Trastuzumab Deruxtecan (DS-8201a) With Nivolumab in Advanced Breast and Urothelial Cancer		Recruiting	No Results Available	Breast Cancer|Urothelial Carcinoma	Drug: Trastuzumab deruxtecan (DS-8201a)|Drug: Nivolumab	Number of participants with dose-limiting toxicity at each dose level|Part 2: Dose expansion - Objective response rate (ORR)|Duration of Response (DoR)|Disease Control Rate (DCR)|Progression Free Survival (PFS)|Time to Response based on central review|Overall Survival (OS)|ORR	Daiichi Sankyo, Inc.|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	99	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DS8201-A-U105|2018-000371-32	June 20, 2018	September 2020	September 2020	May 14, 2018	null	November 27, 2018	UCLA - Medical Center, Santa Monica, California, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Tennessee Oncology - Sara Cannon Research Institute, Nashville, Tennessee, United States|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy		https://ClinicalTrials.gov/show/NCT03523572
138	NCT03245892	A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab in Patients With Ovarian Cancer		Recruiting	No Results Available	High Grade Serous Ovarian|Fallopian Tube|Primary Peritoneal Cancer	Drug: Carboplatin and Paclitaxel|Drug: Nivolumab|Procedure: cytoreductive surgery	number of patients with dose limiting toxicities	Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb	Female	18 Years and older   (Adult, Older Adult)	Phase 1	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-182	August 4, 2017	August 2019	August 2019	August 10, 2017	null	September 7, 2018	Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT03245892
139	NCT02833233	A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer		Active, not recruiting	No Results Available	Breast Cancer	Procedure: Cryoablation|Drug: Ipilimumab|Drug: Nivolumab	Number of adverse events	Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	5	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-495	June 2016	June 2019	June 2019	July 14, 2016	null	July 3, 2018	Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02833233
140	NCT03161379	Phase 2 GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer		Recruiting	No Results Available	Pancreatic Cancer	Drug: Cyclophosphamide|Drug: Nivolumab|Drug: GVAX Pancreas Vaccine|Radiation: Stereotactic Body Radiation (SBRT)	Pathologic complete response (pCR) rate at surgical resection.|Number of subjects who receive an R0 surgical resection.|Objective response rate (ORR)|Overall survival (OS)|Distant metastasis free survival (DMFS)|Number of drug related adverse events	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2	50	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J1756|IRB00130075	December 13, 2017	September 2019	September 2019	May 19, 2017	null	November 6, 2018	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03161379
141	NCT03532217	Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer		Recruiting	No Results Available	Metastatic Hormone-Sensitive Prostate Cancer	Biological: PROSTVAC-V|Biological: PROSTVAC-F|Drug: Nivolumab|Drug: Ipilimumab|Biological: Neoantigen DNA vaccine|Device: TriGrid Delivery System|Procedure: Tumor biopsy|Procedure: Peripheral blood|Procedure: Fecal samples	Safety and tolerability of regimen as defined by incidence of adverse events|Immune response as measured by tetramers|Immune response as measured by genomic studies|Immune response as measured by flow cytometry|Safety and tolerability of regimen as defined by incidence of dose-limiting toxicities (DLTs)|Failure-free survival (FFS)|Milestone survival|Number of participants who have PSA responses at 30% reduction level|Number of participants who have PSA responses at 50% reduction level|Radiographic progression as determined by RECIST 1.1|Radiographic progression as determined by Prostate Cancer Working Group 3 (PCWG3)|Radiographic progression free survival (rPFS)|Comparison of the immune correlates on matched tumor tissue and peripheral blood	Washington University School of Medicine|Bristol-Myers Squibb	Male	18 Years and older   (Adult, Older Adult)	Phase 1	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201808043|CA209-9MW	September 14, 2018	October 14, 2021	September 14, 2023	May 22, 2018	null	September 19, 2018	National Cancer Institute (GU Malignancies Branch), Bethesda, Maryland, United States|Washington University School of Medicine, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT03532217
142	NCT03391869	Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab (LONESTAR)		Recruiting	No Results Available	Malignant Neoplasms of Respiratory and Intrathoracic Organs|Non-small Cell Lung Cancer	Drug: Ipilimumab|Drug: Nivolumab|Procedure: Local Consolidative Therapy (LCT)	Overall Survival (OS)|Overall Survival (OS) in Oligometastatic Patients|Progression-Free Survival (PFS)|Time to Appearance of New Metastases (TANM)|Progression of Target lesions Defined by RECIST 1.1 Criteria|Progression of Non-Target Lesions by RECIST 1.1 Criteria|Toxicity Evaluated Using CTCAE v4.0 Criteria|Quality of Life (QOL)	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	270	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-0311|NCI-2018-00825	December 29, 2017	December 2022	December 2022	January 5, 2018	null	November 26, 2018	MD Anderson Cancer Center Memorial City, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|MD Anderson Cancer Center Katy, Houston, Texas, United States|MD Anderson Cancer Center Bay Area, Nassau Bay, Texas, United States|MD Anderson Cancer Center Sugar Land, Sugar Land, Texas, United States|MD Anderson Cancer Center The Woodlands, The Woodlands, Texas, United States		https://ClinicalTrials.gov/show/NCT03391869
143	NCT03335540	An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment	ADVISE	Recruiting	No Results Available	Advanced Cancer	Biological: Nivolumab|Biological: Relatlimab|Biological: Cabiralizumab|Biological: Ipilimumab|Biological: anti-GITR|Drug: IDO1 Inhibitor|Biological: Lirilumab|Radiation: Radiation Therapy	Number of participants with qualified tumor biopsy specimen at baseline|Percent of change from baseline in histopathologic features|Percent of change from baseline in biomarker expression patterns|Number of Adverse Events (AEs)|Number of Serious Adverse Events (SAEs)|Number of Laboratory Abnormalities	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	50	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA028-001	March 13, 2018	January 30, 2020	January 31, 2022	November 7, 2017	null	October 4, 2018	The University of Chicago Medicine, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Local Institution, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT03335540
144	NCT03711058	Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer		Not yet recruiting	No Results Available	Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor Along With Microsatellite Stable (MSS) Colon Cancer|Colon Cancer	Drug: Copanlisib|Drug: Nivolumab	Determine maximum tolerated dose (MTD) of copanlisib with fixed dose nivolumab|6-month objective response rate (ORR) of patients treated with copanlisib and nivolumab|Disease control rate (DCR) status at 6 months.|Duration of response (DOR) status at 6 months.|Progression free survival (PFS) status at 6 months.|Overall survival (OS) status at 6 months.|Number of participants experiencing study drug-related toxicities	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bayer|Bristol-Myers Squibb	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 1|Phase 2	54	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J1887|IRB00175864|CA209-8LC	November 2018	November 2020	November 2021	October 18, 2018	null	October 18, 2018	Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT03711058
145	NCT03554317	COMbination of Bipolar Androgen Therapy and Nivolumab	COMBAT-CRPC	Recruiting	No Results Available	Castration-resistant Prostate Cancer|Metastatic Prostate Cancer|Prostate Cancer	Drug: Testosterone cypionate|Drug: Nivolumab	Prostate Specific Antigen (PSA) response to Bipolar Androgen Therapy + Nivolumab|Safety of Bipolar Androgen Therapy + Nivolumab As Determined by the Number of CTCAEs ≥ grade 3|PSA Progression-Free Survival (PSA-PFS) to Bipolar Androgen Therapy + Nivolumab|Progression-Free Survival (PFS) to Bipolar Androgen Therapy + Nivolumab|Objective Response Rate (ORR) to Bipolar Androgen Therapy + Nivolumab|Durable Progression-Free Survival (Durable PFS) to Bipolar Androgen Therapy + Nivolumab|Median Overall Survival (OS) to Bipolar Androgen Therapy + Nivolumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb	Male	18 Years and older   (Adult, Older Adult)	Phase 2	44	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J1812|IRB00164973	September 5, 2018	July 2020	July 2021	June 13, 2018	null	November 7, 2018	The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT03554317
146	NCT03333616	Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors		Recruiting	No Results Available	Genitourinary Cancer|Adrenocortical Carcinoma|Non-urothelial Bladder|Non-urothelial Upper Tract|Penile Cancer|Non-adenocarcinoma Prostate Cancer|Refractory Germ-cell	Drug: Ipilimumab|Drug: Nivolumab	Objective Response Rate|Objective Response Rate for all rare GU tumor types|Duration of Response|Immune related objective response rate|Progression-Free Survival for the total cohort and by tumor cohort|Overall Survival for all patients and by tumor cohort|Safety and tolerability according to Common Terminology Criteria for Adverse Events (CTCAE).	Dana-Farber Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	57	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-423	December 28, 2017	May 31, 2021	May 31, 2025	November 7, 2017	null	September 21, 2018	University of California, San Diego Moores Cancer Center, La Jolla, California, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03333616
147	NCT03487666	OXEL: Pilot Study of Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease		Recruiting	No Results Available	Triple Negative Breast Cancer	Drug: Nivolumab|Drug: Capecitabine	Immune activation measured by changes in the peripheral immunoscore (PIS) at week 6|Immune activation measured by changes of PIS at week 12|Grade 3 and 4 toxicities according to the National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0 [NCI CTCAE v4.03]|Distant recurrence free survival (DRFS) and Overall Survival|Immune activation in the tumor by IHC|Immune activation in the tumor by flow cytometry|Immune activation in the tumor by ELISA|Intracellular cytokine staining and CD8+ T-cell clonal expansion|Circulating tumor DNA	Georgetown University|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	45	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-1535	May 21, 2018	December 2021	December 2022	April 4, 2018	null	June 28, 2018	MedStar Georgetown University Hospital, Washington, District of Columbia, United States		https://ClinicalTrials.gov/show/NCT03487666
148	NCT03044613	Nivolumab +/- Relatlimab Prior to Chemoradiation Plus Nivolumab +/- Relatlimab With II/III Gastro/Esophageal Cancer		Recruiting	No Results Available	Gastric Cancer|Esophageal Cancer|GastroEsophageal Cancer	Drug: Nivolumab|Drug: Relatlimab|Drug: Carboplatin|Drug: Paclitaxel|Radiation: Radiation	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Feasibility is assessed through the proportion of eligible patients who proceed to surgery without substantial delay (more than 60 days) due to treatment-related reasons|Pathological Complete Response Rate|Approximate quantitation of infused nivolumab bound to PD-1 receptors on the surface of T cells in the peripheral blood and within the resected tumor and lymph node specimens|Changes in Expression of Selected Immune Markers|Overall Survival|Recurrence-Free Survival	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	32	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J1714|IRB00122689	July 11, 2017	February 2019	February 2022	February 7, 2017	null	October 5, 2018	Johns Hopkins University, Baltimore, Maryland, United States|Alleghany Health Network, Pittsburgh, Pennsylvania, United States|Baylor University, Dallas, Texas, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/13/NCT03044613/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03044613
149	NCT03572478	Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer		Recruiting	No Results Available	Prostate Cancer|Endometrial Cancer	Drug: Rucaparib|Drug: Nivolumab	Dose limiting toxicities (DLT) rate of the combination of rucaparib and nivolumab	University of Chicago|Bristol-Myers Squibb|Clovis Oncology	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	60	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB18-0154	August 14, 2018	October 14, 2020	November 2022	June 28, 2018	null	August 16, 2018	University of Chicago Medical Center, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT03572478
150	NCT03325816	Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer		Active, not recruiting	No Results Available	Small Cell Lung Cancer|Small Cell Lung Cancer Extensive Stage	Drug: Nivolumab|Radiation: 177Lu-DOTA0-Tyr3-Octreotate	Phase I - Recommended phase II dose (RP2D) of 177Lu-DOTA0-Tyr3-Octreotate|Phase II - Progression Free Survival|Safety profile of 177Lu-DOTA0-Tyr3-Octreotate in combination with nivolumab|Phase II - Overall survival|Phase II - Disease Control Rate|Phase II - Objective Response Rate|Phase II - Metabolic Response	Giuseppe Giaccone|Bristol-Myers Squibb|Advanced Accelerator Applications|Georgetown University	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	9	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-1081	November 20, 2017	December 2021	December 2022	October 30, 2017	null	November 6, 2018	Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States		https://ClinicalTrials.gov/show/NCT03325816
151	NCT02259621	Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC	NA_00092076	Recruiting	No Results Available	Non-Small Cell Lung Cancer	Drug: Nivolumab|Drug: Ipilimumab	Safety|Feasibility|Pathologic Reponse|Radiographic Response	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	30	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J1414|NA_00092076	September 2014	January 2023	January 2023	October 8, 2014	null	October 5, 2018	Sibley Memorial Hospital, Washington, District of Columbia, United States|Johns Hopkins at Bayview Medical Center, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Memorial Sloan Kettering, New York, New York, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02259621/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02259621
152	NCT03607890	Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor		Recruiting	No Results Available	Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy|MSI-H Tumors	Drug: Nivolumab|Drug: Relatlimab	Objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Number of participants experiencing study drug-related toxicities|Overall survival (OS) using RECIST 1.1|Progression free survival (PFS) using RECIST 1.1|Disease control rate (DCR) using RECIST 1.1|Best overall response (BOR) using RECIST 1.1|Duration of response (DOR) using RECIST 1.1|Duration of clinical benefit (DCB) using RECIST 1.1|Time to objective response (TTOR) using RECIST 1.1	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2	21	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J18102|IRB00173534	November 6, 2018	October 2022	October 2022	July 31, 2018	null	November 8, 2018	Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT03607890
153	NCT03558087	Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing		Recruiting	No Results Available	Bladder Cancer	Drug: Nivolumab|Drug: Gemcitabine|Drug: Cisplatin	Determine the clinical complete response rate (cT0 or cTa) with gemcitabine, cisplatin, plus nivolumab|Determine the ability of clinical complete response (cT0 or cTa) to predict benefit from treatment.|Assess Adverse Events|Bladder intact overall survival|Recurrence-free survival|Pathologic complete response rate in patients undergoing cystectomy|Determine the association between a prespecified panel of genomic biomarkers and benefit from treatment in patients achieving a clinical complete response.	Matthew Galsky|Bristol-Myers Squibb|Icahn School of Medicine at Mount Sinai|Hoosier Cancer Research Network	All	18 Years and older   (Adult, Older Adult)	Phase 2	63	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCRN GU16-257	July 13, 2018	June 2020	June 2022	June 15, 2018	null	October 5, 2018	Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT03558087
154	NCT02768558	Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC		Active, not recruiting	No Results Available	Non-Small Cell Lung Cancer	Radiation: Thoracic RT|Drug: Cisplatin|Drug: Etoposide|Drug: Nivolumab|Other: Placebo	Overall Survival (OS)|Progression-Free Survival (PFS)	RTOG Foundation, Inc.|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	13	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	RTOG 3505|RF 3505|CA209-333	October 2016	October 2022	October 2024	May 11, 2016	null	November 22, 2017	UC San Diego Moores Cancer Center, La Jolla, California, United States|Stanford University, Stanford, California, United States|University of Florida, Gainesville, Florida, United States|Mount Sinai Cancer Research Center, Miami Beach, Florida, United States|Nancy N. & J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler Hospital, Savannah, Georgia, United States|University of Kentucky, Lexington, Kentucky, United States|Mercy Medical Cancer Center, Baltimore, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Metro Health Medical Center, Cleveland, Ohio, United States|Reading Hospital/McGlinn Cancer Institute, West Reading, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Virginia Mason, Seattle, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT02768558
155	NCT03470922	A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma		Recruiting	No Results Available	Melanoma	Biological: Relatlimab|Biological: Nivolumab	Progression Free Survival (PFS)|PFS|Overall Survival (OS)|ORR|Duration of Response (DOR)|OS|Number of Adverse Events (AEs)|Number of Serious Adverse Events (SAEs)|Number of AEs Leading to Discontinuation|Number of Deaths|Number of Laboratory Abnormalities	Bristol-Myers Squibb	All	12 Years and older   (Child, Adult, Older Adult)	Phase 2|Phase 3	700	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CA224-047|2017-003583-12	April 10, 2018	July 14, 2020	March 16, 2022	March 20, 2018	null	November 20, 2018	University of Arizona Cancer Center, Tucson, Arizona, United States|Local Institution, Los Angeles, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Sansum Santa Barbara Medical Foundation Clinic, Santa Barbara, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Local Institution, Washington, District of Columbia, United States|Local Institution, Jacksonville, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|Moffitt Mckinley Outpatient Center, Tampa, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Local Institution, Chicago, Illinois, United States|Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States|H & J Weinberg Can Int @ Franklin Square, Baltimore, Maryland, United States|Local Institution, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Local Institution, New York, New York, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Texas Oncology Sammons Cancer Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Instituto Alexander Fleming, Caba, Buenos Aires, Argentina|Hospital Britanico De Buenos Aires, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Caba, Argentina|Melanoma Institute Australia, North Sydney, New South Wales, Australia|Local Institution, Waratah, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Bedford Park, South Australia, Australia|Local Institution, Murdoch, Western Australia, Australia|Med University Graz Dermatology, Graz, Austria|PMU Salzburg, Salzburg, Austria|Medizinische Universtaet Wien, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|MUHC - Glen Site, Montreal, Quebec, Canada|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Local Institution, Bogota, Colombia|Local Institution, Medellin, Colombia|Local Institution, Aarhus, Denmark|Local Institution, Herlev, Denmark|Local Institution, Odense, Denmark|Local Institution, Helsinki, Finland|Local Institution, Oulu, Finland|Local Institution, Tampere, Finland|Local Institution, Turku, Finland|Chu D'Amiens - Hopital Nord, Amiens Cedex 1, France|Local Institution, Bordeaux Cedex, France|Local Institution, Lille, France|Local Institution, Marseille Cedex 5, France|Local Institution, Paris, France|Centre Hospitalier Lyon Sud, Pierre-Benite, France|Local Institution, Poitiers, France|Local Institution, Rennes Cedex, France|Elbe Klinikum Buxtehude, Buxtehude, Germany|Helios Klinikum Erfurt, Erfurt, Germany|Universitaetsklinik Essen, Essen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Universitaetsklinikum Des Saarlandes, Homburg / Saar, Germany|Universitaetsklinik Koeln, Koeln, Germany|University Of Lubeck, Lubeck, Germany|Universitaetsklinikum Mannheim, Mannheim, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany|Klinikum Dorothea Christiane Erxleben Quedlinburg GmbH, Quedlinburg, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Univ. Klinikum Wuerzburg, Wuerzburg, Germany|Laiko General Hospital Of Athens, Athens, Greece|BioClinic Thessaloniki, Thessaloniki, Greece|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Bergamo, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Siena, Italy|Local Institution, Torino, Italy|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Cancun, Quintana Roo, Mexico|Local Institution, Veracruz, Mexico|Local Institution, Dunedin, New Zealand|Local Institution, Hamilton, New Zealand|Local Institution, Tauranga, New Zealand|Local Institution, Oslo, Norway|Oddzial Onkologii Klinicznej i Doswiadczalnej, Poznan, Poland|Local Institution, Warszawa, Poland|Local Institution, Krasnodar, Russian Federation|Local Institution, Krasnoyarsk, Russian Federation|Comp. Hosp. Univ. A Coruna, A Coru?a, Spain|H. Univ. Vall dHebron, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Onkologikoa Of San Sebastian, San Sabastian Gipuzkoa, Spain|Hosp Univ Virgen Macarena, Sevilla, Spain|Local Institution, Goteborg, Sweden|Local Institution, Lund, Sweden|Local Institution, Solna, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Bristol, Avon, United Kingdom|Local Institution, Glasgow, Dumfries & Galloway, United Kingdom|Local Institution, Swansea, Glamorgan, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Inverness, Inverness-shire, United Kingdom|Local Institution, Oxford, United Kingdom		https://ClinicalTrials.gov/show/NCT03470922
156	NCT03203473	Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)		Recruiting	No Results Available	Renal Cancer	Drug: Ipilimumab|Drug: Nivolumab	Number of subjects with persistent Partial Response (PR) or Complete Response (CR) at 1 year since nivolumab discontinuation (Arm A)|Number of subjects with Progressive Disease (PD) or Stable Disease (SD) that convert to PR or CR at 1 year upon the addition of ipilimumab to nivolumab (Arm B)|Progression Free Survival|Overall Survival|Salvage therapy-free interval|Immune related objective response rate (irORR)|Safety and tolerability according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.	Dana-Farber Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	58	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-064	September 26, 2017	November 30, 2020	November 30, 2024	June 29, 2017	null	July 16, 2018	University of California, San Diego Moores Cancer Center, La Jolla, California, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Lifespan Comprehensve Cancer Center, Providence, Rhode Island, United States|University of Utah, Huntsman Cancer Center, Salt Lake City, Utah, United States|Unviersity of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT03203473
157	NCT03651271	Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer		Not yet recruiting	No Results Available	Advanced Metastatic Cancer	Biological: Nivolumab|Biological: Ipilimumab	Clinical benefit rate (CBR) of nivolumab with or without ipilimumab|Percentage of CD8 cells in on-treatment biopsies|Safety of nivolumab with or without ipilimumab measured by AEs based on CTCAE v5.0|Objective response rate (ORR) of nivolumab with or without ipilimumab in participants|The association of the percentage of CD8 cells in tumor samples with clinical outcomes	Parker Institute for Cancer Immunotherapy|Bristol-Myers Squibb|Cancer Research Institute, New York City	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PICI0025	October 17, 2018	September 14, 2020	September 14, 2022	August 29, 2018	null	October 22, 2018	M.D. Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03651271
158	NCT03697564	Nivolumab + Cabiralizumab + Gemcitabine Versus Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial).		Not yet recruiting	No Results Available	Pancreatic Cancer Stage IV	Drug: Gemcitabine|Drug: Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|Drug: Cabiralizumab	Progression Free Survival (PFS)|Incidence of Treatment-Emergent Grade 2-5 Adverse Events assessed using NCI CTCAE v5.0 toxicity criteria|Overall Survival (OS)	Hitendra Patel|Stand Up To Cancer|Bristol-Myers Squibb|University of California, San Diego	All	18 Years and older   (Adult, Older Adult)	Phase 4	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	181395	October 2018	October 2020	October 2020	October 5, 2018	null	October 5, 2018	UCSD Moores Cancer Center, La Jolla, California, United States		https://ClinicalTrials.gov/show/NCT03697564
159	NCT02499367	Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients	TONIC	Recruiting	No Results Available	Breast Cancer	Drug: Nivolumab|Radiation: Radiation therapy|Drug: Low dose doxorubicin|Drug: Cyclophosphamide|Drug: Cisplatin	Progression free survival|Overall response rate|Clinical benefit rate|Toxicity of all study regimens	The Netherlands Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	84	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	N15TON	August 2015	August 2019	August 2022	July 16, 2015	null	September 14, 2017	Antoni van Leeuwenhoek, Amsterdam, Netherlands		https://ClinicalTrials.gov/show/NCT02499367
160	NCT03650894	Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients		Not yet recruiting	No Results Available	Breast Neoplasm Female|Breast Cancer|Breast Carcinoma|Breast Tumor	Drug: Nivolumab|Drug: Ipilimumab|Drug: Bicalutamide	iRECIST Clinical Benefit Rate (the number of patients with objective response or ongoing stable disease at week 24 using iRECIST guidelines)|RECIST Clinical Benefit Rate (the number of patients who have a response according to RECIST criteria at week 12)	Providence Health & Services|Bristol-Myers Squibb|Memorial Sloan Kettering Cancer Center	Female	18 Years and older   (Adult, Older Adult)	Phase 2	138	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-8H3	October 2018	October 2022	October 2023	August 29, 2018	null	August 29, 2018	Providence Oncology & Hematology Care Clinic - Eastside, Portland, Oregon, United States		https://ClinicalTrials.gov/show/NCT03650894
161	NCT03121417	Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer		Recruiting	No Results Available	Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer	Biological: Nivolumab	Objective response rate (ORR)|Change in T cell population in the peripheral blood assessed by flow cytometry|Progression Free Survival (PFS)|Overall survival (OS)	Emory University|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	35	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00090380|NCI-2016-02017|Winship3286-16-CA209-461	July 21, 2017	July 2020	July 2022	April 20, 2017	null	August 17, 2018	Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States		https://ClinicalTrials.gov/show/NCT03121417
162	NCT03563248	Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer		Recruiting	No Results Available	Pancreatic Cancer	Drug: FOLFIRINOX|Drug: Losartan|Drug: Nivolumab|Radiation: SBRT|Procedure: Surgery	Proportion of participants with R0 resection|Progression-free survival|Overall survival|Pathologic complete response|Number of participants with treatment related serious adverse events	Massachusetts General Hospital|Bristol-Myers Squibb|Stand Up To Cancer	All	18 Years and older   (Adult, Older Adult)	Phase 2	170	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18-179	August 10, 2018	December 31, 2021	December 31, 2025	June 20, 2018	null	September 17, 2018	Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03563248
163	NCT03021993	Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer		Recruiting	No Results Available	Oral Cavity SCC	Drug: Nivolumab	Objective response rate using pathological response|Level of Treg cells in peripheral blood using immunostaining|Level of activated T-cells in peripheral blood|Level of immune stimulatory cytokines in peripheral blood|Expression of Th1 responses in CD4+ cells from peripheral blood|Expression of Th2 responses in CD4+ cells from peripheral blood|Expression of CD8+ cells expressing granzyme B (ctolytic response) from peripheral blood	Medical University of South Carolina|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	19	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	102510	May 30, 2017	April 2019	March 2020	January 16, 2017	null	November 21, 2018	Medical University of South Carolina, Charleston, South Carolina, United States		https://ClinicalTrials.gov/show/NCT03021993
164	NCT03406715	Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)		Recruiting	No Results Available	Small Cell Lung Cancer|Lung Cancer|Relapsed Small Cell Lung Cancer	Drug: Nivolumab|Drug: Ipilimumab|Biological: Dendritic Cell based p53 Vaccine	Disease Control Rate (DCR)|Progression Free Survival (PFS)|Overall Survival (OS)|Overall Response Rate (ORR)|Immune Response (IR)	H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb|MultiVir, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	41	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-19163|CA209-9KN|MVIR-Adp53DC-001	March 29, 2018	April 2020	April 2021	January 23, 2018	null	September 18, 2018	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT03406715
165	NCT01592370	An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma		Recruiting	No Results Available	Non-Hodgkin's Lymphoma|Hodgkin Lymphoma|Multiple Myeloma	Biological: Nivolumab|Biological: Ipilimumab|Biological: Lirilumab|Biological: Daratumumab|Drug: Pomalidomide|Drug: Dexamethasone	Safety and tolerability of Nivolumab alone and in combination as measured by incidence of drug related adverse events (AEs), serious drug related AEs, dose-limiting toxicities, and laboratory test abnormalities|Maximum observed serum concentration (Cmax)|Serum concentration achieved at the end of dosing interval (trough concentration, all participants) [Cmin]|Time of maximum observed serum concentration (Tmax)|Area under the plasma concentration-time curve from time zero to the last time of the last quantifiable concentration [AUC(0-T)]|Area under the concentration-time curve in one dosing interval [AUC(TAU)]|Serum concentration achieved at the end of study drug infusion (Ceoinf)|Best Overall Response (BOR)|Objective Response Rate (ORR)|Duration of Objective Response|Progression Free Survival Rate (PFSR)|Modified Severity Weighted Assessment Tool (mSWAT) for patients with cutaneous T cell lymphoma|Immunogenicity as measured by the anti-drug antibody (ADA) status both at sample level and at patient level|Minimal Residual Disease (MRD) in patients with multiple myeloma receiving nivolumab in combination with daratumumab|PD-L1 expression	Bristol-Myers Squibb|Janssen, LP	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	375	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-039|2018-001030-17	June 27, 2012	June 14, 2020	June 15, 2020	May 7, 2012	null	November 20, 2018	Local Institution, Little Rock, Arkansas, United States|Local Institution, Fresno, California, United States|Local Institution, Long Beach, California, United States|Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Local Institution, Gainesville, Florida, United States|Local Institution, Miami, Florida, United States|Cancer Institute Of Florida, Orlando, Florida, United States|Local Institution, Tampa, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, Skokie, Illinois, United States|Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States|Local Institution, Lafayette, Indiana, United States|University Of Kansas Medical Center, Kansas City, Kansas, United States|The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Local Institution, Saint Louis, Missouri, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Local Institution, Cleveland, Ohio, United States|Local Institution, Columbus, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|OHSU Center for Hematologic Malignancies, Portland, Oregon, United States|Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Local Institution, Knoxville, Tennessee, United States|Local Institution, Murray, Utah, United States|Local Institution, Saint George, Utah, United States|Huntsman Cancer Institute At The Univ. Of Utah, Salt Lake City, Utah, United States|Local Institution, Salt Lake City, Utah, United States|Local Institution, Milwaukee, Wisconsin, United States|Local Institution, Impact Migration, Belgium|Local Institution, Sint-Niklaas, Belgium|Local Institution, Yvoir, Belgium|Local Institution, Nantes Cedex 1, France|Local Institution, Poitiers, France|Local Institution, Athens, Greece|Local Institution, Chorzow, Poland|Local Institution, Poznan, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland		https://ClinicalTrials.gov/show/NCT01592370
166	NCT02423343	A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma		Recruiting	No Results Available	Solid Tumor|Non-Small Cell Lung Cancer Recurrent|Hepatocellular Carcinoma Recurrent	Drug: Galunisertib|Drug: Nivolumab	Phase 1b: Maximum Tolerated Dose of Galunisertib in Combination with Nivolumab|Pharmacokinetics (PK): Minimum Concentration (Cmin) of Nivolumab|PK: Steady State Concentration of Galunisertib|Number of Participants with Anti-Nivolumab Antibodies When Administered in Combination with Galunisertib|Phase 2: Progression Free Survival (PFS)|Phase 2: Number of Participants who Achieve Best Overall Tumor Response of Complete Response or Partial Response: Objective Response Rate (ORR)|Phase 2: Duration of Response (DoR)|Phase 2: Time to Response|Phase 2: Overall Survival (OS)	Eli Lilly and Company|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	75	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	15702|H9H-MC-JBEF	October 9, 2015	December 15, 2018	December 20, 2019	April 22, 2015	null	November 20, 2018	University of Alabama at Birmingham Medical Center, Birmingham, Alabama, United States|University of California - San Diego, La Jolla, California, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Institut Catala d'Oncologia, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Regional Universitario de Málaga, Malaga, Spain		https://ClinicalTrials.gov/show/NCT02423343
167	NCT03416244	A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer	RAMONA	Recruiting	No Results Available	Esophageal Cancer|Oesophageal Cancer|Oesophageal Cancer Metastatic|Esophageal Cancer Metastatic|Esophageal Cancers NOS|Oesophageal Cancer Nos|GastroEsophageal Cancer|Gastrooesophageal Cancer	Drug: Nivolumab|Drug: Ipilimumab	Overall survival|Time to QoL deterioration|Progression free survival|Objective Response rate|Duration of response|Duration of treatment|Cumulative dose intensity|Quality of Life|Incidence of Treatment-Emergent Adverse Events	AIO-Studien-gGmbH|Bristol-Myers Squibb	All	65 Years and older   (Older Adult)	Phase 2	75	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AIO-STO-0117|2017-002056-86|CA209-9DD	February 21, 2018	September 2019	January 2021	January 31, 2018	null	March 23, 2018	Universitätsmedizin Mannheim, Heidelberg University, II. Medizinische Klinik, Mannheim, Germany		https://ClinicalTrials.gov/show/NCT03416244
168	NCT02919683	Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity		Recruiting	No Results Available	Head and Neck Cancer	Drug: Nivolumab|Drug: Ipilimumab|Procedure: Standard of Care Surgery	Response rates to treatment|Pathological Response|Local failure Rate|Regional Failure Rate|Local Progression Free Survival|Regional Progression Free Survival|Disease Free Survival|Overall Survival|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	Dana-Farber Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-284	November 2016	April 2020	April 2024	September 29, 2016	null	October 16, 2018	Dana Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT02919683
169	NCT02864316	Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure		Terminated	No Results Available	Solid Tumors Induced by Prior Radiation Exposure	Drug: Nivolumab	Best Objective Response Rate|Percentage of patients progression-free at 24 weeks from the time of enrollment|Progression-free survival|Duration of response|Number of participants with treatment-related adverse event as accessed by CTCAE v4.0.|Overall survival	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	6	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J1695|IRB00105682	December 2016	August 2018	September 2018	August 12, 2016	null	October 2, 2018	Sidney Kimmel Cancer Center @ Johns Hopkins, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT02864316
170	NCT02705105	Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors		Active, not recruiting	No Results Available	Solid Tumor|Cancer|Carcinoma|Hepatocellular Carcinoma|HCC	Biological: Mogamulizumab + Nivolumab	Maximum Tolerated Dose (MTD)|Number of subjects experiencing dose-limiting toxicity|Objective tumor response rate according to RECIST	Kyowa Kirin Pharmaceutical Development, Inc.|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	114	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	0761-014	December 2015	October 2018	October 2018	March 10, 2016	null	March 29, 2018	Gilbert, Arizona, United States|Greenbrae, California, United States|Los Angeles, California, United States|Jacksonville, Florida, United States|Augusta, Georgia, United States|Chicago, Illinois, United States|Baltimore, Maryland, United States|Kalamazoo, Michigan, United States|Piscataway, New Jersey, United States|Albuquerque, New Mexico, United States|Goldsboro, North Carolina, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02705105
171	NCT03285321	Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)		Recruiting	No Results Available	Non-small Cell Lung Cancer	Drug: Nivolumab|Drug: Ipilimumab	Progression Free Survival (PFS)|Overall Survival (OS)|Time to Metastatic Disease|Assess Adverse Events	Greg Durm, MD|Bristol-Myers Squibb|Big Ten Cancer Research Consortium	All	18 Years and older   (Adult, Older Adult)	Phase 2	108	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BTCRC-LUN16-081	September 15, 2017	September 30, 2021	September 30, 2022	September 18, 2017	null	August 15, 2018	University of Illinois Cancer Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Johns Hopkins Sidney Kimmel Comprehensive, Baltimore, Maryland, United States|Karmanos Cancer Center (Wayne State University), Detroit, Michigan, United States|Michigan State University, Lansing, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States		https://ClinicalTrials.gov/show/NCT03285321
172	NCT03642067	Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer		Recruiting	No Results Available	Microsatellite Stable (MSS) Colorectal Adenocarcinomas|Colorectal Adenocarcinoma	Drug: Nivolumab|Drug: Relatlimab	Objective response rate (ORR)|Number of participants experiencing study drug-related toxicities|Overall survival (OS)|Progression free survival (PFS)|Time to Progression (TTP)|Disease control rate (DCR)|Best overall response (BOR)|Duration of response (DOR)|Duration of clinical benefit (DCB)|Time to objective response (TTOR)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2	64	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J18119|IRB00173537, CA224-068	November 2018	October 2022	October 2022	August 22, 2018	null	November 15, 2018	Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT03642067
173	NCT03431948	Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer	C4-MOSART	Recruiting	No Results Available	Cancer	Drug: Nivolumab|Drug: Cabiralizumab|Drug: Urelumab|Radiation: Stereotactic Body Radiation Therapy	Recommended dose of SBRT given in combination with immunotherapy|Rates of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher side effects|Rates of long term side effects|Response rate|Progression free survival rate|Overall survival rate|Local disease control of SBRT treated lesions	University of Chicago|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	60	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB17-1317|CA025-002	March 15, 2018	February 2020	February 2020	February 13, 2018	null	June 7, 2018	University of Chicago Medical Center, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT03431948
174	NCT03543189	Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy		Recruiting	No Results Available	Prostate Cancer|Prostate Disease	Drug: Nivolumab|Radiation: Brachytherapy|Radiation: External Beam Radiation Therapy|Drug: Androgen Deprivation Therapy	Phase 1: Safety Run In - Rate of Dose Limiting Toxicity (CTCAE V5.0)|Phase II: Relapse Free Survival Rate|Time to PSA Nadir	H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb	Male	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	34	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-19435|CA209-9MJ	September 26, 2018	September 2020	September 2021	June 1, 2018	null	October 24, 2018	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT03543189
175	NCT02393794	Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)		Recruiting	No Results Available	Triple-Negative Breast Cancer|Breast Cancer	Drug: Romidepsin|Drug: Cisplatin|Drug: Nivolumab	Phase I: Recommended Phase II Dose of romidepsin in combination with cisplatin|Phase II: Objective response rate of treated subjects according to RECIST v1.1 criteria|Phase II: Clinical Benefit Rate at 16 weeks of study treatment for subjects treated at the recommended phase II dose of romidepsin plus cisplatin and nivolumab|Pharmacokinetics - romidepsin plasma concentration vs time profile when given with cisplatin and nivolumab|Pharmacokinetics - cisplatin plasma concentration vs time profile when given with romidepsin|Median Progression-Free Survival and Overall Survival	Priyanka Sharma|Celgene Corporation|Bristol-Myers Squibb|University of Kansas Medical Center	Female	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	54	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IIT-2014-CISRomiNivoTNBC|RM-CL-BRST-PI-002783|IIT-2014-PS-BRST-CISRomiTNBC	July 17, 2015	July 2019	July 2020	March 19, 2015	null	October 11, 2018	University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States|University of Kansas Cancer Center - West, Kansas City, Kansas, United States|University of Kansas Cancer Center - Overland Park, Overland Park, Kansas, United States|University of Kansas Cancer Center - Westwood, Westwood, Kansas, United States|University of Kansas Cancer Center - South, Kansas City, Missouri, United States|University of Kansas Cancer Center - North, Kansas City, Missouri, United States|University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States		https://ClinicalTrials.gov/show/NCT02393794
176	NCT02526017	Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers	FPA008-003	Active, not recruiting	No Results Available	Advanced Solid Tumors, Including But Not Limited to Lung Cancer|Head and Neck Cancer|Pancreatic Cancer|Ovarian Cancer|Renal Cell Carcinoma|Malignant Glioma	Biological: FPA008|Biological: BMS-936558	Safety: Incidence of Grade 3 and Grade 4 Adverse Events (AEs) and clinical laboratory abnormalities defined as Dose Limiting Toxicities (Phase 1a)|Recommended dose (RD) of cabiralizumab with nivolumab (Phase 1a)|Safety: Incidence of AEs, Serious AEs (SAEs), clinical laboratory abnormalities, and ECG abnormalities (Phase 1a and 1b)|Safety: Incidence of treatment discontinuations, modifications, and interruptions due to adverse events (Phase 1b)|Efficacy: Objective response rate (ORR) defined as the total number of patients with confirmed responses of either complete response (CR) or partial response (PR) divided by the total number of patients evaluable for a response (Phase 1b)|Efficacy: Overall survival (OS) including median OS and one-year OS, duration of response (DOR), and progression free survival (PFS) (Phase 1b)|PK parameters of cabiralizumab : Area under the curve (AUC), clearance (CL), maximum observed concentration (Cmax), minimum observed concentration (Cmin), and volume of distribution at steady state (Vss). (Phase 1a and 1b)|Immunogenicity of cabiralizumab: Analysis of anti-FPA008 antibody level in serum (Phase 1a and 1b)|Immunogenicity of nivolumab: Analysis of anti-nivolumab antibody level in serum (Phase 1a and 1b)|PD biomarkers: Changes in macrophage and T-cell levels based on expression of CD68 and CD8 in tumor biopsy samples, changes in cytokine levels by multiplex analysis, and changes in whole blood monocyte subsets (Phase 1a and 1b)	Five Prime Therapeutics, Inc.|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	295	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FPA008-003	September 2015	March 2019	March 2020	August 18, 2015	null	October 1, 2018	Scottsdale Healthcare Hospitals DBA Honor Health, Scottsdale, Arizona, United States|Moores UC San Diego Cancer Center, La Jolla, California, United States|Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, United States|Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Center, Los Angeles, California, United States|UC Davis Comprehensive Cancer Center, Sacramento, California, United States|University of California, San Francisco, San Francisco, California, United States|Sarcoma Oncology Research Center, Santa Monica, California, United States|UCLA Hematology/Oncology- Santa Monica, Santa Monica, California, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Indiana University Health Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Norton Cancer Institute, Norton Healthcare Pavilion, Louisville, Kentucky, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Allina Health, Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering, New York, New York, United States|The Christ Hospital, Cincinnati, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute, William M. Cooper Ambulatory Pavilion of the Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States|Henry-Joyce Cancer Clinic, Vanderbilt-Ingram Cancer Center,, Nashville, Tennessee, United States|Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Mischer Neuroscience Associates, The University of Texas Health Science Center at Houston, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Cancer Therapy & Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT02526017
177	NCT03347838	Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers		Not yet recruiting	No Results Available	Bronchial Dysplasia|Tobacco Smoking|History of Non-Small Cell Lung Cancer|History of Head and Neck Cancer	Drug: Nivolumab	Improvement in endobronchial histology|Incidence of immune-related adverse events (irAEs)|Additional endobronchial histology endpoints using the 2004 WHO classification scale for pre-invasive squamous lesions of the bronchus	University of Colorado, Denver|Bristol-Myers Squibb	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 2	42	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-1492.cc	December 2018	July 2021	December 2021	November 20, 2017	null	October 16, 2018	University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|Denver VA Hospital, Denver, Colorado, United States		https://ClinicalTrials.gov/show/NCT03347838
178	NCT03162731	Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer		Recruiting	No Results Available	Larynx|Lip, Oral Cavity and Pharynx	Biological: Nivolumab|Biological: Ipilimumab|Radiation: Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy|Radiation: Volume Modulated Arc Therapy	Incidence of adverse events assessed using Common Terminology Criteria for Adverse Events version 4.03	Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	24	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17P.082	May 11, 2017	November 2021	January 2022	May 22, 2017	null	October 9, 2018	Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03162731
179	NCT03026140	Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity	NICHE	Recruiting	No Results Available	Colon Carcinoma	Drug: Nivolumab|Drug: Ipilimumab|Drug: Celecoxib 200mg	Incidence of adverse events during the treatment and follow-up (safety)|Immune activating capacity of short-term pre-operative immunotherapy|Relapse free survival	The Netherlands Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	N16NCI	March 29, 2017	June 2019	January 2020	January 20, 2017	null	August 2, 2018	Antoni van Leeuwenhoek, Amsterdam, Netherlands|OLVG, Amsterdam, Netherlands		https://ClinicalTrials.gov/show/NCT03026140
180	NCT03241745	A Study of Nivolumab in Selected Uterine Cancer Patients		Recruiting	No Results Available	Uterine Cancer|Endometrial Carcinoma|Carcinosarcoma|Leiomyosarcoma|Undifferentiated Sarcoma|High Grade Endometrial Stromal Sarcoma|Clear Cell Carcinoma	Drug: Nivolumab	Progression-Free Survival	Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb	Female	18 Years and older   (Adult, Older Adult)	Phase 2	40	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-180	August 3, 2017	August 2020	August 2020	August 7, 2017	null	November 28, 2018	Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States		https://ClinicalTrials.gov/show/NCT03241745
181	NCT02451982	Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab and Urelumab Trial for Surgically Resectable Pancreatic Cancer		Recruiting	No Results Available	Pancreatic Cancer	Drug: Cyclophosphamide|Biological: GVAX pancreatic cancer|Drug: Nivolumab|Drug: Urelumab	Median IL17A expression in vaccine-induced lymphoid aggregates found in surgically resected pancreatic tumors|Number of participants experiencing immune-related toxicities (IRAEs)|Overall Survival|Disease Free Survival	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|Bristol-Myers Squibb	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 1|Phase 2	75	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J1568|IRB00050517|R01CA197296	February 2016	June 2019	February 2020	May 22, 2015	null	October 26, 2018	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT02451982
182	NCT02426892	Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors		Active, not recruiting	No Results Available	Solid Tumors	Biological: ISA 101|Drug: Nivolumab	Overall Response Rate (ORR)	M.D. Anderson Cancer Center|ISA Pharmaceuticals B.V.|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	34	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2014-1047|NCI-2015-01004	December 23, 2015	December 2019	December 2019	April 27, 2015	null	August 6, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02426892
183	NCT01998126	Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer		Completed	No Results Available	Non-small Cell Lung Cancer	Drug: Ipilimumab|Drug: Erlotinib|Drug: Crizotinib|Drug: Nivolumab	toxicity of ipilimumab and erlotinib in EGFR mutated patients|toxicity of ipilimumab and crizotinib in ALK mutated patients|toxicity of nivolumab and erlotinib in EGFR mutated patients|toxicity of nivolumab and crizotinib in ALK mutated patients|Response rate|Progression Free Survival (PFS)|Overall Survival|immune function pre and post immune therapy	University of Utah|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	14	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCI66705	December 2, 2013	May 9, 2017	March 29, 2018	November 28, 2013	null	April 2, 2018	Huntsman Cancer Institute, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT01998126
184	NCT03518320	Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer		Recruiting	No Results Available	Bladder Cancer TNM Staging Primary Tumor (T) T2|Bladder Cancer TNM Staging Primary Tumor (T) T2A|Bladder Cancer TNM Staging Primary Tumor (T) T2B|Bladder Cancer TNM Staging Primary Tumor (T) T3|Bladder Cancer TNM Staging Primary Tumor (T) T3A|Bladder Cancer TNM Staging Primary Tumor (T) T3B|Bladder Cancer TNM Staging Regional Lymph Node (N) N0|Bladder Cancer TNM Staging Regional Lymph Node (N) N1|Bladder Cancer TNM Staging Distant Metastasis (M) M0	Drug: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|Drug: Nivolumab Injection [Opdivo]	Number of participants with incidence of treatment emergent adverse events (TEAEs) over 4 consecutive 21-day dosing cycles of TAR-200 in combination with Nivolumab as assessed by CTCAE V4.0.|Number of participants that do not require treatment discontinuation prior to the scheduled end date due to meeting any of the Subject Stopping Safety criteria or other drug or device related AE	Taris Biomedical LLC|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	25	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TAR-200-104	November 2018	June 2020	September 2020	May 8, 2018	null	November 20, 2018	DuPage Medical Group, Hinsdale, Illinois, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|The University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT03518320
185	NCT03715946	Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer		Recruiting	No Results Available	Carcinoma, Squamous Cell of Head and Neck|Oropharynx Squamous Cell Carcinoma	Drug: Nivolumab Injection|Radiation: Radiotherapy (RT)	Progression-free survival (PFS)|PEG tube dependence|Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-H&N) Score|Locoregional control (LRC)|Distant disease recurrence|MD Anderson Symptom Inventory for head and neck cancer (MDASI-HN)|MD Anderson Dysphagia Inventory (MDADI)|Voice Handicap Index-10 (VHI-10)|Performance Status Scale (PSS-HN)|Modified Barium Swallow (MBS) rating|Overall Survival	Robert Ferris|Bristol-Myers Squibb|University of Pittsburgh	All	18 Years and older   (Adult, Older Adult)	Phase 2	135	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCC 18-034	November 1, 2018	August 31, 2020	August 31, 2021	October 23, 2018	null	November 14, 2018	UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03715946
186	NCT03656627	Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease		Not yet recruiting	No Results Available	Autoimmune Diseases|Non-small Cell Lung Cancer|Rheumatoid Arthritis|Psoriasis|Giant Cell Arteritis|Polymyalgia Rheumatica|Systemic Lupus Erythematosus|Crohn Disease|Multiple Sclerosis|Ulcerative Colitis	Drug: Nivolumab	Dose-Limiting Toxicity (DLT)|Overall Response Rate|Progression-Free Survival|Overall Survival	Alliance Foundation Trials, LLC.|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	72	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AFT-42	October 31, 2018	October 31, 2022	October 31, 2022	September 3, 2018	null	October 23, 2018			https://ClinicalTrials.gov/show/NCT03656627
187	NCT02967133	A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer		Active, not recruiting	No Results Available	Non-Small-Cell Lung Cancer Metastatic|Non-Small Cell Carcinoma of Lung, TNM Stage 4|Nonsmall Cell Lung Cancer|Non Small Cell Lung Cancer Recurrent	Drug: Nivolumab|Drug: nab-paclitaxel	Progression-Free Survival	Alliance Foundation Trials, LLC.|Celgene Corporation|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AFT-31	December 2016	December 2020	December 2020	November 18, 2016	null	March 20, 2018	Mount Siani Medical Center, Miami, Florida, United States|St. Elizabeth's Healthcare, Edgewood, Kentucky, United States|Metro Minnesota community oncology research consortium, Saint Louis Park, Minnesota, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Englewood hospital and medical center, Englewood, New Jersey, United States|Rapid City Regional Hospital/Regional Cancer Care Institute, Rapid City, South Dakota, United States		https://ClinicalTrials.gov/show/NCT02967133
188	NCT03366766	Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery		Recruiting	No Results Available	Non-Squamous Non-Small Cell Lung Carcinoma|Stage I Non-Small Cell Lung Cancer|Stage IA Non-Small Cell Lung Carcinoma|Stage IB Non-Small Cell Lung Carcinoma|Stage II Non-Small Cell Lung Cancer|Stage IIA Non-Small Cell Lung Carcinoma|Stage IIB Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer	Biological: Nivolumab|Drug: Cisplatin|Drug: Pemetrexed Disodium|Drug: Gemcitabine Hydrochloride	Major pathologic response (mpCR) defined as < 10% viable tumor|Incidence of adverse events according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03|Progression free survival|Overall survival|Overall clinical response	Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University	All	18 Years and older   (Adult, Older Adult)	Phase 2	34	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17P.556	December 20, 2017	July 2021	July 2022	December 8, 2017	null	March 5, 2018	Abington Hospital - Jefferson Health, Abington, Pennsylvania, United States|Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03366766
189	NCT02327078	A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)		Active, not recruiting	No Results Available	B-cell Malignancies|Colorectal Cancer (CRC)|Head and Neck Cancer|Lung Cancer|Lymphoma|Melanoma|Ovarian Cancer|Glioblastoma	Drug: Nivolumab (Phase 1)|Drug: Epacadostat (Phase 1)|Drug: Chemotherapy (Phase 1)|Drug: Nivolumab (Phase 2)|Drug: Epacadostat (Phase 2)	Phase 1, Part 1: Safety and tolerability of epacadostat and nivolumab assessed by number of subjects with dose limiting toxicities (DLTs)|Phase 1, Part 2: Safety and tolerability of epacadostat administered in combination with nivolumab and chemotherapy regimen assessed by number of subjects with DLTs|Phase 1, Part 1 and 2: Safety assessed by the frequency of adverse events, serious adverse events, and deaths|Phase 2: Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for subjects with solid tumors and per Cheson criteria for subjects with DLBCL|Phase 2: Progression free survival (PFS)|Phase 2: Overall survival (OS)|Phase 1, Part 1: ORR per RECIST v1.1 and mRECIST for subjects with solid tumors; per Cheson and mCheson criteria for subjects with B-cell NHL; and per RANO and mRANO criteria for subjects with GBM|Phase 1, Part 2: ORR per RECIST v1.1 and modified RECIST for subjects with advanced or metastatic SCCHN and advanced or metastatic NSCLC|Phase 1, Part 2: Duration of response (DOR) for subjects with advanced or metastatic SCCHN and advanced or metastatic NSCLC|Phase 1, Part 2: PFS for subjects with advanced or metastatic SCCHN and advanced or metastatic NSCLC|Phase 2: Duration of response (DOR)|Phase 2: Duration of disease control, defined as CR, PR, and stable disease (SD)|Phase 2: Safety and tolerability measured by the frequency of adverse events (AEs), serious adverse events (SAEs), and deaths	Incyte Corporation|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	309	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	INCB 24360-204 / ECHO-204	November 2014	April 2020	October 2020	December 30, 2014	null	May 11, 2018	UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|The Angeles Clinic and Research Institute, Los Angeles, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|UCSF - University of California San Francisco, San Francisco, California, United States|University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|The University of Kansas Clinical Research Center, Fairway, Kansas, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|NYU Cancer Center, New York, New York, United States|Columbia University, Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Medical Center Boulevard, Winston-Salem, North Carolina, United States|Sanford Research, Fargo, North Dakota, United States|University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States|Sanford Research, North Sioux City, South Dakota, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology Research, Austin, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|The Christie NHS Foundation Trust, Manchester, United Kingdom|Oxford University Hospitals NHS Trust, Oxford, United Kingdom		https://ClinicalTrials.gov/show/NCT02327078
190	NCT02983045	A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors	PIVOT-02	Recruiting	No Results Available	Melanoma|Renal Cell Carcinoma|Non Small Cell Lung Cancer|Urothelial Carcinoma|Triple Negative Breast Cancer	Drug: Combination of NKTR-214 + nivolumab|Drug: Combination of NKTR-214 + nivolumab + ipilimumab	Safety of NKTR-214 in combination with nivolumab as evaluated by incidence of drug-related Adverse Events (AEs), Serious Adverse Events (SAEs), and adverse events leading to discontinuation, deaths, and clinical laboratory test abnormalities|Safety of NKTR-214 in combination with nivolumab and ipilmumab as evaluated by incidence of drug-related AEs, SAEs, and adverse events leading to discontinuation, deaths, and clinical laboratory test abnormalities|Tolerability of NKTR-214 in combination with nivolumab as evaluated by incidence of Dose Limiting Toxicities (DLTs), drug-related AEs, SAEs, adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Tolerability of NKTR-214 in combination with nivolumab and ipilmumab as evaluated by incidence of Dose Limiting Toxicities (DLTs), drug-related AEs, SAEs, adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Efficacy of NKTR-214 in combination with nivolumab as assessed by the Objective Response Rate (ORR) based on RECIST 1.1|Efficacy of NKTR-214 in combination with nivolumab and ipilmumab as assessed by the Objective Response Rate (ORR) based on RECIST 1.1|Overall Survival (OS)|Progression-Free Survival (PFS)	Nektar Therapeutics|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	480	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-214-02	October 2016	June 2020	June 2021	December 6, 2016	null	October 22, 2018	Local Institution - La Jolla, La Jolla, California, United States|Local Institution - Los Angeles, Los Angeles, California, United States|Local Institution- Palo Alto, Stanford, California, United States|Local Institution - Aurora, Aurora, Colorado, United States|Local Institution - New Haven, New Haven, Connecticut, United States|Local Institution - Gainesville, Gainesville, Florida, United States|Local Institution - Tampa, Tampa, Florida, United States|Local Institution - Atlanta, Atlanta, Georgia, United States|Local Institution - Maywood, Maywood, Illinois, United States|Local Institution - Indianapolis, Indianapolis, Indiana, United States|Local Institution - Kansas City, Kansas City, Kansas, United States|Local Institution - Boston, Boston, Massachusetts, United States|Local Institution - Detroit, Detroit, Michigan, United States|Local Institution - St. Louis, Saint Louis, Missouri, United States|Local Institution - Buffalo, Buffalo, New York, United States|Local Institution - New York 1, New York, New York, United States|Local Institution - New York 2, New York, New York, United States|Local Institution - Cleveland, Cleveland, Ohio, United States|Local Institution - Portland, Portland, Oregon, United States|Local Institution - Nashville, Nashville, Tennessee, United States|Local Institution - Houston, Houston, Texas, United States|Local Institution - Fairfax ISC, Fairfax, Virginia, United States|Local Institution - Fairfax VCS, Fairfax, Virginia, United States|Local Institution - Seattle, Seattle, Washington, United States|Local Institution - Edegem, Edegem, Belgium|Local Institution - Kortrijk, Kortrijk, Belgium|Local Institution - Leuven, Leuven, Belgium|Local Institution - Liège, Liège, Belgium|Local Institution - Wilrijk, Wilrijk, Belgium|Local Institution - Vancouver, Vancouver, British Columbia, Canada|Local Institution - Toronto SBH, Toronto, Ontario, Canada|Local Institution - Toronto PMH, Toronto, Ontario, Canada|Local Institution - Montreal, Montréal, Quebec, Canada|Local Institution - Montréal, Montréal, Quebec, Canada|Local Institution - Marseille LPC, Marseille, Brouches-duRhone, France|Local Institution - Saint-Herblain, Saint-Herblain, Loire-Atlantique, France|Local Institution - Lyon, Lyon, France|Local Institution - Marseille HN, Marseille Cedex 20, France|Local Institution - Villejuif Cedex, Villejuif, France|Local Institution - Milano FIIN, Milano, Italy|Local Institution - Milano 2, Milano, Italy|Local Institution - Napoli, Napoli, Italy|Local Institution - Roma, Roma, Italy|Local Institution - Siena, Siena, Italy|Local Institution - Buriasco (Turin), Turin, Italy|Local Institution - Brzozów, Brzozów, Poland|Local Institution - Gdynia, Gdynia, Poland|Local Institution - Kraków, Kraków, Poland|Local Institution - Otwock, Otwock, Poland|Local Institution - Poznań WCPT, Poznań, Poland|Local Institution - Poznań MPS, Poznań, Poland|Local Institution - Lodz, Łódź, Poland|Local Institution - Barcelona HQB, Barcelona, Spain|Local Institution - Barcelona HCB, Barcelona, Spain|Local Institution - Madrid HURCPO, Madrid, Spain|Local Institution - Madrid HU12, Madrid, Spain|Local Institution - Madrid CIOCC, Madrid, Spain|Local Institution - Pamplona, Pamplona, Spain|Local Institution - Sevilla, Sevilla, Spain|Local Institution - London, London, United Kingdom|Local Institution - Northwood, Northwood, United Kingdom|Local Institution - Withington, Withington, United Kingdom		https://ClinicalTrials.gov/show/NCT02983045
191	NCT02892734	Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer		Recruiting	No Results Available	HER2/Neu Negative|Recurrent Inflammatory Breast Carcinoma|Stage IV Breast Cancer|Stage IV Inflammatory Breast Carcinoma	Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab	Progression Free Survival (PFS)|Overall Response Rate (ORR)|Clinical Benefit Rate (CBR)|Overall survival|Incidence of Adverse Events	Northwestern University|Bristol-Myers Squibb|National Cancer Institute (NCI)	Female	18 Years and older   (Adult, Older Adult)	Phase 2	29	Other|Industry|NIH	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 16B07|STU00203191|P30CA060553|NCI-2016-01038	September 5, 2017	April 2019	September 2020	September 8, 2016	null	September 11, 2017	Northwestern University, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT02892734
192	NCT03451331	Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer		Recruiting	No Results Available	Metastatic Urothelial Cancer	Drug: Nivolumab|Drug: Gemcitabine|Drug: Carboplatin|Drug: Oxaliplatin	Objective Response Rate (ORR)|Assess Safety|Duration of Response|Progression-Free Survival (PFS)|Overall Survival (OS)	Matthew Galsky|Bristol-Myers Squibb|Hoosier Cancer Research Network	All	18 Years and older   (Adult, Older Adult)	Phase 2	44	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCRN GU16-287	May 10, 2018	May 1, 2020	December 1, 2020	March 1, 2018	null	November 5, 2018	Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center, New York, New York, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT03451331
193	NCT03421652	Nivolumab and Radiation Therapy in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemotherapy		Recruiting	No Results Available	Stage II Bladder Urothelial Carcinoma AJCC v6 and v7|Stage III Bladder Urothelial Carcinoma AJCC v6 and v7|Stage IV Bladder Urothelial Carcinoma AJCC v7	Drug: Nivolumab|Radiation: Radiation	Progression-free survival (PFS)|Incidence of adverse events graded per Common Terminology Criteria for Adverse Events version 4.0.|Overall response rate (ORR)|Metastasis-free survival (MFS)|Overall survival (OS)|Quality of life (QOL) and bladder functioning questionnaires assessment|PD-1 and PDL-1 expression analysis using immunohistochemistry (IHC)|Th1/Th2 cytokine ratio analysis	Barbara Ann Karmanos Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	34	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2016-195	April 24, 2018	January 2020	January 2020	February 5, 2018	null	May 15, 2018	Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States		https://ClinicalTrials.gov/show/NCT03421652
194	NCT02978404	Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases		Recruiting	No Results Available	Clear-Cell Metastatic Renal Cell Carcinoma|Non Small Cell Lung Cancer Metastatic|Brain Metastases, Adult	Drug: Nivolumab|Radiation: Radiosurgery	Intracranial progression-free survival|Treated brain lesions control rate|Overall survival after receiving Nivolumab.|Maximum response rate of distant non-irradiated disease|Progression-free survival|Correlation between tumor PD-L1 expression and clinical outcomes|Patient quality of life|Neurocognitive function, as measured by the HVLT-R|Neurocognitive function, as measured by TMT|Neurocognitive function, as measured by COWA|Acute and late toxicity of SRS + Nivolumab|Imaging indicators of response	Centre hospitalier de l'Université de Montréal (CHUM)|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16.206|OZM-080	June 2, 2017	June 2020	June 2020	December 1, 2016	null	August 28, 2018	Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada|McGill University Health Centre, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada		https://ClinicalTrials.gov/show/NCT02978404
195	NCT03123783	CD40 Agonistic Antibody APX005M in Combination With Nivolumab		Recruiting	No Results Available	Cancer|Non Small Cell Lung Cancer Metastatic|Metastatic Melanoma|Neoplasm of Lung|Melanoma	Drug: APX005M|Drug: Nivolumab	Incidence of dose limiting toxicities|Incidence of adverse events|Objective response rate|Blood concentrations of APX005M	Apexigen, Inc.|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	100	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APX005M-002	July 10, 2017	May 2019	December 2019	April 21, 2017	null	November 7, 2018	University of Arizona Cancer Center, Tucson, Arizona, United States|City of Hope, Duarte, California, United States|Yale University, New Haven, Connecticut, United States|Hem-Onc Associates of the Treasure Coast, Port Saint Lucie, Florida, United States|University Cancer & Blood Center, Athens, Georgia, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Tennessee Oncology, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT03123783
196	NCT03048500	Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery		Recruiting	No Results Available	Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer	Other: Laboratory Biomarker Analysis|Drug: Metformin Hydrochloride|Biological: Nivolumab	Objective Response Rate (ORR)|Depth of Response|Duration of Response|Persistence of Response|Disease Control Rate (DCR)|Progression-Free Survival (PFS)|Overall Survival (OS)|ORR|Incidence of Adverse Events	Northwestern University|Bristol-Myers Squibb|National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	Phase 2	51	Other|Industry|NIH	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 16L04|STU00204354|P30CA060553|NCI-2017-00060	June 6, 2017	August 2020	February 2021	February 9, 2017	null	October 2, 2018	Northwestern University, Chicago, Illinois, United States|Northwestern University- Lake Forest Hospital, Lake Forest, Illinois, United States		https://ClinicalTrials.gov/show/NCT03048500
197	NCT03583086	Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors		Recruiting	No Results Available	Thymic Carcinoma|Non-small Cell Lung Cancer|Refractory Thoracic Tumors	Drug: VEGFR/PDGFR Dual Kinase Inhibitor X-82|Biological: Nivolumab	Phase II recommended combination dose per Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.03|Phase II best response per Response Evaluation Criteria in Solid Tumors (RECIST)|Phase II best response|Progression-free survival|Overall survival|Objective response rate as related to PD-L1 status measured as < 1%, 1-49%, and > 50%.|Disease control rate	Vanderbilt-Ingram Cancer Center|Bristol-Myers Squibb|Xcovery Holdings, INC	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	140	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VICC THO 1802|CA209-982	July 10, 2018	July 2023	July 2024	July 11, 2018	null	August 16, 2018	Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT03583086
198	NCT03639714	A Study of a Personalized Neoantigen Cancer Vaccine		Not yet recruiting	No Results Available	Non Small Cell Lung Cancer|Colorectal Cancer|Gastroesophageal Adenocarcinoma|Urothelial Carcinoma	Biological: GRT-C901|Biological: GRT-R902|Biological: nivolumab|Biological: ipilimumab	Incidence of adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)|Objective Response Rate (ORR) in Phase 2 using RECIST v1.1|Identify the recommended Phase 2 dose (RP2D) of GRT-C901 and GRT-R902|Measure the immune response to neoantigens encoded by GRT-C901 and GRT-R902|Objective Response Rate (ORR) in Phase 1 using RECIST v1.1|Duration of response (DOR) using RECIST v1.1|Clinical benefit rate (using RECIST v1.1)|Progression-free survival (PFS)|Overall survival (OS)|Percentage of patients for whom vaccine is successfully manufactured and timeframe for vaccine manufacturing	Gritstone Oncology, Inc.|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	214	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GO-004	October 2018	July 2022	March 2023	August 21, 2018	null	October 23, 2018			https://ClinicalTrials.gov/show/NCT03639714
199	NCT03190265	Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer		Recruiting	No Results Available	Pancreatic Cancer	Drug: Cyclophosphamide|Drug: Nivolumab|Drug: Ipilimumab|Drug: GVAX Pancreas Vaccine|Drug: CRS-207	Objective response rate (ORR) using Response Evaluation Criteria for Solid Tumors (RECIST 1.1)|Number of participants experiencing study drug-related toxicities|Overall survival (OS)|Progression free survival (PFS)|Duration of response (DOR)|Time to progression (TTP)|Tumor marker kinetics (CA19-9)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Aduro Biotech, Inc.|Bristol-Myers Squibb	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2	63	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J1790|IRB00137389	December 5, 2017	October 2019	October 2019	June 16, 2017	null	April 18, 2018	Johns Hopkins SKCCC, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT03190265
200	NCT03721757	CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer	NICO	Not yet recruiting	No Results Available	Squamous Cell Carcinoma of the Oral Cavity	Biological: Nivolumab, Surgery, Radiotherapy|Biological: Nivolumab, Surgery, Chemoradiotherapy	Disease free survival|Recruitment Rate|Overall survival|Surgical complications - Infection rate|Surgical complications - length of hospital admission|Surgical complications - free flap failure|Surgical complications - perioperative (30-day mortality)|Assessment of adverse events|The change of Quality of Life: EORTC QLQ-C30 v3|The change of symptom	The Clatterbridge Cancer Centre NHS Foundation Trust|University of Liverpool|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	120	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	C0947|2017-005015-13|ISRCTN17428671|CA209-891	November 2018	May 2021	November 2021	October 26, 2018	null	October 26, 2018			https://ClinicalTrials.gov/show/NCT03721757
201	NCT03117049	Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer		Recruiting	No Results Available	Non-Small Cell Lung Cancer	Drug: ONO-4538|Drug: Carboplatin|Drug: Paclitaxel|Drug: Bevacizumab|Drug: Placebo	Progression Free Survival (PFS) as assessed by the Independent Radiology Review Committee (IRRC)|Overall survival (OS)|PFS (as assessed by the study site's investigator)|Objective response rate (ORR [as assessed by the IRRC and study site's investigator])|Disease control rate (DCR [as assessed by the IRRC and study site's investigator])|Duration of response (DOR [as assessed by the IRRC])|Time to response (TTR [as assessed by the IRRC])|Best overall response (BOR [as assessed by the IRRC and study site's investigator])|Maximum percentage of change in the sum of diameters of target lesions (as assessed by the IRRC)|Safety will be analyzed through the incidence of adverse events, serious adverse events|Patient reported outcome (PRO)	Ono Pharmaceutical Co. Ltd|Bristol-Myers Squibb	All	20 Years and older   (Adult, Older Adult)	Phase 3	530	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ONO-4538-52	June 13, 2017	April 2020	July 2022	April 17, 2017	null	October 2, 2018	Aichi Clinical Site2, Nagoya, Aichi, Japan|Aichi Clinical Site3, Nagoya, Aichi, Japan|Aichi Clinical Site4, Nagoya, Aichi, Japan|Aichi Clinical Site, Nagoya, Aichi, Japan|Aichi Clinical Site, Toyoake, Aichi, Japan|Aomori Clinical Site2, Hirosaki, Aomori, Japan|Aomori Clinical Site, Hirosaki, Aomori, Japan|Chiba Clinical Site, Yachiyo, Chiba, Japan|Ehime Clinical Site, Matsuyama, Ehime, Japan|Fukuoka Clinical Site, Iizuka, Fukuoka, Japan|Fukuoka Clinical Site, Kitakyushu, Fukuoka, Japan|Fukuoka Clinical Site, Koga, Fukuoka, Japan|Fukuoka Clinical Site, Kurume, Fukuoka, Japan|Fukushima Clinical Site, Kōriyama, Fukushima, Japan|Gunma Clinical Site, Ota, Gunma, Japan|Gunma Clinical Site, Shibukawa, Gunma, Japan|Hokkaido Clinical Site, Asahikawa, Hokkaido, Japan|Hokkaido Clinical Site2, Sapporo, Hokkaido, Japan|Hokkaido Clinical Site, Sapporo, Hokkaido, Japan|Hyogo Clinical Site, Akashi, Hyogo, Japan|Hyogo Clinical Site, Amagasaki, Hyogo, Japan|Hyogo Clinical Site, Himeji, Hyogo, Japan|Hyogo Clinical Site, Itami, Hyogo, Japan|Hyogo Clinical Site, Kobe, Hyogo, Japan|Hyogo Clinical Site, Nishinomiya, Hyogo, Japan|Ibaraki Clinical Site, Higashiibaraki, Ibaraki, Japan|Ibaraki Clinical Site, Kasama, Ibaraki, Japan|Ibaraki Clinical Site, Tsuchiura, Ibaraki, Japan|Ishikawa Clinical Site2, Kanazawa, Ishikawa, Japan|Ishikawa Clinical Site3, Kanazawa, Ishikawa, Japan|Ishikawa Clinical Site, Kanazawa, Ishikawa, Japan|Iwate Clinical Site, Morioka, Iwate, Japan|Kanagawa Clinical Site, Isehara, Kanagawa, Japan|Kanagawa Clinical Site2, Kawasaki, Kanagawa, Japan|Kanagawa Clinical Site, Kawasaki, Kanagawa, Japan|Kanagawa Clinical Site, Sagamihara, Kanagawa, Japan|Kanagawa Clinical Site2, Yokohama, Kanagawa, Japan|Kanagawa Clinical Site3, Yokohama, Kanagawa, Japan|Kanagawa Clinical Site, Yokohama, Kanagawa, Japan|Kumamoto Clinical Site, Koshi, Kumamoto, Japan|Kyoto Clinical Site, Jōyō, Kyoto, Japan|Mie Clinical Site, Tsu, Mie, Japan|Miyagi Clinical Site, Natori, Miyagi, Japan|Miyagi Clinical Site, Sendai, Miyagi, Japan|Nagano Clinical Site, Matsumoto, Nagano, Japan|Nagasaki Clinical Site, Ōmura, Nagasaki, Japan|Nara Clinical Site, Ikoma, Nara, Japan|Niigata Clinical Site, Nagaoka, Niigata, Japan|Oita Clinical Site, Beppu, Oita, Japan|Oita Clinical Site, Yufu, Oita, Japan|Osaka Clinical Site2, Osaka, Osaka Clinical Site, Japan|Osaka Clinical Site, Habikino, Osaka, Japan|Osaka Clinical Site, Hirakata, Osaka, Japan|Osaka Clinical Site, Kishiwada, Osaka, Japan|Osaka Clinical Site, Osakasayama, Osaka, Japan|Osaka Clinical Site, Sakai, Osaka, Japan|Osaka Clinical Site, Toyonaka, Osaka, Japan|Saga Clinical Site, Ureshino, Saga, Japan|Saitama Clinical Site, Hidaka, Saitama, Japan|Saitama Clinical Site, Kitaadachi-gun, Saitama, Japan|Shimane Clinical Site, Izumo, Shimane, Japan|Shizuoka Clinical Site, Hamamatsu, Shizuoka, Japan|Shizuoka Clinical Site, Sunto-gun, Shizuoka, Japan|Tokyo Clinical Site2, Bunkyo-ku, Tokyo, Japan|Tokyo Clinical Site, Bunkyo-ku, Tokyo, Japan|Tokyo Clinical Site2, Bunkyō-Ku, Tokyo, Japan|Tokyo Clinical Site2, Chuo-ku, Tokyo, Japan|Tokyo Clinical Site, Chuo-ku, Tokyo, Japan|Tokyo Clinical Site, Fuchū, Tokyo, Japan|Tokyo Clinical Site, Itabashi-ku, Tokyo, Japan|Tokyo Clinical Site, Kiyose, Tokyo, Japan|Tokyo Clinical Site, Koto-ku, Tokyo, Japan|Tokyo Clinical Site, Meguro, Tokyo, Japan|Tokyo Clinical Site, Minato-ku, Tokyo, Japan|Tokyo Clinical Site, Mitaka-shi, Tokyo, Japan|Tokyo Clinical Site, Shibuya, Tokyo, Japan|Tokyo Clinical Site2, Shinjuku-Ku, Tokyo, Japan|Tokyo Clinical Site3, Shinjuku-Ku, Tokyo, Japan|Tokyo Clinical Site, Shinjuku-ku, Tokyo, Japan|Tokyo Clinical Site, Tachikawa, Tokyo, Japan|Tottori Clinical Site, Yonago, Tottori, Japan|Yamaguchi Clinical Site, Iwakuni, Yamaguchi, Japan|Chiba Clinical Site2, Chiba, Japan|Chiba Clinical Site, Chiba, Japan|Fukui Clinical Site, Fukui, Japan|Fukuoka Clinical Site2, Fukuoka, Japan|Fukuoka Clinical Site3, Fukuoka, Japan|Fukuoka Clinical Site4, Fukuoka, Japan|Fukuoka Clinical Site, Fukuoka, Japan|Gifu Clinical Site2, Gifu, Japan|Gifu Clinical Site, Gifu, Japan|Hiroshima Clinical Site2, Hiroshima, Japan|Hiroshima Clinical Site, Hiroshima, Japan|Kochi Clinical Site, Kochi, Japan|Kumamoto Clinical Site, Kumamoto, Japan|Kyoto Clinical Site, Kyoto, Japan|Nagasaki Clinical Site, Nagasaki, Japan|Niigata Clinical Site2, Niigata, Japan|Niigata Clinical Site, Niigata, Japan|Okayama Clinical Site2, Okayama, Japan|Okayama Clinical Site, Okayama, Japan|Osaka Clinical Site3, Osaka, Japan|Osaka Clinical Site, Osaka, Japan|Tokushima Clinical Site, Tokushima, Japan|Toyama Clinical Site2, Toyama, Japan|Toyama Clinical Site, Toyama, Japan|Wakayama Clinical Site, Wakayama, Japan|Yamaguchi Clinical Site, Yamaguchi, Japan|Chungcheongbuk-do Clinical Site, Cheongju-si, Chungcheongbuk-do, Korea, Republic of|Gangwon-Do Clinical Site, Wŏnju, Gangwon-Do, Korea, Republic of|Gyeonggi-do Clinical Site2, Seongnam-si, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site, Suwon, Gyeonggi-do, Korea, Republic of|Gyeongsangnam-do Clinical Site, Jinju-si, Gyeongsangnam-do, Korea, Republic of|Busan Clinical Site, Busan, Korea, Republic of|Daegu Clinical Site, Daegu, Korea, Republic of|Incheon Clinical Site, Incheon, Korea, Republic of|Seoul Clinical Site2, Seoul, Korea, Republic of|Seoul Clinical Site3, Seoul, Korea, Republic of|Seoul Clinical Site4, Seoul, Korea, Republic of|Seoul Clinical Site5, Seoul, Korea, Republic of|Seoul Clinical Site6, Seoul, Korea, Republic of|Seoul Clinical Site, Seoul, Korea, Republic of|Changhua Clinical Site, Changhua, Taiwan|Chiayi Clinical Site, Chiayi City, Taiwan|Kaohsiung Clinical Site2, Kaohsiung, Taiwan|Kaohsiung Clinical Site3, Kaohsiung, Taiwan|Kaohsiung Clinical Site, Kaohsiung, Taiwan|Taichung Clinical Site, Taichung, Taiwan|Tainan Clinical Site, Tainan, Taiwan|Taipei Clinical Site2, Taipei, Taiwan|Taipei Clinical Site, Taipei, Taiwan|Taoyuan Clinical Site, Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT03117049
202	NCT03600350	pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer		Recruiting	No Results Available	Prostate Cancer	Biological: pTVG-HP|Drug: Nivolumab|Drug: GM-CSF	Percentage of subjects within acceptable toxicity boundaries|Prostate-Specific Antigen (PSA) Complete Response (CR) Rate|Metastasis-free Survival Rate|Median Radiographic Progression-free Survival|PSA Doubling Time|PSA Response Rate (</= 50% of baseline)|Number of participants requiring GM-CSF as an adjuvant after week 4	University of Wisconsin, Madison|National Cancer Institute (NCI)|Bristol-Myers Squibb|Madison Vaccines Inc. (MVI)	Male	18 Years and older   (Adult, Older Adult)	Phase 2	41	Other|NIH|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UW18008|2018-0418|P30CA014520	September 10, 2018	October 31, 2020	October 31, 2022	July 25, 2018	null	September 18, 2018	University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT03600350
203	NCT02335918	A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors		Active, not recruiting	No Results Available	Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Ovarian Carcinoma-Enrollment Completed|Colorectal Cancer (CRC)-Enrollment Completed|Renal Cell Carcinoma (RCC) (Phase ll Only)|Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed	Drug: Combination of varlilumab and nivolumab	Phase I: Number of participants with treatment-related adverse events as determined by CTCAE v4.0, dose-limiting toxicities, and laboratory abnormalities.|Phase II: Preliminary antitumor activity of the combination of varlilumab and nivolumab as measured by objective response rate (ORR) in patients with CRC, ovarian cancer, RCC and SCCHN and Overall Survival-12 months in GBM.	Celldex Therapeutics|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	175	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDX1127-02	January 2015	December 2018	December 2018	January 12, 2015	null	November 29, 2018	University of Arizona Cancer Center, Tucson, Arizona, United States|The Stanford Center for Clinical and Translational Education and Research, Palo Alto, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|University of Colorado Medical Center, Aurora, Colorado, United States|Smilow Cancer Hospital at Yale University Cancer Center, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Northwest Georgia Oncology Centers PC, Marietta, Georgia, United States|Parkview Research Center, Fort Wayne, Indiana, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Laura and Isaac Perlmutter Cancer Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Providence Health & Services, Portland, Oregon, United States|Inova Schar Cancer Institute Research, Fairfax, Virginia, United States		https://ClinicalTrials.gov/show/NCT02335918
204	NCT03219775	Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma	TITAN-TCC	Recruiting	No Results Available	Transitional Cell Carcinoma|Advanced Cancer|Metastatic Cancer	Biological: Nivolumab/Ipilimumab	Objective Response Rate (ORR)|Remission Rates (RR)|Time to Immunotherapy Resistance (TIR)|Time to Response (TTR)|Duration of Response (DOR)|Progression free survival (PFS)|Overall survival (OS)|Safety - Incidence of adverse events, serious adverse events, deaths and laboratory abnormalities|EORTC QLQ-C30|EQ-5D|EQ-5D VAS	AIO-Studien-gGmbH|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	250	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	0416-ASG	July 6, 2017	December 2020	December 2020	July 18, 2017	null	April 27, 2018	Univ. Klinik für Innere Medizin, Graz, Austria|Ordensklinikum Linz - KH Barmherzige Schwestern, Linz, Austria|Universitätsklinikum Salzburg, Salzburg, Austria|Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria|KH der Barmherzigen Brüder Wien, Wien, Austria|Universitätsklinikum Jena und Poliklinik für Urologie, Jena, Thüringen, Germany|Uniklinik der RWTH Aachen, Aachen, Germany|Klinikum Bayreuth, Bayreuth, Germany|Charite Universitätsklinikum Campus Benjamin Franklin, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|ATURO, Berlin, Germany|Uniklinik C.-G.-Dresden, Dresden, Germany|Urologicum Duisburg, Duisburg, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Helios Klinikum Erfurt, Erfurt, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Chirurgische Universitätsklinik Freiburg, Freiburg, Germany|Überörtliche Gemeinschaftspraxis für Urologie GbR, Fürth, Germany|Greifswald Universitätsklinikum, Greifswald, Germany|Universitätsklinikum Heidelberg Chirurgische Klinik Klinik für Urologie, Heidelberg, Germany|Marien Hospital, Herne, Germany|Studienzentrum Bayenthal, Köln, Germany|Universitätsklinikum Magdeburg, Magdeburg, Germany|UKGM Marburg, Marburg an der Lahn, Germany|Klinikum der Universität München - Großhadern, München, Germany|Universitätsklinikum Münster, Münster, Germany|Universtätsmedizin Rostock, Rostock, Germany|Universitätsklinikum Ulm, Ulm, Germany|Kliniken Nordoberpfalz AG, Klinikum Weiden, Weiden, Germany|Urologie Praxis am Wasserturm, Würselen, Germany		https://ClinicalTrials.gov/show/NCT03219775
205	NCT02726581	An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma	CheckMate 602	Active, not recruiting	No Results Available	Multiple Myeloma	Biological: Nivolumab|Biological: Elotuzumab|Drug: Pomalidomide|Drug: Dexamethasone	Progression free survival (PFS) by Independent Review Committee (IRC)|Time to objective response (TTR)|Duration of objective response (DOR)|Investigator-assessed PFS|Investigator-assessed ORR|Objective response rate (ORR) by IRC|Overall Survival (OS)	Bristol-Myers Squibb|AbbVie	All	18 Years and older   (Adult, Older Adult)	Phase 3	348	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-602|2015-005699-21	April 21, 2016	March 15, 2020	December 8, 2022	April 1, 2016	null	November 6, 2018	Uab Comprehensive Cancer Center, Birmingham, Alabama, United States|Southern Cancer Center Pc, Mobile, Alabama, United States|Highland Oncology Group, Fayetteville, Arkansas, United States|CBCC Global Research, Inc., Bakersfield, California, United States|Compassionate Cancer Res Grp, Corona, California, United States|Compassionate Cancer Res Grp, Fountain Valley, California, United States|Scripps Health Dba Scripps Clinical Research Services, La Jolla, California, United States|UC San Diego Moores Cancer Ctr, La Jolla, California, United States|Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States|Ronald Reagan Ucla Medical Center, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Compassionate Cancer Res Grp, Riverside, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Poudre Valley Health Care, Fort Collins, Colorado, United States|St. Mary's Hospital Med Ctr, Grand Junction, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|University Cancer Institute, Boynton Beach, Florida, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Cancer Specialists, Tallahassee, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Piedmont Cancer Institute, PC, Atlanta, Georgia, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Indiana University Cancer Ctr, Indianapolis, Indiana, United States|St. Agnes Healthcare, Inc., Baltimore, Maryland, United States|Regional Cancer Care Associates, LLC, Bethesda, Maryland, United States|Department Of Medicine Division Of Hematology/Oncology, Worcester, Massachusetts, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|St. Louis Cancer Care, Llp, Bridgeton, Missouri, United States|HCA Midwest Division, Kansas City, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|Local Institution, Flemington, New Jersey, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|Local Institution, New Brunswick, New Jersey, United States|The Valley Hospital, Paramus, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Broome Oncology, Johnson City, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Mid Ohio Oncology Hematology, Columbus, Ohio, United States|University Of Oklahoma, Oklahoma City, Oklahoma, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Donald Guthrie Foundation, Sayre, Pennsylvania, United States|Greenville Health System, Greenville, South Carolina, United States|The West Clinic, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Baylor Research Institute, Dallas, Texas, United States|Millennium Oncology, Houston, Texas, United States|CTRC at UTHSC San Antonio, San Antonio, Texas, United States|Scott And White Memorial Hosp, Temple, Texas, United States|Northern Utah Associates, Ogden, Utah, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Va Puget Sound Health Care System, Seattle, Washington, United States|Elisabethinen Hospital Dept of Medicine, Linz, Austria|Universitaetsklinik Salzburg, Salzburg, Austria|Akh, Vienna, Austria|Klinikum Wels-Grieskirchen Gmbh, Wels, Austria|Wilhelminenspital, Wien, Austria|Local Institution, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Quebec, Canada|MUHC - Glen Site, Montreal, Quebec, Canada|CIUSSS du Nord-de-l'ile-de-Montreal - Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Local Institution, Quebec, Canada|Interni hematologicka a onkologicka klinika, Brno, Czechia|Klinika hematoonkologie, Ostrava-Poruba, Czechia|I. interni klinika - klinika hematologie 1. LF UK a VFN v Praze, Praha 2, Czechia|Local Institution, Aarhus, Denmark|Local Institution, Odense, Denmark|Charite Universitatsmedizin Berlin, Berlin, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Uniklinikum Duesseldorf, Duesseldorf, Germany|Universitaetsklink Schleswig-Holstein, Kiel, Germany|Klinikum Der Johannes Gutenberg Universitaet Mainz, Mainz, Germany|University Hopistal ULM Dept of Internal Medizin, Ulm, Germany|Alexandra General Hospital Of Athens, Athens, Greece|Local Institution, Beer Sheva, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petah Tikva, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Tel Aviv, Israel|Azienda Ospedaliero Universitaria Ospedali Riuniti Di Ancona, Ancona, Italy|ASST Papa Giovanni XXIII, Bergamo, Italy|A. O. U. Di Bologna, Policlinico S. Orsola Malpighi, Bologna, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy|Azienda Ospedaliera S. Maria, Terni, Italy|Azienda Ospedaliera Citta' Della Salute E Della Scienza Di Torino, Torino, Italy|Local Institution, Oslo, Norway|Local Institution, Stavanger, Norway|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Auxilio Mutuo Cancer Center, San Juan, Puerto Rico|Local Institution, Pozuelo De Alarcon, Madrid, Spain|Local Institution, Badalona-Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Pamplona, Spain|Local Institution, Salamanca, Spain|Local Institution, Stockholm, Sweden|Hopitaux Universitaires de Geneve, Geneve, Switzerland		https://ClinicalTrials.gov/show/NCT02726581
206	NCT02105636	Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)		Active, not recruiting	Has Results	Squamous Cell Carcinoma of the Head and Neck	Drug: Nivolumab|Drug: Cetuximab|Drug: Methotrexate|Drug: Docetaxel	Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint|Overall Survival (OS) Rate in All Randomized Participants at Primary Endpoint|Progression-Free Survival (PFS)|Objective Response Rate (ORR)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	506	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-141|2013-003622-86	May 1, 2014	November 6, 2015	October 27, 2020	April 7, 2014	January 11, 2017	August 2, 2018	Stanford University Medical Center, Stanford, California, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|University Of Chicago, Chicago, Illinois, United States|Crescent City Research Consortium, LLC, Metairie, Louisiana, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan, Ann Arbor, Michigan, United States|Dumc, Durham, North Carolina, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Vanderbilt Cancer Clinic, Nashville, Tennessee, United States|Univ Of Tx. Md Anderson, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Medical College Of Wisconsin, Milwaukee, Wisconsin, United States|COIBA, Berazategui, Buenos Aires, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Sao Paulo, Brazil|British Columbia Cancer Agency-Vancouver Ctr, Vancouver, British Columbia, Canada|London Regional Cancer Program, London, Ontario, Canada|Local Institution, Lyon Cedex 08, France|Local Institution, Nice Cedex 2, France|Local Institution, Villejuif Cedex, France|Local Institution, Berlin, Germany|Universitaetsklinikum Bonn, Bonn, Germany|Universitaetsklinikum Essen, Essen, Germany|Uniklinikum Hamburg-Eppendorf, Hamburg, Germany|Med Hochschule Hannover, Hannover, Germany|Klinikum Der Universitaet, Wuerzburg, Germany|Local Institution, Hong Kong, Hong Kong|Ist.Scient. Romagnolo Per Lo Studio E Cura Tumori, Meldola, FC, Italy|Local Institution, Milano, MI, Italy|Local Institution, Torino, TO, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kashiwa, Chiba, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Takatsuki, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Akashi, Hyogo, Japan|Local Institution, Tokyo, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Leiden, Netherlands|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Valencia, Spain|Universitatsspital Zurich, Zuerich, Switzerland|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Wirral, Merseyside, United Kingdom|Local Institution, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT02105636
207	NCT02612779	A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.		Active, not recruiting	No Results Available	Multiple Myeloma	Drug: Elotuzumab|Drug: Pomalidomide|Drug: Dexamethasone|Drug: Nivolumab	EPd cohort: Progression Free Survival (PFS)|EN Cohort: Objective Response Rate (ORR)|EPd Cohort: Objective Response Rate (ORR)|EPd Cohort: Overall Survival Rate (OS)|EN Cohort: Progression Free Survival (PFS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	95	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA204-142	December 18, 2015	October 27, 2019	January 15, 2020	November 24, 2015	null	February 1, 2018	Southern Cancer Center, Mobile, Alabama, United States|Sansum Clinic - USOR, Santa Barbara, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Rocky Mountain Cancer Centers (Williams) - USOR, Denver, Colorado, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Local Institution, Saint Petersburg, Florida, United States|SCRI Florida Cancer Specialists East, Saint Petersburg, Florida, United States|Local Institution, Atlanta, Georgia, United States|Illinois Cancer Care, Peoria, Illinois, United States|Local Institution, Indianapolis, Indiana, United States|Regional Cancer Care Associates LLC, Bethesda, Maryland, United States|Bay Hematology Oncology, Easton, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States|Washington University, Saint Louis, Missouri, United States|Greenville Health System, Greenville, South Carolina, United States|Local Institution, Germantown, Tennessee, United States|SCRI Tennessee Oncology Nashville, Nashville, Tennessee, United States|Texas Oncology (Loop) - USOR, Arlington, Texas, United States|Virginia Cancer Specialists (Leesburg) - USOR, Leesburg, Virginia, United States|Swedish Medical Center, Seattle, Washington, United States|Cancer Care Northwest, Spokane, Washington, United States|Aurora Health Care, Burlington, Wisconsin, United States|Avera Health Care, Warszawa, Poland		https://ClinicalTrials.gov/show/NCT02612779
208	NCT03071406	Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma		Recruiting	No Results Available	Merkel Cell Carcinoma|Skin Cancer	Drug: Nivolumab|Drug: Ipilimumab|Radiation: Stereotactic Body Radiation Therapy (SBRT)	Overall Response Rate|Progression Free Survival (PFS)|Overall Survival (OS)	H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	50	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-18786|CA209-737	March 3, 2017	July 2023	July 2023	March 6, 2017	null	August 1, 2018	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT03071406
209	NCT02763761	An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo		Withdrawn	No Results Available	Renal Cell Carcinoma|Melanoma|Lung Cancer	Drug: Infliximab + Prednisone|Drug: Methylprednisolone + Prednisone	Improvement in management of immune related grade 3 and 4 diarrhea as measured by proportion of responders to less than or equal to grade 1|Improvement in management of persistent grade 2 diarrhea as measured by proportion of responders to less than or equal to grade 1|Number of days to improvement to less than grade 1 diarrhea|Quality of life as measured by European Quality of Life-5 Dimensions Questionnaire (EQ-5D)|Number of hospitalizations|Duration of hospitalizations|Number of patients with adverse events (AEs)|Number of patients with AEs related to steroid use|Number of patients with Gastrointestinal (GI) specific AEs	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	0	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-601	August 16, 2016	March 31, 2017	March 31, 2017	May 5, 2016	null	October 8, 2018	University of California Los Angeles, Los Angeles, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|University of Louisville, Louisville, Kentucky, United States|University of Michigan, Ann Arbor, Michigan, United States|Atlantic Health System, Morristown, New Jersey, United States|Local Institution, Albuquerque, New Mexico, United States|NYU Langone Medical Center, New York, New York, United States|Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT02763761
210	NCT02845323	Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder		Recruiting	No Results Available	Urothelial Carcinoma|Bladder Cancer	Drug: Nivolumab in combination with Urelumab|Drug: Nivolumab monotherapy	Immune response to treatment with Nivolumab and Urelumab compared to Nivolumab monotherapy measured by tumor infiltrating CD8+ T cell density at cystectomy|To evaluate the number of participants with treatment-related adverse events as assessed by CTCAE v 4.0|Proportion of patients achieving pathologic response (<pT2N0) with Nivolumab and Urelumab and the use of Urelumab alone|Prognostic value of tumor biopsy PD-1 and PD-L1 expression and change in expression for pathologic tumor response as defined by cystectomy pathologic staging <pT2 N0 in patients treated with Nivolumab|Change in expression for pathologic tumor response as defined by cystectomy pathologic staging <pT2 N0 in patients treated with Nivolumab|Prognostic value of tumor bx 4-1BB (CD137)& 4-1BB ligand (CD137L) expression|Change in expression, assessed by (IHC) analysis, for tumor response, defined by cystectomy staging < pT2N0, in cisplatin-ineligible MIBC pts tx w/Urelumab.|Prognostic value of tumor biopsy 4-1BB expression|Change in expression, assessed by (IHC) analysis, for pathologic CR response, defined by cystectomy staging pT0N0, in cisplatin-ineligible MIBC pts tx w/ Urelumab.|Proportion of patients achieving pathologic complete response with neoadjuvant Nivolumab and Urelumab (Arm A) and Nivolumab monotherapy (Arm B).	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	44	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J1682|IRB00103062	September 2016	September 2019	January 2020	July 27, 2016	null	October 17, 2018	Johns Hopkins Hospital, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT02845323
211	NCT03317327	REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors	REPORT	Recruiting	No Results Available	Head and Neck Squamous Cell Carcinoma	Drug: Nivolumab|Radiation: Radiotherapy (RT)	Incidence, nature, and severity of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.|Progression-free survival (PFS)|Objective response rate (ORR)|Overall survival (OS)|Duration of response (DOR)|Durable response rate (DRR)	Oslo University Hospital|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-686_REPORT	September 9, 2017	November 2, 2023	November 2, 2040	October 23, 2017	null	November 14, 2018	Oslo University Hospital, Oslo, Norway	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/27/NCT03317327/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03317327
212	NCT03726281	Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors		Recruiting	No Results Available	Germ Cell Tumors	Drug: Nivolumab	Clinical Benefit Rate (CBR, %)|CR + marker-negative PR (%)|CR + PR with stable or declining tumor markers (αFP and HCG)|Time to response|Duration of clinical response|Progression Free Survival (PFS)|Overall Survival (OS)	Hospital Beatriz Ângelo|Universidade Nova de Lisboa|Bristol-Myers Squibb|Instituto de Patologia e Imunologia Molecular da Universidade do Porto	All	18 Years and older   (Adult, Older Adult)	Phase 2	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HBA_001	October 1, 2018	October 1, 2020	December 1, 2022	October 31, 2018	null	November 2, 2018	Hospital Beatriz Ângelo, Loures, Portugal		https://ClinicalTrials.gov/show/NCT03726281
213	NCT03262779	Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.		Recruiting	No Results Available	Carcinoma, Non-Small-Cell Lung	Biological: combination nivolumab and ipilimumab	Objective response rate using RECIST v1.1 to nivolumab and ipilimumab when administered in combination to patients with pre-treated advanced NSCLC who have experienced primary resistance to anti-PD-1 axis therapy as their last line of systemic therapy.|Progression-free survival with nivolumab and ipilimumab when administered in combination to patients with pre- treated advanced NSCLC who have experienced primary resistance to anti-PD-1 axis therapy as their last line of systemic therapy|Overall survival (OS) with nivolumab and ipilimumab when administered in combination to patients with pre- treated advanced NSCLC who have experienced PRIMARY resistance to anti-PD-1 axis therapy as their last line of systemic therapy.|Objective response rate using irRC to nivolumab and ipilimumab when administered in combination to patients with pre-treated advanced NSCLC who have experienced primary resistance to anti-PD-1 axis therapy as their last line of systemic therapy.|Objective response rate in in advanced non-small cell lung cancer (NSCLC) with ACQUIRED resistance to anti-programmed death (PD)-1 axis therapy as their last line of systemic therapy.|Progression free survival by RECIST v1.1 with nivolumab and ipilimumab in patients with pre-treated advanced NSCLC who have experienced acquired resistance to anti-PD-1 axis therapy as their last line of systemic therapy.|Overall survival with nivolumab and ipilimumab in patients with pre-treated advanced NSCLC who have experienced ACQUIRED resistance to anti-PD-1 axis therapy as their last line of systemic therapy.|Safety of nivolumab and ipilimumab when administered in combination in patients with pre-treated advanced NSCLC who have experienced PRIMARY or ACQUIRED resistance to anti-PD-1 axis therapy as their last line of systemic therapy.|Feasibility of sequential biopsies (performed or not performed) in patients with pre-treated advanced NSCLC who have experienced PRIMARY or ACQUIRED resistance to anti-PD-1 axis therapy as their last line of systemic therapy,	Yale University|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	50	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2000020343	July 20, 2017	November 1, 2019	November 1, 2020	August 25, 2017	null	May 30, 2018	Yale Cancer Center, New Haven, Connecticut, United States		https://ClinicalTrials.gov/show/NCT03262779
214	NCT03502330	APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma		Recruiting	No Results Available	Advanced Melanoma|Non-small Cell Lung Cancer|Renal Cell Carcinoma	Drug: APX005M|Drug: Cabiralizumab|Drug: Nivolumab	Safety and Tolerability measured by assessing serious adverse events (SAEs)and adverse events (AEs)|Safety and Tolerability measured by Eastern Cooperative Oncology Group(ECOG) performance status|Efficacy measured by objective response rate (ORR)	Yale University|Bristol-Myers Squibb|Apexigen, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 1	120	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2000021757	June 9, 2018	May 2022	October 2024	April 18, 2018	null	June 19, 2018	Yale Cancer Center, New Haven, Connecticut, United States		https://ClinicalTrials.gov/show/NCT03502330
215	NCT03529890	Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder	RACE IT	Not yet recruiting	No Results Available	Urinary Bladder Cancer	Drug: Nivolumab|Radiation: Radiation therapy of the pelvis|Procedure: Radical cystectomy with standardized pelvic lymphadenectomy	Rate of patients with completed Treatment|Acute toxicity of preoperative radio-immunotherapy|Rate of immune related toxicities|Late toxicity|Disease free survival|Cancer specific survival|Overall survival|radiological Overall Response rate|ypT0 rate|surgical margin Status	Technische Universität München|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	33	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AB 65/18|CA209-9WT	November 2018	February 2022	August 2022	May 18, 2018	null	May 18, 2018	Department of Radiation Oncology, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt, Germany|Department of Urology, Klinikum rechts der Isar der Technischen Universität München, München, Germany|Department of Urology, Universitätsklinikum Würzburg, Würzburg, Germany		https://ClinicalTrials.gov/show/NCT03529890
216	NCT03083691	BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer		Enrolling by invitation	No Results Available	Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung	Drug: Nivolumab, Ipilimumab	Cohort 1: ORR after addition of ipilimumab to nivolumab treatment.|Cohort 2: ORR of the combination therapy nivolumab and ipilimumab.|Overall survival of nivolumab monotherapy/nivolumab + ipilimumab combination therapy|Progression-free survival of nivolumab monotherapy/nivolumab + ipilimumab combination therapy|Duration of response of nivolumab monotherapy/nivolumab + ipilimumab combination therapy|Incidence, severity and grading of adverse events (AEs) during nivolumab monotherapy/ nivolumab + ipilimumab combination therapy|Incidence, severity and grading of serious adverse events (SAEs) during nivolumab monotherapy/ nivolumab + ipilimumab combination therapy	Lung Cancer Group Cologne|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	106	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Uni-Koeln-2785|2016-003334-25	April 5, 2017	March 2019	August 2020	March 20, 2017	null	May 12, 2017	University Hospital of Cologne, Cologne, NRW, Germany		https://ClinicalTrials.gov/show/NCT03083691
217	NCT02434081	NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma	NICOLAS	Active, not recruiting	No Results Available	Non-small Cell Lung Cancer Stage III	Drug: Nivolumab	Grade ≥3 pneumonitis (CTCAE v4.0) from the end of radiotherapy|1-year progression-free survival by RECIST v1.1 (PFS)|Time to first pneumonitis of grade ≥3 (TFP3)|Objective response|Time to treatment failure (TTF).|Overall Survival (OS)|Adverse events graded according to CTCAE V4.0 (Toxicity)	European Thoracic Oncology Platform|Bristol-Myers Squibb|Frontier Science Foundation, Hellas	All	18 Years and older   (Adult, Older Adult)	Phase 2	94	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ETOP 6-14 NICOLAS|2014-005097-11|SNCTP000001672	November 2015	August 2020	August 2020	May 5, 2015	null	August 7, 2018	University Hospital Leuven, Leuven, Belgium|Thoracic Oncology Centre Munich, Munich, Germany|VUMC, Amsterdam, Netherlands|MAASTRO Clinic, Maastricht, Netherlands|Vall d'Hebron University Hospital, Barcelona, Spain|Catalan Institute of Oncology, Barcelona, Spain|Hospital Virgen de la Salud, Toledo, Spain|HFR Fribourg- Hôpital cantonal, Fribourg, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Hirslanden Klinik Zürich, Zurich, Switzerland|University Hospital Zürich, Zürich, Switzerland		https://ClinicalTrials.gov/show/NCT02434081
218	NCT03353675	A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)		Recruiting	No Results Available	NSCLC	Biological: TG4010|Drug: Chemotherapy|Drug: Nivolumab	Objective Response Rate (ORR)|Progression Free Survival (PFS)|Disease Control Rate (DCR)|Overall Survival (OS)|Duration of overall Response (DoR)|Evaluation of Safety profile	Transgene|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	39	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TG4010.24	January 16, 2018	September 2019	September 2020	November 27, 2017	null	September 24, 2018	Charlotte, Charlotte, North Carolina, United States|Nashville, Nashville, Tennessee, United States|Libramont, Libramont, Belgium|Herlev, Herlev, Denmark|Créteil, Créteil, France|Mulhouse, Mulhouse, France|Rennes, Rennes, France|Strasbourg, Strasbourg, France|Budapest, Budapest, Hungary|Szekesfehervar, Szekesfehervar, Hungary		https://ClinicalTrials.gov/show/NCT03353675
219	NCT03508570	Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis		Recruiting	No Results Available	Malignant Peritoneal Neoplasm|Malignant Retroperitoneal Neoplasm|Peritoneal Carcinomatosis|Recurrent Cervical Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Uterine Corpus Carcinoma|Stage IV Cervical Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IVA Cervical Cancer AJCC v8|Stage IVA Fallopian Tube Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Primary Peritoneal Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVB Cervical Cancer AJCC v8|Stage IVB Fallopian Tube Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Primary Peritoneal Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8	Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Pharmacokinetic Study	Maximum tolerated dose (MTD)/recommended phase II dose (RP2D) of intraperitoneal (i.p.) nivolumab in combination with ipilimumab|PK Parameters|Clinical Benefit Rate	M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	48	Other|NIH|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-0264|NCI-2018-00282|P30CA016672	September 21, 2018	January 2020	January 2020	April 25, 2018	null	September 25, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03508570
220	NCT02897765	A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer		Active, not recruiting	No Results Available	Urinary Bladder Cancer|Bladder Tumors|Transitional Cell Carcinoma of the Bladder|Malignant Melanoma|Melanoma|Skin Cancer|Carcinoma, Non-Small-Cell Lung|Lung Cancer	Biological: NEO-PV-01|Biological: Nivolumab|Other: Adjuvant	Rate of adverse events including SAEs and AEs leading to treatment discontinuation|Rate of adverse events including SAEs and AEs leading to changes in safety laboratory evaluations|Rate of adverse events including SAEs and AEs leading to physical examination findings|Rate of adverse events including SAEs and AEs leading to vital signs findings|Rate of adverse events including SAEs and AEs leading to changes in ECOG status|Objective response rate (ORR)|Duration of response (DOR)|Clinical benefit rate (CBR)|Response conversion rate (RCR)|Progression-free survival (PFS)|Overall survival (OS)	Neon Therapeutics, Inc.|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	55	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NT-001	October 2016	December 2018	December 2020	September 13, 2016	null	September 6, 2018	City of Hope, Duarte, California, United States|UCLA Medical Center, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Center, Boston, Massachusetts, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02897765
221	NCT02350764	Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs		Recruiting	No Results Available	Advanced Stage Non-small Cell Lung Cancer	Drug: nivolumab|Drug: pilimumab	Best overall response rate (confirmed partial + complete response) will be assessed as part of this study. Tumor response will be assessed using RECIST 1.1)	Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	35	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	14-137	January 2015	January 2019	January 2019	January 30, 2015	null	January 30, 2018	Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02350764
222	NCT03146650	Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer		Recruiting	No Results Available	Major Salivary Gland Carcinoma|Minor Salivary Gland Carcinoma|Recurrent Salivary Gland Carcinoma|Stage IV Major Salivary Gland Carcinoma|Stage IVA Major Salivary Gland Carcinoma|Stage IVB Major Salivary Gland Carcinoma|Stage IVC Major Salivary Gland Carcinoma	Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab	Median PFS (median Progression-Free Survival)|PFS at 6 months|PFS at 12 months|Response Rate (RR)|Disease Control Rate (DCR)|Overall Survival (OS)|PFS (RECIST 1.1 criteria)|Overall Response Rate (ORR)|DCR (irRECIST)|PFS (irRECIST criteria)|OS (irRECIST)|Incidence of Adverse Events	Northwestern University|Bristol-Myers Squibb|National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	Phase 2	63	Other|Industry|NIH	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 16N03|STU00204579|P30CA060553|NCI-2017-00406	May 19, 2017	July 2021	June 2022	May 10, 2017	null	August 14, 2018	Northwestern University, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT03146650
223	NCT03547999	A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC		Recruiting	No Results Available	Metastatic Colorectal Cancer	Drug: mFOLFOX6|Biological: MVA-BN-CV301|Biological: FPV-CV301|Drug: Nivolumab	Overall Survival (OS)|Recurrence free survival (RFS)|Evaluate Overall Response Rate (ORR)|Evaluate the proportion of patients amenable to complete resection/ablation|Evaluate the perioperative surgical outcomes|Pathologic Complete Response|Progression Free Survival (PFS)	Darren Carpizo, MD|Bavarian Nordic|Hoosier Cancer Research Network|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	78	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCRN GI16-288	June 26, 2018	June 2019	June 2023	June 6, 2018	null	October 31, 2018	Rutgers Cacner Institute of New Jersey, New Brunswick, New Jersey, United States		https://ClinicalTrials.gov/show/NCT03547999
224	NCT02823990	TG4010 and Nivolumab in Patients With Lung Cancer		Active, not recruiting	No Results Available	Recurrent Non-Small Cell Lung Carcinoma|Stage I Non-Small Cell Lung Cancer|Stage II Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer	Biological: TG4010|Biological: Nivolumab	ORR defined as the proportion of patients whose best overall response (BOR) is either complete response (CR) or partial response (PR) according to RECIST 1.1|Disease control rate defined as the proportion of patients whose BOR is either CR, PR or SD, assessed by RECIST 1.1|Duration of response (DOR) defined as patients whose best overall response is CR or PR (confirmed response)|Incidence of adverse events reported per CTCAE v4.0|Overall survival (OS) defined by RECIST 1.1|Progression free survival (PFS) defined by RECIST 1.1|Stable disease (SD) rate defined as the proportion of patients whose BOR is SD, assessed by RECIST 1.1	Karen Kelly|National Cancer Institute (NCI)|Transgene|Bristol-Myers Squibb|University of California, Davis	All	18 Years and older   (Adult, Older Adult)	Phase 2	33	Other|NIH|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	885316|UCDCC#263|P30CA093373|NCI-2016-00960	December 2016	February 2019	February 2019	July 6, 2016	null	October 9, 2018	City of Hope Comprehensive Cancer Center, Duarte, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|University of California San Diego, San Diego, California, United States|UCSF Medical Center-Mount Zion, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT02823990
225	NCT03012581	Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types	AcSé	Recruiting	No Results Available	Carcinoma, Renal Cell|Head and Neck Neoplasm|Skin Neoplasms|Microsatellite Instability|Penile Neoplasms	Drug: Nivolumab	Objective response rate|Progression-free survival|Overall survival|Best response|Response duration|Time to response|Frequency and severity of adverse events|Objective response rate in subgroups of subjects with high versus low expression (cutoff set at the median for the population measured) of different immune markers (PD-L1, CD4+, FOXP3+, Fas-L, OX40, VEGF, CD31; CD34)|Progression-free survival in subgroups of subjects with high versus low expression (cutoff set at the median for the population measured) of different immune markers (PD-L1, CD4+, FOXP3+, Fas-L, OX40, VEGF, CD31; CD34)|Overall survival in subgroups of subjects with high versus low expression (cutoff set at the median for the population measured) of different immune markers (PD-L1, CD4+, FOXP3+, Fas-L, OX40, VEGF, CD31; CD34)	UNICANCER|National Cancer Institute, France|Ligue contre le cancer, France|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	300	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UC0105/1611|2016-002257-37	June 16, 2017	January 2023	December 2023	January 6, 2017	null	May 21, 2018	Gustave Roussy Cancer Campus, Villejuif, France		https://ClinicalTrials.gov/show/NCT03012581
226	NCT02636036	Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors	SPICE	Recruiting	No Results Available	Colorectal Cancer|Bladder Carcinoma|Squamous Cell Carcinoma of the Head and Neck|Salivary Gland Cancer	Biological: enadenotucirev|Biological: nivolumab	Maximum Tolerated and/or Maximum Feasible Dose|to assess the blood levels of enadenotucirev following combination treatment|To examine the anti-tumor activity of combination treatment with enadenotucirev and nivolumab	PsiOxus Therapeutics Ltd|Bristol-Myers Squibb|Syneos Health	All	18 Years and older   (Adult, Older Adult)	Phase 1	40	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ColoAd1-1003	January 2016	October 2019	March 2020	December 21, 2015	null	September 20, 2018	University of Arizona Cancer Center, 1515 North Campbell Ave., Tucson, Arizona, United States|City of Hope Comprehensive Cancer Center, 1500 E Duarte Str., Duarte, California, United States|UCLA Medical Center, 10945 Le Conte Ave, Ste. 3360, Santa Monica, California, United States|Horizon Oncology Research, 1345 Unity Place, Suite 345, Lafayette, Indiana, United States|Henry Ford Hospital, 2799 West Grand Blvd., Detroit, Michigan, United States		https://ClinicalTrials.gov/show/NCT02636036
227	NCT03575234	Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer		Not yet recruiting	No Results Available	Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma|Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7	Drug: Cyclophosphamide|Biological: IRX-2|Biological: Nivolumab|Procedure: Surgery	Incidence of adverse events (AEs) described using Common Terminology Criteria for Adverse Events 4.03|Change in tumor size determined by central radiology review by radiologists blinded to the treatment regimen	Emory University|Bristol-Myers Squibb|IRX Therapeutics	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	30	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00102105|NCI-2018-00411|Winship4300-18	July 1, 2019	January 31, 2025	January 31, 2025	July 2, 2018	null	July 2, 2018	Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States		https://ClinicalTrials.gov/show/NCT03575234
228	NCT03527108	Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC		Not yet recruiting	No Results Available	Non Small Cell Lung Cancer	Drug: Nivolumab, ramucirumab|Drug: Nivolumab	Number of patients with progression free survival (PFS) at 6 months in IO naive patients.treated with nivolumab and ramucirumab combination therapy vs the nivolumab monotherapy|Disease control rate (DCR) in IO experienced patients.treated with nivolumab and ramucirumab combination therapy|Overall Response Rate (ORR) in IO naive patients treated with nivolumab and ramucirumab combination therapy|Overall Response Rate in IO naive patients treated with nivolumab monotherapy|Number of patients with treatment related toxicities in IO naive patients treated with nivolumab and ramucirumab combination therapy|Number of patients with treatment related toxicities in IO naive patients treated with nivolumab monotherapy|Overall survival in IO naive patients treated with nivolumab and ramucirumab combination.|Overall survival in IO naive patients treated with nivolumab monotherapy|Number of patients with PFS at 6 months in IO experienced patients treated with nivolumab and ramucirumab combination therapy .|ORR in IO experienced patients treated with nivolumab and ramucirumab combination therapy .|Number of patients with treatment related toxicities in IO experienced patients treated with nivolumab and ramucirumab combination therapy .|Overall survival in IO experienced patients treated with nivolumab and ramucirumab combination therapy .	Fox Chase Cancer Center|Bristol-Myers Squibb|Eli Lilly and Company	All	18 Years and older   (Adult, Older Adult)	Phase 2	117	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18-1026|TH-125	December 1, 2018	April 1, 2020	April 1, 2023	May 16, 2018	null	August 1, 2018	Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03527108
229	NCT03572582	Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma	IMMUTACE	Recruiting	No Results Available	Carcinoma, Hepatocellular|Hepatic Carcinoma|Hepatocellular Cancer	Drug: Nivolumab|Drug: TACE	Objective Response Rate (ORR)|Progression Free Survival (PFS)|Time to Progression (TTP)|Overall survival (OS)|Duration of Response (OR)|Objective Response Rate according to RECIST 1.1|Time to Failure of Strategy (TTFS)|Quality of Life (QoL)|Incidence of Treatment Emergent Adverse Events as assessed by NCI CTCAE V4.03 (Safety and Tolerability)	AIO-Studien-gGmbH|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	49	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AIO-HEP-0217|2017‐003553‐42|CA209-9KK	June 14, 2018	December 2021	September 2022	June 28, 2018	null	June 28, 2018	Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie & Endokrinologie, Hannover, Germany		https://ClinicalTrials.gov/show/NCT03572582
230	NCT03585465	Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors or Lymphoma		Not yet recruiting	No Results Available	Childhood Solid Tumor|Childhood Lymphoma	Drug: Vinblastine|Drug: Cyclophosphamide|Drug: Capecitabine|Drug: Nivolumab	Dose Limiting Toxicities according to the NCI-CTCAE V5|Progression-free survival according appropriate criteria (RANO, WHO, INRC, RECIST v1.1, or standard criteria for lymphoma).|Adverse events according to the NCI-CTCAE V5.|Tumor response in terms of complete/partial response or stable/progressive disease (using RANO, WHO, INRC, RECIST v1.1, or standard criteria for lymphoma) and overall survival|Dose-intensity for each drug (ratio between the computed dose-intensity, and the protocol dose-intensity)	Centre Oscar Lambret|Anticancer Fund, Belgium|Bristol-Myers Squibb	All	4 Years to 18 Years   (Child, Adult)	Phase 1|Phase 2	102	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Metro-PD1-1708	September 2018	January 2024	July 2027	July 13, 2018	null	July 13, 2018			https://ClinicalTrials.gov/show/NCT03585465
231	NCT03222076	Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956)		Recruiting	No Results Available	Malignant Neoplasms of Digestive Organs|Hepatocellular Carcinoma	Drug: Nivolumab|Drug: Ipilimumab	Safety of Nivolumab Alone or Nivolumab plus Ipilimumab in Participants with Hepatocellular Carcinoma (HCC) Determined by Adverse Events|Objective Response Rate (ORR)|Progression-free survival (PFS)|Conversion Rate to Surgery for Potentially Resectable Participants.	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	45	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-0097|NCI-2018-01106	September 28, 2017	September 2022	September 2022	July 19, 2017	null	November 5, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03222076
232	NCT03461952	Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)	NIMBLe	Recruiting	No Results Available	Advanced Solid Tumors	Drug: Nivolumab|Drug: Ipilimumab	Objective Response Rate by RECIST 1.1|Efficacy as measured by objective response rate|Duration of response|Number and severity of adverse events using CTCAE 5.0|Correlation between POLE or POLD1 mutations in tumor and POLE or POLD1 mutations in blood|To evaluate response by iRECIST	Canadian Cancer Trials Group|Cancer Research Institute, New York City|Bristol-Myers Squibb|Personal Genome Diagnostics	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I235|0001	August 28, 2018	May 2021	July 2022	March 12, 2018	null	November 14, 2018	Tom Baker Cancer Centre, Calgary, Alberta, Canada		https://ClinicalTrials.gov/show/NCT03461952
233	NCT03576963	Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer		Not yet recruiting	No Results Available	Colorectal Adenocarcinoma|CpG Island Methylator Phenotype|Metastatic Microsatellite Stable Colorectal Carcinoma|Refractory Colorectal Carcinoma|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8	Drug: Guadecitabine|Biological: Nivolumab	Maximum tolerated dose (MTD) of guadecitabine when given in combination with nivolumab|Recommended phase 2 dose (RP2D) of guadecitabine when given in combination with nivolumab|Incidence and severity of adverse events	University of Southern California|National Cancer Institute (NCI)|Bristol-Myers Squibb|Astex Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	45	Other|NIH|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	3C-18-5|NCI-2018-01072|P30CA014089	October 22, 2018	October 22, 2020	October 22, 2021	July 4, 2018	null	August 24, 2018	USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States		https://ClinicalTrials.gov/show/NCT03576963
234	NCT03283046	Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma		Withdrawn	No Results Available	Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic|Multiple Myeloma	Drug: Nivolumab|Drug: Lenalidomide|Drug: Dexamethasone|Drug: Ipilimumab	Maximum Tolerated Dose (MTD) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Adverse Events (AE) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Rate of Response of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Progression Free Survival (PFS) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Overall Survival of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Duration of Response (DOR) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Clinical Benefit Rate (CBR) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	0	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2016-0482	October 2017	October 2020	October 2020	September 14, 2017	null	September 20, 2017			https://ClinicalTrials.gov/show/NCT03283046
235	NCT03409198	Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer	ICON	Recruiting	No Results Available	Breast Cancer|Luminal B	Drug: Ipilimumab|Drug: Nivolumab|Drug: Pegylated liposomal doxorubicin|Drug: Cyclophosphamide	Toxicity: CTCAE v4.0|Progression-free survival (PFS)|Duration of Response (DR)|Overall Survival (OS)|Duration of Response (DR) in cross-over arm|Overall Suvival (OS) in cross-over arm|Toxicity, cross-over arm, CTCAE v4.0|Objective tumor Response Rate (ORR)|Durable tumor Response Rate (DRR)|Objective tumor Response Rate (ORR) in cross-over arm|Durable tumor Response Rate (DRR) in cross-over arm|Clinical Benefit Rate (CBR)|Clinical Benefit Rate (CBR) in cross-over arm|PD-L1 expression|Chalder Fatigue Questionnaire (FQ)|Pain intensity|EORTC QLQ-C15-PAL	Oslo University Hospital|Bristol-Myers Squibb|Helse Stavanger HF|Helse Sor-Ost|Sorlandet Hospital HF	All	18 Years and older   (Adult, Older Adult)	Phase 2	75	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ICON CA209-9FN	January 21, 2018	January 1, 2022	January 1, 2025	January 24, 2018	null	August 20, 2018	Soerlandet Hospital HF Kristiansand, Kristiansand, Norway|Oslo University Hospital, Oslo, Norway|Stavanger University Hospital, Stavanger, Norway		https://ClinicalTrials.gov/show/NCT03409198
236	NCT02553642	Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)		Recruiting	No Results Available	Bladder Cancer|Melanoma	Drug: Nivolumab|Drug: Nivolumab plus Ipilimumab	response rate|PD-L1 expression	Memorial Sloan Kettering Cancer Center|UConn Health|Bristol-Myers Squibb|Adaptive Biotechnologies|MedGenome	All	18 Years and older   (Adult, Older Adult)	Phase 2	70	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	15-126	September 14, 2015	September 2019	September 2019	September 17, 2015	null	August 16, 2018	University of Connecticut Health Center, Farmington, Connecticut, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02553642
237	NCT03465592	Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma		Recruiting	No Results Available	Sarcoma|Solid Tumor, Adult|Solid Tumor, Childhood	Drug: Nivolumab	Adverse events attributed to Nivolumab for patients enrolled in this study|Overall survival	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb	All	12 Months to 40 Years   (Child, Adult)	Phase 1|Phase 2	39	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J17124|IRB00143746	May 1, 2018	March 2022	March 2022	March 14, 2018	null	September 6, 2018	Johns Hopkins Hospital, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT03465592
238	NCT02764593	Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer		Active, not recruiting	No Results Available	Head and Neck Squamous Cell Carcinoma (HNSCC)	Drug: Nivolumab|Drug: Cisplatin|Drug: Cetuximab|Radiation: IMRT	Dose Limiting Toxicity (DLT)	RTOG Foundation, Inc.|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	40	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RTOG 3504|RF 3504|CA209-410	June 2016	March 2019	March 2021	May 6, 2016	null	August 21, 2018	Stanford Cancer Institute, Palo Alto, California, United States|University of Florida Cancer Center at Orlando Health, Orlando, Florida, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|University of Louisville, Louisville, Kentucky, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|UPMC - Shadyside Hospital, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT02764593
239	NCT03521570	Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer		Recruiting	No Results Available	Recurrent Head and Neck Squamous Cell Carcinoma	Radiation: IMRT|Biological: Nivolumab	1 year progression-free survival (PFS)|1 year overall survival (OS)|Pattern of failure|Incidence of acute adverse events|Incidence of late adverse events|Quality of life (QOL)	Emory University|Bristol-Myers Squibb|The Cleveland Clinic|Medical College of Wisconsin	All	18 Years and older   (Adult, Older Adult)	Phase 2	51	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00100923|NCI-2018-00064|Winship4221-17	June 28, 2018	December 31, 2020	December 31, 2020	May 10, 2018	null	July 13, 2018	Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT03521570
240	NCT02529072	Nivolumab With DC Vaccines for Recurrent Brain Tumors	AVERT	Active, not recruiting	No Results Available	Malignant Glioma|Astrocytoma|Glioblastoma	Drug: nivolumab|Biological: DC	The safety of administering DC vaccines with nivolumab, as measured by the percentage of patients who experience unacceptable toxicity during combination treatment|Survival of subjects treated with any protocol treatment (i.e. nivolumab or DC vaccines).|Progression Free Survival (PFS) of subjects treated with any protocol treatment (i.e. nivolumab or DC vaccines).	Gary Archer Ph.D.|Bristol-Myers Squibb|Duke Cancer Institute|Duke University	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 1	7	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00065241	January 2016	September 15, 2017	December 2019	August 19, 2015	null	November 8, 2018	Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT02529072
241	NCT03442569	PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC		Recruiting	No Results Available	Colon Cancer	Drug: Panitumumab|Drug: Nivolumab|Drug: Ipilimumab	Overall Response Rate|Overall Response Rate per irRECIST|Length of Progression Free Survival|Length of Overall Survival|Duration of Response|Toxicity of Treatment	UNC Lineberger Comprehensive Cancer Center|Amgen|Bristol-Myers Squibb	All	18 Years to 120 Years   (Adult, Older Adult)	Phase 2	56	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LCCC1632	March 9, 2018	December 14, 2020	December 14, 2023	February 22, 2018	null	November 9, 2018	Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03442569
242	NCT03527264	BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer		Not yet recruiting	No Results Available	Cervical Cancer	Drug: Nivolumab induction|Drug: Cisplatin|Radiation: Radiation|Drug: Nivolumab with chemoradiation|Drug: Nivolumab maintenance	Feasibility of the incorporation of nivolumab with weekly cisplatin and extended field (EFRT) or whole pelvic radiation therapy (WPRT) in women with cervical cancer.|Feasibility of the regimen through assessment of acute toxicities.|Progression free survival	Don Dizon|Rhode Island Hospital|The Miriam Hospital|Women and Infants Hospital of Rhode Island|Bristol-Myers Squibb|Brown University	Female	18 Years and older   (Adult, Older Adult)	Phase 2	24	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BrUOG 355	July 2018	December 2020	December 2023	May 17, 2018	null	May 17, 2018	Rhode Island Hospital, Providence, Rhode Island, United States|Women and Infants Hospital, Providence, Rhode Island, United States		https://ClinicalTrials.gov/show/NCT03527264
243	NCT03409848	Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma	INTEGA	Recruiting	No Results Available	Gastric Cancer|Esophageal Cancer|Adenocarcinoma Gastric|HER2 Positive Gastric Cancer|Metastatic Gastric Cancer|GastroEsophageal Cancer	Drug: Nivolumab|Drug: Ipilimumab	Overall Survival|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Progression Free Survival|Response Rate|Health related Quality of Life|Translational research tumor block|Translational research blood - immunoprofiling|Translational research blood - circulating Tumor cells (CTC)|Translational research blood - circulating Tumor DNA (ctDNA)|Central Imaging Review - ORR|Central Imaging Review - PFS	AIO-Studien-gGmbH|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	97	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AIO-STO-0217|2017-000624-10|CA209-99R	March 1, 2018	October 2021	January 2022	January 24, 2018	null	March 23, 2018	Universitätsklinikum Hamburg-Eppendorf Hubertus Wald Tumorzentrum - UCCH II. Medizinische Klinik und Poliklinik (Onkologie, Hämatologie, KMT mit Sektion Pneumologie), Hamburg, Germany		https://ClinicalTrials.gov/show/NCT03409848
244	NCT03507699	Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer		Not yet recruiting	No Results Available	Colorectal Neoplasms Malignant|Liver Metastases	Radiation: Liver radiation therapy|Drug: Nivolumab Injection [Opdivo]|Drug: Ipilimumab Injection [Yervoy]|Drug: CMP-001	Number of participants with serious dose-limiting treatment-related adverse events as assessed by CTCAE v5.0|Response rate as assessed by RECIST v1.1|Progression free survival	Sheba Medical Center|Checkmate Pharmaceuticals|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	19	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	4465-17-SMC|CA209-991	July 1, 2018	May 31, 2020	May 31, 2021	April 25, 2018	null	April 25, 2018	Sheba Medical Center, Ramat Gan, Israel		https://ClinicalTrials.gov/show/NCT03507699
245	NCT03044626	Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC	FORCE	Recruiting	No Results Available	Carcinoma，Non-Small-Cell Lung|Metastatic Lung Cancer|Nonsmall Cell Lung Cancer|Lung Adenocarcinoma Metastatic|Large Cell Lung Carcinoma Metastatic	Drug: Radiotherapy|Drug: Nivolumab	objective response rate (ORR) according to RECIST 1.1 criteria|progression free survival (PFS)|PFS using assessment according to irRECIST|ORR using assessment according to irRECIST|Overall Survival (OS)|Adverse Events|Assesment of Quality of life	AIO-Studien-gGmbH|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	130	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AIO-YMO/TRK-0415|2015-005741-31|CA209-430	February 10, 2017	August 2019	November 2021	February 7, 2017	null	July 30, 2018	Evangelische Lungenklinik Berlin, Berlin, Germany|DRK Kliniken Berlin Mitte, Berlin, Germany|Klinikum Chemnitz, Chemnitz, Germany|Universitätsklinikum Carl-Gustav-Carus, Dresden, Germany|Klinikum Esslingen GmbH, Esslingen, Germany|Krankenhaus Nordwest, Frankfurt / Main, Germany|LungenClinic Grosshansdorf, Großhansdorf, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum des Saarlandes, Homburg/Saar, Germany|Klinikverbund Kempten-Oberallgäu, Immenstadt, Germany|Kliniken der Stadt Köln Krankenhaus Merheim, Köln, Germany|Ev. Diakonissenkrankenhaus, Leipzig, Germany|Klinik Löwenstein, Löwenstein, Germany|Universitätsklinikum Mannheim, Mannheim, Germany|Asklepios Fachkliniken München-Gauting, München-Gauting, Germany|Klinikum Nürnberg, Nürnberg, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Universitätsklinikum Ulm, Ulm, Germany		https://ClinicalTrials.gov/show/NCT03044626
246	NCT03250273	A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma		Recruiting	No Results Available	Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Cancer|Cholangiocarcinoma|Pancreatic Cancer|Metastatic Pancreatic Cancer	Drug: Entinostat|Drug: Nivolumab	a. Objective response rate (ORR) using Response Evaluation Criteria for Solid Tumors (RECIST 1.1)|Number of participants experiencing study drug-related toxicities|Progression free survival (PFS) status at 6, 12 and 24 months.|Overall survival (OS)|OS at 6 months, at 1, 2 and 3 years|Duration of response (DOR)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Syndax Pharmaceuticals|Bristol-Myers Squibb	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2	54	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J1798|IRB00142149	November 6, 2017	November 2020	November 2020	August 15, 2017	null	October 18, 2018	Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT03250273
247	NCT03342911	Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery		Recruiting	No Results Available	Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma|Stage II Oropharyngeal Squamous Cell Carcinoma|Stage III Hypopharyngeal Squamous Cell Carcinoma|Stage III Laryngeal Squamous Cell Carcinoma|Stage III Oral Cavity Squamous Cell Carcinoma|Stage III Oropharyngeal Squamous Cell Carcinoma|Stage IV Hypopharyngeal Squamous Cell Carcinoma|Stage IV Laryngeal Squamous Cell Carcinoma|Stage IV Oral Cavity Squamous Cell Carcinoma|Stage IV Oropharyngeal Squamous Cell Carcinoma|Stage IVA Hypopharyngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Oral Cavity Squamous Cell Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma|Stage IVB Hypopharyngeal Squamous Cell Carcinoma|Stage IVB Laryngeal Squamous Cell Carcinoma|Stage IVB Oral Cavity Squamous Cell Carcinoma|Stage IVB Oropharyngeal Squamous Cell Carcinoma|Stage IVC Hypopharyngeal Squamous Cell Carcinoma|Stage IVC Laryngeal Squamous Cell Carcinoma|Stage IVC Oral Cavity Squamous Cell Carcinoma|Stage IVC Oropharyngeal Squamous Cell Carcinoma	Drug: Paclitaxel|Drug: Carboplatin|Biological: Nivolumab	Pathologic complete response rate|Major pathologic response defined as 10% or less residual viable tumor	Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University	All	18 Years and older   (Adult, Older Adult)	Phase 2	37	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17P.513	November 13, 2017	June 2020	June 2021	November 17, 2017	null	February 21, 2018	Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03342911
248	NCT03061188	Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes		Recruiting	No Results Available	Advanced Solid Neoplasm|Aggressive Non-Hodgkin Lymphoma|Recurrent Solid Neoplasm|Refractory Mantle Cell Lymphoma|T-Cell Non-Hodgkin Lymphoma|Unresectable Solid Neoplasm	Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Pharmacological Study|Drug: Veliparib	Maximum Tolerated Dose (MTD)|Incidence of Adverse Events|ORR|Clinical Benefit Rate (CBR)|Progression Free Survival (PFS)|immune-related PFS (irPFS)|Overall Survival (OS)|Proportion of patients alive and progression free	Northwestern University|Bristol-Myers Squibb|AbbVie|National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	Phase 1	50	Other|Industry|NIH	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 16MH03|STU00204250|P30CA060553|NCI-2016-02018	May 23, 2017	September 2020	January 2021	February 23, 2017	null	January 24, 2018	Northwestern University, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT03061188
249	NCT03041181	Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor		Recruiting	No Results Available	Non-Squamous Non-Small Cell Lung Cancer (NSCLC)|Adenocarcinoma of the Lung|Lung Cancer|Squamous Cell Lung Cancer	Drug: Docetaxel|Drug: Nivolumab|Drug: Gemcitabine|Drug: Pemetrexed	Progression free survival (PFS), as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.|Overall Response rate (ORR) for subjects on each treatment arm, as defined by RECIST 1.1 and immune-related response criteria (irRECIST)|Clinical benefit rate (CBR) for subjects on each treatment arm, as defined by RECIST 1.1 and irRECIST|Progression free survival (PFS), as defined by irRECIST|Assess adverse events	Nasser Hanna, M.D.|Hoosier Cancer Research Network|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	62	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCRN LUN15-233	January 27, 2017	March 2019	September 2020	February 2, 2017	null	August 8, 2018	St. Vincent Anderson Regional Hospital, Anderson, Indiana, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|IU Health Central Indiana Cancer Center, Indianapolis, Indiana, United States|Community Regional Cancer Care, Indianapolis, Indiana, United States|IU Health Ball Memorial Hospital Cancer Center, Muncie, Indiana, United States|Community Healthcare System, Munster, Indiana, United States|HealthPartners Institute, Minneapolis, Minnesota, United States|University of Texas Medical Branch at Galveston, Galveston, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States		https://ClinicalTrials.gov/show/NCT03041181
250	NCT03522246	A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy	ATHENA	Recruiting	No Results Available	Epithelial Ovarian Cancer|Primary Peritoneal|Fallopian Tube Cancer|Newly Diagnosed|FIGO Stage III-IV|Partial Response|Complete Response	Drug: Rucaparib|Drug: Nivolumab|Drug: Placebo Oral Tablet|Drug: Placebo IV Infusion	Investigator assessed Progression-free survival (PFS)|Blinded independent central review (BICR) PFS|Overall Survival (OS)|Objective response rate (ORR)|Duration of response (DOR)|Number of participants with treatment-emergent Adverse Events (AEs) as assessed by CTCAE v4 (or higher) as a measure of safety and tolerability|Number of participants with serious AEs as a measure of safety and tolerability|Number of participants with laboratory abnormalities as a measure of safety and tolerability	Clovis Oncology, Inc.|Bristol-Myers Squibb|Gynecologic Oncology Group|European Network of Gynaecological Oncological Trial Groups (ENGOT)|Foundation Medicine	Female	18 Years and older   (Adult, Older Adult)	Phase 3	1012	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CO-338-087/GOG-3020/ENGOT-ov45	May 14, 2018	December 30, 2024	December 30, 2030	May 11, 2018	null	November 8, 2018	Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|The University of Arizona Cancer Center, Tucson, Arizona, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Augusta University, Augusta, Georgia, United States|Dr. Sudarshan K. Sharma, Ltd - Gynecologic Oncology, Hinsdale, Illinois, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Women's Cancer Center of Nevada, Las Vegas, Nevada, United States|Women's Cancer Care Associates, Albany, New York, United States|Broome Oncology, LLC, Johnson City, New York, United States|Oncology Hematology Care, Inc, Cincinnati, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Oklahoma Cancer Specialists and Research Institute, Tulsa, Oklahoma, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, United States|Avera Gynecologic Oncology, Sioux Falls, South Dakota, United States|Texas Oncology - Austin Central, Austin, Texas, United States|Texas Oncology - Bedford, Bedford, Texas, United States|Texas Oncology - Dallas Presbyterian Hospital, Dallas, Texas, United States|Texas Oncology - Fort Worth, Fort Worth, Texas, United States|Texas Oncology - San Antonio Medical Center, San Antonio, Texas, United States|Texas Oncology - The Woodlands, Gynecologic Oncology, The Woodlands, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Border Medical Oncology, Albury, AU, Australia|Newcastle Private Hospital, New Lambton Heights, New South Wales, Australia|Northern Cancer Institute St Leonards, Saint Leonards, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia		https://ClinicalTrials.gov/show/NCT03522246
251	NCT03121677	Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma		Recruiting	No Results Available	Follicular Lymphoma	Biological: Personalized tumor vaccine|Drug: Poly ICLC|Biological: Nivolumab|Procedure: Peripheral blood draws|Procedure: Leukapheresis|Biological: Rituximab|Procedure: Biopsy	Feasibility and safety of vaccine in combination with nivolumab +/1 anti-CD20 monoclonal antibody therapy as measured by the number of participants whose personal vaccines can be manufactured and delivered without unacceptable toxicity|Overall response rate (ORR)|Complete response (CR) rate|Duration of response|Progression-free survival (PFS)|Overall survival (OS)|Partial response (PR) rate	Washington University School of Medicine|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201804151	October 16, 2018	July 31, 2022	January 31, 2028	April 20, 2017	null	November 14, 2018	Washington University School of Medicine, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT03121677
252	NCT03215810	Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer		Recruiting	No Results Available	Non-Small Cell Lung Cancer|Metastatic Non-small Cell Lung Cancer|Squamous Cell Carcinoma|Advanced NSCLC|Adenosquamous Carcinoma|Adenocarcinomas	Procedure: Tumor-infiltrating Lymphocytes (TIL)|Drug: Nivolumab|Drug: Cyclophosphamide|Drug: Fludarabine|Other: Tumor-infiltrating Lymphocyte Therapy|Drug: Interleukin-2 (IL2)	Rate of Dose Limiting Toxicity (DLT)|Objective Response Rate (ORR)	H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb|Prometheus Inc.|Stand Up To Cancer|Iovance Biotherapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 1	18	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-19122|CA209-9JA	October 11, 2017	March 2020	March 2021	July 12, 2017	null	September 3, 2018	University of Florida Health Cancer Center., Gainesville, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT03215810
253	NCT02046733	Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease	STIMULI	Recruiting	No Results Available	Limited Stage Small Cell Lung Cancer|Small Cell Lung Cancer	Drug: Ipilimumab|Drug: Nivolumab	Overall survival|Progression-free survival determined by RECIST 1.1|Objective response|Time to treatment failure|Toxicity	European Thoracic Oncology Platform|Intergroupe Francophone de Cancerologie Thoracique|Ludwig Center for Cancer Research of Lausanne|Frontier Science Foundation, Hellas|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	260	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ETOP/IFCT 4-12|2013-002609-78|CA184-310|SNCTP000000166	July 28, 2014	October 2019	January 2022	January 28, 2014	null	February 20, 2018	University Hospital Gasthuisberg, KU Leuven, Leuven, Belgium|Avignon - Institut Sainte-Catherine, Avignon, France|Caen - Centre François Baclesse, Caen, France|CHU, Caen, France|Percy/Armées, Clamart, France|Clermont-Ferrand, Clermont-Ferrand, France|Créteil - CHI, Creteil, France|CHU, Grenoble, France|Centre Hospitalier Général, Le Mans, France|Hôpital Louis Pradel, Lyon, France|Lyon - Sud, Lyon, France|AP-HM, Marseille, France|Centre Hospitalier Universitaire de Montpellier, Montpellier, France|CH, Mulhouse, France|CRLCC, Nantes, France|Nice - CRLCC, Nice, France|Orléans - CH, Orléans, France|Paris - Bichat, Paris, France|Paris - Saint-Louis, Paris, France|Paris - Tenon, Paris, France|CHU, Rennes, France|Nouvel Hôpital Civil, Strasbourg, France|Suresnes, Suresnes, France|CHI, Toulon, France|CHU, Toulouse, France|CHU, Tours, France|Institut Gustave Roussy, Villejuif, France|Klinikum Esslingen, Esslingen, Germany|LungenClinic Grosshansdorf GmbH, Grosshansdorf, Germany|Klinikum München-Bogenhausen, München, Germany|Thoracic Oncology Centre Munich, München, Germany|Pius-Hospital Oldenburg, Oldenburg, Germany|Krankenhaus der Barmherzigen Brüder, Trier, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|VUMC, Amsterdam, Netherlands|Maastro Clinic, Maastricht, Netherlands|Hospital General Universitario Alicante, Alicante, Spain|Hospital Universitario Cruces, Barakaldo, Spain|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Clinico San Carlos, Madrid, Spain|Hospital Puerta de Hierro, Madrid, Spain|Hospital Universitario 12 Octubre, Madrid, Spain|Hospital Universitario Fundacion Jimenez Díaz, Madrid, Spain|Hospital Universitario Central De Asturias, Oviedo, Spain|Hospital Virgen De La Salud, Toledo, Spain|Hospital Clínico Universitario De Valencia, Valencia, Spain|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|University Hospital Zürich, Zürich, Switzerland|St James' University Hospital, Leeds, United Kingdom|Royal Marsden, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom		https://ClinicalTrials.gov/show/NCT02046733
254	NCT03542461	Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)	EDEN	Recruiting	No Results Available	Squamous Non-small Cell Lung Cancer	Drug: Nivolumab 10 MG/ML Intravenous Solution|Other: Best Supportive Care	Overall survival (OS)|Progression-Free Survival (PFS)|Progression-Free Survival from induction (PFSind)|Time to Treatment Failure (TTF)|Overall Survival from Induction (OSind)	Gruppo Oncologico Italiano di Ricerca Clinica|Mipharm S.p.A.|Bioikos Ambiente Srl|Istituto Toscano Tumori|Temas srl|Bristol Myers Squibb Srl Italia	All	18 Years and older   (Adult, Older Adult)	Phase 3	388	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GOIRC-04-2016	September 25, 2017	September 30, 2022	September 30, 2022	May 31, 2018	null	July 2, 2018	UOC Oncologia - Azienda USL di Imola - Ospedale Santa Maria della Scaletta, Imola, Bologna, Italy|Oncologia Medica - IRST - IRCCS di Meldola, Meldola, Forlì, Italy|AUSL 12 Viareggio, Ospedale Versilia, Lido di Camaiore (LU) - Oncologia Medica, Lido Di Camaiore, Lucca, Italy|UO Medicina Oncologica - Ospedale di Carpi (MO) - Azienda USL di Modena, Carpi, Modena, Italy|UOC di Oncologia Medica - Presidio Santa Croce Azienda Ospedaliera - Ospedale Riuniti Marche NORD, Fano, Pesaro-Urbino, Italy|UOC di Oncologia Medica - ASST Valle Olona - Presidio Ospedaliero di Saronno, Saronno, Varese, Italy|UOC Oncologia Medica - Azienda ULSS21 di Legnago VR, Legnago, Verona, Italy|Oncologia Medica - Ospedale Sacro Cuore - Don Calabria, Negrar, Verona, Italy|SC Oncologia - ASO "SS Antonio e Biagio e Cesare Arrigo", Alessandria, Italy|U.O.C. di Oncologia Medica - Istituto Tumori "Giovanni Paolo II" I.R.C.C.S. Ospedale Oncologico di Bari, Bari, Italy|Humanitas Gavazzeni - Cliniche Gavazzeni spa - Sezione Oncologia Pneumologica ed Urologica, Bergamo, Italy|UO Oncologia Medica - A.S.S.T. Papa Giovanni XXIII di Bergamo, Bergamo, Italy|UO di Oncologia Medica - Azienda Ospedaliero-Universitaria S. Orsola Malpighi, Bologna, Italy|UOC di Oncologia - Azienda USL di Bologna, Ospedale Bellaria, Bologna, Italy|Divisione di Oncologia Medica - Ospedale di Bolzano, Bolzano, Italy|UOC Oncologia Medica - PO A.Perino ASL di Brindisi, Brindisi, Italy|Azienda Ospedaliero - Universitaria "Policlinico - Vittorio Emanuele" - P.O. "G. Rodolico" - Oncologia Medica, Catania, Italy|SC di Oncologia - Istituti Ospitalieri di Cremona, Cremona, Italy|Dipartimento di Oncologia Medica - Azienda Ospedaliera S.Croce e Carle Cuneo - Ospedale Carle, Cuneo, Italy|UO di Oncologia Ematologia - Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy|S.C. Oncologia Medica 1 - Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|UOS Tumori Polmonari - IRCCS AOU San Martino -IST- Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy|Azienda USL Toscana nord ovest - Ospedale San Luca di Lucca - Dipartimento Oncologico, Lucca, Italy|Azienda Ospedaliero-Universitaria di Modena - Policlinico - Dipartimento di Scienze Mediche e Chirurgiche, Materno Infantili e dell'adulto, Modena, Italy|SC di Oncologia Medica - A.O. San Gerardo, Monza, Italy|S. C. di Oncologia Medica - AORN "Antonio Cardarelli", Napoli, Italy|U.O.C Pneumologia ad Indirizzo Oncologico - AORN Ospedali dei Colli Monaldi, Napoli, Italy|IOV Istituto Oncologico Veneto - UOC di Oncologia Medica 2, Padova, Italy|UOC di Oncologia Medica - Azienda Ospedaliero Universitaria di Parma, Parma, Italy|S.C. di Oncologia Medica - Ospedale S.Maria della Misericordia, Perugia, Italy|AUSL - Piacenza - Ospedale "Guglielmo da Saliceto"-Dip.Oncologia e Ematologia- UO di Oncologia Medica Azienda, Piacenza, Italy|Azienda Ospedaliera Universitaria Pisana - Dipartimento Medico in Oncologia, Pisa, Italy|Struttura Complessa di Oncologia - IRCCS - Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|AUSL della Romagna - Ambito di Rimini - Ospedale Infermi di Rimini - UO di Oncologia, Rimini, Italy|Pneumologia ad Indirizzo Oncologico 1 - A.O. San Camillo Forlanini, Roma, Italy|Università la Sapienza - Policlinico Umberto I - Dipartimento di scienze radiologiche, oncologiche e anatomo-patologiche - UOC Oncologia B, Roma, Italy|UO Oncologia Medica - ASL N.1 di Sassari - Ospedale Civile di Sassari, Sassari, Italy|U.O. Oncologia Medica - Ospedale Santa Chiara, Trento, Italy|Reparto di Oncologia - Azienda Sanitaria Universitaria Integrata di Udine - Presidio Ospedaliero Santa Maria della Misericordia, Udine, Italy|U.S.O. GIVOP (Gruppo Interdisciplinare Veronese Oncologia Polmonare) Oncologia - Azienda Ospedaliera Integrata Verona, Verona, Italy		https://ClinicalTrials.gov/show/NCT03542461
255	NCT03502746	Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma		Recruiting	No Results Available	Mesothelioma, Malignant	Drug: Nivolumab|Drug: Ramucirumab	Response Rate|Adverse event assessment|Progression-free survival|Overall survival	Arkadiusz Z. Dudek, MD|HealthPartners Institute Regions Cancer Care Center|Eli Lilly and Company|Bristol-Myers Squibb|Hoosier Cancer Research Network	All	18 Years and older   (Adult, Older Adult)	Phase 2	35	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCRN-LUN15-299	June 26, 2018	June 2020	June 2021	April 19, 2018	null	November 5, 2018	Moffitt Cancer Center, Tampa, Florida, United States|HealthPartners Institute Regions Cancer Care Center, Minneapolis, Minnesota, United States		https://ClinicalTrials.gov/show/NCT03502746
256	NCT03138161	SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma		Recruiting	No Results Available	Advanced Soft Tissue Sarcoma|Metastatic Soft Tissue Sarcoma	Drug: Trabectedin|Drug: Ipilimumab|Drug: Nivolumab	Maximum tolerated dose|Objective response rate (ORR), disease control rate (DCR)|Progression free survival (PFS), 6 month PFS rate|Overall survival (OS), 6 month OS rate	Sarcoma Oncology Research Center, LLC|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	45	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SOC-1702	April 13, 2017	June 30, 2020	August 31, 2020	May 3, 2017	null	September 6, 2018	Sarcoma Oncology Research Center, Santa Monica, California, United States		https://ClinicalTrials.gov/show/NCT03138161
257	NCT03695250	BMS-986205 and Nivolumab as First Line Therapy in Treating Patients With Liver Cancer		Not yet recruiting	No Results Available	Metastatic Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Unresectable Hepatocellular Carcinoma	Drug: IDO1 Inhibitor BMS-986205|Biological: Nivolumab	Incidence of adverse events (AE)|Objective response rate (ORR)|Disease control rate (DCR)|Progression-free survival (PFS)|Duration of response (DOR)|Overall survival (OS)	Edward Kim|National Cancer Institute (NCI)|Bristol-Myers Squibb|University of California, Davis	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	23	Other|NIH|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1229924|NCI-2018-02009|UCDCC#276|P30CA093373	December 1, 2018	December 1, 2021	June 1, 2022	October 4, 2018	null	October 4, 2018	University of California Davis Comprehensive Cancer Center, Sacramento, California, United States		https://ClinicalTrials.gov/show/NCT03695250
258	NCT02837029	Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer		Recruiting	No Results Available	Stage IIIA Hepatocellular Carcinoma|Stage IIIB Hepatocellular Carcinoma|Stage IIIC Hepatocellular Carcinoma|Stage IVA Hepatocellular Carcinoma|Stage IVB Hepatocellular Carcinoma	Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Radiation: Yttrium Y 90 Glass Microspheres	Maximum Tolerated Dose (MTD)|Objective Response Rate (ORR)|Incidence of Adverse Events|Progression Free Survival (PFS)|Disease Control Rate (DCR)	Northwestern University|Bristol-Myers Squibb|National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	Phase 1	35	Other|Industry|NIH	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 16I01|STU00203003|P30CA060553|NCI-2016-01001	July 2016	July 2019	July 2020	July 19, 2016	null	June 19, 2018	Northwestern University, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT02837029
259	NCT03439891	Sorafenib and Nivolumab as First-Line Therapy in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer		Recruiting	No Results Available	Stage III Hepatocellular Carcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v7|Stage IIIC Hepatocellular Carcinoma AJCC v7|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8	Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Drug: Sorafenib	Maximum tolerated dose (MTD) (Part 1)|Overall response rate (ORR) assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Part 2)|Duration of response (DOR)|Incidence of adverse classified using NCI CTCAE version 4.03|ORR assessed by RECIST 1.1 for overall study|Overall survival (OS)|Progression-free survival (PFS)|Rate of immune-related adverse event (irAE) for combination	University of California, San Francisco|Bayer|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	174523|NCI-2018-00051|17-23590|P30CA082103	February 21, 2018	May 29, 2020	December 31, 2020	February 20, 2018	null	March 7, 2018	University of California, San Francisco, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT03439891
260	NCT03404960	Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy	Parpvax	Recruiting	No Results Available	Pancreatic Adenocarcinoma	Drug: Niraparib + Nivolumab|Drug: Niraparib + Ipilimumab	Progression-free survival|Proportion of tumors with homologous recombination deficits (HRD), in patients with stability or response to platinum therapy|Objective response rate (ORR) in those with measurable disease|Duration of response (DOR)|Overall survival (OS)|Safety and tolerability of this combination. Number of participants with treatment-related adverse events as assessed by CTCAE version 4.03|Correlation of HRDs with response to treatment with niraparib plus immune checkpoint blockade|Immune activation prior to treatment|Immune activation prior during treatment	University of Pennsylvania|Bristol-Myers Squibb|Tesaro, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	84	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	828516	January 31, 2018	January 2021	June 2021	January 19, 2018	null	February 21, 2018	University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03404960
261	NCT03136627	Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC		Active, not recruiting	No Results Available	Carcinoma, Renal Cell	Drug: Tivozanib|Drug: Nivolumab	Maximum Tolerated Dose (MTD) of tivozanib administered orally in combination with Nivolumab in subjects with advanced renal cell carcinoma.|Disease status will be summarized by cycle and dose group, including changes from baseline.	AVEO Pharmaceuticals, Inc.|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	28	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AV-951-16-119	March 22, 2017	December 21, 2017	December 2018	May 2, 2017	null	June 26, 2018	Bordeaux Hospital University Center (CHU), Bordeaux, France|Center Léon Bérard, Lyon, France|Institut Paoli-Calmettes, Marseille, France|Centre Paul Strauss, Strasbourg, France|Institut Gustave Roussy, Villejuif, France		https://ClinicalTrials.gov/show/NCT03136627
262	NCT03014804	Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma		Not yet recruiting	No Results Available	Giant Cell Glioblastoma|Gliosarcoma|Oligodendroglioma|Recurrent Glioblastoma|Small Cell Glioblastoma	Biological: autologous dendritic cells pulsed with tumor lysate antigen Vaccine|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Quality-of-Life Assessment|Other: Questionnaire Administration	Incidence of adverse events assessed by National Cancer Institute's Common Terminology Criteria for Adverse Events version 4.03|Overall Survival (OS)|Overall Survival rate|Progression Free Survival (PFS)|Quality of Life (QoL)|Number of participants with complete response (CR)|Number of participants with partial response (PR)|Number of participants with stable disease (SD)|Number of participants with progressive disease (PD)|Objective response rate (ORR) defined as the percentage of participants with CR + PR|Response/Stable Disease Rate (RSDR) defined as the percentage of participants demonstrating CR+PR+SD	Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|Northwest Biotherapeutics|Bristol-Myers Squibb	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	30	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-001706|NCI-2016-01587|P30CA016042	January 1, 2019	January 1, 2020	January 1, 2022	January 9, 2017	null	October 24, 2018	UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT03014804
263	NCT02626962	Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma	GEM1402	Active, not recruiting	No Results Available	Uveal Melanoma	Drug: ipilimumab|Drug: Nivolumab	Overall Survival at 12 months|Overall survival at 24 months.|Progression Free Survival (PFS)|Global PFS according to RECIST 1.1 criteria.|Objective Response Rate (ORR)|Disease Control Rate|Duration of response	Grupo Español Multidisciplinar de Melanoma|Bristol-Myers Squibb	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 2	48	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GEM-1402|2015-004429-15	April 2016	February 2020	February 2020	December 10, 2015	null	November 27, 2018	Hospital Son Espases, Palma De Mallorca, Baleares, Spain|ICO Hospitalet, L'Hospitalet de Llobregat, Spain|H. Insular de Canarias, Las Palmas de Gran Canaria, Spain|Hospital La Paz, Madrid, Spain|H. U. Virgen de la Victoria, Malaga, Spain|Clínica Universidad de Navarra, Pamplona, Spain|H. U. Clínico de Santiago, Santiago, Spain|H.U. Virgen Macarena, Sevilla, Spain|Hospital General Universitario de Valencia, Valencia, Spain|H. C. U. de Valladolid, Valladolid, Spain		https://ClinicalTrials.gov/show/NCT02626962
264	NCT02658981	Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma		Recruiting	No Results Available	Glioblastoma|Gliosarcoma|Recurrent Brain Neoplasm	Biological: Anti-LAG-3 Monoclonal Antibody BMS 986016|Biological: Anti-PD-1|Other: Pharmacological Study|Other: Laboratory Biomarker Analysis|Biological: Anti-CD137	Maximum tolerated dose (MTD) of anti-LAG-3 monoclonal antibody BMS-986016 as monotherapy as determined by frequency of toxicity|Maximum tolerated dose (MTD) of anti-CD137 as monotherapy as determined by frequency of toxicity|MTD of Anti-LAG-3 + Anti-PD-1 as determined by frequency of toxicity|MTD of Anti-CD137 + Anti-PD-1 as determined by frequency of toxicity|Overall Survival|Progression-free survival rate|Overall Response, assessed by RANO and iRANO|Overall Response to anti-LAG-3 monoclonal antibody BMS-98601, assessed by RANO and iRANO|Overall Response to anti-CD137 as monotherapy, assessed by RANO and iRANO|Overall Response to Anti-LAG-3 + Anti-PD-1, assessed by RANO and iRANO	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	100	Other|NIH|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ABTC 1501|IRB00095527|UM1CA137443	August 2016	August 2019	December 2020	January 20, 2016	null	October 11, 2018	UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Abrams Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02658981
265	NCT03238365	Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck		Recruiting	No Results Available	Lip, Oral Cavity and Pharynx|Larynx	Biological: Nivolumab|Drug: Tadalafil|Procedure: Therapeutic Conventional Surgery	Change in immune cell polarization (Th1/Th2; M1/M2) in peripheral blood and tumor specimens using multiplex cytokine analysis|Prevalence of intratumoral immune cell populations	Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	50	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17P.210	August 10, 2017	December 16, 2019	December 16, 2020	August 3, 2017	null	March 27, 2018	Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT03238365
266	NCT02011945	A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia		Active, not recruiting	No Results Available	Chronic Myeloid Leukemia	Drug: Dasatinib|Drug: Nivolumab	Safety and Tolerability for the combination of Dasatinib and Nivolumab|Major Molecular Response (MMR) and Molecular Response (MR) rates|Time to, and duration of, MMR and MR	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	69	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA180-373|2013-002156-33	February 7, 2014	August 8, 2019	August 9, 2019	December 16, 2013	null	August 31, 2018	Winship Cancer Institute, Atlanta, Georgia, United States|Dana Faber Cancer Institute, Boston, Massachusetts, United States|Ut Southwestern Medical Center At Dallas, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Local Institution, St Leonards, New South Wales, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Parkville, Victoria, Australia|QEII Health Sciences Centre-VG Site, Halifax, Nova Scotia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Local Institution, Bordeaux, France|Campus Virchow Klinikum Der Charite, Berlin, Germany|Universitaetsklinikum Bonn, Bonn, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Universitaetsklinik Frankfurt, Frankfurt am Main, Germany|Local Institution, Napoli, Italy|Local Institution, Orbassano, Italy|Local Institution, Roma, Italy|Local Institution, Madrid, Spain|Local Institution, Valencia, Spain		https://ClinicalTrials.gov/show/NCT02011945
267	NCT02899299	Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients	CheckMate743	Active, not recruiting	No Results Available	Mesothelioma	Biological: Nivolumab|Biological: Ipilimumab|Drug: Pemetrexed|Drug: Cisplatin|Drug: Carboplatin	Overall Survival (OS)|Progression Free Survival (PFS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Composite correlation of PD-L1 expression level and efficacy	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	600	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-743|2016-001859-43	October 25, 2016	October 4, 2020	September 28, 2021	September 14, 2016	null	November 20, 2018	Ucsf, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center & Research Inst, Inc, Tampa, Florida, United States|University Of Chicago, Chicago, Illinois, United States|Univ Of Maryland Greenbaum Cancer Center, Baltimore, Maryland, United States|Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States|Cancer & Hematology Centers Of Western Michigan, Grand Rapids, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Allegheny Cancer Center, Jefferson Hills, Pennsylvania, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|West Virginia University, Morgantown, West Virginia, United States|Concord Repatriation General Hospital, Sydney, New South Wales, Australia|Local Institution, Birtinya, Queensland, Australia|Monash Medical Centre Clayton, Clayton, Victoria, Australia|Cabrini Hospital, Malvern, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Brussels, Belgium|Local Institution, Edegem, Belgium|Local Institution, Liege, Belgium|Local Institution, Sint-Niklaas, Belgium|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Haerbin, Heilongjiang, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Hanghzou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Kunming, China|Local Institution, Shanghai, China|Administradora Del Country S.A. - Clinica Del Country, Bogota, Colombia|Hospital Universitario San Ignacio, Bogota, Colombia|Local Institution, Caen, France|Local Institution, Creteil, France|Local Institution, La Tronche, France|Local Institution, Lille Cedex, France|Local Institution, Marseille Cedex 20, France|Local Institution, Paris, France|Local Institution, Saint Herblain, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulon Cedex, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Coswig, Germany|Local Institution, Essen, Germany|Local Institution, Gottingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Homburg an d. Saar, Germany|Local Institution, Immenhausen, Germany|Local Institution, Koeln, Germany|Local Institution, Moers, Germany|Sotiria General Hospital, Athens, Greece|Interbalkan European Medical Center, Thessaloniki, Greece|Centro Di Riferimento Oncologico, Aviano, Italy|Istituto Tumori Giovanni Paolo II, Bari, Italy|Aou Policlinico V. Emanuele Di Catania, Catania, Italy|Ospedale Policlinico San Martino, Genova, Italy|Aorn Dei Colli, Napoli, Italy|Ospedale S. Maria Delle Croci, Ravenna, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Azienda Ospedaliera Universitaria Senese, Siena, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Fukuyama-shi, Hiroshima, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Amagasaki-shi, Hyogo, Japan|Local Institution, Nishinomiya-shi, Hyogo, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Local Institution, Osakasayama-city, Japan|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Medica Sur, Mexico, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Centro Estatal de Cancerologia, Chihuahua, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Bytom, Poland|Local Institution, Krakow, Poland|Local Institution, Warszawa, Poland|Local Institution, Bucharest, Romania|Local Institution, Bucuresti, Romania|Local Institution, Craiova, Romania|Local Institution, Romania, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St.petersburg, Russian Federation|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Parktown, Johannesburg, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, Bern, Switzerland|Local Institution, Lausanne, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Diyarbak?r, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Seyhan, Turkey|Local Institution, Truro, Cornwall, United Kingdom|Edinburgh Cancer Centre, Edinburgh, Midlothian, United Kingdom|Local Institution, Leicester, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Southampton, United Kingdom		https://ClinicalTrials.gov/show/NCT02899299
268	NCT03430791	Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Bevacizumab-naïve, Recurrent Glioblastoma		Recruiting	No Results Available	Recurrent Glioblastoma	Drug: Nivolumab 240 mg IV|Drug: Nivolumab 3 mg/kg|Drug: Ipilimumab 1 mg/kg|Device: NovoTTF200A (Optune)	Objective response rate according to modified iRANO criteria	Baptist Health South Florida|Bristol-Myers Squibb|NovoCure Ltd.	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-ODI-002	November 5, 2018	August 2020	August 2021	February 13, 2018	null	November 15, 2018	Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States		https://ClinicalTrials.gov/show/NCT03430791
269	NCT03227432	An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma		Withdrawn	No Results Available	Multiple Myeloma	Drug: Dexamethasone|Drug: Pomalidomide|Drug: Elotuzumab|Drug: Nivolumab	Response Rate|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|The Rate of Clinical Benefit Response (CBR)|Time to Response|Duration of Response|Progression Free Survival|Overall Survival|Time to Treatment Failure	Dana-Farber Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	0	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-645	December 2018	December 31, 2021	December 31, 2024	July 24, 2017	null	August 14, 2018	Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03227432
270	NCT03341936	Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck		Recruiting	No Results Available	Squamous Cell Carcinoma of the Head and Neck	Drug: Nivolumab|Drug: Lirilumab	Disease-free survival|Best overall Response Rate|Overall Survival Rate	Dana-Farber Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	58	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-411	March 15, 2018	June 30, 2021	June 30, 2025	November 14, 2017	null	March 29, 2018	Dana-Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03341936
271	NCT02460068	A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis	NIBIT-M2	Recruiting	No Results Available	Brain Metastases	Drug: Fotemustine|Drug: Fotemustine and Ipilimumab|Drug: Ipilimumab and nivolumab	Overall Survival (OS)|safety (adverse events)|m-WHO and immune-related Disease Control Rate (DCR) in and outside the brain|Immune-related Progression-free Survival (irPFS)|m-WHO Progression-free Survival (irPFS)|Objective Response Rate (ORR)|Immune-related Objective Response Rate (irORR)|Time to Response (TTR)|Immune-related Time to Response (irTTR)|Duration of Response (DoR)|Immune-related Duration of Response (irDoR)|Brain progression-free survival (Brain-PFS)	Italian Network for Tumor Biotherapy Foundation|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	168	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NIBIT-M2	December 2012	January 2018	January 2020	June 2, 2015	null	June 2, 2015	Medical Oncology, Cancer Institute "Giovanni Paolo II", Bari, Italy|Medical Oncology, Pope Giovanni XXIII Hospital, Bergamo, Italy|National Institute for Cancer Research, Genoa, Italy|Immunotherapy and Somatic Cell Therapy Unit, Scientific Institute of Romagna, Meldola, Italy|Surgical Oncology, National Cancer Institute, Milan, Italy|European Institute of Oncology, Milan, Italy|Medical Oncology and Innovative Therapy, National Cancer Institute, Naples, Italy|esophageal and melanoma oncology, Istituto Oncologico Veneto, Padua, Italy|Medical Oncology, National Cancer Institute "Regina Elena", Rome, Italy|Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Siena, Italy|S C Dermatology, A.O.U. City of Health and Science of Turin, Turin, Italy		https://ClinicalTrials.gov/show/NCT02460068
272	NCT01668784	Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)		Active, not recruiting	Has Results	Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma	Biological: Nivolumab|Drug: Everolimus	Overall Survival (OS) at Primary Endpoint|Investigator-assessed Objective Response Rate (ORR) at Primary Endpoint|Investigator-assessed Duration of Objective Response at Primary Endpoint|Investigator-assessed Time to Objective Response at Primary Endpoint|Investigator-assessed Time of Progression-free Survival (PFS) at Primary Endpoint|Overall Survival (OS) by Programmed Death-Ligand 1 (PD-L1) Expression Level at Primary Endpoint|Number of Participants With Serious Adverse Events, Death, Discontinuation Due to Adverse Events at Primary Endpoint|Percentage of Participants With Disease-related Symptom Progression (DRSP) at Primary Endpoint|Number of Participants Meeting Marked Laboratory Abnormality Criteria in Specific Liver and Thyroid Tests at Primary Endpoint|Number of Participants With Abnormal Hematology and Serum Chemistry Laboratory Parameters by Worse CTC Grade - SI Units	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	1068	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-025|2011‐005132‐26	September 27, 2012	May 6, 2015	September 28, 2018	August 20, 2012	April 29, 2016	January 24, 2018	Highland Oncology Group, Fayetteville, Arkansas, United States|UCSD Moores Cancer Center, La Jolla, California, United States|University Of Southern California, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Ucsf Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Stanford Cancer Institute, Stanford, California, United States|University Of Colorado, Aurora, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Loyola University Chicago, Maywood, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|St Francis Hospital, Greenville, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|CTRC at UTHSC San Antonio, San Antonio, Texas, United States|Virginia Cancer Institute, Richmond, Virginia, United States|University Of Washington, Seattle, Washington, United States|COIBA, Berazategui, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Westmead, New South Wales, Australia|Local Institution, Woodville South, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Melbourne, Australia|Local Institution, Linz, Austria|Local Institution, Vienna, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Centre D'Oncologie Dr-Leon-Richard, Moncton, New Brunswick, Canada|QEII Health Sciences Centre, Halfax, Nova Scotia, Canada|Lakeridge Health Oshawa-Durham Regional Cancer Centre, Oshawa, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Chum, Hopital Notre-Dame, Montreal, Quebec, Canada|Smbd Jewish General Hospital, Montreal, Quebec, Canada|Local Institution, Hradec Kralove, Czechia|Local Institution, Olomouc, Czechia|Local Institution, Prague 5, Czechia|Local Institution, Aarhus C, Denmark|Local Institution, Herlev, Denmark|Local Institution, Odense, Denmark|Local Institution, Helsinki, Finland|Local Institution, Bordeaux, France|Local Institution, Lyon Cedex, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris, France|Local Institution, Poitiers, France|Local Institution, Saint Herblain Cedex, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Vandoeuvre Les Nancy, France|Local Institution, Villejuif Cedex, France|Local Institution, Aachen, Germany|Local Institution, Dresden, Germany|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Munich, Germany|Local Institution, Tuebingen, Germany|Local Institution, Athens, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Tallaght, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Haifa, Israel|Local Institution, Petah Tikva, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Arezzo, Italy|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Rimini, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Rozzano, Italy|Local Institution, Siena, Italy|Local Institution, Terni, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Higashi-ku, Fukuoka, Japan|Local Institution, Sapporo-shi, Hokai-do, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Yokohama, Kangawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Suita, Osaka, Japan|Local Institution, Hamamatsu-shi, Shizuoka, Japan|Local Institution, Tokushima-shi, Tokushima, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Kobe-city, Hyogo, Japan|Local Institution, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Bergen, Norway|Local Institution, Lorenskog, Norway|Local Institution, Gdansk, Poland|Local Institution, Lodz, Poland|Local Institution, Poznan, Poland|Local Institution, Rybnik, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Iasi, Romania|Local Institution, Timisoara, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Hospitalet De Llobregat, Barcelona, Spain|Local Institution, Pamplona, Navarra, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Solna, Sweden|Local Institution, Cambridge, Cambridgeshire, United Kingdom|Local Institution, Swansea, Carmarthenshire, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom		https://ClinicalTrials.gov/show/NCT01668784
273	NCT02939300	Ipilimumab and Nivolumab in Leptomeningeal Metastases		Recruiting	No Results Available	Leptomeningeal Carcinomatosis	Drug: Nivolumab|Drug: Ipilimumab	Overall Survival Rate|Intracranial Response Rate|Extracranial Response Rate|Leptomeningeal Disease Response Rate|Time To The First Occurrence Of Extracranial Disease Progression, Or Death From Any Cause|Time To The First Occurrence Of Intracranial Disease Progression, Or Death From Any Cause|Toxicity by CTCAE Criteria	Massachusetts General Hospital|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	18	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-136	January 2017	January 2020	January 2024	October 20, 2016	null	September 18, 2018	Massachusetts general Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT02939300
274	NCT01585194	Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma		Active, not recruiting	No Results Available	Melanoma|Uveal Melanoma	Drug: Nivolumab|Drug: Ipilimumab	Overall Response Rate|Progression-Free Survival	M.D. Anderson Cancer Center|Bristol-Myers Squibb|National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	Phase 2	67	Other|Industry|NIH	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2011-0919|NCI-2012-00665|1R21CA208609-01	November 29, 2012	November 2019	November 2019	April 25, 2012	null	November 5, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT01585194
275	NCT03436862	Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression		Recruiting	No Results Available	Hodgkin Lymphoma	Drug: Nivolumab	The incidence of treatment-emergent adverse events (AEs) and serious adverse events (SAEs) as a measure of safety|12 month progression-free survival (PFS)	SCRI Development Innovations, LLC|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SCRI BMT 24	May 23, 2018	September 2021	September 2023	February 19, 2018	null	July 16, 2018	Colorado Blood Cancer Institute, Denver, Colorado, United States|Tennessee Oncology, Nashville, Tennessee, United States|St. David's South Austin Medical Center, Austin, Texas, United States|Texas Transplant Institute, San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT03436862
276	NCT03387761	Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy	NABUCCO	Recruiting	No Results Available	Urothelial Carcinoma	Drug: Ipilimumab|Drug: Nivolumab	Number of patients that have surgical resection <12 weeks after study start|Efficacy of immunotherapy, assessed by by the percentage of pathological complete response rate (pCR) at cystectomy|Differences in immune infiltrates in responders vs nonresponders|T-cell (dys)functionality as measured by comparing the transcriptome of tumor-specific T cells in intra-patient pre- and post therapy tissue|Explore whether radiomics-based predictive models can be established for immunotherapy responders vs non-responders	The Netherlands Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	24	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	N17NAB	January 15, 2018	June 1, 2020	December 1, 2020	January 2, 2018	null	November 14, 2018	Antoni van Leeuwenhoek ziekenhuis, Amsterdam, NH, Netherlands		https://ClinicalTrials.gov/show/NCT03387761
277	NCT03267498	Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)		Recruiting	No Results Available	Nasopharyngeal Carcinoma	Drug: Nivolumab|Drug: Cisplatin|Radiation: Radiation Therapy	Feasibility of treatment completion: Rate of completion of all adjuvant immunotherapy, in comparison to the rate of completion of a standard adjuvant cisplatin-based platform.|Overall response rate (ORR)|Number and frequency of Adverse Events (AEs)|Locoregional Control (LRC) Rate|Distant Metastasis (DM) Rate|Overall survival rate (OSR)|Rate of Epstein-Barr Virus (EBV) DNA clearance|Quality of life|Acute and late toxicity rates according to CTCAE version 5, including immune-related AEs	University of California, San Francisco|National University Cancer Institute, Singapore|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	162010|NCI-2017-02291	December 12, 2017	October 15, 2019	October 15, 2020	August 30, 2017	null	May 21, 2018	Helen Diller Family Comprehensive Center, UCSF, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT03267498
278	NCT03316274	Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma		Recruiting	No Results Available	Kaposi Sarcoma|HIV/AIDS|Immunosuppression	Drug: Intra-lesional injection of nivolumab	Safety and tolerability as assessed by Common Terminology Criteria for Adverse Events version 4 (CTCAE v. 4)|The changes in frequency of circulating activated T cells in the skin KS lesions as determined by immunohistochemistry and flow cytometry|The changes in number of circulating activated T cells in the skin KS lesions as determined by immunohistochemistry and flow cytometry|The changes in frequency of circulating activated T cells in the peripheral blood as determined by flow cytometry|The changes in number of circulating activated T cells in the peripheral blood as determined by flow cytometry|The changes in PD-1 expression as determined by immunohistochemistry in lesions|The changes in PD-L1 expression as determined by immunohistochemistry in lesions	University of California, San Francisco|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	12	Other|Industry	Interventional	Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CC17872	April 15, 2018	December 2018	June 2019	October 20, 2017	null	May 2, 2018	Zuckerberg San Francisco General Hospital, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT03316274
279	NCT03620123	A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck	OPTIM	Recruiting	No Results Available	Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Carcinoma, Squamous Cell of Head and Neck	Drug: Nivolumab and Ipilimumab|Drug: Docetaxel	objective response rate in all randomized subjects|overall survival [OS]|Progression-free survival [PFS]|Best overall response [BOR]|Duration of Response [DOR]|Health related quality of life|Health related quality of life: EORTC QLQ-H&N35|Health related quality of life: EQ-5D-5L|Toxicity/Safety according to CTC-AE-criteria	AIO-Studien-gGmbH|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	280	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AIO-KHT-0117|2017-003349-14|CA209-998	July 16, 2018	July 2022	July 2023	August 8, 2018	null	August 8, 2018	Medical School Hannover (MHH) Dept. of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover, Germany		https://ClinicalTrials.gov/show/NCT03620123
280	NCT02857426	A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)	CheckMate 647	Recruiting	No Results Available	Lymphoma	Drug: Nivolumab	Objective response rate (ORR)|Progression-free survival (PFS)|Duration of response (DOR)|Overall survival (OS)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 2	65	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-647|2016-000894-19	October 18, 2016	June 9, 2019	December 6, 2019	August 5, 2016	null	October 23, 2018	University of Alabama at Birmingham, Birmingham, Alabama, United States|City Of Hope Medical Center, Duarte, California, United States|UCSF Medical Center, San Francisco, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|H. Lee Moffitt Cancer Center & Research Inst, Inc, Tampa, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Hospital Of The University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University Of Pittsburgh Medical Center Cancer Center, Pittsburgh, Pennsylvania, United States|Baylor Research Institute, Dallas, Texas, United States|Swedish Medical Center, Seattle, Washington, United States|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHU de Quebec, Quebec, Canada|Local Institution, Praha 2, Czechia|Local Institution, Bordeaux, France|Local Institution, Caen, France|Local Institution, La Tronche, France|Local Institution, Lille Cedex, France|Local Institution, Nancy, France|Local Institution, Paris cedex 13, France|Centre Hospitalier Lyon Sud - UPCO, Pierre Benite, France|Local Institution, Rennes Cedex 9, France|Local Institution, St. Cloud, France|Local Institution, Tours Cedex 9, France|Local Institution, Heidelberg, Germany|Klinikum Stuttgart, Stuttgart, Germany|Local Institution, Hong Kong, Hong Kong|I. sz. Belgyogyaszati Klinika SE, Budapest, Hungary|Belgyogyaszati Onkologia OOI, Budapest, Hungary|II. sz. Belgyogyaszati Klinika DEKK, Debrecen, Hungary|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petah Tikva, Israel|Local Institution, Tel Aviv, Israel|Irccs Ospedale S. Raffaele, Milano, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Istituto Clinico Humanitas, Rozzano (milano), Italy|Local Institution, Nagoya, Aichi, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Kotoku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Yamagata, Japan|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Bellinzona, Switzerland		https://ClinicalTrials.gov/show/NCT02857426
281	NCT02596035	An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma	CheckMate 374	Active, not recruiting	No Results Available	Renal Cell Carcinoma	Drug: Nivolumab	Incidence of high grade (Grade 3-4 and Grade 5) IMAEs in subjects with advanced or metastatic renal cell carcinoma (RCC) who are treated with nivolumab monotherapy|Median time to onset of high grade (Grade 3-4) IMAEs|Median time to resolution of high grade (Grade 3-4) IMAEs|Percentage of subjects who receive immune modulating medication for the immune-mediated event|Percentage of subjects who receive hormonal replacement therapy for the immune-mediated event|Percentage of subjects who receive ≥ 40 mg prednisone equivalents for the immune-mediated event|Total duration of all immune modulating medications given for the immune-mediated event	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 4	197	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	CA209-374|2015-003286-28	November 30, 2015	May 1, 2018	December 1, 2021	November 4, 2015	null	November 1, 2018	Arizona Oncology Associates, Phoenix, Arizona, United States|St. Jude Hospital Yorba Linda, Fullerton, California, United States|Cancer Care Associates Medical Group, Inc., Los Angeles, California, United States|Comprehensive Blood And Cancer Center, Los Angeles, California, United States|Local Institution, Los Angeles, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|University Of Colorado, Aurora, Colorado, United States|St. Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Baptist Health Medical Group Oncology, Miami, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Center For Cancer And Blood Disorders, Bethesda, Maryland, United States|HCA Midwest Division, Kansas City, Missouri, United States|Southeast Nebraska Hematology & Oncology Consultants, P.C., Lincoln, Nebraska, United States|Urology Cancer Center Laboratory, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Local Institution, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Broome Oncology, Johnson City, New York, United States|Weill Cornell Medical College, New York, New York, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States|Northwest Cancer Specialists - East DBA Compass Oncology - East, Portland, Oregon, United States|Local Institution, Springfield, Oregon, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|The West Clinic, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Local Institution, Dallas, Texas, United States|Blue Ridge Cancer Care, DFW Airport, Texas, United States|Cancer Centers of South Texas, DFW Airport, Texas, United States|Nebraska Methodist Hospital, DFW Airport, Texas, United States|Sansum Santa Barbara Medical Foundation Clinic, DFW Airport, Texas, United States|Texas Cancer Center - Sherman, DFW Airport, Texas, United States|The Center For Cancer And Blood Disorders, Fort Worth, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|Texas Oncology, Houston, Texas, United States|Texas Oncology, Paris, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|University Of Washington, Seattle, Washington, United States|Local Institution, Spokane, Washington, United States		https://ClinicalTrials.gov/show/NCT02596035
282	NCT03635983	A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma		Recruiting	No Results Available	Melanoma	Biological: NKTR-214|Biological: Nivolumab	Overall response rate (ORR) by Blinded Independent Central Review (BICR)|Progression-free survival (PFS) by BICR|Overall survival (OS)|Clinical benefit rate (CBR)|Duration of response (DoR)|Duration of overall complete response (DoCR)|Time to response (TTR)|ORR by investigator and in biomarker population|PFS by investigator and in biomarker population|OS in biomarker population|Incidence of participants with non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) leading to discontinuation|Incidence of treatment-related AEs|Incidence of treatment-related SAEs|Incidence of laboratory abnormalities	Bristol-Myers Squibb|Nektar Therapeutics	All	12 Years and older   (Child, Adult, Older Adult)	Phase 3	764	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA045-001|2018-001423-40|17-214-08	September 14, 2018	August 15, 2023	March 15, 2025	August 17, 2018	null	November 20, 2018	Local Institution, La Jolla, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Palo Alto, California, United States|Local Institution, Aurora, Colorado, United States|Local Institution, New Haven, Connecticut, United States|Local Institution, Miami Beach, Florida, United States|Local Institution, Tampa, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, Louisville, Kentucky, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Minneapolis, Minnesota, United States|Local Institution, Saint Louis, Missouri, United States|The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States|Local Institution, Buffalo, New York, United States|Local Institution, New York, New York, United States|Local Institution, Cleveland, Ohio, United States|Local Institution, Cleveland, Ohio, United States|Portland Providence Medical Center, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|St. Luke's Hospital & Health Network, Easton, Pennsylvania, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Houston, Texas, United States|Local Institution, Fairfax, Virginia, United States|Local Institution, Autonoma, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Local Institution, Caba, Argentina|Local Institution, Caba, Argentina|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Cairns, Queensland, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Bruxelles, Belgium|Local Institution, Hasselt, Belgium|Local Institution, Leuven, Belgium|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Abbotsford, British Columbia, Canada|Local Institution, St. John's, Newfoundland and Labrador, Canada|Local Institution, Hamilton, Ontario, Canada|Local Institution, Kitchener, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Quebec, Canada|Local Institution, Brno, Czechia|Local Institution, Hradec Kralove, Czechia|Local Institution, Praha 10, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Wilton, Cork, Ireland|Local Institution, Dublin 7, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Beer Sheva, Israel|Local Institution, Jerusalem, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Bari, Italy|Local Institution, Genova, Italy|Local Institution, Medola, Italy|Local Institution, Milan, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Siena, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Amsterdam, Netherlands|Local Institution, Leiden, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Christchurch, New Zealand|Local Institution, Wellington, New Zealand|Local Institution, Lublin, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Cordoba, Spain|Local Institution, Jaen, Spain|Local Institution, Madrid, Spain|Local Institution, Santiago Compostela, Spain|Local Institution, Valencia, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Edinburgh, Midlothian, United Kingdom|Local Institution, Belfast, United Kingdom|Local Institution, Cambridge, United Kingdom|Local Institution, Cottingham, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Southampton, United Kingdom|Local Institution, Sutton., United Kingdom|Local Institution, Tauton, United Kingdom|Local Institution, Wirral, United Kingdom		https://ClinicalTrials.gov/show/NCT03635983
283	NCT02320058	An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself	CheckMate204	Active, not recruiting	No Results Available	Melanoma	Drug: Ipilimumab|Drug: Nivolumab	Intracranial Clinical Benefit Rate (CBR)|Extracranial Clinical Benefit Rate|Overall Survival (OS)|Number of adverse events (AEs)|Number of serious adverse events (SAEs)|Number AEs leading to death|Number of clinically significant abnormalities in general laboratory tests in combination with Ipilimumab and Nivolumab|Objective response rate (ORR)|Progression free survival (PFS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	119	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-204	January 5, 2015	November 3, 2022	November 4, 2022	December 19, 2014	null	May 22, 2018	City of Hope, Duarte, California, United States|Angeles Clinic and Research Institute, Los Angeles, California, United States|UCLA Medical Hematology and Oncology, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|The California Pacific Medical Research Institute, San Francisco, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Washington Cancer Inst at MedStar Washington Hospital Ctr, Washington, District of Columbia, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Mount Sinai Medical Center, Aventura, Florida, United States|H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Loyola University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Weinberg Cancer Institute At Franklin Square, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Faber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|NYU Langone Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Case School of Medicineuniversity Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|St Luke's Health Network, Easton, Pennsylvania, United States|Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States|Inova Melanoma and Skin Cancer Center, Fairfax, Virginia, United States		https://ClinicalTrials.gov/show/NCT02320058
284	NCT01927419	Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma	CheckMate 069	Active, not recruiting	Has Results	Unresectable Melanoma|Metastatic Melanoma	Drug: Nivolumab|Drug: Ipilimumab|Drug: Placebo	Percentage of Participants With Investigator-assessed Objective Response in the Randomized, BRAF Wild-type Population|Percentage of Participants With Investigator-assessed Objective Response in the Randomized Population|Investigator-assessed Progression-free Survival (PFS) in All Populations|Percentage of BRAF Mutation-positive Participants With Investigator-assessed Objective Response|Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Overall Quality of Life (QOL) Score	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	179	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA209-069|2013-002018-11	August 21, 2013	July 24, 2014	February 6, 2019	August 22, 2013	February 8, 2016	April 9, 2018	San Francisco Oncology Associates, San Francisco, California, United States|Orlando Health Inc, Orlando, Florida, United States|University Of Louisville Medical Center, Inc., Dba, Louisville, Kentucky, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers Of Nevada, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University Of New Mexico Cancer Center, Albuquerque, New Mexico, United States|NYU Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|The Christ Hospital, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|St. Luke's Hospital, Easton, Pennsylvania, United States|GHS Cancer Institute, Greenville, South Carolina, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University Of Wisconsin Paul P Carbone Comprehensive Ca Ctr, Madison, Wisconsin, United States|Local Institution, Toulouse, France|Local Institution, Villejuif, France		https://ClinicalTrials.gov/show/NCT01927419
285	NCT01783938	Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)		Active, not recruiting	Has Results	Advanced or Metastatic Melanoma	Biological: Nivolumab|Biological: Ipilimumab	Percentage of Participants With Treatment-related Grade 3-5 Adverse Events (AEs) During the Induction Periods|Investigator-assessed Response Rate at Week 25|Investigator-assessed Duration of Response (DOR)|Investigator-assessed Rate of Progression	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	177	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-064	April 17, 2013	April 3, 2015	October 18, 2019	February 5, 2013	April 11, 2016	August 2, 2018	H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis, Indiana, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University Of Virginia Health System, Charlottesville, Virginia, United States		https://ClinicalTrials.gov/show/NCT01783938
286	NCT02652455	Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma		Active, not recruiting	No Results Available	Melanoma (Skin)|Skin Cancer	Drug: Nivolumab|Procedure: Surgery to Remove Tumor for Growth of TIL|Drug: CD137|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: TIL Infusion|Drug: Interleukin-2	Occurrence of Study Related Adverse Events	H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb|Prometheus Inc.|Iovance Biotherapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	11	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-18377	March 2, 2016	August 2019	August 2020	January 11, 2016	null	August 2, 2018	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT02652455
287	NCT03068455	An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma	CheckMate 915	Active, not recruiting	No Results Available	Melanoma	Biological: nivolumab|Biological: ipilimumab	Recurrence-free survival (RFS)|Overall Survival (OS)|PD-L1 expression	Bristol-Myers Squibb	All	12 Years and older   (Child, Adult, Older Adult)	Phase 3	2000	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CA209-915|2016-003729-41	April 7, 2017	November 8, 2020	February 17, 2023	March 1, 2017	null	October 9, 2018	University of Arizona Cancer Center, Tucson, Arizona, United States|The Angeles Clinic & Research Institute, Los Angeles, California, United States|California Pacific Medical Center, San Francisco, California, United States|University Of Colorado, Aurora, Colorado, United States|Georgetown University Med Ctr, Washington, District of Columbia, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University Of Chicago, Chicago, Illinois, United States|Oncology Specialists, S.C., Park Ridge, Illinois, United States|Mass General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|NYU Langone Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Carolinas Med Ctr, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Providence Cancer Center Oncology And Hematology Care, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|St. Luke's University Health Network, Bethlehem, Pennsylvania, United States|Local Institution, Nashville, Tennessee, United States|Texas Oncology Sammons Cancer Center, Dallas, Texas, United States|Md Anderson Can Cnt, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|Inova Melanoma and Skin Cancer Center, Fairfax, Virginia, United States|University Of Washington Cancer Care Alliance, Seattle, Washington, United States|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Waratah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Subiaco, Western Australia, Australia|Local Institution, Graz, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Liege, Belgium|Local Institution, Salvador, Bahia, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Florianopolis, Santa Catarina, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose do Rio Preto, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Dermatovenerologicka klinika 3. LF UK a FNKV, Praha 10, Czechia|Dermatovenerologicka klinika VFN a 1. LF UK, Praha 2, Czechia|Centre Hospitalier Universitaire Dijon Bocage, Dijon, France|Hopital Claude Huriez, LILLE Cedex, France|Hopital De La Timone, Marseille Cedex 5, France|Chu Nantes, Nantes, France|Hopital Saint Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France|Institut Claudius Regaud, Toulouse Cedex 9, France|Institut Gustave Roussy, Villejuif, France|Local Institution, Berlin, Germany|Local Institution, Buxtehude, Germany|Local Institution, Essen, Germany|Local Institution, Gera, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Luebeck, Germany|Local Institution, Muenchen, Germany|Local Institution, Tuebingen, Germany|Local Institution, Athens, Greece|Metropolitan Hospital, Athens, Greece|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Tel Hashomer, Israel|Local Institution, Bergamo, Italy|Ospedale Policlinico San Martino, Genova, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Istituto Oncologico Veneto IOV, Padova, Italy|Azienda Ospedaliera Universitaria Senese, Siena, Italy|Local Institution, Tauranga, BAY OF Plenty, New Zealand|Local Institution, Christchurch, New Zealand|Local Institution, Dunedin, New Zealand|Klinika Nowotworow Ukladowych i Uogolnionych, Krakow, Poland|Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow, Warszawa, Poland|Institute Of Oncology "Prof.Dr.Alexandru Trestioreanu" Bucha, Bucharest, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|Local Institution, Krasnodar, Russian Federation|Local Institution, Krasnoyarsk, Russian Federation|Local Institution, Moscow, Russian Federation|Hospital Universitari Germans Trias I Pujol, Badalona-barcelona, Spain|H. Univ. Vall dHebron, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Hospital Gral. Univ. Gregorio Maranon, Madrid, Spain|Hospital Regional Universitario De Malaga, Malaga, Spain|Hosp Univ Virgen Macarena, Sevilla, Spain|Hospital Universitario Y Politecnico La Fe, Valencia, Spain|Local Institution, Lausanne, Switzerland|Local Institution, Zurich, Switzerland|The Beatson West Of Scotland Cancer Centre, Glasgow, Dumfries & Galloway, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|Christie Hospital Nhs Trust, Manchester, United Kingdom|Royal Marsden Hospital - Surrey, Sutton., United Kingdom		https://ClinicalTrials.gov/show/NCT03068455
288	NCT02905266	A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma		Active, not recruiting	No Results Available	Melanoma	Biological: Nivolumab|Biological: Ipilimumab	Incidence of adverse events in anaphylactic reaction SMQ (Standardized Medical Dictionary for Regulatory Activities Queries)|Incidence of events within the hypersensitivity/infusion reaction select Adverse Events (AEs)category|Incidence of grade 3-5 AEs|Objective Response Rate (ORR)|Progression Free Survival (PFS)|Pharmacokinetics (PK) as measured using serum concentration-time data.	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	139	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-742|2016-001941-26	October 27, 2016	October 23, 2017	November 17, 2020	September 19, 2016	null	December 13, 2017	Local Institution, North Sydney, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Cabrini Hospital, Malvern, Victoria, Australia|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes Cedex 1, France|Local Institution, Paris Cedex 14, France|Local Institution, Paris, France|Local Institution, Tours, France|Istituto Nazionale Per La Ricerca Sul Cancro - Oncologia Med, Genova, Italy|Istituto Scientifico Romagnolo Per Lo Studio E Cura Tumori, Meldola (FC), Italy|Istituto Europeo Di Oncologia, Milan, Italy|Azienda Ospedaliera Citta della Salute e della Scienza, Torino, Italy|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain		https://ClinicalTrials.gov/show/NCT02905266
289	NCT02599402	Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma	CheckMate 401	Active, not recruiting	No Results Available	Melanoma	Drug: Nivolumab|Drug: Ipilimumab	Rate and frequency for high-grade (CTCAE v4.0 Grade 3-5) treatment-related, select adverse events in study subjects|Incidence of all high-grade (Grades 3-5), select adverse events|Median time to onset (Grades 3-4) of select adverse events|Median time to resolution (Grades 3-4) of select adverse events|Resolution of an Adverse Event (AE)|Overall survival time from first dosing date to the date of death.|Safety will be measured by the incidence of all AEs, treatment-related AEs, serious AEs, deaths, laboratory abnormalities, and select AEs|Tolerability will be measured by the incidence of all AEs, treatment-related AEs, serious AEs, deaths, laboratory abnormalities, and select AEs|ORR|Investigator-assessed Progression free survival (PFS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	615	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-401|2015-001274-17	December 8, 2015	December 19, 2021	December 20, 2021	November 6, 2015	null	August 1, 2018	Local Institution, Garran, Australian Capital Territory, Australia|Local Institution, Coffs Harbour, New South Wales, Australia|Local Institution, Gateshead, New South Wales, Australia|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Tiwi, Northern Territory, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Cairns, Queensland, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Bedford Park, South Australia, Australia|Local Institution, Hobart, Tasmania, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Murdoch, Western Australia, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Camperdown, Australia|Local Institution, Nedlands, Australia|Local Institution, Graz, Austria|Local Institution, Innsbruck, Austria|Local Institution, Salzburg, Austria|Local Institution, Vienna, Austria|Local Institution, Brussel, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Helsinki, Finland|Local Institution, Oulu, Finland|Local Institution, Tampere, Finland|Local Institution, Turku, Finland|Local Institution, Angers, France|Local Institution, Bordeaux, France|Local Institution, Boulogne Billancourt, France|Local Institution, Cedex, France|Local Institution, Clermont-Ferrand, France|Local Institution, Dijon, France|Local Institution, Le Mans, France|Local Institution, Lille, France|Local Institution, Marseille, France|Local Institution, Montpellier, France|Local Institution, Nantes, France|Local Institution, Nice, France|Local Institution, Paris, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Rennes, France|Local Institution, Rouen, France|Local Institution, TOULOUSE Cedex 9, France|Local Institution, Vandoeuvre les Nancy, France|Local Institution, Villejuif, France|Local Institution, Berlin, Germany|Local Institution, Dresden, Germany|Local Institution, Erfurt, Germany|Local Institution, Erlangen, Germany|Local Institution, Frankfurt, Germany|Local Institution, Freiburg im Breisgau, Germany|Local Institution, Gottingen, Germany|Local Institution, Hannover, Germany|Local Institution, Leipzig, Germany|Local Institution, Ludwigshafen, Germany|Local Institution, Luebeck, Germany|Local Institution, Mainz, Germany|Local Institution, Mannheim, Germany|Local Institution, Regensburg, Germany|Local Institution, Schwerin, Germany|Local Institution, Stade, Germany|Local Institution, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Bari, Italy|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Meldola, Italy|Local Institution, Milano, Italy|Local Institution, Milan, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Pisa, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Terni, Italy|Local Institution, Torino, Italy|Local Institution, Oslo, Norway|Local Institution, Stavanger, Norway|Local Institution, Eskilstuna, Sweden|Local Institution, Gavle, Sweden|Local Institution, Karlskrona, Sweden|Local Institution, Karlstad, Sweden|Local Institution, Linkoping, Sweden|Local Institution, Solna, Sweden|Local Institution, Sundsvall, Sweden|Local Institution, Vaxjo, Sweden|Local Institution, Basel, Switzerland|Local Institution, Lausanne, Switzerland|Local Institution, Sheffield, Yorkshire, United Kingdom|Local Institution, Cambridge, United Kingdom|Local Institution, Cottingham, United Kingdom|Local Institution, Glasgow, United Kingdom|Local Institution, Headington, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Newcastle Upon Tyne, United Kingdom|Mount Vernon Cancer Centre, Northwood, United Kingdom|Local Institution, Nottingham, United Kingdom|Local Institution, Preston, United Kingdom|Local Institution, Southampton, United Kingdom|Local Institution, Sutton., United Kingdom|Local Institution, Swansea, United Kingdom|Local Institution, Truro, United Kingdom		https://ClinicalTrials.gov/show/NCT02599402
290	NCT02903381	A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma		Suspended	No Results Available	Smoldering Multiple Myeloma	Drug: Nivolumab|Drug: Lenalidomide|Drug: Dexamethasone	2 Year Progression Free Rate|Objective Response Rate|Time to Progression Rate|Duration of Response Rate|Progression Free Survival (PFS) Rate|Overall Survival Rate|Progression Free Survival Rate-Without cyclophosphamide|Number of Participants with Adverse Events	Dana-Farber Cancer Institute|Bristol-Myers Squibb|Multiple Myeloma Research Consortium	All	18 Years and older   (Adult, Older Adult)	Phase 2	41	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-242|CA209-607	October 2016	June 2020	February 2024	September 16, 2016	null	December 22, 2017	Dana Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT02903381
291	NCT02156804	A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)		Active, not recruiting	No Results Available	Melanoma	Drug: Nivolumab (BMS-936558)	Rate and frequency for high-grade (CTCAE v4.0 Grade 3 or higher) treatment-related, select adverse events in subjects with melanoma|Rate and frequency of AEs regardless of causality|Rate and frequency of treatment-related AEs|Rate and frequency of any AEs of special interest (AEOSI), such as pulmonary, gastrointestinal, cuteaneous, renal, hepatic, pancreatic, endocrine, infusion-related, or hypersensitivity|Incidence of all high-grade (Grade 3 and higher) select adverse events|Median time to onset (Grades 3-4) of select adverse events|Median time to resolution (Grades 3-4) of select adverse events|Time to overall survival (OS)|Investigator assessed objective response rate (ORR)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	1215	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-172|2014-001286-28	October 7, 2014	January 30, 2019	January 30, 2019	June 5, 2014	null	July 13, 2018	Local Institution, Graz, Austria|Local Institution, Innsbruck, Austria|Local Institution, Salzburg, Austria|Local Institution, St. Polten, Austria|Local Institution, Wien, Austria|Local Institution, Wien, Austria|Universitair Ziekenhuis Brussel, Brussels, Belgium|Institut Jules Bordet, Bruxelles, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Hasselt, Belgium|Az Groeninge, Kortrijk, Belgium|Local Institution, Leuven, Belgium|Chu De Liege, Liege, Belgium|Local Institution, Brno, Czechia|Local Institution, Hradec Kralove, Czechia|Local Institution, Praha 10, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Helsinki, Finland|Local Institution, Jyvaskyla, Finland|Local Institution, Oulu, Finland|Local Institution, Tampere, Finland|Local Institution, Luebeck, Schleswig-holstein, Germany|Local Institution, Augsburg, Germany|Local Institution, Bochum, Germany|Local Institution, Buxtehude, Germany|Local Institution, Chemnitz, Germany|Local Institution, Dessau, Germany|Local Institution, Dresden, Germany|Local Institution, Erfurt, Germany|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Frankfurt Am Main, Germany|Local Institution, Freiburg, Germany|Local Institution, Gera, Germany|Local Institution, Giessen, Germany|Local Institution, Goettingen, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Heilbronn, Germany|Local Institution, Jena, Germany|Local Institution, Kassel, Germany|Local Institution, Kiel, Germany|Local Institution, Koln, Germany|Local Institution, Leipzig, Germany|Local Institution, Ludwigshafen, Germany|Local Institution, Magdeburg, Germany|Local Institution, Mainz, Germany|Local Institution, Marburg, Germany|Local Institution, Minden, Germany|Local Institution, Muenster, Germany|Local Institution, Munchen, Germany|Local Institution, Munich, Germany|Local Institution, Munster, Germany|Local Institution, Nuernberg, Germany|Local Institution, Quedlinburg, Germany|Local Institution, Recklinghausen, Germany|Local Institution, Regensburg, Germany|Local Institution, Schwerin, Germany|Local Institution, Traunstein, Germany|Local Institution, Tubingen, Germany|Local Institution, Wurzbug, Germany|Local Institution, Heraklion, Creta, Greece|Local Institution, Athens, Greece|Local Institution, Athens, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Pecs, Hungary|Local Institution, Szegedi, Hungary|Local Institution, Szombathely, Hungary|Local Institution, Wilton, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Waterford, Ireland|Local Institution, Bari, Italy|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Meldola (FC), Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Palermo, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Terni, Italy|Local Institution, Torino, Italy|Local Institution, Luxembourg, Luxembourg|Local Institution, Amsterdam, Netherlands|Local Institution, Amsterdam, Netherlands|Local Institution, Breda, Netherlands|Local Institution, Enschede, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Leeuwarden, Netherlands|Local Institution, Leiden, Netherlands|Local Institution, Maastrict, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Sittard-Geleen, Netherlands|Local Institution, Utrecht, Netherlands|Local Institution, Veldhoven, Netherlands|Local Institution, Zwolle, Netherlands|Local Institution, Alesund, Norway|Local Institution, Bergen, Norway|Local Institution, Oslo, Norway|Local Institution, Bydgoszcz, Poland|Local Institution, Gdansk, Poland|Local Institution, Lodz, Poland|Local Institution, Warszawa, Poland|Local Institution, Coimbra, Portugal|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Local Institution, Bucharest, Romania|Local Institution, Romania, Romania|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Albacete, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Bilbao, Spain|Local Institution, Granada, Spain|Local Institution, Las Palmas de Gran Canaria, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Hospital De Madrid, Norte Sanchinarro, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Oviedo, Spain|Local Institution, Palma de Mallorca, Spain|Local Institution, Salamanca, Spain|Local Institution, San Sebastian, Spain|Comp. H. U. De Santiago, Santiago de Compostela, Spain|Local Institution, Sevilla, Spain|Local Institution, Toledo, Spain|Local Institution, Valencia, Spain|Local Institution, Valencia, Spain|Local Institution, Lund, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Aarau, Switzerland|Local Institution, Basel, Switzerland|Local Institution, Bellinzona, Switzerland|Local Institution, Bern, Switzerland|Local Institution, Chur, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Bristol, Avon, United Kingdom|Local Institution, Northwood, Middlesex, United Kingdom|Local Institution, Birmingham, United Kingdom|Local Institution, Cambridge, United Kingdom|Local Institution, Cottingham, United Kingdom|Local Institution, Essex, United Kingdom|Local Institution, Glasgow, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Newcastle Upon Tyne, United Kingdom|Local Institution, Oxford, United Kingdom|Local Institution, Southampton, United Kingdom|Local Institution, Surrey, United Kingdom|Local Institution, Swansea, United Kingdom|Local Institution, Truro, United Kingdom|Local Institution, Wirral, United Kingdom		https://ClinicalTrials.gov/show/NCT02156804
292	NCT03029780	An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma	CheckMate 800	Active, not recruiting	No Results Available	Renal Cell Carcinoma	Biological: Opdivo|Biological: Yervoy	Incidence of adverse events (AEs) in anaphylactic reaction SMQ (Standardized Medical Dictionary for Regulatory Activities Queries)|Incidence of AEs in anaphylactic reaction SMQ (Standardized Medical Dictionary for Regulatory Activities Queries)|Incidence of grade 3-5 AEs|Nivolumab as measured using serum concentration- time data|Ipilimumab as measured using serum concentration- time data|Anti-nivolumab antibody|Anti-ipilimumab antibody|Maximum observed serum concentration (Cmax)|Objective Response Rate (ORR)|Progression Free Survival (PFS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	118	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-800	February 9, 2017	November 27, 2017	February 21, 2021	January 24, 2017	null	April 30, 2018	Cancer Specialists of North FL, Jacksonville, Florida, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Local Institution, Waratah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Herston, Queensland, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Malvern, Victoria, Australia|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile		https://ClinicalTrials.gov/show/NCT03029780
293	NCT01844505	Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)		Active, not recruiting	Has Results	Unresectable or Metastatic Melanoma	Biological: Nivolumab|Biological: Ipilimumab|Biological: Placebo for Nivolumab|Biological: Placebo for Ipilimumab	Progression Free Survival (PFS)|Overall Survival (OS)|Rate of Overall Survival|Rate of Progression-Free Survival|Objective Response Rate (ORR) Per Investigator Assessment|Progression-Free Survival Based on PD-L1 Expression Level|Overall Survival Based on PD-L1 Expression Level|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Social Functioning|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Cognitive Functioning|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Emotional Functioning|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Role Functioning|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Physical Functioning	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	1296	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA209-067|2012-005371-13	May 23, 2013	August 1, 2016	March 31, 2019	May 1, 2013	September 26, 2017	March 16, 2018	Banner-MD Anderson Cancer Center, Gilbert, Arizona, United States|University Of Arizona Cancer Center, Tucson, Arizona, United States|UC San Diego Moores Cancer Ctr, La Jolla, California, United States|The Angeles Clinic And Research Institute., Los Angeles, California, United States|University Of California - Los Angeles, Los Angeles, California, United States|Comprehensive Cancer Center At Desert Regional Medical Ctr, Palm Springs, California, United States|Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|Ucsf Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|University Of Colorado Cancer Center, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Medstar Washington Hospital Center, Washington, District of Columbia, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Maine Center For Cancer Medicine, Scarborough, Maine, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Lutherville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Allina Health, Minneapolis, Minnesota, United States|University Of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers Of Nevada, Las Vegas, Nevada, United States|Atlantic Melanoma Center, Morristown, New Jersey, United States|University Of New Mexico Cancer Center, Albuquerque, New Mexico, United States|New York Oncology Hematology, Pc, Clifton Park, New York, United States|NYU Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke Cancer Institute, Durham, North Carolina, United States|University Hospitals, Cleveland, Ohio, United States|Providence Cancer Center Oncology and Hematology Care- Eastside, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|St. Luke's Cancer Center - Anderson Campus, Easton, Pennsylvania, United States|Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Greenville Health System, Greenville, South Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Texas Oncology, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Washington, Seattle, Washington, United States|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Coffs Harbour, New South Wales, Australia|Local Institution, Gateshead, New South Wales, Australia|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Melbourne, Australia|Local Institution, Salzburg, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|London Regional Cancer Program, London, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|CHUM, Montreal, Quebec, Canada|CHU de Quebec, Quebec, Canada|Local Institution, Brno, Czechia|Local Institution, Hradec Kralove, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Praha 8, Czechia|Aarhus University Hospital, Aarhus C, Denmark|Herlev University Hospital, Herlev, Denmark|Odense University Hospital, Odense, Denmark|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Boulogne Billancourt, France|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes Cedex, France|Local Institution, Paris Cedex 10, France|Local Institution, Pierre Benite, France|Local Institution, Rennes, France|Local Institution, Villejuif, France|Local Institution, Buxtehude, Germany|Local Institution, Erfurt, Germany|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kiel, Germany|Local Institution, Leipzig, Germany|Local Institution, Munich, Germany|Local Institution, Tubingen, Germany|Local Institution, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Jerusalem, Israel|Local Institution, Tel Hashomer, Israel|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Meldola (FC), Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Leiden, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Auckland, New Zealand|Local Institution, Oslo, Norway|Local Institution, Bydgoszcz, Poland|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Warsaw, Poland|Local Institution, Badalona-Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Pamplona-Navarra, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Geneva, Switzerland|Local Institution, Lausanne, Switzerland|Local Institution, St. Gallen, Switzerland|Local Institution, Zürich, Switzerland|Local Institution, Cambridge, Cambridgeshire, United Kingdom|Local Institution, Swansea, Carmarthenshire, United Kingdom|Local Institution, Glasgow, Dumfries & Galloway, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Northwood, Middlesex, United Kingdom|Local Institution, Nottingham, Nottinghamshire, United Kingdom		https://ClinicalTrials.gov/show/NCT01844505
294	NCT02231749	Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)		Active, not recruiting	Has Results	Advanced Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma	Biological: Nivolumab|Biological: Ipilimumab|Drug: Sunitinib	Investigator-assessed Objective Response Rate(ORR) in Intermediate/Poor Risk Participants Per IRRC Using RECIST v1.1|Overall Survival (OS) in Intermediate/Poor-Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)|Progression-Free Survival (PFS) in Intermediate/Poor-Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)|Investigator-assessed Objective Response Rate(ORR) in Any Risk Participants Per IRRC Using RECIST v1.1|Overall Survival (OS) in Any Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)|Progression-Free Survival (PFS) in Any Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	1390	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-214|2014-001750-42	October 13, 2014	June 26, 2017	September 30, 2019	September 4, 2014	October 16, 2018	October 16, 2018	City Of Hope, Duarte, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Stanford Cancer Center, Stanford, California, United States|Smilow Cancer Hospital. At Yale New Haven, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis, Indiana, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|University Of Kansas Cancer Center, Fairway, Kansas, United States|Uof Md,Greenebaum Cancer Ctr., Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Isr. Deacon. Med Cnt, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute Cancer Services, Pittsburgh, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology, P.A., Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|COIBA, Berazategui, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Tucuman, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Instituto Medico Especialazado Alexander Fleming, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Kogarah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Herston, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Elizabeth Vale, Australia|Local Institution, Murdoch, Australia|Local Institution, Linz, Austria|Local Institution, Vienna, Austria|Local Institution, Wels, Austria|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Calgary, Alberta, Canada|Local Institution, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Centro De Cancer, Pontificia Universidad Catolica, Santiago, Metropolitana, Chile|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Instituto Oncologico, Vina del Mar, Chile|Local Institution, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Instituto de Cancerologia SA, Medellin, Colombia|Local Institution, Brno, Czechia|Local Institution, Hradec Kralove, Czechia|Local Institution, Liberec, Czechia|Local Institution, Olomouc, Czechia|Aarhus University Hospital, Aarhus C, Denmark|Herlev University Hospital, Herlev, Denmark|Local Institution, Odense, Denmark|Helsinki University Hospital, Helsinki, Finland|Tampere University Hospital, Tampere, Finland|Local Institution, Besancon, France|Local Institution, Bordeaux, France|Local Institution, La Roche sur Yon, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris, France|Local Institution, Saint Herblain, France|Local Institution, Strasbourg, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Villejuif, France|Local Institution, Aachen, Germany|Local Institution, Erlangen, Germany|Local Institution, Frankfurt, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Homburg, Germany|Local Institution, Jena, Germany|Local Institution, Magdeburg, Germany|Local Institution, Muenchen, Germany|Local Institution, Muenster, Germany|Local Institution, Ulm, Germany|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Gyula, Hungary|Local Institution, Pecs, Hungary|Local Institution, Wilton, Cork, Ireland|Local Institution, Dublin 7, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Beer Jacob, Israel|Local Institution, Haifa, Israel|Local Institution, Kfar Saba, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Ramat-gan, Israel|Ospedal S. Donato Usl 8, Arezzo, Italy|Ist.Scient. Romagnolo Per Lo Studio E Cura Tumori, Meldola (fc), Italy|Local Institution, Milano, Italy|Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli, Napoli, Italy|Istituto Oncologico Veneto IOV, Padova, Italy|Local Institution, Pavia, Italy|Local Institution, Roma, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Sapporo-shi, Hokai-do, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Hamamatsu-shi, Shizuoka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Tokyo, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Mexico D.f., Distrito Federal, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Santiago de Queretaro, Queretaro, Mexico|Local Institution, Oaxaca, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Krakow, Poland|Local Institution, Olsztyn, Poland|Local Institution, Poznan, Poland|Local Institution, Wroclaw, Poland|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|H. Univ. Vall dHebron, Barcelona, Spain|Hospital Ramon Y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hospital General De Asturias, Oviedo, Spain|Hospital General Universitario Virgen Del Rocio, Sevilla, Spain|Karolinska University Hospital, Solna, Sweden|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Istanbul, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Northwood, United Kingdom|Local Institution, Swansea, United Kingdom	"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02231749/SAP_000.pdf|"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02231749/Prot_001.pdf	https://ClinicalTrials.gov/show/NCT02231749
295	NCT03138512	A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma	CheckMate 914	Recruiting	No Results Available	Renal Cell Carcinoma	Biological: Nivolumab|Biological: Ipilimumab|Drug: Placebo	Disease-free survival (DFS)|Overall Survival (OS)|Common Terminology Criteria for Adverse Events (CTCAE) version 4.0	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	800	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CA209-914|2016-004502-34	July 5, 2017	September 5, 2022	July 7, 2023	May 3, 2017	null	November 20, 2018	Alabama Oncology, Birmingham, Alabama, United States|Highland Oncology Group, Fayetteville, Arkansas, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|Local Institution, New Haven, Connecticut, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Local Institution, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Local Institution, Evansville, Indiana, United States|Washington University, Saint Louis, Missouri, United States|Meridan Health System-Jersey Shore Medical Center, Neptune, New Jersey, United States|Local Institution, Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Ohio State University, Columbus, Ohio, United States|Providence Newburg Medical Center, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Bon Secours-St Francis Hosp, Greenville, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Inova Schar Cancer Institute, Fairfax, Virginia, United States|Local Institution, Seattle, Washington, United States|Local Institution, Ciudad Autonoma Beunos Aires, Buenos Aires, Argentina|Hospital Privado De Comunidad, Mar Del Plata, Buenos Aires, Argentina|Instituto Medico Rio Cuarto S.A., Rio Cuarto, Cordoba, Argentina|Hospital Italiano De Buenos Aires, Caba, Argentina|Local Institution, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Clinica Privada Universitaria Reina Fabiola, Cordoba, Argentina|Centro Polivalente de Asistencia e Investigacion Clinica CER San Juan, San Juan, Argentina|Centro Medico San Roque, Tucuman, Argentina|Local Institution, Randwick, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|ICON Cancer Center, Chermside, Queensland, Australia|Local Institution, Malvern, Victoria, Australia|St John of God Murdoch Hospital, Perth, Western Australia, Australia|Lyell McEwin Hospital, Elizabeth Vale, Australia|Krankenhaus Der Barmherzigen Schwestern, Linz, Austria|Local Institution, Wien, Austria|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Hasselt, Belgium|Local Institution, Liege, Belgium|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Saint John, New Brunswick, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Rimouski, Quebec, Canada|Local Institution, Oshawa, Canada|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Wuhan, Hubei, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Changchun, Jilin, China|Local Institution, Yantai, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Guangzhou, China|Local Institution, Hangzhou, China|Local Institution, Shanghai, China|Local Institution, Shanghai, China|Local Institution, Xi?an, China|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Onkologicka klinika, Olomouc, Czechia|Local Institution, Besancon, France|Local Institution, La Roche sur Yon, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 9, France|Local Institution, Strasbourg, France|Local Institution, Tours Cedex, France|Local Institution, Vandoeuvre Les Nancy, France|Local Institution, Villejuif, France|Universitaetsklinikum Aachen, Aachen, Germany|Universitaetsklinikum Essen, Essen, Germany|Asklepios Klinik Altona, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinikum Jena, Jena, Germany|Klinikum Grosshadern, Munich, Germany|Klinikum Nuernberg Nord, Urologische Klinik, Nuernberg, Germany|Universitaetsklinikum Rostock, Rostock, Germany|Univ. Klinikum Wuerzburg, Wuerzburg, Germany|Local Institution, Arezzo, Italy|A.O. Istituti Ospitalieri Di Cremona, Cremona, Italy|Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli, Napoli, Italy|Azienda Ospedaliera Di Parma, Parma, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Policlinico G. Rossi, Verona, Italy|Local Institution, Toyoake Shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Nagasaki-shi, Nagasaki, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Tokushima-shi, Tokushima, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Ube, Yamaguchi, Japan|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Mazatlan, Sinaloa, Mexico|Local Institution, Chihuahua, Mexico|Local Institution, San Luis Potosi, Mexico|Local Institution, San Luis Potosi, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Zwolle, Netherlands|Local Institution, Biala Podlaska, Poland|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Local Institution, Lublin, Poland|Local Institution, Warsaw, Poland|Oddzial Onkologii Klinicznej, Wroclaw, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Nizhniy Novgorod, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Hospital San Pedro De Alcantara, Caceres, Spain|H. Lucus Augusti, Lugo, Spain|Local Institution, Madrid, Spain|Hospital Parc Tauli, Sabadell, Spain|Hospital General Universitario Virgen Del Rocio, Sevilla, Spain|Local Institution, Sevilla, Spain|Local Institution, Glasgow, Dumfries & Galloway, United Kingdom|Local Institution, Swansea, Glamorgan, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Preston, United Kingdom		https://ClinicalTrials.gov/show/NCT03138512
296	NCT01621490	PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma	PD-1	Active, not recruiting	No Results Available	Advanced Melanoma|Metastatic Melanoma	Biological: Nivolumab|Drug: Ipilimumab	Immunomodulatory effects of Nivolumab and Nivolumab in combination with Ipilimumab as measured by changes from baseline in activated and memory T cells, interferon, interferon inducible factors, and CD4 and CD8 T cell infiltration|Safety and tolerability of Nivolumab, Ipilimumab and Nivolumab in combination with Ipilimumab as measured by the incidence of adverse events (AEs), serious AEs, death, and changes in vital signs|Safety and tolerability of Nivolumab, Ipilimumab and Nivolumab in combination with Ipilimumab as measured by laboratory test abnormalities|Antitumor Activity of Nivolumab and Nivolumab in combination with Ipilimumab as measured by the objective response rate (ORR), duration of response, and progression free survival (PFS)|Immunogenicity of Nivolumab and Nivolumab in combination with Ipilimumab as measured by the frequency of baseline positive subjects and the frequency of ADA positive subjects|Association between Programmed cell death ligand 1 (PD-L1) and clinical efficacy will be measured by PDL1 expression levels clinical activity (ORR, PFS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	237	Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	CA209-038|2012-001840-23	September 27, 2012	September 12, 2017	December 2, 2018	June 18, 2012	null	August 1, 2018	Ucla, Los Angeles, California, United States|University Of Chicago, Chicago, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Lutherville, Maryland, United States|Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|University Of Virginia, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Amsterdam, Netherlands|Local Institution, Pamplona, Spain		https://ClinicalTrials.gov/show/NCT01621490
297	NCT02374242	Anti‐PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases	ABC	Active, not recruiting	No Results Available	Melanoma|Brain Metastases	Drug: Nivolumab|Drug: Ipilimumab	Intracranial response rate|Extracranial response rate|Overall response rate|Progression free survival in intracranial disease|Progression free survival in extracranial disease|Overall progression free survival|Overall survival|Safety and tolerability of nivolumab and nivolumab + ipilimumab (verse events by type, frequency and severity using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.)|Patient rated quality of life|Clinical response using immune related response criteria (irRC)|Tissue and blood biomarkers of response and progression|FET‐PET response in the brain at 6 and 12 weeks on therapy (Proportion of patients with a lower standardised uptake value from baseline in intracranial metastases, following at least ONE dose of study treatment)	Melanoma Institute Australia|Australia and New Zealand Melanoma Trials Group|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	76	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209‐170|ACTRN12614001315606|ANZMTG 01.14	November 4, 2014	September 4, 2017	December 2022	February 27, 2015	null	April 11, 2018	Melanoma Institute Australia, North Sydney, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia		https://ClinicalTrials.gov/show/NCT02374242
298	NCT02576509	An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma		Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Nivolumab|Drug: Sorafenib	Overall Survival (OS)|Progression-Free Survival (PFS)|Programmed death (PD)-L1 expression|Overall Response Rate (ORR)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	726	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-459	November 25, 2015	June 9, 2019	July 14, 2020	October 15, 2015	null	November 6, 2018	University Of Alabama At Birmingham, Birmingham, Alabama, United States|Ucla-Division Of Hematology/Oncology, Los Angeles, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|University Of California San Francisco, San Francisco, California, United States|University Of Chicago, Chicago, Illinois, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Icahn School Of Medicine At Mount Sinai, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The University Of Texas Health Science Center, San Antonio, Texas, United States|Scott & White Memorial Hospital And Clinic, Temple, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University Of Wisconsin, Madison, Wisconsin, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Monash Medical Centre Clayton, Clayton, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|The Alfred Hospital, Prahran, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Universitaetsklinikum Graz, Graz, Austria|AKH Wien, Wien, Austria|Local Institution, Bruxelles, Belgium|Local Institution, Leuven, Belgium|Local Institution, Liege, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency-Vancouver Ctr, Vancouver, British Columbia, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Local Institution, Hefei, Anhui, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Nanning, Guangxi, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Changsha, Hunan, China|Local Institution, Changzhou, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Chang Chun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Dalian, Liaoning, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Onkologicka klinika, Olomouc, Czechia|Local Institution, La Tronche, France|Local Institution, Lille Cedex, France|Local Institution, Lyon, France|Local Institution, Montpellier Cedex, France|Local Institution, Paris Cedex 13, France|Local Institution, Pessac, France|Local Institution, Rennes Cedex, France|Local Institution, Toulouse Cedex 9, France|Charite Campus Virchow Klinikum, Berlin, Germany|Kliniken Essen-Mitte/Huyssens-Stift, Essen, Germany|Klinikum Der Johann Wolfgang Goethe-Universitat, Frankfurt, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitaetsklinikum Leipzig, Leipzig, Germany|Johannes -Gutenberg Universitat, Mainz, Germany|Klinikum Grosshadern, Munich, Germany|Universitaetsklinikum Regensburg, Regensburg, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petah-tikva, Israel|Local Institution, Tel Aviv, Israel|Ospedale G.Rummo, Benevento, Italy|Azienda Ospedaliera Papa Giovanni Xxiii, Bergamo, Italy|Istituto Nazionale Per Lo Studio E La Cura, Milano, Italy|Local Institution, Orbassano, Italy|AOUS - Policlinico S.Maria Alle Scotte, Siena, Italy|Local Institution, Chiba City, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Ogaki-shi, Gifu, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Kawasaki-shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Osaka-Sayama-Shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Saga-shi, Saga, Japan|Local Institution, Chiyoda-ku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Musashino-shi, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Daegu, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Hwasun-gun, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radiote, Gdansk, Poland|Klinika Gastroenterologii Onkologicznej, Warszawa, Poland|Oddzial Onkologii, Wroclaw, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Alicante, Spain|Local Institution, Majadahonda - Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Santiago Compostela, Spain|Local Institution, Goteborg, Sweden|Local Institution, Stockholm, Sweden|Universitaetsspital Basel, Basel, Switzerland|Inselspital Bern, Bern, Switzerland|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, Wirral, Merseyside, United Kingdom		https://ClinicalTrials.gov/show/NCT02576509
299	NCT01354431	BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)		Active, not recruiting	Has Results	Renal Cell Carcinoma	Biological: nivolumab	Median Progression Free Survival (PFS) at Primary Endpoint - Randomized Population|Objective Response Rate (ORR) at Primary Endpoint- Randomized Population|Number of Participants With Best Overall Response at Primary Endpoint - Randomized Population|Median Overall Survival in Months at Interim Data Cut-off - Randomized Population|Median Progression Free Survival (PFS) in Months at Interim Data Cut-off - Randomized Population	Bristol-Myers Squibb|Ono Pharma USA Inc	All	18 Years and older   (Adult, Older Adult)	Phase 2	198	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	CA209-010	May 17, 2011	May 15, 2013	July 1, 2019	May 16, 2011	October 20, 2015	September 25, 2018	UCSD Moores Cancer Center, La Jolla, California, United States|Ucla, Los Angeles, California, United States|Samuel Oschin Comprehensive Cancer Inst., Los Angeles, California, United States|Stanford Cancer Center, Stanford, California, United States|University Of Colorado, Aurora, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Northwestern University Feinberg School Of Medicine, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis, Indiana, United States|University Of Kansas Medical Center, Kansas City, Kansas, United States|University Of Maryland, Baltimore, Maryland, United States|The Bunting-Blaustein Cancer Research Building, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Ctr., Boston, Massachusetts, United States|University Of Michigan Medical Center, Ann Arbor, Michigan, United States|Wayne State University, Detroit, Michigan, United States|Masonic Cancer Ctr, University Of Minnesota, Minneapolis, Minnesota, United States|North Mississippi Hematology And Oncology Associates, Ltd, Tupelo, Mississippi, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|St. Luke'S Roosevelt Hospital Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Blumenthal Cancer Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Wheaton Franciscan Health Care, Wauwatosa, Wisconsin, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Centre D'Oncologie Dr-Leon-Richard, Moncton, New Brunswick, Canada|Local Institution, Halifax, Nova Scotia, Canada|London Regional Cancer Program, London, Ontario, Canada|Centre Hospitalier Universitaire De Montreal-Notre-Dame Hosp, Montreal, Quebec, Canada|Local Institution, Helsinki, Finland|Local Institution, Siena, Italy		https://ClinicalTrials.gov/show/NCT01354431
300	NCT02017717	A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients	CheckMate 143	Active, not recruiting	No Results Available	Recurrent Glioblastoma	Biological: Nivolumab|Biological: Bevacizumab|Biological: Ipilimumab	Cohorts 1,1b, 1c and 1d : Safety and tolerability based on drug related events leading to permanent discontinuation prior to completing 4 doses|Cohort 2: Overall Survival (OS)|Cohort 2: Overall Survival rate (OS)|Cohort 2: Progression Free Survival (PFS)|Cohort 2: Objective Response Rate(ORR)	Bristol-Myers Squibb	All	Child, Adult, Older Adult	Phase 3	626	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-143|2013-003738-34	January 27, 2014	January 10, 2017	October 26, 2018	December 23, 2013	null	March 16, 2018	University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|UCLA Neuro-Oncology Program, Los Angeles, California, United States|The Regents of the University of California, San Francisco, San Francisco, California, United States|Anschutz Cancer Pavilion, Aurora, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States|Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Local Institution, Liverpool, New South Wales, Australia|Local Institution, East Bentleigh, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Aarhus University Hospital, Aarhus C, Denmark|Odense University Hospital, Odense C, Denmark|Local Institution, Bron cedex, France|Local Institution, Marseille Cedex 5, France|Local Institution, Paris cedex 13, France|Local Institution, Paris, France|Universitaetsklinikum Bonn, Bonn, Germany|Klinikum Der J. W. Goethe-Universitaet Frankfurt/Main, Frankfurt Am Main, Germany|Local Institution, Heidelberg, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Siena, Italy|Local Institution, Torino, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Gdansk, Poland|Local Institution, Warszawa, Poland|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|UniversitaetsSpital Zurich, Zuerich, Switzerland|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Wirral, Merseyside, United Kingdom		https://ClinicalTrials.gov/show/NCT02017717
301	NCT02388906	Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)		Active, not recruiting	No Results Available	Melanoma	Drug: Ipilimumab|Drug: Nivolumab|Other: Placebo matching Ipilimumab|Other: Placebo matching Nivolumab	Recurrence -free-survival|Overall survival	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	15 Years and older   (Child, Adult, Older Adult)	Phase 3	800	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA209-238|2014-002351-26	March 12, 2015	November 29, 2018	November 26, 2019	March 17, 2015	null	July 3, 2018	University Of Arkansas For Medical Sciences, Little Rock, Arkansas, United States|UC San Diego Moores Cancer Ctr, La Jolla, California, United States|The Angeles Clinic & Research Institute, Los Angeles, California, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|Ucsf-Comprehensive Cancer Center, San Francisco, California, United States|University Of Colorado Cancer Center, Aurora, Colorado, United States|Medstar Washington Hospital Center, Washington, District of Columbia, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Allina Health, Fridley, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Nyu Clinical Cancer Institute, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Carolinas Healthcare System / Carolinas Medical Center, Charlotte, North Carolina, United States|Duke Cancer Center, Durham, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Providence Cancer Center Oncology And Hematology Care, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|St. Luke's Cancer Center - Anderson Campus, Easton, Pennsylvania, United States|Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Texas Oncology Sammons Cancer Center, Dallas, Texas, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|University Of Washington Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, San Miguel de Tucuman, Tucuman, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Gateshead, New South Wales, Australia|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Prahran, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Camperdown, Australia|Local Institution, Graz, Austria|Local Institution, Salzburg, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Mcgill University Dept Of Oncology, Montreal, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Local Institution, Hradec Kralove, Czechia|Local Institution, Ostrava-Poruba, Czechia|Local Institution, Praha 10, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Lille, France|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes Cedex 1, France|Local Institution, Paris, France|Local Institution, Pierre Benite, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Athens, Greece|Local Institution, Neo Faliro, Greece|Local Institution, Budapest, Hungary|Local Institution, Dublin 7, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Meldola (FC), Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Matsumoto-shi, Nagano, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Chuo-shi, Yamanashi, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Veldhoven, Netherlands|Local Institution, Bergen, Norway|Local Institution, Oslo, Norway|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Warszawa, Poland|Local Institution, Craiova, Romania|Local Institution, Romania, Romania|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Saxonwold, Johannesburg, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Hospital Clinic I Provincial, Barcelona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hosp Univ Virgen Macarena, Sevilla, Spain|Hospital General Univ De Valencia, Valencia, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Lund, Sweden|Local Institution, Zurich, Switzerland|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Bristol, Avon, United Kingdom|Local Institution, Swansea, Carmarthenshire, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Northwood, Middlesex, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|Local Institution, Newcastle Upon Tyne, Tyne and Wear, United Kingdom|Local Institution, Leicester, United Kingdom|Local Institution, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT02388906
302	NCT02714218	A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma		Active, not recruiting	No Results Available	Melanoma	Biological: Nivolumab 3 mg/kg IV|Biological: Ipilimumab 1 mg/kg IV|Biological: Nivolumab 1 mg/kg IV|Biological: Ipilimumab 3 mg/kg IV|Biological: Nivolumab 6 mg/kg IV	Incidence of drug-related Grade 3 - 5 Adverse Events (AEs)|Objective I Response Rate (ORR)|Overall survival (OS)|Mean changes from baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) global health status/quality of life (Qol) composite scale|Progression Free Survival (PFS) in all treated subjects	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	483	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA209-511	March 24, 2016	April 20, 2017	April 15, 2022	March 21, 2016	null	April 27, 2018	University Of Colorado Cancer Center, Aurora, Colorado, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Allina Health, Fridley, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Waratah, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Melbourne, Victoria, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Local Institution, Aarhus, Denmark|Local Institution, Herlev, Denmark|Local Institution, Odense, Denmark|Hopital Saint Andre, Bordeaux, France|Chru De Lille, Lille, France|Hopital De La Timone, Marseille Cedex 5, France|Hopital Hotel Dieu, Nantes Cedex, France|Hopital Saint Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Institut Claudius Regaud, Toulouse Cedex 9, France|Institut Gustave Roussy, Villejuif, France|Universitaetsklinikum Essen, Essen, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Ludwig-Maximilians-Universitaet, Muenchen, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Local Institution, Ramat Gan, Israel|Local Institution, Bergamo, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Siena, Italy|Local Institution, Taormina, Italy|Netherland Cancer Institute, Amsterdam, Netherlands|Local Institution, Amsterdam, Netherlands|University Medical Center Groningen (Umcg), Groningen, Netherlands|Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radiote, Gdansk, Poland|Klinika Nowotworow Ukladowych i Uogolnionych, Krakow, Poland|Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow, Warszawa, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Badalona-barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, San Sabastian Gipuzkoa, Spain|Local Institution, Valencia, Spain|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|Local Institution, Guildford, Surrey, United Kingdom|Local Institution, London, United Kingdom		https://ClinicalTrials.gov/show/NCT02714218
303	NCT01721772	Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma	CheckMate 066	Active, not recruiting	Has Results	Melanoma	Biological: BMS-936558 (Nivolumab)|Biological: Placebo matching BMS-936558 (Nivolumab)|Drug: Dacarbazine|Drug: Placebo matching Dacarbazine	Overall Survival (OS)|Overall Survival (OS) Rate|Progression-free Survival (PFS)|Progression-free Survival (PFS) Rate|Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST)|Overall Survival by Programmed Cell Death Ligand 1 (PD-L1) Expression Level|Change From Baseline in Health-related Quality of Life (HRQoL) Scores	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	583	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CA209-066|2012‐003718‐16	January 17, 2013	June 24, 2014	February 23, 2019	November 6, 2012	February 25, 2016	August 8, 2018	Fundacion Cidea, Capital Federal, Buenos Aires, Argentina|Instituto Medico Especialazado Alexander Fleming, Buenos Aires, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Coffs Harbour, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Malvern, Victoria, Australia|Local Institution, North Sydney, Australia|Tom Baker Cancer Centre, Calgary, Alberta, Canada|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Qe Ii Health Science Centre, Halfax, Nova Scotia, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Mcgill University, Dept. Oncology, City, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Vi?a Del Mar, Valparaiso, Chile|Local Institution, Santiago, Chile|Aarhus Universitetshospital, Aarhus, Denmark|Herlev Hospital, Herlev, Denmark|Odense University Hospital, Odense, Denmark|Helsinki University Hospital, Helsinki, Finland|Local Institution, Bordeaux, France|Local Institution, Grenoble, France|Local Institution, Lille, France|Local Institution, Montpellier, France|Local Institution, Paris, France|Local Institution, Villejuif, France|Local Institution, Wuerzburg, Bayern, Germany|Local Institution, Essen, Germany|Local Institution, Gera, Germany|Local Institution, Goettingen, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kiel, Germany|Local Institution, Koeln, Germany|Local Institution, Magdeburg, Germany|Local Institution, Mainz, Germany|Local Institution, Nuernberg, Germany|Local Institution, Recklinghausen, Germany|Local Institution, Tubingen, Germany|Local Institution, Athens, Greece|Local Institution, Neo Faliro, Greece|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Tel Hashomer, Israel|Local Institution, Bari, Italy|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Leon, Guanajato, Guanajuato, Mexico|Local Institution, Morelia, Michoacan, Mexico|Local Institution, Mexico City, Mexico|Local Institution, Oslo, Norway|Local Institution, Gdansk, Poland|Local Institution, Lodz, Poland|Local Institution, Warszawa, Poland|Local Institution, San Sebastian, Guipuzcoa, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Lund, Sweden|Local Institution, Umea, Sweden		https://ClinicalTrials.gov/show/NCT01721772
304	NCT02038946	Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)		Active, not recruiting	Has Results	Lymphoma	Drug: Nivolumab	Overall Response Rate (ORR) as Determined by IRRC|Duration of Response (DOR) Based on IRRC Assessments|Complete Remission Rate (CRR) Based on IRRC Assessment|Partial Remission (PR) Rate Based on IRRC Assessment|Progression Free Survival (PFS) Based on IRRC Assessment|Overall Response Rate (ORR) Based on Investigator Assessments	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	116	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-140|2013-003645-42	March 6, 2014	May 17, 2017	April 8, 2019	January 17, 2014	June 12, 2018	November 14, 2018	Mayo Clinic Arizona, Phoenix, Arizona, United States|Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Weill Cornell Medical College, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Local Institution, Woodville, South Australia, Australia|Local Institution, Parkville, Victoria, Australia|Local Institution, B-leuven, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Jewish General Hospital, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Local Institution, Creteil, France|Local Institution, Montpellier Cedex 05, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Rennes, France|Universitaetsklinikum Essen, Essen, Germany|Universitaetsklinikum Des Saarlandes, Homburg, Germany|Local Institution, Regensburg, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Roma, Italy|Local Institution, Oslo, Norway|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Hospital Duran I Reynals, Hospitalet Llobregat- Barcelona, Spain|Local Institution, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Local Institution, Salamanca, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Withington, Manchester, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02038946/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02038946/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02038946
305	NCT02038933	Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)		Active, not recruiting	Has Results	Lymphoma. Non-Hodgkin	Drug: Nivolumab	Objective Response Rate (ORR) Per Independent Radiologic Review Committee (IRRC) Assessment|Duration of Response (DOR)|Complete Remission Rate|Duration of Complete Remission|Rate of Partial Remission|Duration of Partial Remission|Progression Free Survival|Objective Response Rate (ORR) Per Investigator Assessment	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	161	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-139|2013-003621-28	February 10, 2014	April 8, 2016	April 1, 2019	January 17, 2014	May 30, 2017	October 24, 2018	Mayo Clinic Arizona, Phoenix, Arizona, United States|Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States|Winship Cancer Center, Atlanta, Georgia, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Local Institution, Waratah, New South Wales, Australia|Local Institution, Woodville, South Australia, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, B-leuven, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Creteil, France|Local Institution, Montpellier Cedex 05, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Rennes, France|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Homburg, Germany|Local Institution, Ulm, Germany|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Roma, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Utrecht, Netherlands|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Hospitalet Llobregat- Barcelona, Spain|Local Institution, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Local Institution, Salamanca, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Lund, Sweden|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Withington, Manchester, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT02038933
306	NCT01024231	Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma		Active, not recruiting	No Results Available	Malignant Melanoma	Drug: BMS-936558 (MDX1106-04)|Drug: Ipilimumab	Safety assessments will be based on adverse event reports and the results of clinical laboratory tests, immune safety tests, physical examinations, vital sign measurements, ECOG performance status, and ECG evaluations|Pharmacokinetic peak and trough concentration of each study drug when given in combination together or in a sequenced regimen|Blood samples to test immunogenicity|Tumor response evaluations	Bristol-Myers Squibb|Medarex|Ono Pharma USA Inc	All	18 Years and older   (Adult, Older Adult)	Phase 1	136	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-004|(MDX1106-04)	December 14, 2009	April 7, 2019	December 30, 2019	December 2, 2009	null	December 13, 2017	Yale University School Of Medicine, New Haven, Connecticut, United States|Medstar Georgetown-Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Hillman Cancer Research Pavilion, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT01024231
307	NCT03141177	A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma	CheckMate 9ER	Recruiting	No Results Available	Renal Cell Carcinoma	Biological: Nivolumab|Drug: Cabozantinib|Drug: Sunitinib|Biological: Ipilimumab	Progression Free Survival (PFS) per blinded independent central review (BICR)|Overall Survival (OS)|Objective Response Rate (ORR)|Incidence of adverse events (AEs)|Incidence of Serious Adverse Events (SAEs)	Bristol-Myers Squibb|Exelixis|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	630	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-9ER|2017-000759-20	July 11, 2017	September 22, 2019	April 22, 2023	May 4, 2017	null	November 20, 2018	Southern Cancer Center, Inc., Daphne, Alabama, United States|Cancer Treatment Centers of America-Western, Goodyear, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|CBCC Global Research, Inc., Bakersfield, California, United States|Local Institution, Los Angeles, California, United States|UCLA Hematology Oncology, Los Angeles, California, United States|Cancer Care Associates Medical Group, Inc., Redondo Beach, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|University Of Colorado Cancer Center, Aurora, Colorado, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Southeastern Regional Medical Center - CTCA, Newnan, Georgia, United States|Rush University Med Ctr, Chicago, Illinois, United States|Midwestern Regional Medical Center, Zion, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|University Of Michigan, Ann Arbor, Michigan, United States|HCA Midwest Division, Kansas City, Missouri, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Local Institution, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Local Institution, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology, Austin, Texas, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Local Institution, Midland, Texas, United States|Local Institution, Plano, Texas, United States|Texas Cancer Center - Sherman, Sherman, Texas, United States|Local Institution, Salt Lake City, Utah, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Local Institution, Seattle, Washington, United States|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Local Institution, Córdoba, Cordoba, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Centro Medico San Roque, San Miguel De Tucuman, Tucuman, Argentina|Centro De Diagnostico Urologico S.R.L., Buenos Aires, Argentina|Local Institution, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Clinica Privada Universitaria Reina Fabiola, Cordoba, Argentina|The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia|Macquarie University, North Ryde, New South Wales, Australia|Local Institution, Sydney, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Local Institution, South Brisbane, Queensland, Australia|Tasman Oncology Research Pty Ltd, Southport, Queensland, Australia|Cabrini Hospital, Malvern, Victoria, Australia|Affinity Clinical Research Services Pty Ltd, Doubleview, Western Australia, Australia|Local Institution, Elizabeth Vale, Australia|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Onkologicka klinika, Olomouc, Czechia|Local Institution, Bordeaux, France|Local Institution, Caen, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 9, France|Local Institution, Montpellier Cedex, France|Local Institution, Nantes, France|Local Institution, Paris, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Universitaetsklinikum Aachen, Aachen, Germany|Universitaetsklinikum Bonn, Bonn, Germany|Klinik Essen-Mitte, Essen, Germany|Universitaetsklinikum Jena, Jena, Germany|Klinikum Rechts Der Isar Der Tum, Muenchen, Germany|Klinikum Nuernberg Nord, Urologische Klinik, Nuernberg, Germany|Uniklinik Tuebingen, Tuebingen, Germany|Alexandra General Hospital, Athens, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Haifa, Israel|Local Institution, Kfar Saba, Israel|Local Institution, Petah Tikva, Israel|Local Institution, Ramat Gan, Israel|Ospedale S. Donato - Usl 8, Arezzo, Italy|Ospedale San Raffaele, Milano, Italy|Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli, Napoli, Italy|I.O.V. Istituto Oncologico Veneto Ircss, Padova, Italy|IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy|Local Institution, Pavia, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Kobe, Hyogo, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Nagasaki-shi, Nagasaki, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osakasayama-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Tokushima-shi, Tokushima, Japan|Local Institution, Arakawa-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Minato-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Fukuoka, Japan|Comite Mexicano para la Prevenion de la Osteoporosis A.C., Ciudad de Mexico, Distrito Federal, Mexico|Instituto Nacional De Ciencias Medicas Y Nutricion S.Z., Mexico, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Investigacion Biomedica para el desarrollo de Farmacos, S.A. de C.V., Zapopan, Jalisco, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, Mexico|Merida Investigacion Clincia, Merida, Yucatan, Mexico|Local Institution, Monterrey, NL, Mexico|Hospital Medica Tec 100, Queretaro, Mexico|WSS w Bialej Podlaskiej, Biala Podlaska, Poland|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Wojewodzkie Centrum Onkologii, Gdansk, Poland|Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Depar, Cluj-napoca, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Nizhniy Novgorod, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, A Coru?a, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Santander, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Ankara, Turkey|Local Institution, Ankara, Turkey|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Denizli, Turkey|Local Institution, Edirne, Turkey|Local Institution, Istanbul, Turkey|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Newcastle Upon Tyne, United Kingdom|Local Institution, Truro, United Kingdom		https://ClinicalTrials.gov/show/NCT03141177
308	NCT01472081	Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)		Active, not recruiting	No Results Available	Renal Cell Carcinoma|Clear-cell Metastatic Renal Cell Carcinoma	Biological: Nivolumab|Biological: Pazopanib|Drug: Sunitinib|Biological: Ipilimumab	Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of Adverse event (AE)|Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of Serious adverse event (SAE)|Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of lab abnormality|Antitumor activity of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by Objective Response Rate (ORR)|Antitumor activity of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by duration of response according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 1	175	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-016	January 2012	February 2016	June 2018	November 16, 2011	null	April 19, 2017	City Of Hope, Duarte, California, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Tennessee Oncology, Pllc, Nashville, Tennessee, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Bc Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Princess Margaret Hospital-Uhn, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT01472081
309	NCT03380130	A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC	NASIR-HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Nivolumab|Device: SIR-Spheres	Rate and type of adverse events, liver decompensation, and transient and permanent drug discontinuations due to toxicity.|Response rate|Disease control rate|Duration of response|Time to progression|Progression-free survival|Overall survival|Pattern of progression according to RECIST 1.1 criteria.	Clinica Universidad de Navarra, Universidad de Navarra|Sirtex Medical|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NASIR-HCC/CA209-992	September 11, 2017	October 1, 2019	October 1, 2019	December 20, 2017	null	April 13, 2018	Hospital Universitario de Cruces, Baracaldo, Spain|Hospital Clinic, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario Donostia, San Sebastián, Spain|Hospital Universitario Lozano Blesa, Zaragoza, Spain		https://ClinicalTrials.gov/show/NCT03380130
310	NCT03355976	BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas		Recruiting	No Results Available	Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|Extra Renal Origin|Clear Cell Adenocarcinoma	Drug: Nivolumab|Drug: Ipilimumab	Proportion of patients who have objective tumor response (complete or partial) by modified RECIST 1.1 in patients with clear cell carcinomas treated with nivolumab or the combination of nivolumab and ipilimumab|Compare median PFS for patients treated with nivolumab (Arm 1) and the combination of nivolumab and ipilimumab (Arm 2)	Don Dizon|Bristol-Myers Squibb|Rhode Island Hospital|The Miriam Hospital|Brown University	All	18 Years and older   (Adult, Older Adult)	Phase 2	62	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BrUOG 354	April 30, 2018	February 2020	February 2022	November 29, 2017	null	July 26, 2018	Rhode Island Hospital, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States		https://ClinicalTrials.gov/show/NCT03355976
311	NCT03149120	Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas		Withdrawn	No Results Available	Soft Tissue Sarcomas	Biological: Nivolumab|Drug: Pazopanib	Progression-free survival (PFS) at 6 months for nivolumab alone or nivolumab in combination with pazopanib|Measure of Tolerability|Overall Response Rate|Median Progression Free Overall Survival (OS)	New York University School of Medicine|Bristol-Myers Squibb	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2	0	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-02078	August 2017	August 17, 2017	June 2022	May 11, 2017	null	August 22, 2017	New York University School of Medicine, New York, New York, United States		https://ClinicalTrials.gov/show/NCT03149120
312	NCT02581631	An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas	CheckMate 436	Recruiting	No Results Available	Non-Hodgkin's Disease	Biological: Nivolumab|Drug: Brentuximab Vedotin	Safety of combination of nivolumab and brentuximab vedotin based on incidence of deaths, adverse events (AE), serious adverse events (SAE), AE leading to discontinuation, AE leading to dose delay, drug-related adverse events|Tolerability of combination of nivolumab and brentuximab vedotin based on incidence of deaths, AE, SAE, adverse events leading to discontinuation, adverse events leading to dose delay, drug-related adverse events|Overall Response Rate (ORR)|Overall duration of response (DOR)|Complete response rate (CRR)|Duration of complete response|Progression-Free Survival (PFS)|Overall Survival (OS)	Bristol-Myers Squibb|Seattle Genetics, Inc.	All	15 Years and older   (Child, Adult, Older Adult)	Phase 1|Phase 2	146	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-436|2015-003286-28	December 18, 2015	June 9, 2019	February 13, 2020	October 21, 2015	null	September 25, 2018	University of Alabama At Birmingham, Birmingham, Alabama, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|University Of Chicago, Chicago, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Local Institution, Hackensack, New Jersey, United States|Icahn School Of Medicine At Mount Sinai, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Of Rochester, Rochester, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|Bon Secours-St Francis Hosp, Greenville, South Carolina, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Local Institution, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Rozzano (milano), Italy|Hospital Duran I Reynals, Hospitalet de Llobregat - Barcelona, Spain|Churchill Hospital, Oxford, Oxfordshire, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT02581631
313	NCT03138499	A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,	CheckMate 812	Recruiting	No Results Available	Hodgkin's Disease	Biological: Nivolumab|Biological: Brentuximab vedotin	Progression Free Survival (PFS)|Complete Response Rate (CRR)|Objective Response Rate (ORR)|Duration of response (DOR)|Duration of complete response (DOCR)|Overall Survival (OS)	Bristol-Myers Squibb|Seattle Genetics, Inc.|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	340	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-812|2017-000847-41	May 16, 2017	November 29, 2020	July 27, 2023	May 3, 2017	null	November 20, 2018	Dr. Moh'd Khushman MD, Office of, Mobile, Alabama, United States|University Of Arkansas For Medical Sciences, Little Rock, Arkansas, United States|City of Hope National Medical Center, Duarte, California, United States|University of California San Diego (UCSD), La Jolla, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|University of Califomia, Los Angeles, Los Angeles, California, United States|Local Institution, Palo Alto, California, United States|UC Davis Comprehensive Cancer Center, Sacramento, California, United States|Hartford Healthcare Cancer Institute at The Hospital of Central Connecticut, Plainville, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Miami Cancer Institute, Baptist Health South Florida, Miami, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|H. Lee Moffit Cancer center and research institute, Tampa, Florida, United States|Parkview Cancer Center, Fort Wayne, Indiana, United States|University of Kansas Hospital, Westwood, Kansas, United States|Louisville Oncology, Louisville, Kentucky, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Dana Farber Cancer Institute (DFCI), Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Local Institution, Rochester, Minnesota, United States|Mercy Clinic Oncology and Hematology - Joplin, Joplin, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Memorial Sloan-Kettering Cancer Center (MSKCC) - Basking Ridge, Basking Ridge, New Jersey, United States|John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center Monmouth, Middletown, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Local Institution, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Local Institution, Rochester, New York, United States|Memorial Sloan Kettering Cancer Center Rockville Centre, Rockville Centre, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina University Brody School of Medicine(ECU), Greenville, North Carolina, United States|Local Institution, Raleigh, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Local Institution, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Bon Secours Saint Francis Cancer Center, Greenville, South Carolina, United States|Greenville Health System Cancer Institute, Spartanburg, South Carolina, United States|Center For Biomedical Research, Knoxville, Tennessee, United States|UT Medical Center Cancer Institute, Knoxville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Local Institution, San Antonio, Texas, United States|Local Institution, Charlottesville, Virginia, United States|Vista Oncology - East Olympia, Olympia, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|Local Institution, Albury, New South Wales, Australia|Local Institution, Randwick, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Prague 2, Czechia|Local Institution, Debrecen, Hungary|Local Institution, Milano, Italy|Local Institution, Reggio Emilia, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Isehara, Kanagawa, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Osakasayaha, Osaka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, San Juan, Puerto Rico|Local Institution, Ankara, Turkey|Local Institution, Samsun, Turkey		https://ClinicalTrials.gov/show/NCT03138499
314	NCT02181738	Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)	CheckMate 205	Active, not recruiting	No Results Available	Hodgkin Disease	Drug: Nivolumab|Drug: Doxorubicin|Drug: Vinblastine|Drug: Dacarbazine	Independent radiologic review committee (IRRC) assessed objective response rate (ORR)|proportion of subjects who experienced at least one treatment-related Grade 3 5 AEs (per NCI CTCAE version 4.0 criteria, any PT term) with an onset date after or on the first dose date and no later than 30 days after the last study dose date|Duration of response (DOR)|Complete remission (CR) rate|CR duration|Partial remission (PR) rate|PR duration|Investigator-assessed ORR|Investigator-assessed DOR|Treatment discontinuation rate, defined by the number of subjects who were treated with fewer than 12 doses|Treatment discontinuation rate of nivolumab monotherapy|Treatment discontinuation rate of the Nivolumab-AVD combination therapy|Treatment discontinuation rate of the combination therapy|Incidence of treatment related grade 3-5 AEs during the monotherapy phase|Incidence of treatment related grade 3-5 AEs during the combination phase	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	338	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-205|2014-001509-42	July 19, 2014	August 31, 2017	October 1, 2020	July 4, 2014	null	January 23, 2018	Cedars Sinai Medical Center, Los Angeles, California, United States|Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States|Winship Cancer Center, Atlanta, Georgia, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Med Coll/Ny Pres, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Md Anderson Can Cnt, Houston, Texas, United States|Universitaetsklinikum Innsbruck, Innsbruck, Austria|Department Fuer Haematologie, Wien, Austria|Local Institution, B-leuven, Belgium|Local Institution, Gent, Belgium|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Praha 2, Czechia|Local Institution, Berlin, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Universitaetsklinik Koeln, Koeln, Germany|University Hopistal ULM Dept of Internal Medizin, Ulm, Germany|Local Institution, Bologna, Italy|Local Institution, Napoli, Italy|Istituto Clinico Humanitas, Rozzano (milano), Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Utrecht, Netherlands|Hospital Costa Del Sol, Marbella, Malaga, Spain|Hospital Duran I Reynals, Hospitalet Llobregat- Barcelona, Spain|Hosp. Univ. Puerta De Hierro, Majadahonda - Madrid, Spain|Singleton Hospital, Swansea, Carmarthenshire, United Kingdom|The Christie NHS Foundation Trust, Withington, Manchester, United Kingdom|Churchill Hospital, Oxford, Oxfordshire, United Kingdom|The Royal Marsden Hospital, Sutton, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT02181738
315	NCT02927769	A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment	CheckMate 744	Recruiting	No Results Available	Hodgkin Disease	Biological: Nivolumab|Biological: brentuximab vedotin|Biological: bendamustine	Event Free Survival (EFS)|Complete Metabolic Response (CMR) rate prior to HDCT/ASCT|Complete Metabolic Response (CMR) rate at any time prior to radiation therapy|Overall Response Rate (ORR) after 4 cycles of nivolumab + brentuximab vedotin treatment|Progression Free Survival Rate (PFSR)|Duration of Response (DOR)|Incidence of serious and non-serious adverse events of nivolumab (BMS-936558) and brentuximab when given in combination.|Incidence of clinically significant abnormalities in general laboratory tests of nivolumab (BMS-936558) and brentuximab when given in combination.|Incidence of clinically significant vital sign measurements of nivolumab (BMS-936558) and brentuximab when given in combination.	Bristol-Myers Squibb|Seattle Genetics, Inc.	All	5 Years to 30 Years   (Child, Adult)	Phase 2	80	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-744|2016-002347-41	March 27, 2017	March 28, 2021	March 27, 2022	October 7, 2016	null	November 20, 2018	Children'S Hospital Of Alabama, Birmingham, Alabama, United States|Phoenix Children'S Hospital, Phoenix, Arizona, United States|Loma Linda University Cancer Center, Loma Linda, California, United States|Local Institution, Los Angeles, California, United States|Southern California Permanente Medical Group, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|Children'S Hospital & Research Center At Oakland, Oakland, California, United States|Local Institution, Orange, California, United States|Local Institution, Palo Alto, California, United States|Local Institution, San Francisco, California, United States|Childrens Hospital of Colorado, Aurora, Colorado, United States|Local Institution, Hartford, Connecticut, United States|Smilow Cancer Hospital At Yale New Haven Hospital, New Haven, Connecticut, United States|Nemours / A. I. duPont Hospital for Children, Wilmington, Delaware, United States|Children'S National Medical Center, Washington, District of Columbia, United States|Nemours Children'S Clinic, Jacksonville, Florida, United States|All Children'S Hospital, Saint Petersburg, Florida, United States|Children's Healthcare Of Atlanta, Atlanta, Georgia, United States|Local Institution, Chicago, Illinois, United States|Indiana University - Riley Children'S Hospital, Indianapolis, Indiana, United States|University Of Iowa, Iowa City, Iowa, United States|Local Institution, Louisville, Kentucky, United States|John Hopkins University, Baltimore, Maryland, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Local Institution, Ann Arbor, Michigan, United States|Local Institution, Detroit, Michigan, United States|Local Institution, Grand Rapids, Michigan, United States|Local Institution, Minneapolis, Minnesota, United States|University Of Mississippi Medical Center, Jackson, Mississippi, United States|Children'S Mercy Hospital And Clinics, Kansas City, Missouri, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Local Institution, New Hyde Park, New York, United States|Local Institution, New York, New York, United States|Local Institution, New York, New York, United States|Local Institution, Valhalla, New York, United States|UNC Lineberger Cancer Center, Chapel Hill, North Carolina, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Cincinnati Children'S Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children'S Hospital, Columbus, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|Local Institution, Portland, Oregon, United States|Penn State Hershey Children'S Hospital, Hershey, Pennsylvania, United States|Childrens Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|Dell Children'S Medical Center Of Central Texas, Austin, Texas, United States|The University Of Texas, Dallas, Texas, United States|Local Institution, Fort Worth, Texas, United States|Baylor College Of Medicine, Houston, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|Local Institution, Fairfax, Virginia, United States|Children'S Hosp-Kings Daughter, Norfolk, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Seattle Childrens Hospital, Seattle, Washington, United States|Children'S Hospital Of Wisconsin, Milwaukee, Wisconsin, United States|Local Institution, Calgary, Alberta, Canada|Local Institution, Toronto, Ontario, Canada|The Montreal Children's Hospital of the MUHC, Montreal, Quebec, Canada|Klinika detske hematologie a onkologie, Praha 5, Czechia|Local Institution, Lille cedex, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes, France|Local Institution, Paris Cedex 12, France|Hopital Robert Debre, Paris, France|Local Institution, Toulouse cedex 9, France|Local Institution, Vandoeuvre les Nancy, France|Local Institution, Villejuif Cedex, France|Campus Virchow Klinikum Der Charite, Berlin, Germany|Uniklinikum Giessen und Marburg, Giessen, Germany|Mhh Kinderklinik, Hannover, Germany|Dr. von Haunersches Kinderspital, Muenchen, Germany|Local Institution, Dublin, Ireland|Cro-Aviano, Aviano (PN), Italy|Policlinico S. Orsola Malpighi, Bologna, Italy|Irccs Istituto G. Gaslini, Genova, Italy|Fondazione Monza e Brianza per il Bambino e la sua Mamma MBBM, Monza (mb), Italy|Ao Santobono - Pausilipon, Napoli, Italy|AOU Policlinico Umberto I, Roma, Italy|Local Institution, Rotterdam, Netherlands|Local Institution, Utrecht, Netherlands|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Poznan, Poland|Local Institution, Warszawa, Poland|Local Institution, Esplugues de Llobregat, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Leeds, North Yorkshire, United Kingdom|Local Institution, Leeds, WEST Yorkshire, United Kingdom|Local Institution, Leeds, Yorkshire, United Kingdom|Local Institution, Birmingham, United Kingdom|Local Institution, Glasgow, United Kingdom|Local Institution, Glasgow, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Nottingham, United Kingdom		https://ClinicalTrials.gov/show/NCT02927769
316	NCT03370276	Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma		Recruiting	No Results Available	Squamous Cell Carcinoma of the Oropharynx|Squamous Cell Carcinoma of the Larynx|Squamous Cell Carcinoma of the Oral Cavity|Squamous Cell Carcinoma of the Hypopharynx|Squamous Cell Carcinoma of the Paranasal Sinus|Head and Neck Squamous Cell Carcinoma|Squamous Cell Cancer|Head and Neck Carcinoma	Drug: Nivolumab|Drug: Cetuximab	Phase I: Recommended Phase 2 Dose (RP2D)|Phase II: Overall Survival (OS) Rate|Overall Response Rate (ORR)|Progression Free Survival (PFS)|Occurrence of Study Treatment Related Adverse Events	H. Lee Moffitt Cancer Center and Research Institute|James and Esther King Biomedical Research Program|Eli Lilly and Company|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	52	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-19178	December 6, 2017	December 2021	December 2022	December 12, 2017	null	September 12, 2018	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|The Ohio State University, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT03370276
317	NCT01358721	Phase I Biomarker Study (BMS-936558)		Active, not recruiting	No Results Available	Renal Cell Carcinoma	Drug: BMS-936558 (Anti-PD-1)	Immunomodulatory activity as measured by the functional and phenotypic characterization of peripheral immune cells, modulation/changes in soluble factors, and the characterization of tumor immune infiltrates and the expression of tumor markers|Safety and tolerability of BMS-936558 as measured by the incidence and severity of adverse events|Progression free survival in the BMS-936558 arms|The tumor response rate in the BMS-936558 arms as assessed by the Investigator assessment of best overall response|Overall response rate for BMS-936558 as assessed by the number of subjects which demonstrate an objective response divided by the total number of treated subjects with measurable disease at baseline|Disease control rate for BMS-936558 as measured by the number of subjects with an objective response + the number of subjects with stable disease divided by the total number of treated subjects with measurable disease at baseline|Duration of objective response for BMS-936558 as measured by the time when the criteria for an objective response are first met until the date of documented disease progression or death|Duration of stable disease for BMS-936558 as measured in subjects whose best overall response is stable disease as the time from baseline until the date of documented disease progression or death|Immunogenicity of BMS-936558 as measured by the detection of human antibodies against BMS-936558	Bristol-Myers Squibb|Ono Pharma USA Inc	All	18 Years and older   (Adult, Older Adult)	Phase 1	119	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	CA209-009|2011-005379-18	August 11, 2011	December 1, 2014	November 16, 2018	May 24, 2011	null	January 23, 2018	Ucsf Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|The Bunting-Blaustein Cancer Research Building, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana Farber Cancer Inst, Boston, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Upmc Cancer Pavilion, Pittsburgh, Pennsylvania, United States|University Of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|Local Institution, Villejuif Cedex, France|Local Institution, Pamplona, Spain		https://ClinicalTrials.gov/show/NCT01358721
318	NCT03177239	Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)	UNISoN	Recruiting	No Results Available	Renal Cell Carcinoma|Papillary Renal Cell Carcinoma Type 1|Papillary Renal Cell Carcinoma Type 2|Chromophobe Renal Cell Carcinoma|Sarcomatoid Renal Cell Carcinoma|Xp11 Translocation Carcinoma	Drug: Nivolumab|Drug: Ipilimumab	The objective tumour response rate, as assessed by RECIST1.1|Duration of objective tumour response, as assessed by RECIST1.1|Progression-free survival (PFS), as assessed by RECIST1.1|Immune-related tumour response rate, as assessed by irRECIST.|Immune-related disease control rate (irDCR6), as assessed by irRECIST.|The number of patients alive at the end of the study, as assessed by date of death.|The number of patients with adverse events, particularly immune-related adverse events, that are related to study drug, as assessed and graded according to CTCAE v4.03.|The number of participants with permanent discontinuation of treatment or delays due to toxicity, as assessed and graded according to CTCAE v4.03.	Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	85	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ANZUP 1602	October 19, 2017	December 2021	December 2022	June 6, 2017	null	June 29, 2018	Border Medical Oncology, Albury, New South Wales, Australia|Campbelltown Hospital, Campbelltown, New South Wales, Australia|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|St Vincents Hospital, Darlinghurst, New South Wales, Australia|Northern Cancer Institute, French Forest, New South Wales, Australia|St. George Hospital, Kogarah, New South Wales, Australia|Calvary Mater Newcastle, Newcastle, New South Wales, Australia|Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Tamworth Hospital - North West Cancer Centre, Tamworth, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia|Flinders Medical Centre, Adelaide, South Australia, Australia|Ashford Cancer Centre, Adelaide, South Australia, Australia|Ballarat Oncology & Haematology Services, Ballarat, Victoria, Australia|Box Hill Hospital - Eastern Health, Box Hill, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia		https://ClinicalTrials.gov/show/NCT03177239
319	NCT01721746	A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)		Active, not recruiting	Has Results	Unresectable or Metastatic Melanoma	Biological: BMS-936558|Drug: Dacarbazine|Drug: Carboplatin|Drug: Paclitaxel	Objective Response Rate (ORR)|Median Overall Survival (OS) at Primary Endpoint|Median Months of Progression-free Survival (PFS) Per Independent Radiology Review Committee (IRC/IRRC)|Objective Response Rate (ORR) by Baseline PD-L1 Expression|Median Overall Survival (OS) Time in Months by Baseline PD-L1 Expression|Mean Change From Baseline in Health-related Quality of Life (HRQoL) Global Health Status Scores	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	631	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-037|2012-001828-35	December 13, 2012	February 16, 2016	March 6, 2019	November 6, 2012	March 22, 2017	September 26, 2017	Mayo Clinic, Scottsdale, Arizona, United States|UCSD Moores Cancer Center, La Jolla, California, United States|The Angeles Clinic & Research Institute, Los Angeles, California, United States|University Of California - Los Angeles, Los Angeles, California, United States|San Francisco Oncology Associates, San Francisco, California, United States|Ucsf Comprehensive Cancer Center, San Francisco, California, United States|University Of Colorado, Aurora, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Allina Health, Minneapolis, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|NYU Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals, Cleveland, Ohio, United States|Providence Oncology And Hematology, Portland, Oregon, United States|Network Office of Research and Innovation, Allentown, Pennsylvania, United States|St. Luke'S Health System, Easton, Pennsylvania, United States|Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Local Institution, Innsbruck, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Leuven, Belgium|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Chum-Hopital Notre-Dame, Montreal, Quebec, Canada|Sir Mortimer B Davis - Jewish General Hospital, Montreal, Quebec, Canada|Aarhus Universitetshospital, Aarhus, Denmark|Herlev Hospital, Herlev, Denmark|Odense University Hospital, Odense, Denmark|Local Institution, Clermont Ferrand, France|Local Institution, Lille Cedex, France|Local Institution, Marseille, France|Local Institution, Nantes Cedex 1, France|Local Institution, Nice, France|Local Institution, Paris, France|Local Institution, Pierre Benite, France|Local Institution, Villejuif, France|Local Institution, Wuerzburg, Bayern, Germany|Local Institution, Buxtehude, Germany|Local Institution, Dresden, Germany|Local Institution, Essen, Germany|Local Institution, Frankfurt am Main, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kiel, Germany|Local Institution, Luebeck, Germany|Local Institution, Magdeburg, Germany|Local Institution, Munich, Germany|Local Institution, Tubingen, Germany|Local Institution, Jerusalem, Israel|Local Institution, Ramat Gan, Israel|Local Institution, Bari, Italy|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Maastricht, Netherlands|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Valencia, Spain|Local Institution, Lausanne, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|Local Institution, London, Surrey, United Kingdom|Local Institution, Newcastle Upon Tyne, Tyne and Wear, United Kingdom		https://ClinicalTrials.gov/show/NCT01721746
320	NCT03496662	BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)		Recruiting	No Results Available	Pancreatic Ductal Adenocarcinoma	Drug: BMS-813160|Drug: Nivolumab|Drug: Gemcitabine|Drug: Nab-paclitaxel|Procedure: Biopsy|Procedure: Peripheral blood	(Part A only) Safety of the combination of BMS-813160 plus nivolumab plus gemcitabine plus nab-paclitaxel as measured by frequency, type, and severity of adverse events|(Part B only) Objective response rate|(Part B only) Percentage of patients who disease becomes resectable after treatment|(Part B only) Progression-free survival (PFS)|(Part B only) Overall survival (OS)	Washington University School of Medicine|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	53	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201806007	August 31, 2018	January 31, 2026	January 31, 2026	April 12, 2018	null	September 13, 2018	Washington University School of Medicine, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT03496662
321	NCT03333746	Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma		Recruiting	No Results Available	Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma	Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Biological: Nivolumab|Other: Pharmacological Study	ORR (Overall Response Rate)|Overall survival (OS)|Progression free survival (PFS)|Time to progression (TTP)	Yvonne Efebera|National Cancer Institute (NCI)|American Cancer Society, Inc.|Bristol-Myers Squibb|Ohio State University Comprehensive Cancer Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	18	Other|NIH|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OSU-17160|NCI-2017-01653|P30CA016058	March 21, 2018	December 31, 2020	December 31, 2020	November 7, 2017	null	July 18, 2018	Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT03333746
322	NCT03274258	Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma		Recruiting	No Results Available	Renal Medullary Carcinoma|Other Disorders of Kidney and Ureter	Drug: Nivolumab|Drug: Ipilimumab	Overall Response Rate (ORR) of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma|Progression-Free Survival (PFS) of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma|Safety of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma by CTCAE v4.03	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	35	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-0201|NCI-2018-01066	December 13, 2017	July 2020	July 2020	September 6, 2017	null	September 14, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03274258
323	NCT03729245	A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)		Not yet recruiting	No Results Available	Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma	Biological: NKTR-214|Drug: Sunitinib|Biological: Nivolumab|Drug: Cabozantinib	Overall response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Blinded Independent Central Review (BICR)|Overall survival (OS)|Progression-free survival (PFS) by BICR|Incidence of treatment-related Adverse Events (AEs)|ORR using RECIST 1.1 by investigator and in biomarker population|PFS by investigator and in biomarker population|OS in biomarker population|Changes in cancer-related symptoms and quality-of-life in patients using the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy (NCCN/FACT) Symptom Index for Kidney Cancer (FKSI-19)	Nektar Therapeutics|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	600	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-214-09|CA045002	December 2018	December 2021	June 2024	November 2, 2018	null	November 2, 2018	Investigator Site - Whittier, Whittier, California, United States|Investigator Site - Houston, Houston, Texas, United States|Investigator Site - Leesburg, Leesburg, Virginia, United States|Investigator Site - Kurralta Park, Kurralta Park, South Australia, Australia		https://ClinicalTrials.gov/show/NCT03729245
324	NCT03493932	Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade		Recruiting	No Results Available	Glioblastoma	Drug: Nivolumab|Drug: BMS-986016	The primary outcome measure is the proportion of patients that have a rise in interferon gamma levels within the tumor microenvironment of 4 pg/ml or higher before the first dose of Nivolumab as compared to after the first dose, the safety of th...|1)change in IFNg in body 2)response of immune environment of brain tumor tissue to Nivolumab 3)To evaluate clinical response of pts 4)the difference in survival between responders and non-responders 5)differences in the immune cells and secreted...	National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)	All	18 Years and older   (Adult, Older Adult)	Phase 1	15	NIH	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	180077|18-N-0077	September 24, 2018	June 1, 2021	June 1, 2021	April 11, 2018	null	October 26, 2018	National Institutes of Health Clinical Center, Bethesda, Maryland, United States		https://ClinicalTrials.gov/show/NCT03493932
325	NCT03023527	Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma		Terminated	No Results Available	Multiple Myeloma	Drug: Nivolumab|Drug: Pomalidomide|Drug: Dexamethasone|Drug: Elotuzumab	Safety of Nivolumab: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	PETHEMA Foundation|Celgene|Bristol-Myers Squibb|Adknoma Health Research, S.L.	All	18 Years and older   (Adult, Older Adult)	Phase 1	6	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GEM-NIVOPOMDEX	January 2017	January 2018	January 2018	January 18, 2017	null	May 23, 2018	ICO Badalona, Badalona, Spain|Hospital Clinic, Barcelona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital Universitario de Canarias, Las Palmas de Gran Canaria, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de octubre, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Complejo Hospitalario Regional Virgen del Rocío, Sevilla, Spain		https://ClinicalTrials.gov/show/NCT03023527
326	NCT02846376	Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant	CPIT-002	Recruiting	No Results Available	Acute Myeloid Leukemia and Myelodysplastic Syndrome	Drug: Nivolumab|Drug: Ipilimumab	Safety: The occurrence of at least one treatment-related limiting toxicity defined as a ≥ grade 4 non-hematologic toxicity as specified by the CTCAE 4.0.|Toxicities: Common Terminology Criteria for Adverse Events (CTCAE) will be used for the assessment and grading of all toxicities experienced by patients enrolled into this study.|Assessment of blood immune reconstitution by sequencing to determine diversity and highest frequency clonal specificities|Tumor site immune phenotyping|Assessment of complete response (CR) rate|Assessment of blood phenotype|Assessment of blood TCR repertoire via TCR Immunoseq Assay Profiling|Assess tumor site TCR repertoire using Poisson regression analysis with generalized estimating equations (GEE)|Assess tumor site PD-L1/2 expression|Efficacy as assessed by progression free survival (PFS)	Hackensack Meridian Health	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 1	21	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro2016-0526	October 2018	July 2019	July 2023	July 27, 2016	null	October 2, 2018	John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States		https://ClinicalTrials.gov/show/NCT02846376
327	NCT02532231	Nivolumab in Acute Myeloid Leukemia (AML) in Remission at High Risk for Relapse		Recruiting	No Results Available	Leukemia|Acute Myeloid Leukemia	Drug: Nivolumab	Recurrence-Free Survival (RFS)	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2015-0213|NCI-2015-01522	October 2015	October 2019	October 2020	August 25, 2015	null	March 26, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02532231
328	NCT02575222	Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma		Active, not recruiting	No Results Available	Clear Cell Renal Cell Carcinoma	Drug: Nivolumab	Safety as assessed by number of participants experiencing adverse events|Objective Tumor Response Rate (by RECIST)|Objective Tumor Response Rate (by irRC)|Quality of Life as assessed by the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI) -15 questionnaire|Metastasis-Free Survival|Overall Survival	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J15179|IRB00068726	February 2016	December 2018	December 2019	October 14, 2015	null	September 19, 2018	The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT02575222
329	NCT02304458	Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas		Recruiting	No Results Available	Metastatic Melanoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Hodgkin Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Rhabdomyosarcoma|Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Melanoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Rhabdomyosarcoma|Stage III Cutaneous Melanoma AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7	Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Pharmacological Study	Maximum tolerated dose of nivolumab (Phase I)|Response rate of nivolumab, defined as either complete response, partial response, stable disease, or progressive disease, according to the Response Evaluation Criteria in Solid Tumors (Part B)|Response rate of nivolumab in expanded cohorts of patients with neuroblastoma, osteosarcoma, rhabdomyosarcoma, Ewing sarcoma, Hodgkin lymphoma, and non-Hodgkin lymphoma (Part B)|Recommended phase 2 dose of nivolumab plus ipilimumab (Part C)|Response rate of nivolumab combined with ipilimumab, defined as either complete response, partial response, stable disease, or progressive disease, according to the Response Evaluation Criteria in Solid Tumors (Part D)|Response rate of nivolumab combined with ipilimumab in expanded cohorts of patients with neuroblastoma, osteosarcoma, rhabdomyosarcomas, Ewing sarcoma, Hodgkin lymphoma, and non-Hodgkin lymphoma (Part D)|Response rate assessed according to Response Evaluation Criteria in Solid Tumors (Part E)	National Cancer Institute (NCI)	All	12 Months to 30 Years   (Child, Adult)	Phase 1|Phase 2	484	NIH	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2014-01222|ADVL1412|UM1CA097452	February 2, 2015	October 31, 2020	null	December 2, 2014	null	November 26, 2018	Children's Hospital of Alabama, Birmingham, Alabama, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Hospital for Sick Children, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT02304458
330	NCT03299946	Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)		Recruiting	No Results Available	Locally Advanced Hepatocellular Carcinoma	Drug: Cabozantinib|Drug: Nivolumab	Number of adverse events in participants of neoadjuvant cabozantinib plus nivolumab.|Number of patients who complete pre-op treatment and proceed to surgery.|Percentage of participants who obtain R0 resection.|Percentage of participants who obtain a pathologic complete response (CR).|Percentage of participants who obtain a major pathologic responses (MPR)|Objective response rate (ORR)|Median Overall Survival (OS)|Disease free survival (DFS)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Exelixis|Bristol-Myers Squibb	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 1	15	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J17136|IRB00149350	January 24, 2018	March 2022	March 2022	October 3, 2017	null	November 7, 2018	Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT03299946
331	NCT02497508	Nivolumab in Patients With Recurrent Malignant Mesothelioma	NivoMes	Completed	No Results Available	Malignant Pleural Mesothelioma	Drug: nivolumab	DCR|PFS|OS|TTP|ORR|Safety and tolerability (The incidence of (serious) adverse events)	The Netherlands Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	33	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	N14MPN	July 2015	July 2017	July 2017	July 14, 2015	null	September 14, 2017			https://ClinicalTrials.gov/show/NCT02497508
332	NCT03048474	Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma	INITIATE	Active, not recruiting	No Results Available	Malignant Pleural Mesothelioma	Drug: nivolumab and ipilimumab	Disease Controle Rate (DCR) at 12 weeks|Safety: the incidence of adverse events, serious adverse events, deaths and laboratory abnormalities.|Disease Controle Rate (DCR) at 6 months|Progression Free Survival (PFS)|Overall Survival (OS)|Overall Response Rate (ORR)	The Netherlands Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	36	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	N16INM	September 2016	December 2017	December 2019	February 9, 2017	null	November 1, 2018	Netherlands Cancer Institute-Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, North-Holland, Netherlands		https://ClinicalTrials.gov/show/NCT03048474
333	NCT03590210	Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas	NiTraSarc	Recruiting	No Results Available	Metastatic Adult Soft Tissue Sarcoma	Drug: Trabectedin|Drug: Nivolumab	progression free survival rate at 6 months - PFSR6|safety, as measured by: - Incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, and deaths - Incidence of clinical laboratory test abnormalities|overall response rate (ORR)|overall survival (OS)|progression-free survival (PFS)|duration of disease stabilization (DoDS)|PDL-1 expression	University Medicine Greifswald|IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest|PharmaMar|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	74	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GISG-15	June 8, 2018	December 2019	July 2021	July 18, 2018	null	July 20, 2018	Helios Klinikum Bad Saarow, Klinik für Hämatologie, Onkologie und Palliativmedizin, Sarkomzentrum Berlin-Brandenburg, Bad Saarow, Germany|Helios Klinikum Berlin Buch, Klinik für interdisziplinäre Onkologie, Sarkomzentrum Berlin-Brandenburg, Berlin, Germany|Universitätsmedizin Greifswald, Klinik und Poliklinik für Innere Medizin C, Hämatologie und Onkologie, Greifswald, Germany		https://ClinicalTrials.gov/show/NCT03590210
334	NCT02599649	Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)		Active, not recruiting	No Results Available	Leukemia	Drug: Lirilumab|Drug: Nivolumab|Drug: Azacitidine	Overall Response Rate (ORR)	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	12	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2014-0934|NCI-2015-02120	March 21, 2016	March 2025	March 2026	November 6, 2015	null	February 23, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02599649
335	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma		Recruiting	No Results Available	Metastatic Pancreatic Adenocarcinoma	Drug: APX005M|Drug: Nivolumab|Drug: Nab-Paclitaxel|Drug: Gemcitabine	Number and percentage of subjects with adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)|Overall survival (OS) defined as the time from initiation of study therapy to date of death due to any cause or date of most recent subject contact.|Objective response rate (ORR) as determined by RECIST criteria|Duration of response (DOR) defined as time from first documentation of response (complete response [CR] or partial response [PR]) to first documentation of progressive disease|Disease control rate (DCR) is defined as the proportion of subjects who achieve a CR or PR or SD|Progression free survival (PFS) defined as the time from initiation of study therapy to date of first documented progression of disease, date of death due to any cause or date of most recent subject contact which documented progression free status	Parker Institute for Cancer Immunotherapy|Bristol-Myers Squibb|Apexigen, Inc.|Cancer Research Institute, New York City	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	105	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PICI0002|UPCC 11217	July 21, 2017	July 1, 2022	September 1, 2022	July 11, 2017	null	August 13, 2018	University of California, Los Angeles, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States|M.D. Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03214250
336	NCT03628209	Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma		Not yet recruiting	No Results Available	Osteosarcoma|Osteosarcoma in Children|Osteosarcoma Recurrent|Sarcoma	Drug: Nivolumab|Drug: Azacitidine|Procedure: Post Treatment Surgery	Phase I: Recommended Phase II Dose (RP2D)|Phase II: Rate of Continued Complete Remission (CR)|Percentage of Participants with Event Free Survival (EFS)|Overall Survival (OS) Rate	H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb	All	up to 39 Years   (Child, Adult)	Phase 1|Phase 2	51	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-19487|CA209-9WW	January 2019	January 2021	January 2022	August 14, 2018	null	November 6, 2018	Phoenix Children's Hospital, Phoenix, Arizona, United States|Children's Hospital of Los Angeles, USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Alfred I DuPont Hospital for Children, Wilmington, Delaware, United States|Shand's Hospital for Children at the University of Florida, Gainesville, Florida, United States|Nemours Children's Hospital, Jacksonville, Florida, United States|Holtz Children's Hospital at the University of Miami, Miami, Florida, United States|Nemours Children's Clinic, Orlando, Florida, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Coordinating Center, Tampa, Florida, United States|University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States|Johns Hopkins University, Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, New York, United States|University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Carolina Medical Center, Levine Cancer Institute, Charlotte, North Carolina, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Primary Children's Hospital, Huntsman Cancer Institute, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT03628209
337	NCT03337919	ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma	ANIMATE	Not yet recruiting	No Results Available	Hodgkin Lymphoma	Drug: Nivolumab	Overall response rate (ORR) by PET-CT scan following 4-8 cycles of nivolumab|Progression-free survival|Overall survival|Proportion of patients progressing to stem cell transplant|Adverse events [Safety and toxicity of nivolumab]|Transplant-related mortality|Transplant-related morbidity	University College, London|Bristol-Myers Squibb	All	16 Years and older   (Child, Adult, Older Adult)	Phase 2	120	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UCL/15/0515|CA-209-445	November 2018	May 2022	May 2025	November 9, 2017	null	October 24, 2018			https://ClinicalTrials.gov/show/NCT03337919
338	NCT02917772	Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma	TITAN-RCC	Recruiting	No Results Available	Carcinoma, Renal Cell|Clear-cell Metastatic Renal Cell Carcinoma	Biological: Nivolumab/Ipilimumab	Objective Response Rate (ORR)|General considerations: RR, TTR, DoR, PFS, TIR (Time to Immunotherapy Resistance), OS|Remission Rates during TITAN treatment: RR1, RR2, RR2SD, RR3|Time to Immunotherapy Resistance: TIR|Time-to-Response: TTR|Duration of Response: DOR|Overall survival:OS|Safety: Adverse events assessment|Safety: Frequency of abnormal laboratory parameters|Patient reported outcomes|Exploratory objectives: Immune monitoring	AIO-Studien-gGmbH|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	0216-ASG	October 2016	October 2018	July 2021	September 28, 2016	null	July 16, 2018	Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria|AKH Wien Universitätsklinik für Innere Medizin I, Wien, Austria|ZNA Middelheim, Antwerpen, Belgium|CHR Verviers, Verviers, Belgium|Fakultní nemocnice Hradec Králové, Hradec Králové, Czechia|Fakultní nemocnice Olomouc, Olomouc, Czechia|FN Motol, Praha, Czechia|Všeobecné fakultní nemocnice, Praha, Czechia|CHD Vendée, La Roche-Sur-Yon, France|Centre Hôpitalier Lyon Sud, Lyon, France|Hôpitaux Universitaires de Strasbourg Hôpital Civil, Strasbourg, France|Institut Claudius Regaud, Toulouse, France|Institut Gustave Roussy, Villejuif, France|Universitätsklinikum Jena und Poliklinik für Urologie, Jena, Thüringen, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Universitätsklinikum, Düsseldorf, Germany|Universität des Saarlandes Medizinische Fakultät, Homburg/Saar, Germany|Azienda USL8 Arezzo U.O.C. Oncologia Medica, Arezzo, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|IRCCS Fondazione Policlinico San Matteo, Pavia, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Italy|Policlinico Universitario A. Gemelli, Roma, Italy|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Broomfield Hospital, Chelmsford, United Kingdom|Charing Cross Hospital, London, United Kingdom|Kent Oncology Centre, Maidstone, United Kingdom|Royal Preston Hospital, Preston, United Kingdom		https://ClinicalTrials.gov/show/NCT02917772
339	NCT03557359	Nivolumab for Recurrent or Progressive IDH Mutant Gliomas		Recruiting	No Results Available	Gliomas	Drug: Nivolumab	Overall Response Rate|Duration of Response|Progression-Free Survival (PFS)|Overall Survival (OS)	Columbia University|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	37	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AAAR6354	June 12, 2018	June 2020	June 2021	June 15, 2018	null	October 5, 2018	Miami Cancer Center, Miami, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Columbia University Medical Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT03557359
340	NCT03692325	Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia		Not yet recruiting	No Results Available	Leukoplakia, Oral	Drug: Nivolumab	Best Overall Response Rate|Quality of Life (QOL)|Evaluate safety and toxicity (Adverse Events and Serious Adverse Events)|Evaluate the time to the next surgery for a head and neck malignancy|Estimate Cancer Free Survival (CFS) from the time of study registration|Estimate Overall Survival (OS) from the time of study registration|Characterize distinct tumor and circulating immunophentoypes (biomarkers in biopsy and blood samples)	Dana-Farber Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	33	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	18-387	October 31, 2018	June 30, 2021	June 30, 2024	October 2, 2018	null	October 2, 2018	Dana Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03692325
341	NCT03013335	Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen	NIVOREN	Recruiting	No Results Available	Metastatic Renal Cell Carcinoma	Drug: Nivolumab	Incidence for high-grade (Grade3-4-5) adverse reactions of interest|Assessment of Overall Survival (OS) by Follow-up continued|Number of patients with a Best Overall Response (BOR) by RECIST v1.1|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Percentage of patients who received immune modulating concomitant medication|Percentage of patients who received hormonal replacement therapy|Median time to resolution of adverse reactions of interest|Assessment of quality of life by questionnaire FACT-G|Assessment of quality of life by questionnaire FKSI-19|Assessment of quality of life by questionnaire EQ-5D	UNICANCER|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	450	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UC 0160/1506 GETUG-AFU 26	January 2016	January 2023	January 2023	January 6, 2017	null	January 6, 2017	Centre Francois Baclesse, Caen, France|Centre Georges-Francois Leclerc, Dijon, France|Centre Leon Berard, Lyon, France|Institut Paoli-Calmettes, Marseille, France|Centre Antoine Lacassagne, Nice, France|Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France|Gustave Roussy Cancer Campus Grand Paris, Villejuif, France		https://ClinicalTrials.gov/show/NCT03013335
342	NCT02925234	The Drug Rediscovery Protocol (DRUP Trial)	DRUP	Recruiting	No Results Available	Cancer|Tumors|Neoplasm|Neoplasia	Drug: Panitumumab|Drug: Olaparib|Drug: Dabrafenib|Drug: Nilotinib|Drug: Trametinib|Drug: Erlotinib|Drug: Trastuzumab and Pertuzumab (combination treatment)|Drug: Vemurafenib and Cobimetinib (combination treatment)|Drug: Vismodegib|Drug: Regorafenib|Drug: Nivolumab	Percentage of patients that are treated based on their molecular tumor profile|Objective tumor response|Stable disease|Treatment-related grade≥3 and serious adverse events|Progression-free survival|Overall survival|Duration of treatment on study (time on drug)	The Netherlands Cancer Institute|Amgen|AstraZeneca|Bayer|Bristol-Myers Squibb|Novartis|Roche Pharma AG	All	18 Years and older   (Adult, Older Adult)	Phase 2	400	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	M15DRU	August 2016	August 2019	December 2019	October 5, 2016	null	October 5, 2016	Meander Medical Center, Amersfoort, Utrecht, Netherlands|Netherlands Cancer Institute, Amsterdam, Netherlands|AZVU, Amsterdam, Netherlands|Amphia Hospital, Breda, Netherlands|Maxima Medisch Centrum, Eindhoven, Netherlands|Orbis Concern, Geleen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Radboud umc, NIjmegen, Netherlands|St. Fransicus Gasthuis, Rotterdam, Netherlands|Erasmus MC, Rotterdam, Netherlands|St. Elisabeth, Tilburg, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands		https://ClinicalTrials.gov/show/NCT02925234
343	NCT03630640	Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation	NIVOLEP	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Nivolumab Injection [Opdivo]	Local recurrence-free survival during a 2-years follow-up after Nivolumab neoadjuvant/adjuvant therapy and EP procedure|Changes of tumorous and non-tumorous perfusion parameters observed with CUS and MRI after one months of neoadjuvant treatments|Per nodule rates of early response|Incidences of intra segmental/ extra segmental distant recurrence|Assessment of overall survival|Assessment of tolerance of the immunotherapy treatment:|Compliance to neoadjuvant treatments|Compliance to adjuvant treatments|Frequency of SAEs|Frequency of discontinuations treatment due to AEs	Assistance Publique - Hôpitaux de Paris|Bristol-Myers Squibb	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 2	50	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P171001J	October 11, 2018	September 30, 2020	September 30, 2020	August 15, 2018	null	November 14, 2018	Hôpital Jean Verdier, Bondy, France		https://ClinicalTrials.gov/show/NCT03630640
344	NCT03528408	Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma		Recruiting	No Results Available	Melanoma	Drug: Nivolumab|Drug: Ipilimumab	3 year Relapse Free Survival (RFS)|Median RFS|Overall Survival (OS)|3 year OS|Assess Adverse Events	Suthee Rapisuwon|Bristol-Myers Squibb|Hoosier Cancer Research Network	All	18 Years and older   (Adult, Older Adult)	Phase 2	50	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCRN-MEL17-309	July 26, 2018	July 2020	June 2023	May 17, 2018	null	September 21, 2018	Georgetown University, Washington, District of Columbia, United States		https://ClinicalTrials.gov/show/NCT03528408
345	NCT02572167	A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma		Active, not recruiting	No Results Available	Hodgkin Lymphoma	Drug: brentuximab vedotin|Drug: nivolumab	Incidence of adverse events|Complete response rate|Objective response rate|Duration of complete response|Duration of objective response|Progression-free survival post-autologous stem cell transplant	Seattle Genetics, Inc.|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	93	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SGN35-025	October 2015	March 1, 2018	October 2020	October 8, 2015	null	March 14, 2018	City of Hope National Medical Center, Duarte, California, United States|Stanford Cancer Center, Stanford, California, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States|Mayo Clinic Minnesota, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center - Commack, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|James Cancer Hospital / Ohio State University, Columbus, Ohio, United States|Charles A. Sammons Cancer Center / Baylor University Medical Center, Dallas, Texas, United States		https://ClinicalTrials.gov/show/NCT02572167
346	NCT03405155	Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery		Recruiting	No Results Available	Melanoma (Skin)	Biological: Nivolumab	Recurrence-free survival|Median duration of overall survival|Median duration of distant metastases-free survival|Incidence of adverse events	Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University	All	18 Years and older   (Adult, Older Adult)	Phase 2	73	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17P.641	January 17, 2018	October 11, 2022	October 2023	January 19, 2018	null	May 16, 2018	Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03405155
347	NCT03743766	Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting		Not yet recruiting	No Results Available	Melanoma	Drug: Relatlimab|Drug: Nivolumab|Drug: Relatlimab + Nivolumab	Change in LAG3 Expression|Change in PD1 expression|Change in Tumor Size|Overall Response Rate (ORR)|Clinical Benefit Rate|Duration of Response|Progression-free Survival (PFS)|Overall Survival (OS)|LAG3 Expression|PD-1 Expression|Change in CD4+ tumor infiltrating lymphocytes|Change in CD8+ tumor infiltrating lymphocytes|Change in granzyme B serum levels|Change in cell effector/memory status|Change in activation and maturation of dendritic cells|Change in T cell count|Change in soluble LAG3 levels|Soluble LAG3 levels|Change in Regulatory T cell (Treg) marker level|Regulatory T cell (Treg) marker levels	John Kirkwood|Bristol-Myers Squibb|University of Pittsburgh	All	18 Years and older   (Adult, Older Adult)	Phase 2	42	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18-071	November 2018	October 2020	October 2022	November 16, 2018	null	November 16, 2018	UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03743766
348	NCT03382886	Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma	NUANCE	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Nivolumab|Drug: Bevacizumab	Adverse Events that occur|Determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D)|Progression Free Survival (PFS)|Overall Survival	University of Utah|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	12	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCI103945	April 11, 2018	March 2023	March 2023	December 26, 2017	null	November 14, 2018	Huntsman Cancer Institute, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT03382886
349	NCT03605719	Dexamethasone, Carfilzomib, & Nivolumab With Reovirus for Relapsed/Refractory Multiple Myeloma		Recruiting	No Results Available	Recurrent Plasma Cell Myeloma	Drug: Carfilzomib|Drug: Dexamethasone|Biological: Nivolumab|Biological: Wild-type Reovirus	Dose-limiting toxicity (DLT) of 4-drug regimen evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)|Maximum tolerated dose (MTD) of 4-drug regimen|DLT of 3-drug regimen evaluated according to NCI CTCAE version 5.0|Time to progression|Progression-free survival|Overall survival	Emory University|Bristol-Myers Squibb|Oncolytics Biotech|University of Utah|City of Hope Medical Center|Phylogeny	All	18 Years and older   (Adult, Older Adult)	Phase 1	62	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00104234|NCI-2018-01217|Winship4398-18	October 24, 2018	October 31, 2021	October 31, 2024	July 30, 2018	null	November 5, 2018	Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States		https://ClinicalTrials.gov/show/NCT03605719
350	NCT02970981	Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma		Active, not recruiting	No Results Available	Melanoma	Biological: Nivolumab|Biological: Ipilimumab	Safety (adverse events) of the protocol therapy|Immune Response Assessment|Time to relapse	New York University School of Medicine|Bristol-Myers Squibb	All	16 Years and older   (Child, Adult, Older Adult)	Phase 2	16	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-00098	November 29, 2016	November 2018	November 2020	November 22, 2016	null	December 18, 2017	Laura and Isaac Perlmutter Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02970981
351	NCT03374839	Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients	Nivo-TIL	Recruiting	No Results Available	Melanoma	Drug: TIL + IL-2 + Nivolumab	Incidence of Treatment (adoptive T cell therapy associated to intravenous injections of Nivolumab) - Emergent Adverse Events|Efficacy of adoptive T cell therapy associated to intravenous injections of Nivolumab|Duration of the clinical response|Progression-free survival|Overall survival|Specific immune monitoring n°1: Evaluate the fraction of TIL specific to Melan-A and MELOE-1|Specific immune monitoring n°2: Evaluate the proportion of regulatory T cells|Specific immune monitoring n°3: Analyse the expression of tumor antigens|Specific immune monitoring n°4: Analyse the expression of immunosuppressive cytokines|Specific immune monitoring n°5: Analyse the expression of indoleamine 2,3-dioxygenase (IDO)|Specific immune monitoring n°6: Analyse the expression of FoxP3|Specific immune monitoring n°7: Analyse the expression of regulatory molecules|Specific immune monitoring n°8: Analyse the mutations of BRAF|Specific immune monitoring n°9: Analyse the mutations of Neuroblastoma Ras viral oncogene homolog (NRAS)|Specific immune monitoring n°10: Analyse the mutations of proto-oncogene ckit (cKit)|Specific immune monitoring n°11: Determine the percentage of reactive T cells in the expanded cells|Specific immune monitoring n°12: Determine the phenotype of the expanded T cells|Specific immune monitoring n°13: Test TIL reactivity	Nantes University Hospital|Bristol-Myers Squibb	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 1|Phase 2	11	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RC15_0247	February 12, 2018	March 12, 2021	March 12, 2021	December 15, 2017	null	February 20, 2018	Nantes University Hospital, Nantes, France		https://ClinicalTrials.gov/show/NCT03374839
352	NCT02731729	Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy		Active, not recruiting	No Results Available	Melanoma	Drug: ipilimumab|Drug: nivolumab	objective response as defined by RECIST v1.1 criteria	Parker Institute for Cancer Immunotherapy|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	70	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PICI0001|16-043	April 2016	August 2018	January 1, 2021	April 7, 2016	null	July 9, 2018	University of California, Los Angeles, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02731729
353	NCT02754726	Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma		Recruiting	No Results Available	Untreated Metastatic Pancreatic Ductal Adenocarcinoma	Drug: Nivolumab|Drug: Albumin-bound paclitaxel|Drug: Paricalcitol|Drug: Cisplatin|Drug: Gemcitabine	Complete response rate|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	HonorHealth Research Institute|Translational Genomics Research Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	10	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NAPPCG-EB 2015-001	April 2016	July 2019	July 2020	April 28, 2016	null	October 10, 2018	HonorHealth Research Institute, Scottsdale, Arizona, United States		https://ClinicalTrials.gov/show/NCT02754726
354	NCT03149159	Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab		Withdrawn	No Results Available	Clear Cell Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma	Drug: Nivolumab|Drug: Ipilimumab|Radiation: Steriotactic radiation therapy	Number of patients with a partial or complete response|Progression free survival (PFS)	Medical University of South Carolina|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	0	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	102576|CA209-927	April 1, 2018	April 1, 2018	April 1, 2018	May 11, 2017	null	June 18, 2018	Medical University of South Carolina, Charleston, South Carolina, United States		https://ClinicalTrials.gov/show/NCT03149159
355	NCT03682276	Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma	PRIME-HCC	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Biological: Ipilimumab|Biological: Nivolumab	Delay to surgery|Incidence of treatment-emergent adverse events [Safety and Tolerability]|Objective response rate|Pathologic response rate	Imperial College London|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	32	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	C/36/2017|2018-000987-27|CA209-9LC	December 1, 2018	December 1, 2020	September 1, 2022	September 24, 2018	null	September 24, 2018	Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom		https://ClinicalTrials.gov/show/NCT03682276
356	NCT03219671	Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)		Not yet recruiting	No Results Available	Classic Kaposi Sarcoma	Drug: Nivolumab|Drug: Ipilimumab	ORR|PFS rate|Safety - Incidence of Treatment-Emergent Adverse Events according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, Version 4.0 (CTCAE v4)|Tolerability - treatment related adverse events (AEs) that caused study drug interruption and discontinuation	Alona Zer|Bristol-Myers Squibb|Rabin Medical Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-937|0095-17-RMC	December 1, 2017	September 1, 2020	September 1, 2022	July 17, 2017	null	September 29, 2017			https://ClinicalTrials.gov/show/NCT03219671
357	NCT03739619	Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma		Not yet recruiting	No Results Available	Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Classical Hodgkin Lymphoma|Hodgkin Lymphoma	Drug: Bendamustine|Drug: Gemcitabine|Biological: Nivolumab	Maximum tolerable dose (Phase I)|Complete response (CR) rate (Phase II)|Overall response rate (Phase II)|Duration of response (Phase II)|Progression free survival (PFS) (Phase II)|Overall survival (OS) (Phase II)	Emory University|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	54	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00104033|NCI-2018-02221|Winship4388-18	November 1, 2019	November 30, 2023	November 30, 2023	November 14, 2018	null	November 14, 2018	Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States		https://ClinicalTrials.gov/show/NCT03739619
358	NCT02736123	Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone		Withdrawn	No Results Available	Melanoma	Drug: Nivolumab - Arm A|Drug: Nivolumab + Ipilimumab - Arm B	Assess the pathologic complete response rate (absence of viable tumor on histologic assessment)|Evaluate preoperative clinical/radiologic response rate|Assess progression free survival|Assess overall survival|Assess biomarkers CD8 T cell, PD-L1 and IDO expression by immunohistochemistry|Assess safety and adverse events	University of Pittsburgh|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	0	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	15-113	October 2016	February 9, 2017	February 9, 2017	April 13, 2016	null	September 20, 2017	UPMC Cancer Center Hillman Cancer Center, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02736123
359	NCT02959554	Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control	NIVOSWITCH	Active, not recruiting	No Results Available	Metastatic Renal Cell Carcinoma	Drug: Nivolumab|Drug: Sunitinib|Drug: Pazopanib	Overall survival (OS)|Best overall response rate|Progression free survival (PFS)|Quality of Life|Safety - Absolute and relative frequencies of emergent adverse events according to CTCAE 4.03	AIO-Studien-gGmbH|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	244	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AIO-NZK-0116ass.|CA209-443	December 2016	September 2020	December 2021	November 9, 2016	null	October 25, 2018	Medizinische Universität Wien - Universitätsklinik für Innere Medizin I, Klinische Abteilung für Onkologie, Wien, Austria|Universitätsklinikum Essen (AöR) - Klinik und Poliklinik für Urologie / Kinderurologie und Uroonkologie, Essen, Germany		https://ClinicalTrials.gov/show/NCT02959554
360	NCT03724968	Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression		Not yet recruiting	No Results Available	Metastatic Melanoma|Advanced Melanoma|Metastatic Melanoma Stratified by MHC-II Expression	Drug: Nivolumab|Drug: Relatlimab|Drug: Ipilimumab	Change in activated GZMB+ CD8+T-cell density intratumorally, of two immunotherapy regimens|Response rate|Median progression free survival|Median overall survival|Number of participants with treatment-related adverse events as assessed by CTCAE version 5.0	Elizabeth Davis|Bristol-Myers Squibb|Vanderbilt-Ingram Cancer Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	36	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VICC MEL 18114|NCI-2018-02469	November 2018	November 2022	November 2023	October 30, 2018	null	October 30, 2018	Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT03724968
361	NCT03015896	Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma		Recruiting	No Results Available	Grade 3a Follicular Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Waldenstrom Macroglobulinemia|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma	Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Biological: Nivolumab	Incidence of adverse events summarized by NCI CTCAE version 4|Maximum tolerated dose (MTD) defined as the dose level at which no more than one of 6 patients experiences a dose-limiting toxicity summarized by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4|Complete response rate (CR) in patients|Overall Response Rate (ORR)|Overall Survival (OS)|Progression free survival (PFS)	Kami Maddocks|Bristol-Myers Squibb|Ohio State University Comprehensive Cancer Center	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	102	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OSU-16167|NCI-2016-01966	February 14, 2017	April 30, 2020	April 30, 2020	January 10, 2017	null	September 12, 2018	Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT03015896
362	NCT02196961	Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies Versus Observation	ADMEC-O	Recruiting	No Results Available	Merkel Cell Carcinoma	Drug: Ipilimumab|Drug: Nivolumab	Disease-free survival (DFS) at 12 months|Number of adverse events|Overall survival rate at 12 months|DFS rate at 12 months	Prof. Dr. med. Dirk Schadendorf|Bristol-Myers Squibb|University Hospital, Essen	All	18 Years and older   (Adult, Older Adult)	Phase 2	177	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA184-205	June 2014	March 2021	March 2021	July 22, 2014	null	August 29, 2017	University Hospital Essen, Dermatology, Essen, NRW, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|Elbeklinikum Buxtehude, Buxtehude, Germany|University Hospital Dresden, Dermatology, Dresden, Germany|SRH Wald-Klinikum Gera, Gera, Germany|Hannover Medical School, Hannover, Germany|National Centre for Tumour Diseases (NCT), Heidelberg, Germany|University Hospital Schleswig-Holstein, Kiel, Kiel, Germany|University Hospital München (LMU), Munich, Germany|Specialist clinic in Hornheide, Münster, Germany|University Hospital Tübingen, Tübingen, Germany		https://ClinicalTrials.gov/show/NCT02196961
363	NCT03707457	Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma		Not yet recruiting	No Results Available	Glioblastoma|Glioblastoma Multiforme	Drug: Nivolumab|Drug: Anti-GITR Monoclonal Antibody MK-4166|Drug: IDO1 inhibitor INCB024360|Drug: Ipilimumab	Proportion of subjects with dose limiting toxicities evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	30	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J17154	November 2018	November 2021	November 2023	October 16, 2018	null	October 16, 2018			https://ClinicalTrials.gov/show/NCT03707457
364	NCT03638375	TIL and Anti-PD1 in Metastatic Melanoma	ACTME	Recruiting	No Results Available	Toxicity, Drug|Adverse Drug Event|Effects of Immunotherapy	Drug: Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha	Incidence of treatment-related serious adverse events as assessed by CTCAE 4.0 criteria|Evaluation of disease control rate according to RECIST 1.1 criteria|Evaluation of disease control rate according to immune RECIST response criteria|To study the potential working mechanisms of the different treatment compounds. Therefore, blood will be drawn to analyse changes in circulating immune cells and their function during treatment.|To establish a possible prognostic biomarker profile in patients tumor material, blood, serum and TILs used for infusion|To characterize the infusion product|To analyse potential correlations between the clinical response and hypothesis related immune parameters|To analyse the overall survival following treatment	Leiden University Medical Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	34	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NL64805.000.18	July 31, 2018	May 9, 2022	May 9, 2023	August 20, 2018	null	August 20, 2018	Leiden University Medical Center, Leiden, Netherlands		https://ClinicalTrials.gov/show/NCT03638375
365	NCT02357732	Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib		Withdrawn	No Results Available	Metastatic Melanoma	Drug: Nivolumab|Drug: Trametinib|Drug: Dabrafenib	To determine the Maximally Tolerated Dose and/or Recommended Phase II Dose (RP2D) of nivolumab in combination with dabrafenib and/or trametinib in patients with BRAF- or NRAS-mutated metastatic melanoma|Antitumor Effects and Immune Related Response	University of Pittsburgh|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	0	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	14-115	August 2015	August 2015	August 2015	February 6, 2015	null	December 11, 2015			https://ClinicalTrials.gov/show/NCT02357732
366	NCT03340129	Anti-PD 1 Brain Collaboration + Radiotherapy: The ABC-X Study		Not yet recruiting	No Results Available	Melanoma Stage Iv	Drug: Ipilimumab|Drug: Nivolumab|Radiation: Stereotactic Radiotherapy|Radiation: Whole Brain Radiotherapy	Intracranial response to immunotherapy|Intracranial progression free survival for patients receiving the addition of radiotherapy|Best extracranial response rate|Overall response rate|Overall progression free survival|Overall survival|Change in neurocognitive function scores|Neurological adverse events requiring an intervention|Description of impaired neurological function and neurological adverse events|Time to neurological deterioration|Duration of neurological deterioration|Patient rated quality of life|Proxy rated quality of life|Functional performance status|Adverse events|Tissue and blood biomarkers of response, progression and neurotoxicity	Melanoma Institute Australia|Bristol-Myers Squibb	All	18 Years to 120 Years   (Adult, Older Adult)	Phase 2	155	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MIA2017/CT	February 2019	August 2020	August 2023	November 13, 2017	null	November 2, 2018	Westmead Hospital, Sydney, New South Wales, Australia|Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia		https://ClinicalTrials.gov/show/NCT03340129
367	NCT02437279	Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients	OpACIN	Active, not recruiting	No Results Available	Stage III Skin Melanoma	Procedure: Surgery of the tumor|Drug: Infusion with ipilimumab 3 mg/kg q3wks|Drug: Infusion with nivolumab 1 mg/kg q3wks	The alteration in magnitude of the neo-antigen specific T cell response in the time interval pre- to post-adjuvant therapy in peripheral blood|Safety as measured by SUSARs.|The alteration in breadth of the neo-antigen specific T cell response in the time interval pre- to post-adjuvant therapy in peripheral blood|Feasibility as measured adherence to the timelines in the study protocol.|Recurrence Free Survival, as determined according to RECIST 1.1 criteria.|Rate of adverse events and late adverse events|Type of adverse events and late adverse events	The Netherlands Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	20	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	N14OPC|CA209-278|NL51280.031.14	August 12, 2015	December 2017	April 2018	May 7, 2015	null	July 18, 2017	Netherlands Cancer Institute, Amsterdam, NH, Netherlands		https://ClinicalTrials.gov/show/NCT02437279
368	NCT03305445	Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL		Recruiting	No Results Available	Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma	Drug: Ipilimumab|Drug: Nivolumab	Dose Limiting Toxicities (DLTs)|Completion Remission (CR) Rate|Progression Free Survival (PFS)|Overall Survival (OS)|IgVH level|Delayed CR|Overall Response Rate (ORR)	Icahn School of Medicine at Mount Sinai|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	13	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GCO 17-2164	May 14, 2018	February 1, 2020	April 1, 2020	October 10, 2017	null	May 24, 2018	Icahn School of Medicine at Mount Sinai, New York, New York, United States		https://ClinicalTrials.gov/show/NCT03305445
369	NCT02420912	Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)		Recruiting	No Results Available	Leukemia|Chronic Lymphocytic Leukemia	Drug: Nivolumab|Drug: Ibrutinib	Cohort 1 and 3: Response Rate of Nivolumab in Combination with Ibrutinib|Cohort 2: Conversion Rate of Nivolumab in Combination with Ibrutinib	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	72	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2014-0931|NCI-2015-00844	June 2015	June 2021	June 2021	April 20, 2015	null	January 17, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02420912
370	NCT02659540	A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma		Active, not recruiting	No Results Available	Melanoma	Drug: Ipilimumab|Drug: Nivolumab|Radiation: Radiotherapy	Assessment of Safety according to to the National Cancer Institute Common Terminology Criteria for Adverse Events.|Overall response rate at weeks 12 and 18.|Disease control rate at weeks 12 and 18.|Progression-Free Survival|Overall Survival|Duration of Response	Ludwig Institute for Cancer Research|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	20	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LUD2015-006	October 13, 2016	December 2018	December 2021	January 20, 2016	null	September 13, 2018	Research Facility, Palo Alto, California, United States|Research Facility, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02659540
371	NCT02977052	Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab	OpACIN-neo	Recruiting	No Results Available	Malignant Melanoma Stage III	Drug: Ipilimumab|Drug: Nivolumab|Procedure: Surgery|Procedure: Blood for PBMCs|Procedure: Biopsies	Safety as measured by the frequency of grade 3/4 immune-related adverse events, using CTCAE 4.03|Response rate according to RECIST 1.1|Pathological response according to central pathological revision, according to pathological response criteria|Pathologic response rate according to central revision of the marked index lymph node|RFS at 24 months in patients achieving pCR or pnCR in their marked index lymph node and did not undergo CLND. RFS will be calculated from date of resection of the marked lymph node.|RFS at 24 months in patients with pNR and being subsequently treated with adjuvant nivolumab+optional radiotherapy (or dabrafenib/trametinib if BRAFV600E pos. and treatment is approved). RFS will be calculated from day of resection of marked lymph node.|Recurrence Free Survival|Description of late adverse events using CTCAE 4.03|Description of associations of mutational load, RNA tumor signatures, and tumor educated platelet signatures with tumor immune infiltrates and response|Response rate according to RECIST 1.1 at week 6|RFS at 2, 3 and 5 years	The Netherlands Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	110	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	M16OPN|2016-001984-35|CA209-701	November 2016	June 2020	June 2022	November 30, 2016	null	November 6, 2018	Melanoma Institute Australia, Sydney, New South Wales, Australia|Medical University of Vienna, Vienna, Austria|Netherlands Cancer Institute, Amsterdam, NH, Netherlands|Karolinska Institutet, Stockholm, Sweden		https://ClinicalTrials.gov/show/NCT02977052
372	NCT03307616	Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma		Recruiting	No Results Available	Systemic Connective Tissue Disorders	Drug: Nivolumab|Drug: Ipilimumab|Radiation: Radiation Therapy	Pathologic Response|Immunologic Response|Change in Immune Infiltrate in Response to Neoadjuvant Nivolumab Monotherapy and Neoadjuvant Nivolumab and Ipilimumab Combination Therapy|Objective Response Rate (ORR) of Nivolumab Monotherapy and Nivolumab and Ipilimumab Combination Therapy|Recurrence-Free Survival (RFS)|Overall Survival (OS)|Safety of Nivolumab Monotherapy and Combination Ipilimumab and Nivolumab in the Neoadjuvant Setting and Peri-Operatively	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-0143|NCI-2018-01031	October 4, 2017	October 2021	October 2021	October 12, 2017	null	October 12, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03307616
373	NCT03245021	Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A	1stFLOR	Recruiting	No Results Available	Follicular Lymphoma	Drug: Opdivo	To evaluate the feasibility and safety of combination nivolumab and rituximab as determined by the proportion of toxicity grade 3 or higher per CTCAE v4.0 occurring on induction treatment (ie first 16 weeks of therapy)|Overall toxicity|Response rate|Complete response rate|Time to treatment failure|Progression free survival|Overall survival	Dr. Eliza Hawkes|Bristol-Myers Squibb|Austin Health	All	18 Years and older   (Adult, Older Adult)	Phase 1	39	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-676	September 7, 2017	June 2022	June 2024	August 10, 2017	null	September 11, 2017	Ballarat Health, Ballarat, Victoria, Australia|Eastern Health, Box Hill, Victoria, Australia|Monash Health, Clayton, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|St Vincent's Hospital, Melbourne, Victoria, Australia		https://ClinicalTrials.gov/show/NCT03245021
374	NCT03259425	Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma		Recruiting	No Results Available	Melanoma	Drug: Nivolumab|Drug: HF10	Pathological Response after 12 weeks|Recurrence-free survival|Overall Survival|Complete Surgical Resecetion|Rate of adverse events for patients while taking nivolumab and HF10	University of Utah|Bristol-Myers Squibb|Takara Bio Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCI102346	December 21, 2017	October 2022	October 2022	August 23, 2017	null	September 13, 2018	Huntsman Cancer Institute, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT03259425
375	NCT03117309	Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma		Recruiting	No Results Available	Advanced Renal Cell Carcinoma	Drug: Nivolumab 240 mg|Drug: Ipilimumab 1mg/kg|Drug: Nivolumab 3mg/kg|Drug: Nivolumab 360mg	Progression Free Survival (PFS) rate|Objective Response Rate (CR/PR)|Response Rate|Clinical Activity (Complete Response (CR), Partial Response (PR) and Stable Disease (SD)|Progression Free Survival (PFS) at one year|Toxicity by calculating the frequency and percentage of adverse event terms (CTCAE v4)	Michael B. Atkins, MD|Bristol-Myers Squibb|Hoosier Cancer Research Network	All	18 Years and older   (Adult, Older Adult)	Phase 2	120	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCRN GU16-260	April 24, 2017	February 2020	February 2021	April 17, 2017	null	November 5, 2018	Georgetown University, Washington, District of Columbia, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Northwestern University Feinberg Schooll Of Medicine, Chicago, Illinois, United States|University of Illinois Cancer Center, Chicago, Illinois, United States|Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Univeristy of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States		https://ClinicalTrials.gov/show/NCT03117309
376	NCT03241186	Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma		Recruiting	No Results Available	Mucosal Melanoma	Drug: Ipilimumab|Drug: Nivolumab	Assess Recurrence-free survival time (RFS)|Assess the Adverse Events|Overall Survival (OS)	Robert R. McWilliams, MD|Bristol-Myers Squibb|Hoosier Cancer Research Network	All	18 Years and older   (Adult, Older Adult)	Phase 2	36	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MEL16-252	September 12, 2017	April 2019	April 2021	August 7, 2017	null	July 13, 2018	University of Iowa Hospital and Clinics, Iowa City, Iowa, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States		https://ClinicalTrials.gov/show/NCT03241186
377	NCT02983006	Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma		Recruiting	No Results Available	Melanoma	Biological: DS-8273a|Biological: Nivolumab	Safety (adverse events) of the protocol therapy|Anti-tumor activity of the protocol therapy	New York University School of Medicine|Bristol-Myers Squibb|Daiichi Sankyo, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 1	36	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	15-00906	October 2016	October 2019	December 2019	December 6, 2016	null	November 8, 2018	Laura and Isaac Perlmutter Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02983006
378	NCT03681561	Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma		Recruiting	No Results Available	Hodgkin Lymphoma	Drug: Ruxolitinib|Drug: Nivolumab	Maximum Tolerated Dose|Overall Response Rate|Progression Free Survival|Duration of Response|Overall Survival|Frequency and Severity of Adverse Events as assessed by CTCAE v4.0	Veronika Bachanova|Incyte Corporation|Bristol-Myers Squibb|Big Ten Cancer Research Consortium	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BTCRC-HEM15-027	September 13, 2018	September 2020	March 2024	September 24, 2018	null	September 24, 2018	University of Minnesota, Minneapolis, Minnesota, United States		https://ClinicalTrials.gov/show/NCT03681561
379	NCT03692338	INTENSE: A Study of a Supervised or Semi-Supervised Exercise InterveNtion or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects Receiving Ipilimumab and Nivolumab for Advanced or Metastatic Renal Cell Carcinoma		Recruiting	No Results Available	Metastatic Renal Cell Carcinoma	Behavioral: Exercise	Change in Cardiopulmonary function,|Patient-reported fatigue as measured by the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale|Patient-reported activity as measured by the Godin Leisure Time Exercise Questionnaire|Patient-reported symptoms as measured by the Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 (FKSI-19)|Patient health outcome as measured by the EQ-5D health questionnaire	Duke University|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Not Applicable	30	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	Pro00082941	November 19, 2018	August 31, 2020	August 31, 2020	October 2, 2018	null	November 26, 2018	Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03692338
380	NCT02464657	Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)		Recruiting	No Results Available	Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome	Drug: Nivolumab|Drug: Idarubicin|Drug: Cytarabine|Drug: Solu-medrol|Drug: Dexamethasone	Maximum Tolerated Dose (MTD) of Nivolumab|Event-Free Survival (EFS)	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	75	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2014-0907|NCI-2015-01258	July 2015	July 2019	July 2019	June 8, 2015	null	May 30, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02464657
381	NCT02243371	GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab		Active, not recruiting	No Results Available	Previously Treated Metastatic Adenocarcinoma of the Pancreas	Biological: CRS-207|Biological: GVAX|Drug: nivolumab|Drug: CY	Overall survival (OS) in metastatic pancreatic cancer patients treated with cyclophosphamide (CY)/nivolumab/GVAX pancreas vaccine followed by nivolumab/CRS-207 (Arm A) versus patients treated with CY/GVAX pancreas vaccine followed by CRS-207 (Arm B)|Number of patients experiencing treatment-related toxicities|Progression-free survival (PFS) by RECIST 1.1 in metastatic pancreatic cancer patients treated with CY/GVAX/CRS-207/nivolumab (Arm A) versus patients treated with CY/GVAX/CRS-207 (Arm B)|Immune-related progression-free survival (irPFS) by IRRC in metastatic pancreatic cancer patients treated with CY/GVAX/CRS-207/nivolumab (Arm A) versus patients treated with CY/GVAX/CRS-207 (Arm B)|Time to progression (TTP) by RECIST 1.1 and IRRC in metastatic pancreatic cancer patients treated with CY/GVAX/CRS-207/nivolumab (Arm A) versus patients treated with CY/GVAX/CRS-207 (Arm B)|Response rate measured by RECIST 1.1 in metastatic pancreatic cancer patients treated with CY/GVAX/CRS-207/nivolumab (Arm A) versus patients treated with CY/GVAX/CRS-207 (Arm B)|Tumor marker kinetics (CA 19-9) in metastatic pancreatic cancer patients treated with CY/GVAX/CRS-207/nivolumab (Arm A) versus patients treated with CY/GVAX/CRS-207 (Arm B)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb|Stand Up To Cancer|Aduro Biotech, Inc.|American Association for Cancer Research	All	18 Years and older   (Adult, Older Adult)	Phase 2	96	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J14113|ADU-CL-06|IRB00043936	December 2014	January 2019	January 2019	September 17, 2014	null	July 23, 2018	University of California, San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Providence Portland Medical Center, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02243371
382	NCT02530463	Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS)		Recruiting	No Results Available	Leukemia|Myelodysplastic Syndrome	Drug: Nivolumab|Drug: Ipilimumab|Drug: 5-azacitidine	Overall Response Rate (ORR) in MDS Participants with Hypomethylating Agent Failure|Overall Response Rate (ORR) in MDS Participants Who Have Not Received Hypomethylating Agents	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	120	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2014-0930|NCI-2015-01494	September 8, 2015	September 2021	September 2022	August 21, 2015	null	April 30, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02530463
383	NCT03704714	Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma		Not yet recruiting	No Results Available	Aggressive Non-Hodgkin Lymphoma|B-Cell Non-Hodgkin Lymphoma|CD20 Positive|Diffuse Large B-Cell Lymphoma Unclassifiable|Intravascular Large B-Cell Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Biological: Nivolumab|Drug: Prednisone|Other: Quality-of-Life Assessment|Biological: Rituximab|Drug: Vincristine Sulfate	Maximum tolerated dose (MTD) for the combination treatment of nivolumab and R-CHOP|Progression Free Survival (PFS)|Overall response rate (ORR)|Overall survival (OS) rate|Event-free survival (EFS)|Overall response rates as defined by the RECIL and LYRIC criteria|Frailty/Geriatric Assessments|Incidence of Adverse Events|Quality of life Assessment	Northwestern University|Bristol-Myers Squibb (BMS)|National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	30	Other|NIH	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 17H08|STU00207793|P30CA060553|NCI-2018-01666	November 8, 2018	May 11, 2021	June 11, 2022	October 15, 2018	null	October 15, 2018	Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT03704714
384	NCT02693535	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer	TAPUR	Recruiting	No Results Available	Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors	Drug: Axitinib|Drug: Bosutinib|Drug: Crizotinib|Drug: Palbociclib|Drug: Sunitinib|Drug: Temsirolimus|Drug: Trastuzumab and Pertuzumab|Drug: Vemurafenib and Cobimetinib|Drug: Cetuximab|Drug: Dasatinib|Drug: Regorafenib|Drug: Olaparib|Drug: Pembrolizumab|Drug: Nivolumab and Ipilimumab	Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria|Overall survival (OS)	American Society of Clinical Oncology|AstraZeneca|Bayer|Bristol-Myers Squibb|Eli Lilly and Company|Genentech, Inc.|Merck Sharp & Dohme Corp.|Pfizer	All	12 Years and older   (Child, Adult, Older Adult)	Phase 2	1440	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00014171	March 2016	March 2019	null	February 26, 2016	null	September 11, 2018	University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|Cancer Treatment Centers of America-Phoenix, Phoenix, Arizona, United States|The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California, United States|Sutter Cancer Research Consortium, San Francisco, California, United States|University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Cancer Treatment Centers of America - Atlanta, Atlanta, Georgia, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States|Cancer Treatment Centers of America-Chicago, Chicago, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States|Cancer Research Consortium of West Michigan, Grand Rapids, Michigan, United States|Michigan Cancer Research Consortium, Traverse City, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Carolina's HealthCare System's Levine Cancer Institute, Charlotte, North Carolina, United States|Sanford Health- Bismarck, Bismarck, North Dakota, United States|Sanford Health- Fargo, Fargo, North Dakota, United States|Cancer Treatment Centers of America-Tulsa, Tulsa, Oklahoma, United States|Providence Health & Services, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Cancer Treatment Centers of America-Philadelphia, Philadelphia, Pennsylvania, United States|Sanford Cancer Center Oncology Clinic and Pharmacy, Sioux Falls, South Dakota, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Intermountain Healthcare, Salt Lake City, Utah, United States|Inova Schar Cancer Institute, Fairfax, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT02693535
385	NCT03558750	Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma		Recruiting	No Results Available	Recurrent Central Nervous System Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Refractory Central Nervous System Lymphoma|Refractory Diffuse Large B-Cell Lymphoma	Biological: Nivolumab|Biological: Rituximab|Drug: Lenalidomide	Dose limiting toxicity (DLT) (Phase I)|Overall response rate (complete response, partial response, or stable disease) (Phase II)|Time to progression (complete response, partial response, or stable disease)|Progression free survival|Overall survival|Incidence of adverse events per national Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.03|Difference in overall response rate between those with and without programmed cell death ligand 1 (PD-L1) protein expression in tumor (subgroup analysis)|Difference in overall response rate between those with and without MYD88 mutation in tumor (subgroup analysis)	Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)|Bristol-Myers Squibb	All	19 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	48	Other|NIH|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VICC PCL 1758|NCI-2018-01092	June 14, 2018	May 31, 2022	May 31, 2023	June 15, 2018	null	June 18, 2018	Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT03558750
386	NCT03552380	Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma		Recruiting	No Results Available	Renal Cell Carcinoma	Drug: Entinostat|Drug: Nivolumab|Drug: Ipilimumab	Establish the recommended Phase II dose (RP2D)|Objective Response Rate (ORR) via RECIST 1.1|Assess Adverse Events|ORR via irRC|Progression Free Survival (PFS) via RECIST 1.1|Progression Free Survival (PFS) via irRC|Overall Survival (OS)	Roberto Pili|Bristol-Myers Squibb|Syndax Pharmaceuticals|Indiana University School of Medicine|Hoosier Cancer Research Network	All	18 Years and older   (Adult, Older Adult)	Phase 2	53	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCRN GU17-326	August 31, 2018	August 2019	August 2020	June 11, 2018	null	September 10, 2018	Indiana Univeristy Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States		https://ClinicalTrials.gov/show/NCT03552380
387	NCT03749018	Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma		Not yet recruiting	No Results Available	Aggressive Non-Hodgkin Lymphoma|Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Indolent Non-Hodgkin Lymphoma|Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|Transformed Non-Hodgkin Lymphoma	Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Biological: Nivolumab|Drug: Prednisone|Biological: Rituximab|Drug: Vincristine Sulfate	Progression-free survival (PFS)|Objective response rate|Duration of response defined for all patients who have achieved an objective response (CR or PR)|Incidence of adverse events per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0	Kami Maddocks|National Cancer Institute (NCI)|Bristol-Myers Squibb|Ohio State University Comprehensive Cancer Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	30	Other|NIH|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OSU-18281|NCI-2018-02699|P30CA016058	January 1, 2019	December 31, 2021	December 31, 2021	November 21, 2018	null	November 21, 2018	Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT03749018
388	NCT03297606	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)	CAPTUR	Recruiting	No Results Available	Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors	Drug: Olaparib|Drug: Dasatinib|Drug: Nivolumab plus Ipilimumab|Drug: Axitinib|Drug: Bosutinib|Drug: Crizotinib|Drug: Palbociclib|Drug: Sunitinib|Drug: Temsirolimus|Drug: Erlotinib|Drug: Trastuzumab plus Pertuzumab|Drug: Vemurafenib plus Cobimetinib|Drug: Vismodegib	Objective response rate defined as the number of patients with complete response or partial response|Number and severity of adverse events|Progression-free survival confirmed by disease-appropriate objective criteria	Canadian Cancer Trials Group|AstraZeneca|Bristol-Myers Squibb|Hoffmann-La Roche|Pfizer	All	18 Years and older   (Adult, Older Adult)	Phase 2	720	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PM1|ESR‐17‐12831|CA209‐9DL|ML39800|WI233446	October 6, 2017	September 2021	September 2021	September 29, 2017	null	August 22, 2018	BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|London Regional Cancer Program, London, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|The Jewish General Hospital, Montreal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT03297606
389	NCT03366272	Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients	NIVEAU	Recruiting	No Results Available	Lymphoma, Non-Hodgkin	Drug: Nivolumab|Drug: Rituximab|Drug: Gemcitabine|Device: Oxaliplatin	PFS|CR rate|PR rate|ORR rate|Duration of response|Primary Progression rate|Treatment related deaths rate|Relapse rate|EFS|OS|Toxicities: rates and grades of adverse events|Protocol adherence according to number of given chemotherapy cycles|Protocol adherence according to duration of given chemotherapy cycles|Protocol adherence according to cumulative dose of immunochemotherapy given|Protocol adherence according to relative dose of immunochemotherapy given|QoL|Biological Parameters according to PD-L1 expression alterations|Biological Parameters according to PD-1 expression|Biological Parameters according to cell of origin|Biological Parameters according to 9p24.1 alterations	University Hospital, Saarland|Bristol-Myers Squibb|Lymphoma Study Association|University of Leipzig	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	388	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DSHNHL 2015-1	December 5, 2017	November 2022	November 2024	December 8, 2017	null	October 18, 2018	INSTITUT JULES BORDET -Hematology, Brüssel, Belgium|UNIVERSITE CATHOLIQUE DE LOUVAIN SAINT-LUC - Hematology, Brüssel, Belgium|UNIVERSITAIR ZIEKENHUIS GENT - Hematology, Gent, Belgium|CHU DE LIEGE - Hematology, Liège, Belgium|UNIVERSITE CATHOLIQUE DE LOUVAIN MONT GODINNE - Hematology, Yvoir, Belgium|CHU Côte de Nacre - Service Hématologie Clinique, Caen, France|Hôpital Henri Mondor - Unité "Hémopathies Lymphoïdes" - HDJ 11è, Créteil Cedex, France|CHU Dijon - Hôpital d'Enfants - Hématologie Clinique, Dijon, France|CHU de Grenoble - Hôpital Albert Michallon - Hématologie Clinique, Grenoble, France|CH Départemental Vendée - Onco-Hématologie, La Roche-sur-Yon, France|CHRU de Lille - Hôpital Claude Hurriez, Lille, France|Institut Paoli Calmettes - Hématologie, Marseille, France|CHU de Montpellier - Hématologie Clinique, Montpellier, France|CHU de Nantes - Hôtel Dieu - Hématologie, Nantes, France|Hôpital Saint Louis - Onco-Hématologie, Paris cedex 20, France|Hôpital Necker - Hématologie Clinique, Paris, France|CHU de Bordeaux - Hôpital Haut Lévêque - Centre François Magendie, Pessac, France|CHU Lyon Sud - Hématologie, Pierre-Bénite, France|Hôpital Pontchaillou - Hématologie, Rennes, France|Centre Henri Becquerel - Hématologie, Rouen, France|Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre, Strasbourg, France|IUCT Oncopole - Hématologie, Toulouse, France|CHU Nancy - Hôpital de Brabois - Service d'Hématologie et Médecine Interne, Vandoeuvre-les-Nancy, France|Charité - Universitätsklinikum Berlin, Med. Klinik m. S. Hämatologie, Berlin, Germany|Vivantes Klinikum am Urban, Klinik für Innere, Hämatologie und Onkologie, Berlin, Germany|Klinikum Chemnitz, Innere Medizin III, Chemnitz, Germany|BAG Freiberg-Richter, Jacobasch, Wolf, Illmer, Dresden, Germany|Gemeinschaftspraxis Dres. Mohm, Prange-Krex, Dresden, Germany|St. Antonius-Hospital Eschweiler, Klinik für Hämatologie, Eschweiler, Germany|Universitätsklinikum Essen, Klinik für Hämatologie, Essen, Germany|Universitätsmedizin Göttingen, Klinik für Hämatologie, Göttingen, Germany|Universitätsklinikum Haale (Saale), Klinik für Innere Medizin IV, Haale, Germany|Med. Hochschule Hannover, Klinik für Hämatologie, Hannover, Germany|Medizinische Hochschule Hannover, Klinik für Hämatologie, Hannover, Germany|Universitätsklinikum des Saarlandes, Innere Med. I, Homburg, Germany|Westpfalz-Klinikum, Klinik für Innere Medizin I, Kaiserslautern, Germany|St. Vincentius Kliniken Karlsruhe, Med. Klinik Abt. 2, Karlsruhe, Germany|Klinikum der Universität zu Köln, Klinik I für Innere Medizin, Köln, Germany|Uni Gießen und Marburg, Klinik für Hämatologie, Marburg, Germany|Stauferklinikum Schwäbisch Gmünd, Zentrum für Innere Medizin, Mutlangen, Germany|Klinikum der Universität München, Med. Klinik und Poliklinik III, München, Germany|Universitätsklinikum Münster, Münster, Germany|Universitätsklinikum Regensburg, Klinik für Innere Medizin III, Regensburg, Germany|Universitätsmedizin Rostock, Klinik für Hämatologie, Rostock, Germany|Klinikum Stuttgart, Klinik für Hämatologie, Stuttgart, Germany|Klinikum Mutterhaus der Borromäerinnen, Med. Abteilung I, Trier, Germany|Krankenhaus der Barmherzigen Brüder, I. Med. Abteilung, Trier, Germany|Universitätsklinikum Tübingen, Innere Medizin II, Tübingen, Germany|Uniklinikum Ulm, Klinik für Innere Medizin III, Ulm, Germany|Schwarzwald-Baar Klinikum, Innere Medizin II, Villingen-Schwenningen, Germany|The Chaim Sheba Medical Center - Division of Hematology and Bone-Marrow Transplantation, Ramat Gan, Israel|Instituto Português Oncologia - Hematology, Lisboa, Portugal		https://ClinicalTrials.gov/show/NCT03366272
390	NCT03033914	A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)		Recruiting	No Results Available	Hodgkin Lymphoma	Drug: doxorubicin|Drug: Bleomycin|Drug: vinblastine|Drug: dacarbazine|Drug: Nivolumab	number of patients who have dose limiting toxicity|Phase II- progression free survival	Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb|Barbara Ann Karmanos Cancer Institute|British Columbia Cancer Agency	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	26	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-1536|CA209-447	January 25, 2017	January 2020	January 2020	January 27, 2017	null	November 20, 2018	Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States		https://ClinicalTrials.gov/show/NCT03033914
391	NCT01176474	Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma		Active, not recruiting	No Results Available	Melanoma (Skin)	Biological: NY-ESO-1 157-165 (165V)|Drug: Nivolumab|Biological: gp100:280-288 (288V)|Drug: Montanide ISA 51 vegetable grade (VG)|Drug: Ipilimumab|Procedure: Apheresis Procedure	Time to Relapse|Overall Survival (OS)	H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|Medarex|Bristol-Myers Squibb	All	16 Years and older   (Child, Adult, Older Adult)	Phase 1	73	Other|NIH|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-15651|NCI-8316	July 28, 2010	October 2019	October 2020	August 6, 2010	null	July 12, 2018	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT01176474
392	NCT03161756	Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma	CHARLI	Recruiting	No Results Available	Melanoma Stage Iv|Melanoma Stage Iii|Melanoma	Drug: Denosumab|Drug: Nivolumab|Drug: Ipilimumab	Median Progression-Free Survival|Occurrence of Grade 3 and 4 Selected Immune-related Adverse Events (irAEs) of interest|Rate of Grade 3 and 4 irAEs|Best Overall Response According to RECIST 1.1|Progression-Free Survival|Overall Survival|Toxicity Profiles of the Checkpoint-Denosumab Combinations|Occurrence of Treatment Discontinuation Due to Toxicity	Australia and New Zealand Melanoma Trials Group|Peter MacCallum Cancer Centre, Australia|Amgen|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	72	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ANZMTG 01.15	December 7, 2017	June 2021	June 2023	May 22, 2017	null	September 26, 2018	Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia		https://ClinicalTrials.gov/show/NCT03161756
393	NCT01716806	A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)		Recruiting	No Results Available	Hodgkin Disease	Drug: brentuximab vedotin|Drug: bendamustine|Drug: dacarbazine|Drug: nivolumab	Objective response rate|Incidence of adverse events|Incidence of laboratory abnormalities|Complete remission rate (CR)|Duration of response|Progression-free survival|B symptom resolution rate|Blood concentrations of brentuximab vedotin and metabolites|Incidence of brentuximab vedotin antitherapeutic antibodies (ATA)|Blood concentrations of nivolumab and metabolites|Incidence of nivolumab antitherapeutic antibodies (ATA)	Seattle Genetics, Inc.|Bristol-Myers Squibb	All	60 Years and older   (Adult, Older Adult)	Phase 2	100	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SGN35-015	October 2012	July 2019	July 2021	October 30, 2012	null	November 1, 2018	University of Alabama at Birmingham, Birmingham, Alabama, United States|Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|Providence St Joseph Medical Center, Burbank, California, United States|City of Hope National Medical Center, Duarte, California, United States|Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States|Georgia Cancer Specialists / Northside Hospital Cancer Institute, Sandy Springs, Georgia, United States|Illinois Cancer Specialists / Advocate Lutheran General Hospital, Niles, Illinois, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Minnesota Oncology Hematology P.A., Minneapolis, Minnesota, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|New York Oncology Hematology, P.C., Albany, New York, United States|James P. Wilmot Cancer Center / University of Rochester Medical Center, Rochester, New York, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|Northwest Cancer Specialists, P.C., Tualatin, Oregon, United States|Greenville Health System Cancer Institute, Greenville, South Carolina, United States|Texas Oncology - Bedford, Bedford, Texas, United States|Texas Oncology - Fort Worth 12th Avenue, Fort Worth, Texas, United States|Texas Oncology - Longview, Longview, Texas, United States|Texas Oncology - Seton Williamson, Round Rock, Texas, United States|Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care, Blacksburg, Virginia, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT01716806
394	NCT01176461	Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558		Active, not recruiting	No Results Available	Melanoma (Skin)	Biological: MART-1|Biological: NY-ESO-1|Biological: gp100:209-217(210M)|Biological: gp100:280-288(288V)|Drug: Montanide ISA 51 VG|Biological: BMS-936558	Best Overall Response Rate (BORR)|Time to Response|Duration of Response	H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|Bristol-Myers Squibb|Medarex	All	16 Years and older   (Child, Adult, Older Adult)	Phase 1	127	Other|NIH|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-15400|NCI-P-7997|CA209-006/007|10-15526-99-01	August 4, 2010	December 12, 2016	December 2019	August 6, 2010	null	July 12, 2018	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT01176461
